CA2371633A1 - Thio-oxindole derivatives - Google Patents
Thio-oxindole derivatives Download PDFInfo
- Publication number
- CA2371633A1 CA2371633A1 CA002371633A CA2371633A CA2371633A1 CA 2371633 A1 CA2371633 A1 CA 2371633A1 CA 002371633 A CA002371633 A CA 002371633A CA 2371633 A CA2371633 A CA 2371633A CA 2371633 A1 CA2371633 A1 CA 2371633A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- substituted
- aryl
- heterocyclic
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 235
- 238000000034 method Methods 0.000 claims abstract description 86
- 150000003839 salts Chemical class 0.000 claims abstract description 58
- 201000009030 Carcinoma Diseases 0.000 claims abstract description 3
- 208000009956 adenocarcinoma Diseases 0.000 claims abstract description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 128
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 101
- 125000000623 heterocyclic group Chemical group 0.000 claims description 71
- 125000003118 aryl group Chemical group 0.000 claims description 70
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 70
- 125000003545 alkoxy group Chemical group 0.000 claims description 65
- 229910052736 halogen Inorganic materials 0.000 claims description 63
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 59
- 125000001424 substituent group Chemical group 0.000 claims description 49
- 150000002367 halogens Chemical class 0.000 claims description 44
- -1 indol-4-yl Chemical group 0.000 claims description 44
- 229910052739 hydrogen Inorganic materials 0.000 claims description 43
- 125000003107 substituted aryl group Chemical group 0.000 claims description 39
- 229910052799 carbon Inorganic materials 0.000 claims description 36
- 238000011282 treatment Methods 0.000 claims description 33
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 29
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 23
- 125000002252 acyl group Chemical group 0.000 claims description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 19
- 125000004001 thioalkyl group Chemical group 0.000 claims description 19
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical group O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 18
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 18
- 125000005842 heteroatom Chemical group 0.000 claims description 18
- 125000003435 aroyl group Chemical group 0.000 claims description 17
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 13
- 229910052717 sulfur Inorganic materials 0.000 claims description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 12
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 12
- 229910052731 fluorine Inorganic materials 0.000 claims description 12
- 125000005309 thioalkoxy group Chemical group 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 11
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 10
- 229930192474 thiophene Natural products 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 8
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 7
- 125000000304 alkynyl group Chemical group 0.000 claims description 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 claims description 3
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 3
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 claims description 2
- LFOKDLJVIJPCIT-UHFFFAOYSA-N 5-(3-chlorophenyl)spiro[1h-indole-3,1'-cyclohexane]-2-thione Chemical compound ClC1=CC=CC(C=2C=C3C4(CCCCC4)C(=S)NC3=CC=2)=C1 LFOKDLJVIJPCIT-UHFFFAOYSA-N 0.000 claims description 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 2
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 2
- 230000000740 bleeding effect Effects 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000004696 endometrium Anatomy 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 18
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims 7
- 125000006664 (C1-C3) perfluoroalkyl group Chemical group 0.000 claims 6
- CRDUPEZGPAEXIK-UHFFFAOYSA-N 4-(2-sulfanylidenespiro[1h-indole-3,1'-cyclohexane]-5-yl)thiophene-2-carbonitrile Chemical compound S=C1NC2=CC=C(C=3C=C(SC=3)C#N)C=C2C11CCCCC1 CRDUPEZGPAEXIK-UHFFFAOYSA-N 0.000 claims 1
- 150000001555 benzenes Chemical group 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 abstract description 16
- 102000003998 progesterone receptors Human genes 0.000 abstract description 16
- 108090000468 progesterone receptors Proteins 0.000 abstract description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 292
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 146
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 135
- 239000000243 solution Substances 0.000 description 119
- 235000019439 ethyl acetate Nutrition 0.000 description 115
- 238000005481 NMR spectroscopy Methods 0.000 description 112
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 103
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 98
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 94
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 75
- 239000007787 solid Substances 0.000 description 73
- 239000000047 product Substances 0.000 description 69
- 238000010992 reflux Methods 0.000 description 68
- 238000006243 chemical reaction Methods 0.000 description 65
- 229940093499 ethyl acetate Drugs 0.000 description 62
- 239000000203 mixture Substances 0.000 description 58
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 56
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 54
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 54
- 239000002904 solvent Substances 0.000 description 51
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 47
- 125000003003 spiro group Chemical group 0.000 description 46
- 239000012044 organic layer Substances 0.000 description 45
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 45
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 42
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 39
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 39
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 38
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 36
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 35
- 229910052757 nitrogen Inorganic materials 0.000 description 35
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 35
- 239000012267 brine Substances 0.000 description 34
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 33
- 239000011541 reaction mixture Substances 0.000 description 33
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 31
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 31
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 31
- 238000004440 column chromatography Methods 0.000 description 30
- 101150041968 CDC13 gene Proteins 0.000 description 29
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 26
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 25
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 238000005160 1H NMR spectroscopy Methods 0.000 description 23
- 239000003921 oil Substances 0.000 description 23
- 235000019198 oils Nutrition 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 22
- 239000002585 base Substances 0.000 description 22
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 21
- 238000000746 purification Methods 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 239000000186 progesterone Substances 0.000 description 20
- 125000004432 carbon atom Chemical group C* 0.000 description 19
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 18
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 18
- 231100000673 dose–response relationship Toxicity 0.000 description 18
- 235000019341 magnesium sulphate Nutrition 0.000 description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- 239000002609 medium Substances 0.000 description 17
- 229960003387 progesterone Drugs 0.000 description 17
- 239000000741 silica gel Substances 0.000 description 16
- 229910002027 silica gel Inorganic materials 0.000 description 16
- 238000010898 silica gel chromatography Methods 0.000 description 16
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 15
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 15
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 14
- 239000005557 antagonist Substances 0.000 description 14
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 14
- 230000000708 anti-progestin effect Effects 0.000 description 13
- 239000003418 antiprogestin Substances 0.000 description 13
- 239000000543 intermediate Substances 0.000 description 13
- 102000027411 intracellular receptors Human genes 0.000 description 13
- 108091008582 intracellular receptors Proteins 0.000 description 13
- 239000010410 layer Substances 0.000 description 13
- 229910000029 sodium carbonate Inorganic materials 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 12
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 12
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 12
- 229910000027 potassium carbonate Inorganic materials 0.000 description 12
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 12
- VJFBVGNRQKZDCK-UHFFFAOYSA-N 5'-bromo-n-phenylmethoxyspiro[cyclohexane-1,3'-indole]-2'-amine Chemical compound C1CCCCC21C1=CC(Br)=CC=C1NC2=NOCC1=CC=CC=C1 VJFBVGNRQKZDCK-UHFFFAOYSA-N 0.000 description 11
- 229960000583 acetic acid Drugs 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 239000012298 atmosphere Substances 0.000 description 11
- 238000009835 boiling Methods 0.000 description 11
- 238000010828 elution Methods 0.000 description 11
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 11
- 239000000583 progesterone congener Substances 0.000 description 11
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 10
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 10
- 239000005089 Luciferase Substances 0.000 description 10
- 238000003818 flash chromatography Methods 0.000 description 10
- CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 10
- 239000001632 sodium acetate Substances 0.000 description 10
- 235000017281 sodium acetate Nutrition 0.000 description 10
- 235000017557 sodium bicarbonate Nutrition 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 10
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- PCKPVGOLPKLUHR-UHFFFAOYSA-N OH-Indolxyl Natural products C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 description 9
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 150000002923 oximes Chemical class 0.000 description 9
- 229910052763 palladium Inorganic materials 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 8
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 8
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 229910000104 sodium hydride Inorganic materials 0.000 description 8
- JUNDJWOLDSCTFK-MTZCLOFQSA-N trimegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)[C@@H](O)C)(C)[C@@]1(C)CC2 JUNDJWOLDSCTFK-MTZCLOFQSA-N 0.000 description 8
- 229950008546 trimegestone Drugs 0.000 description 8
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 7
- 235000019270 ammonium chloride Nutrition 0.000 description 7
- 229910052794 bromium Inorganic materials 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 239000012312 sodium hydride Substances 0.000 description 7
- MOCOBMQLHAVEMT-UHFFFAOYSA-N 5-bromospiro[1h-indole-3,1'-cyclohexane]-2-one Chemical compound C12=CC(Br)=CC=C2NC(=O)C21CCCCC2 MOCOBMQLHAVEMT-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Chemical class 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- 230000016117 decidualization Effects 0.000 description 6
- 239000012299 nitrogen atmosphere Substances 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
- 230000036515 potency Effects 0.000 description 6
- 230000001072 progestational effect Effects 0.000 description 6
- 239000008096 xylene Substances 0.000 description 6
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 5
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 230000001911 anti-progestational effect Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 5
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 5
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 5
- 238000001543 one-way ANOVA Methods 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- CUPOOAWTRIURFT-UHFFFAOYSA-N thiophene-2-carbonitrile Chemical compound N#CC1=CC=CS1 CUPOOAWTRIURFT-UHFFFAOYSA-N 0.000 description 5
- SDEAGACSNFSZCU-UHFFFAOYSA-N (3-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(Cl)=C1 SDEAGACSNFSZCU-UHFFFAOYSA-N 0.000 description 4
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 4
- 125000005157 alkyl carboxy group Chemical group 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 125000004104 aryloxy group Chemical group 0.000 description 4
- 239000002285 corn oil Substances 0.000 description 4
- 235000005687 corn oil Nutrition 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 102000015694 estrogen receptors Human genes 0.000 description 4
- 108010038795 estrogen receptors Proteins 0.000 description 4
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 4
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 4
- 229910000105 potassium hydride Inorganic materials 0.000 description 4
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 4
- 229910052814 silicon oxide Inorganic materials 0.000 description 4
- LLHRWZOIAVWPKH-UHFFFAOYSA-N spiro[1h-indole-3,1'-cyclohexane]-2-one Chemical compound O=C1NC2=CC=CC=C2C11CCCCC1 LLHRWZOIAVWPKH-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 4
- CCRMAATUKBYMPA-UHFFFAOYSA-N trimethyltin Chemical compound C[Sn](C)C.C[Sn](C)C CCRMAATUKBYMPA-UHFFFAOYSA-N 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 3
- JYUXDXWXTPSAEL-UHFFFAOYSA-N 1,4-dioxane;oxolane Chemical compound C1CCOC1.C1COCCO1 JYUXDXWXTPSAEL-UHFFFAOYSA-N 0.000 description 3
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 3
- IADLVSLZPQYXIF-UHFFFAOYSA-N 3-bromo-5-fluorobenzonitrile Chemical compound FC1=CC(Br)=CC(C#N)=C1 IADLVSLZPQYXIF-UHFFFAOYSA-N 0.000 description 3
- LRQOLFHQTKOVQZ-UHFFFAOYSA-N 5-bromo-4-methylthiophene-2-carbonitrile Chemical compound CC=1C=C(C#N)SC=1Br LRQOLFHQTKOVQZ-UHFFFAOYSA-N 0.000 description 3
- YVVHCBNJWHPMCQ-UHFFFAOYSA-N 5-bromothiophene-2-carbonitrile Chemical compound BrC1=CC=C(C#N)S1 YVVHCBNJWHPMCQ-UHFFFAOYSA-N 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 3
- 101000574060 Homo sapiens Progesterone receptor Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 125000005110 aryl thio group Chemical group 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 229940125851 compound 27 Drugs 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 3
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000012039 electrophile Substances 0.000 description 3
- 150000002081 enamines Chemical class 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000005462 in vivo assay Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229960004400 levonorgestrel Drugs 0.000 description 3
- 229910052808 lithium carbonate Inorganic materials 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 235000011056 potassium acetate Nutrition 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 125000005415 substituted alkoxy group Chemical group 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 3
- ULWKGFWNTFEOGC-UHFFFAOYSA-N tert-butyl 2-(2-oxospiro[1h-indole-3,1'-cyclohexane]-5-yl)pyrrole-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C=CC=C1C1=CC=C(NC(=O)C23CCCCC3)C2=C1 ULWKGFWNTFEOGC-UHFFFAOYSA-N 0.000 description 3
- BPLUKJNHPBNVQL-UHFFFAOYSA-N triphenylarsine Chemical compound C1=CC=CC=C1[As](C=1C=CC=CC=1)C1=CC=CC=C1 BPLUKJNHPBNVQL-UHFFFAOYSA-N 0.000 description 3
- 238000010626 work up procedure Methods 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- NLLGFYPSWCMUIV-UHFFFAOYSA-N (3-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(B(O)O)=C1 NLLGFYPSWCMUIV-UHFFFAOYSA-N 0.000 description 2
- VTWKXBJHBHYJBI-VURMDHGXSA-N (nz)-n-benzylidenehydroxylamine Chemical compound O\N=C/C1=CC=CC=C1 VTWKXBJHBHYJBI-VURMDHGXSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 2
- WFQDTOYDVUWQMS-UHFFFAOYSA-N 1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1 WFQDTOYDVUWQMS-UHFFFAOYSA-N 0.000 description 2
- BQMPGKPTOHKYHS-UHFFFAOYSA-N 1h-pyrrole-2-carbonitrile Chemical compound N#CC1=CC=CN1 BQMPGKPTOHKYHS-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- RXWOHFUULDINMC-UHFFFAOYSA-N 2-(3-nitrothiophen-2-yl)acetic acid Chemical compound OC(=O)CC=1SC=CC=1[N+]([O-])=O RXWOHFUULDINMC-UHFFFAOYSA-N 0.000 description 2
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
- FFNVQNRYTPFDDP-UHFFFAOYSA-N 2-cyanopyridine Chemical compound N#CC1=CC=CC=N1 FFNVQNRYTPFDDP-UHFFFAOYSA-N 0.000 description 2
- JOAHCWIICCHHOU-UHFFFAOYSA-N 3,3-diethyl-1h-indol-2-one Chemical compound C1=CC=C2C(CC)(CC)C(=O)NC2=C1 JOAHCWIICCHHOU-UHFFFAOYSA-N 0.000 description 2
- RNIRKEQGYHHNSE-UHFFFAOYSA-N 3-bromothiophene-2-carbonitrile Chemical compound BrC=1C=CSC=1C#N RNIRKEQGYHHNSE-UHFFFAOYSA-N 0.000 description 2
- MXVLGQWQGUUHIV-UHFFFAOYSA-N 3-ethylindol-2-one Chemical compound C1=CC=CC2=NC(=O)C(CC)=C21 MXVLGQWQGUUHIV-UHFFFAOYSA-N 0.000 description 2
- KYMCOOXGQFSTAY-UHFFFAOYSA-N 4-bromofuran-2-carbonitrile Chemical compound BrC1=COC(C#N)=C1 KYMCOOXGQFSTAY-UHFFFAOYSA-N 0.000 description 2
- WLCSPMUHIPMWML-UHFFFAOYSA-N 4-butylthiophene-2-carbonitrile Chemical compound CCCCC1=CSC(C#N)=C1 WLCSPMUHIPMWML-UHFFFAOYSA-N 0.000 description 2
- BIUDHHGROGJSHN-UHFFFAOYSA-N 4-fluoro-3-(trifluoromethyl)benzaldehyde Chemical group FC1=CC=C(C=O)C=C1C(F)(F)F BIUDHHGROGJSHN-UHFFFAOYSA-N 0.000 description 2
- VARVNBJDZWIXOY-UHFFFAOYSA-N 5'-(3-chlorophenyl)spiro[cyclohexane-1,3'-indole]-2'-amine Chemical compound NC1=NC2=CC=C(C=3C=C(Cl)C=CC=3)C=C2C11CCCCC1 VARVNBJDZWIXOY-UHFFFAOYSA-N 0.000 description 2
- RZEOLFBSKONBFI-UHFFFAOYSA-N 5'-(4-fluorophenyl)-n-phenylmethoxyspiro[cyclohexane-1,3'-indole]-2'-amine Chemical compound C1=CC(F)=CC=C1C1=CC=C(NC(=NOCC=2C=CC=CC=2)C23CCCCC3)C2=C1 RZEOLFBSKONBFI-UHFFFAOYSA-N 0.000 description 2
- NMLQXQMHBIJXLJ-UHFFFAOYSA-N 5-(2-oxospiro[1h-indole-3,1'-cyclohexane]-5-yl)furan-3-carbonitrile Chemical compound O=C1NC2=CC=C(C=3OC=C(C=3)C#N)C=C2C11CCCCC1 NMLQXQMHBIJXLJ-UHFFFAOYSA-N 0.000 description 2
- NIOCARGZGKGNDA-UHFFFAOYSA-N 5-(3,3-dimethyl-2-oxo-1h-indol-5-yl)-4-methylthiophene-2-carbonitrile Chemical compound C1=C(C#N)SC(C=2C=C3C(C)(C)C(=O)NC3=CC=2)=C1C NIOCARGZGKGNDA-UHFFFAOYSA-N 0.000 description 2
- WQFMXZOYAIPMFZ-UHFFFAOYSA-N 5-(3-chlorophenyl)-3,3-dimethyl-1h-indol-2-one Chemical compound C1=C2C(C)(C)C(=O)NC2=CC=C1C1=CC=CC(Cl)=C1 WQFMXZOYAIPMFZ-UHFFFAOYSA-N 0.000 description 2
- OWQAYYLCRJWAKR-UHFFFAOYSA-N 5-(3-methoxyphenyl)-3,3-dimethyl-1h-indol-2-one Chemical compound COC1=CC=CC(C=2C=C3C(C)(C)C(=O)NC3=CC=2)=C1 OWQAYYLCRJWAKR-UHFFFAOYSA-N 0.000 description 2
- QUXWTPUEQGPBEQ-UHFFFAOYSA-N 5-bromo-3,3-diethyl-1h-indol-2-one Chemical compound C1=C(Br)C=C2C(CC)(CC)C(=O)NC2=C1 QUXWTPUEQGPBEQ-UHFFFAOYSA-N 0.000 description 2
- YCHSJOIHTKPUCQ-UHFFFAOYSA-N 5-bromo-3,3-dimethyl-1h-indol-2-one Chemical compound C1=C(Br)C=C2C(C)(C)C(=O)NC2=C1 YCHSJOIHTKPUCQ-UHFFFAOYSA-N 0.000 description 2
- ZAXSHDQOFNHDIM-UHFFFAOYSA-N 5-bromospiro[1,2-dihydroindole-3,1'-cyclopropane] Chemical compound C12=CC(Br)=CC=C2NCC21CC2 ZAXSHDQOFNHDIM-UHFFFAOYSA-N 0.000 description 2
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 238000008940 Alkaline Phosphatase assay kit Methods 0.000 description 2
- 102000052567 Anaphase-Promoting Complex-Cyclosome Apc1 Subunit Human genes 0.000 description 2
- 102100032187 Androgen receptor Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 2
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 2
- 102100033417 Glucocorticoid receptor Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 2
- 102100021316 Mineralocorticoid receptor Human genes 0.000 description 2
- 241001024304 Mino Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- 108091006463 SLC25A24 Proteins 0.000 description 2
- 241001061127 Thione Species 0.000 description 2
- ZWGMJLNXIVRFRJ-UHFFFAOYSA-N [1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrol-2-yl]boronic acid Chemical compound CC(C)(C)OC(=O)N1C=CC=C1B(O)O ZWGMJLNXIVRFRJ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 108010080146 androgen receptors Proteins 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000001499 aryl bromides Chemical class 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 230000002508 compound effect Effects 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- ZOCHARZZJNPSEU-UHFFFAOYSA-N diboron Chemical compound B#B ZOCHARZZJNPSEU-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- NSPJNIDYTSSIIY-UHFFFAOYSA-N methoxy(methoxymethoxy)methane Chemical compound COCOCOC NSPJNIDYTSSIIY-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 150000002940 palladium Chemical class 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- SHNUBALDGXWUJI-UHFFFAOYSA-N pyridin-2-ylmethanol Chemical compound OCC1=CC=CC=N1 SHNUBALDGXWUJI-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- WFPNMCKAQLBEMD-UHFFFAOYSA-N spiro[1h-indole-3,1'-cyclopentane]-2-one Chemical compound O=C1NC2=CC=CC=C2C11CCCC1 WFPNMCKAQLBEMD-UHFFFAOYSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- QJCAHDJXZHTKKP-UHFFFAOYSA-N (2-oxospiro[1h-indole-3,2'-cyclopentane]-1'-yl)boronic acid Chemical compound OB(O)C1CCCC11C2=CC=CC=C2NC1=O QJCAHDJXZHTKKP-UHFFFAOYSA-N 0.000 description 1
- XGTSJMJONREESW-UHFFFAOYSA-N (2-oxospiro[1h-indole-3,3'-cyclohexane]-1'-yl)boronic acid Chemical compound C1C(B(O)O)CCCC21C1=CC=CC=C1NC2=O XGTSJMJONREESW-UHFFFAOYSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- RMGYQBHKEWWTOY-UHFFFAOYSA-N (3,4-difluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C(F)=C1 RMGYQBHKEWWTOY-UHFFFAOYSA-N 0.000 description 1
- XDBHWPLGGBLUHH-UHFFFAOYSA-N (3-cyanophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(C#N)=C1 XDBHWPLGGBLUHH-UHFFFAOYSA-N 0.000 description 1
- HJBGZJMKTOMQRR-UHFFFAOYSA-N (3-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(C=O)=C1 HJBGZJMKTOMQRR-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- AMGNHZVUZWILSB-UHFFFAOYSA-N 1,2-bis(2-chloroethylsulfanyl)ethane Chemical compound ClCCSCCSCCCl AMGNHZVUZWILSB-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- IRFSXVIRXMYULF-UHFFFAOYSA-N 1,2-dihydroquinoline Chemical compound C1=CC=C2C=CCNC2=C1 IRFSXVIRXMYULF-UHFFFAOYSA-N 0.000 description 1
- ASWYHZXKFSLNLN-UHFFFAOYSA-N 1,3-dibromo-5-fluorobenzene Chemical compound FC1=CC(Br)=CC(Br)=C1 ASWYHZXKFSLNLN-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- ROUYUBHVBIKMQO-UHFFFAOYSA-N 1,4-diiodobutane Chemical compound ICCCCI ROUYUBHVBIKMQO-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- IAEOYUUPFYJXHN-UHFFFAOYSA-N 1,5-diiodopentane Chemical compound ICCCCCI IAEOYUUPFYJXHN-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- WMIPEGGWIZEEMY-UHFFFAOYSA-N 1-methyl-5-(2-oxospiro[1h-indole-3,1'-cyclohexane]-5-yl)pyrrole-2-carbonitrile Chemical compound CN1C(C#N)=CC=C1C1=CC=C(NC(=O)C23CCCCC3)C2=C1 WMIPEGGWIZEEMY-UHFFFAOYSA-N 0.000 description 1
- HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical compound O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 1
- YYJBWYBULYUKMR-UHFFFAOYSA-N 2-bromo-3-methylthiophene Chemical compound CC=1C=CSC=1Br YYJBWYBULYUKMR-UHFFFAOYSA-N 0.000 description 1
- DVILXCSWAIINKD-UHFFFAOYSA-N 2-bromo-5-fluoro-5-(trifluoromethyl)cyclohexa-1,3-diene Chemical compound BrC=1C=CC(CC=1)(C(F)(F)F)F DVILXCSWAIINKD-UHFFFAOYSA-N 0.000 description 1
- GDHXJNRAJRCGMX-UHFFFAOYSA-N 2-fluorobenzonitrile Chemical compound FC1=CC=CC=C1C#N GDHXJNRAJRCGMX-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- VBFFHMKZQVPQGX-UHFFFAOYSA-N 3,3-dimethylindol-2-one Chemical compound C1=CC=C2C(C)(C)C(=O)[N]C2=C1 VBFFHMKZQVPQGX-UHFFFAOYSA-N 0.000 description 1
- VJEWIKPUMZOACV-UHFFFAOYSA-N 3-benzyl-5-(3-chlorophenyl)-3-methyl-1h-indol-2-one Chemical compound O=C1NC2=CC=C(C=3C=C(Cl)C=CC=3)C=C2C1(C)CC1=CC=CC=C1 VJEWIKPUMZOACV-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- NPSWMUAGCQRBOA-UHFFFAOYSA-N 3-fluoro-5-(2-methylsulfanylspiro[cyclohexane-1,3'-indole]-5'-yl)benzonitrile Chemical compound CSC1CCCCC11C2=CC(C=3C=C(C=C(F)C=3)C#N)=CC=C2N=C1 NPSWMUAGCQRBOA-UHFFFAOYSA-N 0.000 description 1
- SIVWNWQUUDHRMU-UHFFFAOYSA-N 3-fluoro-5-(2-oxospiro[1h-indole-3,1'-cyclopentane]-5-yl)benzonitrile Chemical compound FC1=CC(C#N)=CC(C=2C=C3C4(CCCC4)C(=O)NC3=CC=2)=C1 SIVWNWQUUDHRMU-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- ZNRGSYUVFVNSAW-UHFFFAOYSA-N 3-nitrophenylboronic acid Chemical compound OB(O)C1=CC=CC([N+]([O-])=O)=C1 ZNRGSYUVFVNSAW-UHFFFAOYSA-N 0.000 description 1
- GQVNYESQPHYYIK-UHFFFAOYSA-N 3-trimethylstannylthiophene-2-carbonitrile Chemical compound C[Sn](C)(C)C=1C=CSC=1C#N GQVNYESQPHYYIK-UHFFFAOYSA-N 0.000 description 1
- FAWMIQLXLZNXQY-UHFFFAOYSA-N 4-(3,3-dimethyl-2-oxo-1h-indol-5-yl)furan-2-carbonitrile Chemical compound C1=C2C(C)(C)C(=O)NC2=CC=C1C1=COC(C#N)=C1 FAWMIQLXLZNXQY-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- LRDIEHDJWYRVPT-UHFFFAOYSA-N 4-amino-5-hydroxynaphthalene-1-sulfonic acid Chemical compound C1=CC(O)=C2C(N)=CC=C(S(O)(=O)=O)C2=C1 LRDIEHDJWYRVPT-UHFFFAOYSA-N 0.000 description 1
- DWNXGZBXFDNKOR-UHFFFAOYSA-N 4-bromo-2-fluoro-1-methoxybenzene Chemical compound COC1=CC=C(Br)C=C1F DWNXGZBXFDNKOR-UHFFFAOYSA-N 0.000 description 1
- VQCWSOYHHXXWSP-UHFFFAOYSA-N 4-bromo-2-fluoro-1-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(Br)C=C1F VQCWSOYHHXXWSP-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 1
- YXOZMFMNOYPEFX-UHFFFAOYSA-N 4-methyl-5-(2-sulfanylidenespiro[1h-indole-3,1'-cyclohexane]-5-yl)thiophene-2-carbonitrile Chemical compound C1=C(C#N)SC(C=2C=C3C4(CCCCC4)C(=S)NC3=CC=2)=C1C YXOZMFMNOYPEFX-UHFFFAOYSA-N 0.000 description 1
- INEJGRGKGIWLMC-UHFFFAOYSA-N 4-trimethylstannylthiophene-2-carbonitrile Chemical compound C[Sn](C)(C)C1=CSC(C#N)=C1 INEJGRGKGIWLMC-UHFFFAOYSA-N 0.000 description 1
- GEEYWCRIJVIGSE-UHFFFAOYSA-N 5'-(3,4-difluorophenyl)-n-phenylmethoxyspiro[cyclohexane-1,3'-indole]-2'-amine Chemical compound C1=C(F)C(F)=CC=C1C1=CC=C(NC(=NOCC=2C=CC=CC=2)C23CCCCC3)C2=C1 GEEYWCRIJVIGSE-UHFFFAOYSA-N 0.000 description 1
- UYIQHSZZXQVYFR-UHFFFAOYSA-N 5'-(3-methoxyphenyl)-n-phenylmethoxyspiro[cyclohexane-1,3'-indole]-2'-amine Chemical compound COC1=CC=CC(C=2C=C3C4(CCCCC4)C(=NOCC=4C=CC=CC=4)NC3=CC=2)=C1 UYIQHSZZXQVYFR-UHFFFAOYSA-N 0.000 description 1
- LTKKFRLFZGOYIH-UHFFFAOYSA-N 5'-(3-nitrophenyl)-n-phenylmethoxyspiro[cyclohexane-1,3'-indole]-2'-amine Chemical compound [O-][N+](=O)C1=CC=CC(C=2C=C3C4(CCCCC4)C(=NOCC=4C=CC=CC=4)NC3=CC=2)=C1 LTKKFRLFZGOYIH-UHFFFAOYSA-N 0.000 description 1
- OVLRAVRAJDZCTF-UHFFFAOYSA-N 5'-bromo-2'-methylsulfanylspiro[cyclohexane-1,3'-indole] Chemical compound CSC1=NC2=CC=C(Br)C=C2C11CCCCC1 OVLRAVRAJDZCTF-UHFFFAOYSA-N 0.000 description 1
- DMIDBPNELJMKBW-UHFFFAOYSA-N 5-(3,5-difluorophenyl)spiro[1h-indole-3,1'-cyclohexane]-2-one Chemical compound FC1=CC(F)=CC(C=2C=C3C4(CCCCC4)C(=O)NC3=CC=2)=C1 DMIDBPNELJMKBW-UHFFFAOYSA-N 0.000 description 1
- HSLVRHXMKFFCFO-UHFFFAOYSA-N 5-(3-chlorophenyl)-2-methylsulfanylspiro[cyclohexane-1,3'-indole] Chemical compound C1C2(C3=CC=CC=C3N=C2)C(SC)CCC1C1=CC=CC(Cl)=C1 HSLVRHXMKFFCFO-UHFFFAOYSA-N 0.000 description 1
- XVGXCHRWZFIARX-UHFFFAOYSA-N 5-(3-chlorophenyl)spiro[1h-indole-3,1'-cyclohexane]-2-one Chemical compound ClC1=CC=CC(C=2C=C3C4(CCCCC4)C(=O)NC3=CC=2)=C1 XVGXCHRWZFIARX-UHFFFAOYSA-N 0.000 description 1
- BEDSGKNDSGNPHR-UHFFFAOYSA-N 5-(3-fluorophenyl)spiro[1h-indole-3,1'-cyclohexane]-2-one Chemical compound FC1=CC=CC(C=2C=C3C4(CCCCC4)C(=O)NC3=CC=2)=C1 BEDSGKNDSGNPHR-UHFFFAOYSA-N 0.000 description 1
- SNTOAPCSBXCCAG-UHFFFAOYSA-N 5-(3-fluorophenyl)spiro[1h-indole-3,1'-cyclohexane]-2-thione Chemical compound FC1=CC=CC(C=2C=C3C4(CCCCC4)C(=S)NC3=CC=2)=C1 SNTOAPCSBXCCAG-UHFFFAOYSA-N 0.000 description 1
- AZNQMVPZZPHIPT-UHFFFAOYSA-N 5-bromo-3,3-dimethyl-1H-indol-2-one 5-(3-methoxyphenyl)-3,3-dimethyl-1H-indole-2-thione Chemical compound BrC=1C=C2C(C(NC2=CC1)=O)(C)C.COC=1C=C(C=CC1)C=1C=C2C(C(NC2=CC1)=S)(C)C AZNQMVPZZPHIPT-UHFFFAOYSA-N 0.000 description 1
- CFPMNZZMIBAQEJ-UHFFFAOYSA-N 5-bromo-4-butylthiophene-2-carbonitrile Chemical compound CCCCC=1C=C(C#N)SC=1Br CFPMNZZMIBAQEJ-UHFFFAOYSA-N 0.000 description 1
- FATNNNCLTSHUQL-UHFFFAOYSA-N 5-bromo-4-methylthiophene-2-carbaldehyde Chemical compound CC=1C=C(C=O)SC=1Br FATNNNCLTSHUQL-UHFFFAOYSA-N 0.000 description 1
- MZMCUPHVWYWUCW-UHFFFAOYSA-N 5-bromo-4-propylthiophene-2-carbonitrile Chemical compound CCCC=1C=C(C#N)SC=1Br MZMCUPHVWYWUCW-UHFFFAOYSA-N 0.000 description 1
- FTFFHWWIPOQCBC-UHFFFAOYSA-N 5-bromopyridine-3-carbonitrile Chemical compound BrC1=CN=CC(C#N)=C1 FTFFHWWIPOQCBC-UHFFFAOYSA-N 0.000 description 1
- GFBVUFQNHLUCPX-UHFFFAOYSA-N 5-bromothiophene-2-carbaldehyde Chemical compound BrC1=CC=C(C=O)S1 GFBVUFQNHLUCPX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 101100022267 Bacillus subtilis (strain 168) gmuG gene Proteins 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 238000010599 BrdU assay Methods 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- SINRXCCDLXKCHO-UHFFFAOYSA-N CC(C=C[S+]1C#N)=C1Br Chemical compound CC(C=C[S+]1C#N)=C1Br SINRXCCDLXKCHO-UHFFFAOYSA-N 0.000 description 1
- QONZYPJAJSMYTF-UHFFFAOYSA-N CC1(C(NC2=CC=C(C=C12)C=1C=C(OC1)C#N)=O)C.CC1(C(NC2=CC=C(C=C12)C=1C=C(OC1)C#N)=S)C Chemical compound CC1(C(NC2=CC=C(C=C12)C=1C=C(OC1)C#N)=O)C.CC1(C(NC2=CC=C(C=C12)C=1C=C(OC1)C#N)=S)C QONZYPJAJSMYTF-UHFFFAOYSA-N 0.000 description 1
- 101100491335 Caenorhabditis elegans mat-2 gene Proteins 0.000 description 1
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 101000738977 Homo sapiens Reverse transcriptase/ribonuclease H Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 229910003204 NH2 Inorganic materials 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- UANNSXMPNZFKGN-UHFFFAOYSA-N O=CC1=CC=C[S+]1Br Chemical compound O=CC1=CC=C[S+]1Br UANNSXMPNZFKGN-UHFFFAOYSA-N 0.000 description 1
- WOXCABIJUVOPTJ-UHFFFAOYSA-N OBO.CC(C)(C)OC(=O)N1C=CC=C1 Chemical compound OBO.CC(C)(C)OC(=O)N1C=CC=C1 WOXCABIJUVOPTJ-UHFFFAOYSA-N 0.000 description 1
- 229910002666 PdCl2 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229910003074 TiCl4 Inorganic materials 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 241000347391 Umbrina cirrosa Species 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- AYVGBNGTBQLJBG-UHFFFAOYSA-N [3-(hydroxymethyl)cyclopentyl]methanol Chemical compound OCC1CCC(CO)C1 AYVGBNGTBQLJBG-UHFFFAOYSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- CXADQLLYLMBGTG-UHFFFAOYSA-N acetonitrile;1,4-dioxane Chemical compound CC#N.C1COCCO1 CXADQLLYLMBGTG-UHFFFAOYSA-N 0.000 description 1
- WGZCUXZFISUUPR-UHFFFAOYSA-N acetonitrile;oxolane Chemical compound CC#N.C1CCOC1 WGZCUXZFISUUPR-UHFFFAOYSA-N 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000001118 alkylidene group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 150000001543 aryl boronic acids Chemical class 0.000 description 1
- 150000001500 aryl chlorides Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- JPUHPGALPBINPO-UHFFFAOYSA-N benzotriazole-1-carbonitrile Chemical compound C1=CC=C2N(C#N)N=NC2=C1 JPUHPGALPBINPO-UHFFFAOYSA-N 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000007333 cyanation reaction Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- XXUFLAUHHBETOY-UHFFFAOYSA-N di(propan-2-yloxy)borinic acid Chemical compound CC(C)OB(O)OC(C)C XXUFLAUHHBETOY-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- DAKIDYQCFJQMDF-UHFFFAOYSA-N dichloromethane;pyridine Chemical compound ClCCl.C1=CC=NC=C1 DAKIDYQCFJQMDF-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 150000002084 enol ethers Chemical class 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 150000002476 indolines Chemical class 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 231100000546 inhibition of ovulation Toxicity 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 1
- GXHFUVWIGNLZSC-UHFFFAOYSA-N meldrum's acid Chemical compound CC1(C)OC(=O)CC(=O)O1 GXHFUVWIGNLZSC-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- RDCBQVMNQVQETP-UHFFFAOYSA-N n-[(3-bromo-5-fluorophenyl)methylidene]hydroxylamine Chemical compound ON=CC1=CC(F)=CC(Br)=C1 RDCBQVMNQVQETP-UHFFFAOYSA-N 0.000 description 1
- PIHJXATVBDABNM-UHFFFAOYSA-N n-[4-(3-chlorophenyl)spiro[cyclohexane-2,3'-indole]-1-yl]hydroxylamine Chemical compound C1C2(C3=CC=CC=C3N=C2)C(NO)CCC1C1=CC=CC(Cl)=C1 PIHJXATVBDABNM-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- HYDZPXNVHXJHBG-UHFFFAOYSA-N o-benzylhydroxylamine;hydron;chloride Chemical compound Cl.NOCC1=CC=CC=C1 HYDZPXNVHXJHBG-UHFFFAOYSA-N 0.000 description 1
- 229940078552 o-xylene Drugs 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001979 organolithium group Chemical group 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000005623 oxindoles Chemical class 0.000 description 1
- WYURNTSHIVDZCO-SVYQBANQSA-N oxolane-d8 Chemical compound [2H]C1([2H])OC([2H])([2H])C([2H])([2H])C1([2H])[2H] WYURNTSHIVDZCO-SVYQBANQSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 238000001408 paramagnetic relaxation enhancement Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000002379 progesterone receptor modulator Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- OKULHRWWYCFJAB-UHFFFAOYSA-N pyrimidine-4-carbaldehyde Chemical compound O=CC1=CC=NC=N1 OKULHRWWYCFJAB-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229940095745 sex hormone and modulator of the genital system progesterone receptor modulator Drugs 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229910000080 stannane Inorganic materials 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- 150000003509 tertiary alcohols Chemical class 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000006089 thiamorpholinyl sulfoxide group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003556 thioamides Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- KAKQVSNHTBLJCH-UHFFFAOYSA-N trifluoromethanesulfonimidic acid Chemical compound NS(=O)(=O)C(F)(F)F KAKQVSNHTBLJCH-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000012991 xanthate Substances 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
This invention relates to compounds which are agonists of the progesterone receptor which have general structures (1) or (2) wherein the substituents a re as defined; or a pharmaceutically acceptable salt thereof, as well as method s of using these compounds to induce contraception or treat progesterone-relat ed carcinomas and adenocarcinomas.
Description
THIO-OXINDOLE DERIVATIVES
Field of the Invention This invention relates to compounds which are agonists of the progesterone receptor, their preparation and utility.
Background of the Invention Intracellular receptors (IR) form a class of structurally related gene regulators known as "ligand dependent transcription factors" (R. M. Evans, Science, 240, 889, 1988). The steroid receptor family is a subset of the IR family, including progesterone receptor (PR), estrogen receptor (ER), androgen receptor (AR), glucocorticoid receptor (GR), and mineralocorticoid receptor (MR).
The natural hormone, or ligand, for the PR is the steroid progesterone, but 1 S synthetic compounds, such as medroxyprogesterone acetate or levonorgestrel, have been made which also serve as ligands. Once a ligand is present in the fluid surrounding a cell, it passes through the membrane via passive diffusion, and binds to the IR to create a receptor/ligand complex. This complex binds to specific gene promoters present in the cell's DNA. Once bound to the DNA the complex modulates the production of mRNA and protein encoded by that gene.
A compound that binds to an IR and mimics the action of the natural hormone is termed an agonist, whilst a compound which inhibits the effect of the hormone is an antagonist.
PR agonists (natural and synthetic) are known to play an important role in the health of women. PR agonists are used in birth control formulations, typically in the presence of an ER agonist, alternatively they may be used in conjunction with a PR
antagonist. ER agonists are used to treat the symptoms of menopause, but have been associated with a proliferative effect on the uterus which can lead to an increased risk of uterine cancers. Co-administration of a PR agonist reduces/ablates that risk.
Field of the Invention This invention relates to compounds which are agonists of the progesterone receptor, their preparation and utility.
Background of the Invention Intracellular receptors (IR) form a class of structurally related gene regulators known as "ligand dependent transcription factors" (R. M. Evans, Science, 240, 889, 1988). The steroid receptor family is a subset of the IR family, including progesterone receptor (PR), estrogen receptor (ER), androgen receptor (AR), glucocorticoid receptor (GR), and mineralocorticoid receptor (MR).
The natural hormone, or ligand, for the PR is the steroid progesterone, but 1 S synthetic compounds, such as medroxyprogesterone acetate or levonorgestrel, have been made which also serve as ligands. Once a ligand is present in the fluid surrounding a cell, it passes through the membrane via passive diffusion, and binds to the IR to create a receptor/ligand complex. This complex binds to specific gene promoters present in the cell's DNA. Once bound to the DNA the complex modulates the production of mRNA and protein encoded by that gene.
A compound that binds to an IR and mimics the action of the natural hormone is termed an agonist, whilst a compound which inhibits the effect of the hormone is an antagonist.
PR agonists (natural and synthetic) are known to play an important role in the health of women. PR agonists are used in birth control formulations, typically in the presence of an ER agonist, alternatively they may be used in conjunction with a PR
antagonist. ER agonists are used to treat the symptoms of menopause, but have been associated with a proliferative effect on the uterus which can lead to an increased risk of uterine cancers. Co-administration of a PR agonist reduces/ablates that risk.
The compounds of this invention have been shown to act as competitive inhibitors of progesterone binding to the PR and act as agonists These compounds may be used for contraception and post menopausal hormone replacement therapy.
Jones, et al, described in U.S. Patent No. 5,688,810 the PR antagonist dihydroquinoline A.
N
Me A
Jones, et al, described the enol ether B (U.S. Patent No. 5,693,646) as a PR
ligand.
F
B
Jones, et al, described compound C (U.S. Patent No. 5,696,127) as a PR
ligand.
Me H
C
Zhi, et al, described lactones D, E and F as PR antagonists (J. Med.
Chem., 41, 291, 1998).
a E
Zhi, et al, described the ether G as a PR antagonist (J. Med. Chem., 41, 291, 1998).
Jones, et al, described in U.S. Patent No. 5,688,810 the PR antagonist dihydroquinoline A.
N
Me A
Jones, et al, described the enol ether B (U.S. Patent No. 5,693,646) as a PR
ligand.
F
B
Jones, et al, described compound C (U.S. Patent No. 5,696,127) as a PR
ligand.
Me H
C
Zhi, et al, described lactones D, E and F as PR antagonists (J. Med.
Chem., 41, 291, 1998).
a E
Zhi, et al, described the ether G as a PR antagonist (J. Med. Chem., 41, 291, 1998).
H
G
Combs, et al., disclosed the amide H as a ligand for the PR (J. Med. Chem., 38, 4880, 1995).
F
Br H
Penman, et. al., described the vitamin D analog I as a PR ligand (Tet.
Letters, 35, 2295, 1994).
G
Combs, et al., disclosed the amide H as a ligand for the PR (J. Med. Chem., 38, 4880, 1995).
F
Br H
Penman, et. al., described the vitamin D analog I as a PR ligand (Tet.
Letters, 35, 2295, 1994).
Hamann, et al, described the PR antagonist J (Ann. N. Y. Acad. Sci., 761, 383, 1995).
J
Chen, et al, described the PR antagonist K (Chen, et al, POI-37, 16'" Int.
Cong. Het. Chem., Montana, 1997).
I
\ ~ci ~",N
S H
N
H
K
J
Chen, et al, described the PR antagonist K (Chen, et al, POI-37, 16'" Int.
Cong. Het. Chem., Montana, 1997).
I
\ ~ci ~",N
S H
N
H
K
Kurihari, et. al., described the PR ligand L (J. Antibiotics, 50, 360, 1997).
L
Kuhla, et al, taught the oxindole M as a cardiotonic (WO 86/03749).
S
N
O
N
H
M
Weber, described the oxindole N for cardiovascular indications (WO 91/06545).
\ N I W
N
H
N
Fischer, et al, claim a preparation for making compounds which include the generic structure O (U.S. Patent No. 5,453,516).
_7_ HzC
O
R = various Singly et al, described the PDE III inhibitor P (J. Med. Chem., 37, 248, 1994).
N
P
Andreani, et al, described the cytotoxic agent Q (Acta. Pharn. Nord., 2, 407, 1990).
N
Q
Binder, et al, described structure R which is an intermediate for preparing COX II
inhibitors (WO 97/13767).
_g_ A
N
H
R
Walsh (A.H. Robins) described the oxindole S as an intermediate (U.S. Patent No.
4,440,785, U.S. Patent No. 4,670,566).
S
R1 = F, C1, Br, alkyl, NHz R2 = alkyl, alkoxy, F, Cl, NH2, CF3 Bohm, et al, claim the oxindole T as cardiovascular agents (WO 91/06545).
~N
H3C0 ~ / H3C CH3 N
O
N
H
T
Bohm, et al, include the generic structure U (WO 91/04974).
C~
H
U
JP 63112584 A contains the generic structure V:
Y
N
R~
X
N ~ \ CH~~
N O
V
Boar, et al, described the dioxolane W as an intermediate for preparation of acetyl-cholinesterase inhibitors (WO 93/12085 A1).
W
Kende, et al, described methodology for preparing 3,3-substituted oxindoles, e.g. X, that was utilized in the present invention (Synth. Commun., 12, l, 1982).
H
$ X
Description of the Invention This invention provides compounds of the formulae 1 or 2:
R~ R, or wherein:
R, and RZ are chosen independently from the group of H, alkyl, substituted alkyl; OH; O(alkyl); O(substituted alkyl); OAc; aryl; optionally substituted aryl;
heteroaryl; optionally substituted heteroaryl; alkylaryl; alkylheteroaryl; 1-propynyl;
or 3-propynyl:
or R, and R~ are joined to form a ring comprising one of the following:
-CH2(CHz)nCHz-; -CHzCH2CMe2CH2CHz-; -O(CHZ)mCHr; O(CHZ)PO-;
-CHZCHZOCHzCH2-; or -CHzCH2N(H or alkyl)CHZCHz-;
m is an integer from 1 to 4;
n is an integer from 1 to 5;
p is an integer from 1 to 4;
or R, and RZ together comprise a double bond to one of the following:
CMe2; C(cycloalkyl), O, C(cyloether).
R3 is selected from H, OH, NH2, C, to C6 alkyl, substituted C, to C6 alkyl, C3 to C6 alkenyl, alkynyl or substituted alkynyl, or COR";
R" is selected from H, C, to C3 alkyl, substituted C, to C3 alkyl, C, to C3 alkoxy, substituted C, to C3 alkoxy, C, to C3 aminoalkyl, or substituted C, to aminoalkyl;
R4 is selected from H, halogen, CN, NHZ, C, to C6 alkyl, substituted C, to C6 alkyl, C, to C6 alkoxy, substituted C, to C6 alkoxy, C, to C6 aminoalkyl, or substituted C, to C6 aminoalkyl;
RS is selected from the groups a), b) or c):
a) RS is a trisubstituted benzene ring containing the substituents X, Y
and Z as shown below:
Y, X I Z
X is selected from halogen, OH, CN, C, to C3 alkyl, substituted C, to C3 alkyl, C, to C3 alkoxy, substituted C, to C3 alkoxy, C, to C3 thioalkyl, substituted C, to C3 thioalkyl, S(O)alkyl, S(O)Zalkyl, C, to C, aminoalkyl, substituted C, to C3 aminoalkyl, NOz, C, to C3 perfluoroalkyl, S or 6 membered heterocyclic ring containing 1 to 3 heteroatoms, CONHZ, CSNHz, CONHalkyl, CSNHalkyl, CON(alkyl)2, CSN(alkyl)Z, CORE, OCORB, NR~CORB;
RB is selected from H, C, to C3 alkyl, substituted C, to C3 alkyl, aryl, substituted aryl, C, to C3 alkoxy, substituted C, to C3 alkoxy, C, to C3 aminoalkyl, or substituted C, to C3 aminoalkyl;
R~ is H, C, to C3 alkyl, or substituted C, to C3 alkyl;
Y and Z are independently selected from H, halogen, CN, NO2, C, to C3 alkoxy, C, to C3 alkyl, or C, to C3 thioalkyl;
or b) RS is a five or six membered heterocyclic ring with l, 2, or 3 heteroatoms selected from O, S, SO, SOZ or NR6 and containing one or two independent substituents from the group of H, halogen, CN, NOz and C, to C3 alkyl, C, to C3 alkoxy, C, to C, aminoalkyl, COR°, or NRECOR°;
R° is H, C, to C3 alkyl, substituted C, to C3 alkyl, aryl, substituted aryl, C, to C3 alkoxy, substituted C, to C3 alkoxy, C, to C3 aminoalkyl, or substituted C, to C3 aminoalkyl;
RE is H, C, to C3 alkyl, or substituted C, to C3 alkyl;
R6 is H, or C, to C3 alkyl; or c) RS is an indol-4-yl, indol-7-yl or benzo-2-thiophene moiety, the moiety being optionally substituted by from 1 to 3 substituents selected from halogen, lower alkyl, CN, NO2, lower alkoxy, or CF3;
Q' is S, NR" CRgR9;
R, is selected from the group including CN, C, to C6 alkyl, substituted C, to alkyl, C3 to C8 cycloalkyl, substituted C, to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, acyl, substituted acyl, aroyl, substituted aroyl, SOZCF3, OR" or NR"R'2;
R8 and R, are independent substituents selected from the group of H, C, to C6 alkyl, substituted C, to C6 alkyl, C3 to Cg cycloalkyl, substituted C3 to C8 eycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO2, CN, or COZR,o, R,o is C, to C3 alkyl; or CRBRg comprises a six membered ring as shown by the structure below O
QZ is selected from the moieties:
11 D11 p12 11 -N_p-R12 -'I~'~'NI/~-R13 or -p-N-Rlg.
R", R'z and R'3 are independently selected from H, C, to C6 alkyl, substituted C, to C6 alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyl, substituted acyl, aroyl or substituted aroyl or sulfonyl;
or a pharmaceutically acceptable salt thereof.
A preferred list of substituents represented by R", R'z and R'3 in groups of the compounds described herein are H, C, to C6 alkyl, substituted C, to C6 alkyl, -C(O)-(C, to C6 alkyl), -S(O)z-(C, to C6 alkyl), phenyl or benzyl.
It will be understood that this invention includes all tautomeric forms of the compounds, chemical formulae and substituents described herein.
Two preferred sets of compounds of this invention is depicted by structures 2 and 3, respectively:
each wherein RS is a disubstituted benzene ring containing the substituents X
and Y as shown below X
3' 4' ~
5' ~~
Y
X is selected from halogen, CN, CONHz, CSNH2, CONHalkyl, CSNHalkyl, CONa1ky12, CSNalkylz, C, to C3 alkoxy, C, to C3 alkyl, NO2, C, to C3 perfluoroalkyl, membered heterocyclic ring containing 1 to 3 heteroatoms, or C, to C3 thioalkoxy;
Y is a substituent on the 4' or 5'position from the group including H, halogen, 5 CN, NO2, C, to C3 alkoxy, C, to C4 alkyl, or C, to C3 thioalkyl;
or a pharmaceutically acceptable salt thereof.
Another preferred group of formula 2 are those wherein RS is a five membered ring with the structure shown below X' Y' wherein:
U is O, S, or NR6;
R~ is H, or C, to C3 alkyl, or C, to C4 COzalkyl;
X' is selected from halogen, CN, NO~, CONHZ, CSNH2, CONHalkyl, CSNHalkyl, CONa1ky12, CSNalkyl2, C, to C3 alkyl, or C, to C3 alkoxy;
Y' is from the group of H, F or C, to C4 alkyl;
or a pharmaceutically acceptable salt thereof.
A further preferred subgroup of the compounds above are those in which RS is a thiophene or furan ring substituted by X' and Y', as described above.
A further preferred subgroup group of compounds of formulas 2 and 3 are those wherein RS is a six membered ring with the structure:
X' N
wherein X' is N or CXZ, Xz is halogen, CN, CONH2, CSNH2, CONHalkyl, CSNHalkyl, CONalkyl2, CSNalkylz or NOz;
Q' is S, NR,, CRBR,;
R, is from the group including CN, C, to C6 alkyl, substituted C, to C6 alkyl, C3 to C8 cycloalkyl, substituted C, to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or SOZCF3;
R8 and R9 are independent substituents from the group including H, C, to C6 alkyl, substituted C, to C6 alkyl, C3 to C8 cycloalkyl, substituted C, to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO2, CN
COZR,o, R,o is C, to C3 alkyl;
CRBR, are within a six membered ring as shown by the structure below ~3 or pharmaceutically acceptable salt thereof.
Still another preferred group of these compounds includes those having the general formulae:
or each wherein RS is a disubstituted benzene ring containing the substituents X
and Y as shown below X
3' 4' ~
5' /~
Y
X is selected from halogen, CN, CONHz, CSNHZ, CONHalkyl, CSNHalkyl, CONa1ky12, CSNa1ky12, C, to C3 alkoxy, C, to C3 alkyl, NOz, C, to C3 perfluoroalkyl, membered heterocyclic ring containing 1 to 3 heteroatoms, or C, to C3 thioalkoxy;
5 Y is a substituent on the 4' or 5'position from the group including H, halogen, CN, NOz, C, to C3 alkoxy, C, to Cq alkyl, or C, to C3 thioalkyl;
or a pharmaceutically acceptable salt thereof.
A further preferred subgroup group of compounds of formulae:
or are those wherein RS is a six membered ring with the structure:
~i wherein X' is N or CXZ, XZ is halogen, CN, CONHz, CSNH2, CONHalkyl, CSNHalkyl, CONalkyl2, CSNalkylz or NOz;
QZ is as defined above;
R, is from the group including CN, C, to C6 alkyl, substituted C, to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to Cg cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or SOZCF3;
Rg and R, are independent substituents from the group including H, C, to C6 alkyl, substituted C, to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NOz, CN
COZR,o, R,o is C, to C3 alkyl;
CR$Rg are within a six membered ring as shown by the structure below O
O
O
or pharmaceutically acceptable salt thereof.
A further preferred set of compounds of this invention is depicted by structure 4, Rs H
~Rt4 4a Wherein R,4 is chosen from the group H, acyl, substituted acyl, aroyl, substituted amyl, sulfonyl, substituted sulfonyl.
Wherein RS is a disubstituted benzene ring containing the substituents X and Y as shown below X
3' 4' ~
5'~~
Y
X is selected from halogen, CN, CONH2, CSNH2, CONHalkyl, CSNHalkyl, CON(alkyl)2, CSN(alkyl)z, CNHNHOH, CNHzNOH, C, to C3 alkoxy, C, to C3 alkyl, NOz, C, to C3 perfluoroalkyl, 5 membered heterocyclic ring containing 1 to 3 heteroatoms, or C, to C3 thioalkoxy;
Y is a substituent on the 4' or 5'position from the group including H, halogen, CN, NOz, C, to C3 alkoxy, C, to C4 alkyl, or C, to C3 thioalkyl;
or a pharmaceutically acceptable salt thereof.
Another preferred group of formula 4 are those wherein RS is a five membered ring with the structure shown below X' u~~
wherein:
U is O, S, or NR6;
R6 is H, or C, to C3 alkyl, or C, to C4 COZalkyl;
X' is selected from halogen, CN, NOz, CONH2, CNHNHOH, CNH2NOH, CSNH2, CONHalkyl, CSNHalkyl, CONa1ky12, CSNalkylz, C, to C3 alkyl, or C, to C3 alkoxy;
Y' is from the group of H, F or C, to Cq alkyl;
or a pharmaceutically acceptable salt thereof.
A further preferred subgroup of the compounds above are those in which RS is a thiophene or furan ring substituted by X' and Y', as described above.
A further preferred subgroup group of compounds of formula 4 are those wherein RS is a six membered ring with the structure:
~,i~
wherein X' is N or CXz, XZ is halogen, CN, CONH2, CSNHz, CONHalkyl, CSNHalkyl, CONalkylz, CSNalkylZ or NOZ;
R, is from the group including CN, C, to C6 alkyl, substituted C, to C6 alkyl, C, to C8 cycloalkyl, substituted C3 to Cg cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or SOZCF3;
R8 and R, are independent substituents from the group including H, C, to C6 alkyl, substituted C, to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NOz, CN
COZR,o, R,o is C, to C3 alkyl;
or pharmaceutically acceptable salt thereof.
A further preferred set of compounds of this invention is depicted by structure 5, Wherein RS is a disubstituted benzene ring containing the substituents X and Y as shown below X
3' 4' ~
5'~~
Y
X is selected from halogen, CN, CONH2, CSNH2, CONHalkyl, CSNHalkyl, CONalkylz, CSNalkylz, CNHNOH, C, to Cj alkoxy, C, to C3 alkyl, NO2, C, to C3 perfluoroalkyl, 5 membered heterocyclic ring containing 1 to 3 heteroatoms, or C, to C3 thioalkoxy;
Y is a substituent on the 4' or 5'position from the group including H, halogen, CN, NO2, C, to C3 alkoxy, C, to C4 alkyl, or C, to C3 thioalkyl;
or a pharmaceutically acceptable salt thereof.
Another preferred group of formula 5 are those wherein RS is a five membered ring with the structure shown below Y' wherein:
U is O, S, or NR~;
R6 is H, or C, to C3 alkyl, or C, to Cq COZalkyl;
X' is selected from halogen, CN, NOZ, CONH2, CSNHZ, CONHalkyl, CSNHalkyl, CONa1ky12, CSNalkyl2, C, to C3 alkyl, or C, to C3 alkoxy;
Y' is from the group of H, F or C, to C4 alkyl;
or a pharmaceutically acceptable salt thereof.
A further preferred subgroup of the compounds above are those in which RS is a thiophene or furan ring substituted by X' and Y', as described above.
A further preferred subgroup group of compounds of formula 5 are those wherein RS is a six membered ring with the structure:
N
wherein X' is N or CXz, Xz is halogen, CN, CONH2, CSNHZ, CONHalkyl, CSNHalkyl, CONa1ky12, CSNalkylz or NOz;
R, is from the group including CN, C, to C6 alkyl, substituted C, to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or SOZCF3;
Rg and R9 are independent substituents from the group including H, C, to C6 alkyl, substituted C, to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to Cg cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NOz, CN
COzR,o, R,o is C, to C3 alkyl;
or pharmaceutically acceptable salt thereof.
A further preferred set of compounds of this invention is depicted by structure 6, Rs Wherein R,5 is selected from the group H, Me, COzR, acyl, substituted acyl, aroyl, substituted aroyl, alkyl, substituted alkyl, CN.
Wherein RS is a disubstituted benzene ring containing the substituents X and Y as shown below X
3' 4' ~
5'~~
Y
X is selected from halogen, CN, CONH2, CSNHz, CONHalkyl, CSNHalkyl, CONalkyl2, CSNalkyl2, CNHNOH, C, to C3 alkoxy, C, to C3 alkyl, NOZ, C, to C3 perfluoroalkyl, S membered heterocyclic ring containing 1 to 3 heteroatoms, or C, to C3 thioalkoxy;
Y is a substituent on the 4' or 5'position from the group including H, halogen, CN, NOz, C, to C3 alkoxy, C, to Cq alkyl, or C, to C3 thioalkyl;
or a pharmaceutically acceptable salt thereof.
Another preferred group of formula 6 are those wherein RS is a five membered ring with the structure shown below X' u~~
wherein:
U is O, S, or NR6;
R6 is H, or C, to C3 alkyl, or C, to Cq COZalkyl;
X' is selected from halogen, CN, NOz, CONHz, CSNHZ, CONHalkyl, CSNHalkyl, CONalkylz, CSNalkyl2, C, to C3 alkyl, or C, to C3 alkoxy;
Y' is from the group of H, F or C, to CQ alkyl;
or a pharmaceutically acceptable salt thereof.
A further preferred subgroup of the compounds above are those in which RS is a thiophene or furan ring substituted by X' and Y', as described above.
A further preferred subgroup group of compounds of formula 6 are those wherein RS is a six membered ring with the structure:
~.i~
wherein X' is N or CXz, XZ is halogen, CN, CONHz, CSNH2, CONHalkyl, CSNHalkyl, CONalkylz, CSNa1ky12 or NOz;
R, is from the group including CN, C, to C6 alkyl, substituted C, to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or SOzCF3;
R8 and R, are independent substituents from the group including H, C, to C6 alkyl, substituted C, to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO2, CN
COZR,o, R,o is C, to C3 alkyl;
or pharmaceutically acceptable salt thereof.
A further preferred set of compounds of this invention is depicted by structure 7, Wherein RS is a disubstituted benzene ring containing the substituents X and Y as shown below X
3' 4' ~
5'~~
Y
X is selected from halogen, CN, CONH2, CSNHZ, CONHalkyl, CSNHalkyl, CONalkylz, CSNalkylz, CNHNOH, C, to C, alkoxy, C, to C3 alkyl, NOz, C, to C3 perfluoroalkyl, 5 membered heterocyclic ring containing 1 to 3 heteroatoms, or C, to C3 thioalkoxy;
Y is a substituent on the 4' or 5'position from the group including H, halogen, CN, NOz, C, to C3 alkoxy, C, to CQ alkyl, or C, to C3 thioalkyl;
or a pharmaceutically acceptable salt thereof.
Another preferred group of formula 7 are those wherein RS is a five membered ring with the structure shown below X' u~~
wherein:
U is O, S, or NR6;
R6 is H, or C, to C3 alkyl, or C, to C4 COZalkyl;
X' is selected from halogen, CN, NO2, CONH2, CSNH2, CONHalkyl, CSNHalkyl, CONa1ky12, CSNalkyl2, C, to C3 alkyl, or C, to C3 alkoxy;
Y' is from the group of H, F or C, to C4 alkyl;
or a pharmaceutically acceptable salt thereof.
A further preferred subgroup of the compounds above are those in which RS is a thiophene or furan ring substituted by X' and Y', as described above.
A further preferred subgroup group of compounds of formula 7 are those wherein RS is a six membered ring with the structure:
~.i~
wherein X' is N or CX2, XZ is halogen, CN, CONH2, CSNHZ, CONHalkyl, CSNHalkyl, CONalkylz, CSNa1ky12 or NOz;
R, is from the group including CN, C, to C6 alkyl, substituted C, to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or S02CF3;
Rg and R, are independent substituents from the group including H, C, to C6 alkyl, substituted C, to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NOZ, CN
COzR,o, R,o is C, to C3 alkyl;
or pharmaceutically acceptable salt thereof.
The compounds of this invention may contain an asymmetric carbon atom and some of the compounds of this invention may contain one or more asymmetric centers and may thus give rise to optical isomers and diastereomers. While shown without respect to stereochemistry in Formula 1 and 2 the present invention includes such optical isomers and diastereomers; as well as the racemic and resolved, enantiomerically pure R and S stereoisomers; as well as other mixtures of the R and S
stereoisomers and pharmaceutically acceptable salts thereof.
The term "alkyl" is used herein to refer to both straight- and branched-chain saturated aliphatic hydrocarbon groups having 1 to 8 carbon atoms, preferably 1 to 6 carbon atoms; "alkenyl" is intended to include both straight- and branched-chain alkyl group with 1 or 2 carbon-carbon double bonds and containing 2 to 8 carbon atoms, preferably 2 to 6 carbon atoms; "alkynyl" group is intended to cover both straight- and branched-chain alkyl group with at least 1 or 2 carbon-carbon triple bonds and containing 2 to 8 carbon atoms, preferably 2 to 6 carbon atoms.
The term "acyl" refers to a carbonyl substituent, including both straight- and branched-chain saturated aliphatic hydrocarbon groups having 1 to 8 carbon atoms, preferably 1 to 6 carbon atoms. The term "substituted acyl" refers to an acyl group as just described optionally substituted with from 1 to 6 groups chosen from the list halogen, CN, OH, and N02.
The term "aroyl" also refers to a carbonyl substituent carrying a phenyl group or a heteroaromatic group. The heteroaromatic groups of this include 2-, 3- or pyridinyl, 2- and 3-furanyl, 2- or 3-thiophenyl, or 2- or 4-pyrimidinal. The term "substituted amyl" also refers to an aroyl group as just described optionally substituted with from 1 to 6 groups chosen from the list halogen, CN, OH, and N02, The terms "substituted alkyl", "substituted alkenyl", and "substituted alkynyl" refer to alkyl, alkenyl, and alkynyl as just described having one or more substituents from the group including halogen, CN, OH, NOz, amino, aryl, heterocyclic, substituted aryl, substituted heterocyclic, alkoxy, aryloxy, substituted alkyloxy, alkylcarbonyl, alkylcarboxy, alkylamino, arylthio. These substituents may be attached to any carbon of alkyl, alkenyl, or alkynyl group provided that the attachment constitutes a stable chemical moiety.
The term "aryl" is used herein to refer to an aromatic system which may be a single ring or multiple aromatic rings fused or linked together as such that at least one part of the fused or linked rings forms the conjugated aromatic system. The aryl groups include, but are not limited to, phenyl, naphthyl, biphenyl, anthryl, tetrohydronaphthyl, phenanthryl.
The term "substituted aryl" refers to aryl as just defined having 1 to 4 substituents from the group including halogen, CN, OH, NO2, amino, alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, aryloxy, substituted alkyloxy, alkylcarbonyl, alkylcarboxy, alkylamino, or arylthio.
The term "heterocyclic" is used herein to describe a stable 4- to 7-membered monocyclic or a stable multicyclic heterocyclic ring which is saturated, partially unsaturated, or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group including N, O, and S atoms. The N and S
atoms may be oxidized. The heterocyclic ring also includes any multicyclic ring in which any of above defined heterocyclic rings is fused to an aryl ring. The heterocyclic ring may be attached at any heteroatom or carbon atom provided the resultant structure is chemically stable. Such heterocyclic groups include, for example, tetrahydrofuran, piperidinyl, piperazinyl, 2-oxopiperidinyl, azepinyl, pyrrolidinyl, imidazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, isoxazolyl, morpholinyl, indolyl, quinolinyl, thienyl, furyl, benzofuranyl, benzothienyl, thiamorpholinyl, thiamorpholinyl sulfoxide, and isoquinolinyl.
The term "substituted heterocyclic" is used herein to describe the heterocyclic just defined having 1 to 4 substituents selected from the group which includes halogen, CN, OH, NOz, amino, alkyl, substituted alkyl, cycloalkyl, alkenyl, substituted alkenyl, alkynyl, alkoxy, aryloxy, substituted alkyloxy, alkylcarbonyl, alkylcarboxy, alkylamino, or arylthio.
The term "thioalkyl" is used herein to refer to the SR group, where R is alkyl or substituted alkyl, containing 1 to 8 carbon atoms, preferably 1 to 6 carbon atoms.
The term "alkoxy" is used herein to refer to the OR group, where R is alkyl or substituted alkyl, containing lto 8 carbon atoms, preferably 1 to 6 carbon atoms. The term "aryloxy" is used herein to refer to the OR group, where R is aryl or substituted aryl, as defined above. The term "alkylcarbonyl" is used herein to refer to the RCO
group, where R is alkyl or substituted alkyl, containing 1 to 8 carbon atoms, preferably 1 to 6 carbon atoms. The term "alkylcarboxy" is used herein to refer to the COOR group, where R is alkyl or substituted alkyl, containing 1 to 8 carbon atoms, preferably 1 to 6 carbon atoms. The term "aminoalkyl" refers to both secondary and tertiary amines wherein the alkyl or substituted alkyl groups, containing 1 to 8 carbon atoms, preferably 1 to 6 carbon atoms, which may be either the same or different and the point of attachment is on the nitrogen atom. The term "halogen" refers to Cl, Br, F, or I.
The compounds of this invention may be prepared according to the methods described below.
Scheme 1 R: Rz R ....:
Rz ~~ I ~° I ~ °
N
H H
R.~' R.~' R2 Rz Ar I ~°
N ~ N
H H
According to scheme 1, commercially available oxindole 3 is treated with a strong organo-metallic base (e.g. butyl lithium, lithium diisopropylamide, potassium hexamethyldisilazide) in an inert solvent (e.g. THF, diethyl ether) under nitrogen at reduced temperature (ca. -20 °C) (Kende, et al, Synth. Commun., 12, 1, 1982) in the presence of lithium chloride or N,N,N',N'-tetramethylethylene-diamine. The resulting di-anion is then treated with excess electrophile such as an alkyl halide, preferably an iodide. If R, and RZ are to be joined such as the product 4 contains a spirocycle at position 3, then the electrophile should be bifunctional, i.e. a diiodide.
Subsequent bromination of 4 proceeds smoothly with bromine in acetic acid (an organic co-solvent such as dichloromethane may be added as required) in the presence of sodium acetate, to afford the aryl bromide 5. The bromide 5 is reacted with a palladium salt (e.g. tetrakis(triphenylphoshine)palladium(0) or palladium acetate), in a suitable solvent (e.g. THF, dimethoxyethane, acetone, ethanol or toluene) at room temperature under an inert atmosphere (argon, nitrogen). The mixture is then treated with an aryl or heteroaryl boronic acid or boronic acid ester and a base (sodium carbonate, triethylamine, potassium phosphate) in water or fluoride source (cesium fluoride) under anhydrous conditions. The required product 6 is then isolated and purified by standard means.
Reaction of the indoline-2-one derivative 6 with either Lawessen's reagent or phosphorous pentasulfide in a suitable organic solvent (pyridine, THF, dioxane, dimethoxyethane, dichloromethane, benzene, toluene, xylene) at a temperature between room temperature and the reflux temperature of the solvent provides access to the thiocarbonyl derivative 7. An additive such as sodium hydrogen carbonate may also be useful.
If R, and RZ are different then the intermediate 4 is prepared by reacting the dianion of 3 with one equivalent of the electrophile R,-X (X = leaving group e.g.
iodine). The resultant mono-alkylated compound may then be isolated and re-subjected to the reaction conditions using Rz-X, or alternatively used in-situ for the second alkylation with RZ-X. Alternatively if the desired product 7 is to contain RZ =
H, then the isolated mono-alkylated intermediate is taken though the subsequent steps.
Scheme 2 R' Rz Ar N
H
5 Other methodologies are also available for coupling the pendant aryl or heteroaryl group, Ar, to the oxindole platform, for example reaction of compound 5 with an aryl or heteroaryl stannane, aryl or heteroaryl zinc, or aryl or heteroaryl magnesium halide in the presence of a palladium or nickel catalyst (scheme 2).
The required aryl or heteroaryl-metallic species described above are formed through standard techniques.
Other functionalities can also be installed into the 3-position of the indoline platform according to scheme 3. Oxidation of the unsubstituted indoline 8, preferably under neutral or acidic conditions (e.g. selenium dioxide in dry dioxane at reflux) affords the isatin 9. Compound 9 may be further functionalized to provide a ketal 11 by treatment with an alcohol and acid catalyst under dehydrating conditions.
Alternatively reaction of 9 with a second ketone under suitable conditions (piperidine in toluene at reflux; or TiCl4/Zn in THF at reflux) affords alkylidene derivatives 11.
Reaction of the isatin 9 with a grignard reagent or organolithium affords tertiary alcohols 12 (R = H). These alcohols may then be further functionalized by alkylation or acylation procedures.
Scheme 3 o'~
Ar ~o ; I ~o > I ~o N ~ N ~ N
H H H
L
Kuhla, et al, taught the oxindole M as a cardiotonic (WO 86/03749).
S
N
O
N
H
M
Weber, described the oxindole N for cardiovascular indications (WO 91/06545).
\ N I W
N
H
N
Fischer, et al, claim a preparation for making compounds which include the generic structure O (U.S. Patent No. 5,453,516).
_7_ HzC
O
R = various Singly et al, described the PDE III inhibitor P (J. Med. Chem., 37, 248, 1994).
N
P
Andreani, et al, described the cytotoxic agent Q (Acta. Pharn. Nord., 2, 407, 1990).
N
Q
Binder, et al, described structure R which is an intermediate for preparing COX II
inhibitors (WO 97/13767).
_g_ A
N
H
R
Walsh (A.H. Robins) described the oxindole S as an intermediate (U.S. Patent No.
4,440,785, U.S. Patent No. 4,670,566).
S
R1 = F, C1, Br, alkyl, NHz R2 = alkyl, alkoxy, F, Cl, NH2, CF3 Bohm, et al, claim the oxindole T as cardiovascular agents (WO 91/06545).
~N
H3C0 ~ / H3C CH3 N
O
N
H
T
Bohm, et al, include the generic structure U (WO 91/04974).
C~
H
U
JP 63112584 A contains the generic structure V:
Y
N
R~
X
N ~ \ CH~~
N O
V
Boar, et al, described the dioxolane W as an intermediate for preparation of acetyl-cholinesterase inhibitors (WO 93/12085 A1).
W
Kende, et al, described methodology for preparing 3,3-substituted oxindoles, e.g. X, that was utilized in the present invention (Synth. Commun., 12, l, 1982).
H
$ X
Description of the Invention This invention provides compounds of the formulae 1 or 2:
R~ R, or wherein:
R, and RZ are chosen independently from the group of H, alkyl, substituted alkyl; OH; O(alkyl); O(substituted alkyl); OAc; aryl; optionally substituted aryl;
heteroaryl; optionally substituted heteroaryl; alkylaryl; alkylheteroaryl; 1-propynyl;
or 3-propynyl:
or R, and R~ are joined to form a ring comprising one of the following:
-CH2(CHz)nCHz-; -CHzCH2CMe2CH2CHz-; -O(CHZ)mCHr; O(CHZ)PO-;
-CHZCHZOCHzCH2-; or -CHzCH2N(H or alkyl)CHZCHz-;
m is an integer from 1 to 4;
n is an integer from 1 to 5;
p is an integer from 1 to 4;
or R, and RZ together comprise a double bond to one of the following:
CMe2; C(cycloalkyl), O, C(cyloether).
R3 is selected from H, OH, NH2, C, to C6 alkyl, substituted C, to C6 alkyl, C3 to C6 alkenyl, alkynyl or substituted alkynyl, or COR";
R" is selected from H, C, to C3 alkyl, substituted C, to C3 alkyl, C, to C3 alkoxy, substituted C, to C3 alkoxy, C, to C3 aminoalkyl, or substituted C, to aminoalkyl;
R4 is selected from H, halogen, CN, NHZ, C, to C6 alkyl, substituted C, to C6 alkyl, C, to C6 alkoxy, substituted C, to C6 alkoxy, C, to C6 aminoalkyl, or substituted C, to C6 aminoalkyl;
RS is selected from the groups a), b) or c):
a) RS is a trisubstituted benzene ring containing the substituents X, Y
and Z as shown below:
Y, X I Z
X is selected from halogen, OH, CN, C, to C3 alkyl, substituted C, to C3 alkyl, C, to C3 alkoxy, substituted C, to C3 alkoxy, C, to C3 thioalkyl, substituted C, to C3 thioalkyl, S(O)alkyl, S(O)Zalkyl, C, to C, aminoalkyl, substituted C, to C3 aminoalkyl, NOz, C, to C3 perfluoroalkyl, S or 6 membered heterocyclic ring containing 1 to 3 heteroatoms, CONHZ, CSNHz, CONHalkyl, CSNHalkyl, CON(alkyl)2, CSN(alkyl)Z, CORE, OCORB, NR~CORB;
RB is selected from H, C, to C3 alkyl, substituted C, to C3 alkyl, aryl, substituted aryl, C, to C3 alkoxy, substituted C, to C3 alkoxy, C, to C3 aminoalkyl, or substituted C, to C3 aminoalkyl;
R~ is H, C, to C3 alkyl, or substituted C, to C3 alkyl;
Y and Z are independently selected from H, halogen, CN, NO2, C, to C3 alkoxy, C, to C3 alkyl, or C, to C3 thioalkyl;
or b) RS is a five or six membered heterocyclic ring with l, 2, or 3 heteroatoms selected from O, S, SO, SOZ or NR6 and containing one or two independent substituents from the group of H, halogen, CN, NOz and C, to C3 alkyl, C, to C3 alkoxy, C, to C, aminoalkyl, COR°, or NRECOR°;
R° is H, C, to C3 alkyl, substituted C, to C3 alkyl, aryl, substituted aryl, C, to C3 alkoxy, substituted C, to C3 alkoxy, C, to C3 aminoalkyl, or substituted C, to C3 aminoalkyl;
RE is H, C, to C3 alkyl, or substituted C, to C3 alkyl;
R6 is H, or C, to C3 alkyl; or c) RS is an indol-4-yl, indol-7-yl or benzo-2-thiophene moiety, the moiety being optionally substituted by from 1 to 3 substituents selected from halogen, lower alkyl, CN, NO2, lower alkoxy, or CF3;
Q' is S, NR" CRgR9;
R, is selected from the group including CN, C, to C6 alkyl, substituted C, to alkyl, C3 to C8 cycloalkyl, substituted C, to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, acyl, substituted acyl, aroyl, substituted aroyl, SOZCF3, OR" or NR"R'2;
R8 and R, are independent substituents selected from the group of H, C, to C6 alkyl, substituted C, to C6 alkyl, C3 to Cg cycloalkyl, substituted C3 to C8 eycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO2, CN, or COZR,o, R,o is C, to C3 alkyl; or CRBRg comprises a six membered ring as shown by the structure below O
QZ is selected from the moieties:
11 D11 p12 11 -N_p-R12 -'I~'~'NI/~-R13 or -p-N-Rlg.
R", R'z and R'3 are independently selected from H, C, to C6 alkyl, substituted C, to C6 alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyl, substituted acyl, aroyl or substituted aroyl or sulfonyl;
or a pharmaceutically acceptable salt thereof.
A preferred list of substituents represented by R", R'z and R'3 in groups of the compounds described herein are H, C, to C6 alkyl, substituted C, to C6 alkyl, -C(O)-(C, to C6 alkyl), -S(O)z-(C, to C6 alkyl), phenyl or benzyl.
It will be understood that this invention includes all tautomeric forms of the compounds, chemical formulae and substituents described herein.
Two preferred sets of compounds of this invention is depicted by structures 2 and 3, respectively:
each wherein RS is a disubstituted benzene ring containing the substituents X
and Y as shown below X
3' 4' ~
5' ~~
Y
X is selected from halogen, CN, CONHz, CSNH2, CONHalkyl, CSNHalkyl, CONa1ky12, CSNalkylz, C, to C3 alkoxy, C, to C3 alkyl, NO2, C, to C3 perfluoroalkyl, membered heterocyclic ring containing 1 to 3 heteroatoms, or C, to C3 thioalkoxy;
Y is a substituent on the 4' or 5'position from the group including H, halogen, 5 CN, NO2, C, to C3 alkoxy, C, to C4 alkyl, or C, to C3 thioalkyl;
or a pharmaceutically acceptable salt thereof.
Another preferred group of formula 2 are those wherein RS is a five membered ring with the structure shown below X' Y' wherein:
U is O, S, or NR6;
R~ is H, or C, to C3 alkyl, or C, to C4 COzalkyl;
X' is selected from halogen, CN, NO~, CONHZ, CSNH2, CONHalkyl, CSNHalkyl, CONa1ky12, CSNalkyl2, C, to C3 alkyl, or C, to C3 alkoxy;
Y' is from the group of H, F or C, to C4 alkyl;
or a pharmaceutically acceptable salt thereof.
A further preferred subgroup of the compounds above are those in which RS is a thiophene or furan ring substituted by X' and Y', as described above.
A further preferred subgroup group of compounds of formulas 2 and 3 are those wherein RS is a six membered ring with the structure:
X' N
wherein X' is N or CXZ, Xz is halogen, CN, CONH2, CSNH2, CONHalkyl, CSNHalkyl, CONalkyl2, CSNalkylz or NOz;
Q' is S, NR,, CRBR,;
R, is from the group including CN, C, to C6 alkyl, substituted C, to C6 alkyl, C3 to C8 cycloalkyl, substituted C, to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or SOZCF3;
R8 and R9 are independent substituents from the group including H, C, to C6 alkyl, substituted C, to C6 alkyl, C3 to C8 cycloalkyl, substituted C, to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO2, CN
COZR,o, R,o is C, to C3 alkyl;
CRBR, are within a six membered ring as shown by the structure below ~3 or pharmaceutically acceptable salt thereof.
Still another preferred group of these compounds includes those having the general formulae:
or each wherein RS is a disubstituted benzene ring containing the substituents X
and Y as shown below X
3' 4' ~
5' /~
Y
X is selected from halogen, CN, CONHz, CSNHZ, CONHalkyl, CSNHalkyl, CONa1ky12, CSNa1ky12, C, to C3 alkoxy, C, to C3 alkyl, NOz, C, to C3 perfluoroalkyl, membered heterocyclic ring containing 1 to 3 heteroatoms, or C, to C3 thioalkoxy;
5 Y is a substituent on the 4' or 5'position from the group including H, halogen, CN, NOz, C, to C3 alkoxy, C, to Cq alkyl, or C, to C3 thioalkyl;
or a pharmaceutically acceptable salt thereof.
A further preferred subgroup group of compounds of formulae:
or are those wherein RS is a six membered ring with the structure:
~i wherein X' is N or CXZ, XZ is halogen, CN, CONHz, CSNH2, CONHalkyl, CSNHalkyl, CONalkyl2, CSNalkylz or NOz;
QZ is as defined above;
R, is from the group including CN, C, to C6 alkyl, substituted C, to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to Cg cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or SOZCF3;
Rg and R, are independent substituents from the group including H, C, to C6 alkyl, substituted C, to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NOz, CN
COZR,o, R,o is C, to C3 alkyl;
CR$Rg are within a six membered ring as shown by the structure below O
O
O
or pharmaceutically acceptable salt thereof.
A further preferred set of compounds of this invention is depicted by structure 4, Rs H
~Rt4 4a Wherein R,4 is chosen from the group H, acyl, substituted acyl, aroyl, substituted amyl, sulfonyl, substituted sulfonyl.
Wherein RS is a disubstituted benzene ring containing the substituents X and Y as shown below X
3' 4' ~
5'~~
Y
X is selected from halogen, CN, CONH2, CSNH2, CONHalkyl, CSNHalkyl, CON(alkyl)2, CSN(alkyl)z, CNHNHOH, CNHzNOH, C, to C3 alkoxy, C, to C3 alkyl, NOz, C, to C3 perfluoroalkyl, 5 membered heterocyclic ring containing 1 to 3 heteroatoms, or C, to C3 thioalkoxy;
Y is a substituent on the 4' or 5'position from the group including H, halogen, CN, NOz, C, to C3 alkoxy, C, to C4 alkyl, or C, to C3 thioalkyl;
or a pharmaceutically acceptable salt thereof.
Another preferred group of formula 4 are those wherein RS is a five membered ring with the structure shown below X' u~~
wherein:
U is O, S, or NR6;
R6 is H, or C, to C3 alkyl, or C, to C4 COZalkyl;
X' is selected from halogen, CN, NOz, CONH2, CNHNHOH, CNH2NOH, CSNH2, CONHalkyl, CSNHalkyl, CONa1ky12, CSNalkylz, C, to C3 alkyl, or C, to C3 alkoxy;
Y' is from the group of H, F or C, to Cq alkyl;
or a pharmaceutically acceptable salt thereof.
A further preferred subgroup of the compounds above are those in which RS is a thiophene or furan ring substituted by X' and Y', as described above.
A further preferred subgroup group of compounds of formula 4 are those wherein RS is a six membered ring with the structure:
~,i~
wherein X' is N or CXz, XZ is halogen, CN, CONH2, CSNHz, CONHalkyl, CSNHalkyl, CONalkylz, CSNalkylZ or NOZ;
R, is from the group including CN, C, to C6 alkyl, substituted C, to C6 alkyl, C, to C8 cycloalkyl, substituted C3 to Cg cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or SOZCF3;
R8 and R, are independent substituents from the group including H, C, to C6 alkyl, substituted C, to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NOz, CN
COZR,o, R,o is C, to C3 alkyl;
or pharmaceutically acceptable salt thereof.
A further preferred set of compounds of this invention is depicted by structure 5, Wherein RS is a disubstituted benzene ring containing the substituents X and Y as shown below X
3' 4' ~
5'~~
Y
X is selected from halogen, CN, CONH2, CSNH2, CONHalkyl, CSNHalkyl, CONalkylz, CSNalkylz, CNHNOH, C, to Cj alkoxy, C, to C3 alkyl, NO2, C, to C3 perfluoroalkyl, 5 membered heterocyclic ring containing 1 to 3 heteroatoms, or C, to C3 thioalkoxy;
Y is a substituent on the 4' or 5'position from the group including H, halogen, CN, NO2, C, to C3 alkoxy, C, to C4 alkyl, or C, to C3 thioalkyl;
or a pharmaceutically acceptable salt thereof.
Another preferred group of formula 5 are those wherein RS is a five membered ring with the structure shown below Y' wherein:
U is O, S, or NR~;
R6 is H, or C, to C3 alkyl, or C, to Cq COZalkyl;
X' is selected from halogen, CN, NOZ, CONH2, CSNHZ, CONHalkyl, CSNHalkyl, CONa1ky12, CSNalkyl2, C, to C3 alkyl, or C, to C3 alkoxy;
Y' is from the group of H, F or C, to C4 alkyl;
or a pharmaceutically acceptable salt thereof.
A further preferred subgroup of the compounds above are those in which RS is a thiophene or furan ring substituted by X' and Y', as described above.
A further preferred subgroup group of compounds of formula 5 are those wherein RS is a six membered ring with the structure:
N
wherein X' is N or CXz, Xz is halogen, CN, CONH2, CSNHZ, CONHalkyl, CSNHalkyl, CONa1ky12, CSNalkylz or NOz;
R, is from the group including CN, C, to C6 alkyl, substituted C, to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or SOZCF3;
Rg and R9 are independent substituents from the group including H, C, to C6 alkyl, substituted C, to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to Cg cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NOz, CN
COzR,o, R,o is C, to C3 alkyl;
or pharmaceutically acceptable salt thereof.
A further preferred set of compounds of this invention is depicted by structure 6, Rs Wherein R,5 is selected from the group H, Me, COzR, acyl, substituted acyl, aroyl, substituted aroyl, alkyl, substituted alkyl, CN.
Wherein RS is a disubstituted benzene ring containing the substituents X and Y as shown below X
3' 4' ~
5'~~
Y
X is selected from halogen, CN, CONH2, CSNHz, CONHalkyl, CSNHalkyl, CONalkyl2, CSNalkyl2, CNHNOH, C, to C3 alkoxy, C, to C3 alkyl, NOZ, C, to C3 perfluoroalkyl, S membered heterocyclic ring containing 1 to 3 heteroatoms, or C, to C3 thioalkoxy;
Y is a substituent on the 4' or 5'position from the group including H, halogen, CN, NOz, C, to C3 alkoxy, C, to Cq alkyl, or C, to C3 thioalkyl;
or a pharmaceutically acceptable salt thereof.
Another preferred group of formula 6 are those wherein RS is a five membered ring with the structure shown below X' u~~
wherein:
U is O, S, or NR6;
R6 is H, or C, to C3 alkyl, or C, to Cq COZalkyl;
X' is selected from halogen, CN, NOz, CONHz, CSNHZ, CONHalkyl, CSNHalkyl, CONalkylz, CSNalkyl2, C, to C3 alkyl, or C, to C3 alkoxy;
Y' is from the group of H, F or C, to CQ alkyl;
or a pharmaceutically acceptable salt thereof.
A further preferred subgroup of the compounds above are those in which RS is a thiophene or furan ring substituted by X' and Y', as described above.
A further preferred subgroup group of compounds of formula 6 are those wherein RS is a six membered ring with the structure:
~.i~
wherein X' is N or CXz, XZ is halogen, CN, CONHz, CSNH2, CONHalkyl, CSNHalkyl, CONalkylz, CSNa1ky12 or NOz;
R, is from the group including CN, C, to C6 alkyl, substituted C, to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or SOzCF3;
R8 and R, are independent substituents from the group including H, C, to C6 alkyl, substituted C, to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO2, CN
COZR,o, R,o is C, to C3 alkyl;
or pharmaceutically acceptable salt thereof.
A further preferred set of compounds of this invention is depicted by structure 7, Wherein RS is a disubstituted benzene ring containing the substituents X and Y as shown below X
3' 4' ~
5'~~
Y
X is selected from halogen, CN, CONH2, CSNHZ, CONHalkyl, CSNHalkyl, CONalkylz, CSNalkylz, CNHNOH, C, to C, alkoxy, C, to C3 alkyl, NOz, C, to C3 perfluoroalkyl, 5 membered heterocyclic ring containing 1 to 3 heteroatoms, or C, to C3 thioalkoxy;
Y is a substituent on the 4' or 5'position from the group including H, halogen, CN, NOz, C, to C3 alkoxy, C, to CQ alkyl, or C, to C3 thioalkyl;
or a pharmaceutically acceptable salt thereof.
Another preferred group of formula 7 are those wherein RS is a five membered ring with the structure shown below X' u~~
wherein:
U is O, S, or NR6;
R6 is H, or C, to C3 alkyl, or C, to C4 COZalkyl;
X' is selected from halogen, CN, NO2, CONH2, CSNH2, CONHalkyl, CSNHalkyl, CONa1ky12, CSNalkyl2, C, to C3 alkyl, or C, to C3 alkoxy;
Y' is from the group of H, F or C, to C4 alkyl;
or a pharmaceutically acceptable salt thereof.
A further preferred subgroup of the compounds above are those in which RS is a thiophene or furan ring substituted by X' and Y', as described above.
A further preferred subgroup group of compounds of formula 7 are those wherein RS is a six membered ring with the structure:
~.i~
wherein X' is N or CX2, XZ is halogen, CN, CONH2, CSNHZ, CONHalkyl, CSNHalkyl, CONalkylz, CSNa1ky12 or NOz;
R, is from the group including CN, C, to C6 alkyl, substituted C, to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or S02CF3;
Rg and R, are independent substituents from the group including H, C, to C6 alkyl, substituted C, to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NOZ, CN
COzR,o, R,o is C, to C3 alkyl;
or pharmaceutically acceptable salt thereof.
The compounds of this invention may contain an asymmetric carbon atom and some of the compounds of this invention may contain one or more asymmetric centers and may thus give rise to optical isomers and diastereomers. While shown without respect to stereochemistry in Formula 1 and 2 the present invention includes such optical isomers and diastereomers; as well as the racemic and resolved, enantiomerically pure R and S stereoisomers; as well as other mixtures of the R and S
stereoisomers and pharmaceutically acceptable salts thereof.
The term "alkyl" is used herein to refer to both straight- and branched-chain saturated aliphatic hydrocarbon groups having 1 to 8 carbon atoms, preferably 1 to 6 carbon atoms; "alkenyl" is intended to include both straight- and branched-chain alkyl group with 1 or 2 carbon-carbon double bonds and containing 2 to 8 carbon atoms, preferably 2 to 6 carbon atoms; "alkynyl" group is intended to cover both straight- and branched-chain alkyl group with at least 1 or 2 carbon-carbon triple bonds and containing 2 to 8 carbon atoms, preferably 2 to 6 carbon atoms.
The term "acyl" refers to a carbonyl substituent, including both straight- and branched-chain saturated aliphatic hydrocarbon groups having 1 to 8 carbon atoms, preferably 1 to 6 carbon atoms. The term "substituted acyl" refers to an acyl group as just described optionally substituted with from 1 to 6 groups chosen from the list halogen, CN, OH, and N02.
The term "aroyl" also refers to a carbonyl substituent carrying a phenyl group or a heteroaromatic group. The heteroaromatic groups of this include 2-, 3- or pyridinyl, 2- and 3-furanyl, 2- or 3-thiophenyl, or 2- or 4-pyrimidinal. The term "substituted amyl" also refers to an aroyl group as just described optionally substituted with from 1 to 6 groups chosen from the list halogen, CN, OH, and N02, The terms "substituted alkyl", "substituted alkenyl", and "substituted alkynyl" refer to alkyl, alkenyl, and alkynyl as just described having one or more substituents from the group including halogen, CN, OH, NOz, amino, aryl, heterocyclic, substituted aryl, substituted heterocyclic, alkoxy, aryloxy, substituted alkyloxy, alkylcarbonyl, alkylcarboxy, alkylamino, arylthio. These substituents may be attached to any carbon of alkyl, alkenyl, or alkynyl group provided that the attachment constitutes a stable chemical moiety.
The term "aryl" is used herein to refer to an aromatic system which may be a single ring or multiple aromatic rings fused or linked together as such that at least one part of the fused or linked rings forms the conjugated aromatic system. The aryl groups include, but are not limited to, phenyl, naphthyl, biphenyl, anthryl, tetrohydronaphthyl, phenanthryl.
The term "substituted aryl" refers to aryl as just defined having 1 to 4 substituents from the group including halogen, CN, OH, NO2, amino, alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, aryloxy, substituted alkyloxy, alkylcarbonyl, alkylcarboxy, alkylamino, or arylthio.
The term "heterocyclic" is used herein to describe a stable 4- to 7-membered monocyclic or a stable multicyclic heterocyclic ring which is saturated, partially unsaturated, or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group including N, O, and S atoms. The N and S
atoms may be oxidized. The heterocyclic ring also includes any multicyclic ring in which any of above defined heterocyclic rings is fused to an aryl ring. The heterocyclic ring may be attached at any heteroatom or carbon atom provided the resultant structure is chemically stable. Such heterocyclic groups include, for example, tetrahydrofuran, piperidinyl, piperazinyl, 2-oxopiperidinyl, azepinyl, pyrrolidinyl, imidazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, isoxazolyl, morpholinyl, indolyl, quinolinyl, thienyl, furyl, benzofuranyl, benzothienyl, thiamorpholinyl, thiamorpholinyl sulfoxide, and isoquinolinyl.
The term "substituted heterocyclic" is used herein to describe the heterocyclic just defined having 1 to 4 substituents selected from the group which includes halogen, CN, OH, NOz, amino, alkyl, substituted alkyl, cycloalkyl, alkenyl, substituted alkenyl, alkynyl, alkoxy, aryloxy, substituted alkyloxy, alkylcarbonyl, alkylcarboxy, alkylamino, or arylthio.
The term "thioalkyl" is used herein to refer to the SR group, where R is alkyl or substituted alkyl, containing 1 to 8 carbon atoms, preferably 1 to 6 carbon atoms.
The term "alkoxy" is used herein to refer to the OR group, where R is alkyl or substituted alkyl, containing lto 8 carbon atoms, preferably 1 to 6 carbon atoms. The term "aryloxy" is used herein to refer to the OR group, where R is aryl or substituted aryl, as defined above. The term "alkylcarbonyl" is used herein to refer to the RCO
group, where R is alkyl or substituted alkyl, containing 1 to 8 carbon atoms, preferably 1 to 6 carbon atoms. The term "alkylcarboxy" is used herein to refer to the COOR group, where R is alkyl or substituted alkyl, containing 1 to 8 carbon atoms, preferably 1 to 6 carbon atoms. The term "aminoalkyl" refers to both secondary and tertiary amines wherein the alkyl or substituted alkyl groups, containing 1 to 8 carbon atoms, preferably 1 to 6 carbon atoms, which may be either the same or different and the point of attachment is on the nitrogen atom. The term "halogen" refers to Cl, Br, F, or I.
The compounds of this invention may be prepared according to the methods described below.
Scheme 1 R: Rz R ....:
Rz ~~ I ~° I ~ °
N
H H
R.~' R.~' R2 Rz Ar I ~°
N ~ N
H H
According to scheme 1, commercially available oxindole 3 is treated with a strong organo-metallic base (e.g. butyl lithium, lithium diisopropylamide, potassium hexamethyldisilazide) in an inert solvent (e.g. THF, diethyl ether) under nitrogen at reduced temperature (ca. -20 °C) (Kende, et al, Synth. Commun., 12, 1, 1982) in the presence of lithium chloride or N,N,N',N'-tetramethylethylene-diamine. The resulting di-anion is then treated with excess electrophile such as an alkyl halide, preferably an iodide. If R, and RZ are to be joined such as the product 4 contains a spirocycle at position 3, then the electrophile should be bifunctional, i.e. a diiodide.
Subsequent bromination of 4 proceeds smoothly with bromine in acetic acid (an organic co-solvent such as dichloromethane may be added as required) in the presence of sodium acetate, to afford the aryl bromide 5. The bromide 5 is reacted with a palladium salt (e.g. tetrakis(triphenylphoshine)palladium(0) or palladium acetate), in a suitable solvent (e.g. THF, dimethoxyethane, acetone, ethanol or toluene) at room temperature under an inert atmosphere (argon, nitrogen). The mixture is then treated with an aryl or heteroaryl boronic acid or boronic acid ester and a base (sodium carbonate, triethylamine, potassium phosphate) in water or fluoride source (cesium fluoride) under anhydrous conditions. The required product 6 is then isolated and purified by standard means.
Reaction of the indoline-2-one derivative 6 with either Lawessen's reagent or phosphorous pentasulfide in a suitable organic solvent (pyridine, THF, dioxane, dimethoxyethane, dichloromethane, benzene, toluene, xylene) at a temperature between room temperature and the reflux temperature of the solvent provides access to the thiocarbonyl derivative 7. An additive such as sodium hydrogen carbonate may also be useful.
If R, and RZ are different then the intermediate 4 is prepared by reacting the dianion of 3 with one equivalent of the electrophile R,-X (X = leaving group e.g.
iodine). The resultant mono-alkylated compound may then be isolated and re-subjected to the reaction conditions using Rz-X, or alternatively used in-situ for the second alkylation with RZ-X. Alternatively if the desired product 7 is to contain RZ =
H, then the isolated mono-alkylated intermediate is taken though the subsequent steps.
Scheme 2 R' Rz Ar N
H
5 Other methodologies are also available for coupling the pendant aryl or heteroaryl group, Ar, to the oxindole platform, for example reaction of compound 5 with an aryl or heteroaryl stannane, aryl or heteroaryl zinc, or aryl or heteroaryl magnesium halide in the presence of a palladium or nickel catalyst (scheme 2).
The required aryl or heteroaryl-metallic species described above are formed through standard techniques.
Other functionalities can also be installed into the 3-position of the indoline platform according to scheme 3. Oxidation of the unsubstituted indoline 8, preferably under neutral or acidic conditions (e.g. selenium dioxide in dry dioxane at reflux) affords the isatin 9. Compound 9 may be further functionalized to provide a ketal 11 by treatment with an alcohol and acid catalyst under dehydrating conditions.
Alternatively reaction of 9 with a second ketone under suitable conditions (piperidine in toluene at reflux; or TiCl4/Zn in THF at reflux) affords alkylidene derivatives 11.
Reaction of the isatin 9 with a grignard reagent or organolithium affords tertiary alcohols 12 (R = H). These alcohols may then be further functionalized by alkylation or acylation procedures.
Scheme 3 o'~
Ar ~o ; I ~o > I ~o N ~ N ~ N
H H H
R
R
Ar Ar O
'N H
H
g 11 R
Nu O ~~ ~ O
N ~ N
H H
g 12 Reaction of the indoline-2-one derivative 6 with either Lawessen's reagent or phosphorous pentasulfide in a suitable organic solvent (pyridine, THF, dioxane, dimethoxyethane, dichloromethane, benzene, toluene, xylene) at a temperature between room temperature and the reflux temperature of the solvent provides access to the thiocarbonyl derivative 7. An additive such as sodium hydrogen carbonate may also be useful.
Scheme 4 (HO
R' ~S
N
H
An alternative mode of preparation is to react compound 5 with either Lawessen's reagent or phosphorous pentasulfide in a suitable organic solvent (pyridine, THF, dioxane, dimethoxyethane, dichloromethane, benzene, toluene, xylene) at a temperature between room temperature and the reflux temperature of the solvent, under an inert atmosphere (nitrogen or argon) providing access to the thiocarbonyl derivative 13. Then reaction of bromide 13 in an anhydrous solvent (e.g.
THF, EtzO) with a strong base (sodium hydride preferred, sodium hexamethyldisilazide, potassium hydride) followed by reaction at reduced temperature (-50 to -20 °C) with n-butyllithium and N,N,N,N'-tetramethylethylenediamine followed after a suitable period of time by a trialkylborate (trimethyl or triisopropylborate) gives after acidic work-up the boronic acid 14 (scheme 4). Compound 14 may then be reacted under palladium catalyzed conditions (tetrakis(triphenylphosphine)palladium(0) or palladium acetate, base (NaHC03, Na2C03, KZC03, triethylamine, CsF) solvent (toluene/EtOH/water, THF/water, dimethoxyethane/water, anhydrous dimethoxyethane) with an aryl or heteroaryl bromide, aryl or heteroaryl iodide, aryl or heteroaryl trifluoromethane sulfonate or aryl or heteroaryl fluorosulfonate, to provide the desired compounds 7.
Alternatively reaction of compound 13 under palladium catalyzed conditions (tetrakis(triphenylphosphine)palladium(0) or palladium acetate, base (NaHC03, NazC03, KzC03, triethylamine, CsF) solvent (acetone/water, toluene/EtOH/water, THF/water, dimethoxyethane/water, anhydrous dimethoxyethane) with an aryl or heteroaryl bromide, aryl or heteroaryl iodide, aryl or heteroaryl trifluoromethane sulfonate or aryl or heteroaryl fluorosulfonate, to provide the desired compounds 7.
Scheme 5 R :~ ;.
Rz ~~H~B Rz ~o > I ~ ~O
N ~N
H H
R.~' R:
Rz ~ Rz ~O ~S
N ~ N
H H
Treatment of the bromide 5 in an anhydrous solvent (e.g. THF, Et20) with a strong base (sodium hydride preferred, sodium hexamethyldisilazide, potassium hydride) followed by reaction at reduced temperature (-50 to -20 °C) with n-butyllithium and N,N,N,N'-tetramethylethylenediamine followed after a suitable period of time by a trialkylborate (trimethyl or triisopropylborate) gives after acidic work-up the boronic acid 15 (scheme 5). Compound 15 may then be reacted under palladium catalyzed conditions (tetrakis(triphenylphosphine)palladium(0), base (NaHC03, NaZC03, KZC03, triethylamine, CsF) solvent (toluene/EtOH/water, THF/water, dimethoxyethane/water, anhydrous dimethoxyethane) with an aryl or heteroaryl bromide, aryl or heteroaryl iodide, aryl or heteroaryl trifluoromethane sulfonate or aryl or heteroaryl fluorosulfonate, to provide the desired compounds 6.
An alternative strategy would be to prepare an organo zinc or magnesium reagent from compound 5 and react it in-situ with an aryl or heteroaryl bromide, aryl or heteroaryl iodide, aryl or heteroaryl trifluoromethane sulfonate of aryl or heteroaryl fluorosulfonate, under palladium catalyzed conditions to afford compound 6.
Such an organo zinc or magnesium species could be prepared by treatment of the bromide in an anhydrous solvent (e.g. THF, EtzO) with a strong base (sodium hydride preferred, sodium hexamethyldisilazide, potassium hydride) followed by reaction at reduced temperature (-50 to -20 °C) with n-butyllithium and N,N,N',N'-tetramethylethylenediamine followed after a suitable period of time by reaction with anhydrous zinc chloride or magnesium bromide.
Reaction of the indoline-2-one derivative 6 with either Lawesson's reagent or phosphorous pentasulfide in a suitable organic solvent (pyridine, THF, dioxane, dimethoxyethane, dichloromethane, benzene, toluene, xylene) at a temperature between room temperature and the reflux temperature of the solvent, under an inert atmosphere (nitrogen or argon) provides access to the thiocarbonyl derivative 15. An additive such as sodium hydrogen carbonate may also be useful.
Scheme 6 R~ R' Rz B ~ R2 S > I ~ ~Y
N N
H H
Y = CHN4z = NCN
= NSOzCF3 _ o Me Me O
O
According to scheme 6 thioamide derivatives 7 may be converted into enamine derivatives 16 (Wrobel, et al, J. Med. Chem., 1989, 2493).
Thus reaction of thioamide 7 (Pg = H, 2-(trimethylsilyl)-ethoxymethyl, benzyl, etc) with triethyloxonium tetrafluoroborate followed by reaction with a nucleophile (nitromethane, cyanamide, trifluoromethanesulfonamide, Meldrum's acid, etc) followed by removal of the protecting group under appropriate conditions (e.g. tetrabutylammonium fluoride in THF for Pg = 2-(trimethylsilyl)-ethoxymethyl) then gives the enamine derivatives 16. Appropriate solvents for the two steps are selected from dichloromethane, THF, dioxane, 1,2-dichloroethane, and the reaction is conducted at a temperature from -78 °C to the boiling point of the solvent under an inert atmosphere (nitrogen or argon).
Ar R ~~wynu.~ A ~ Rp. nrk7 ~ / ~~~~m / H aM
y.. Rn..
Ar \ ~z hydroxylamine Ar \ kz -N
~aky1 H OH
17 Ig '~. yuy EWG~R \ R ~ ~ R ~ \ R ~anrunuR H
g decarboxylat'ron EWG ~ H EWG
a<N
Scheme 7 According to Scheme 7, treatment of intermediate 7 with an alkylating agent, e.g., methyl iodide, ethyl iodide, 2,4-dinitrofluoro benzene, or 4-nitro fluorobenzene, in the presence of a suitable base (e.g. an amine base such as pyridine, triethylamine or di-iso-propylethylamine or lithium, sodium, potassium or cesium carbonate) in a suitable organic solvent (e.g. DMF, THF, DMSO, dioxane or acetonitrile) at a temperature between -78 °C and the boiling point of the solvent, would then afford thioimino ethers 17. Subsequent reaction of intermediates 17 with hydroxylamine or an acid salt of hydroxylamine (e.g. the hydrochloride) in a suitable solvent (for example but not limited to pyridine methanol, ethanol, iso-propanol, DMF, THF
or DMSO and optionally in the presence of an additive such as a tertiary amine base or sodium or potassium acetate) at a temperature between -78 °C and the boiling point of the solvent would then afford the N hydroxyamidines 18.
Similarly treatment of intermediates 17 with a carbon nucleophile such as a malonate derivative (e.g., malononitrile, a cyano acetate ester, a nitro acetate ester or a malonate) in the presence of a suitable base (e.g. an amine base such as pyridine, triethylamine or di-iso-propylethylamine or lithium, sodium, potassium or cesium carbonate) or a Lewis acid (e.g. boron trifluoride etherate, a lead II salt, titanium tetrachloride, a magnesium II salt, or a silver salt) in a solvent compatible with the chosen base or Lewis acid (e.g. DMF, THF, DMSO, dioxane or acetonitrile, chloroform, benzene, toluene or dichloromethane) would then afford the adduct 19. If the group R3 in adduct 19 is an ester of a carboxylic acid, then it may be decarboxylated directly to give the enamine derivative 20 by treatment with, e.g.
sodium iodide in DMSO at a temperature between room temperature and thee boiling point of the solvent. Alternatively the ester may be first hydrolysed to the carboxylic acid (by treatment with an aqueous base (e.g. lithium, sodium, or potassium hydroxide) in a suitable solvent (e.g. THF, dioxane acetonitrile, methanol or ethanol), followed by decarboxylation in the presence of an acid (e.g. hydrochloric or sulfuric acid) in a suitable solvent (e.g. acetonitrile, THF, dioxane) to afford the derivatives 20. Alternatively the xanthate ester of the carboxylic acid may be prepared by reaction with a base such as sodium or potassium hydride in THF, followed by treatment with carbon disulfide. Subsequent reaction with tributyl tin hydride at elevated temperatures in a solvent such as benzene or toluene under an inert nitrogen or argon atmosphere in the presence of a radical initiator such as benzoyl peroxide or azo-bis-iso-butyronitrile would then give the product 20.
Rn.' ftn Br Rz Br ~ Rz S ~ ~ ~ S
N V N ~ kN
H a aryl Rt c R1 - '' 3 Br '\ Ra hydroxylamine Br \ RZ R' __ _ Br ~ Rz S~ rkN ~ ~ H N OH / N N OProrectirg aryl H 9~uD
Rn Rn.' Ar ~ Rz lv ~ Rz N '' N
~mbceng ~ ~ N~ ~ H
H gmuG N
Scheme 8 An alternative strategy for synthesizing the product 18 is illustrated by Scheme 8. Thus the bromide 13 (the corresponding chloride, iodide or triflate ester may also be employed) is treated with an alkylating agent, eg methyl iodide, ethyl iodide, 2,4-dinitrofluoro benzene, or 4-nitro fluorobenzene, in the presence of a suitable base (e.g. an amine base such as pyridine, triethylamine or di-iso-propylethylamine or lithium, sodium, potassium or cesium carbonate) in a suitable organic solvent (e.g. DMF, THF, DMSO, dioxane or acetonitrile) at a temperature between -78 °C and the boiling point of the solvent, would then afford thioimino ethers 21. Subsequent reaction of intermediate 21 with hydroxylamine or an acid salt of hydroxylamine (e.g. the hydrochloride, hydrobromide) in a suitable solvent (for example but not limited to pyridine methanol, ethanol, iso-propanol, DMF, THF
or DMSO and optionally in the presence of an additive such as a tertiary amine base or sodium or potassium acetate) at a temperature between -78 °C and the boiling point of the solvent, would then afford the N hydroxyamidine 22. Intermediate 22 could then be protected with a compatible group (e.g. benzyl ether, acyl derivative, _38_ tetrahydropyranyl ether, methoxy methyl ether, silyl ether) to give the derivative 23.
Alternately compound 21 could be reacted directly with a protected hydroxlamine derivative (chosen, but not limited to the protecting groups described above) to directly afford derivative 23. Compound 23 may then be reacted with a palladium salt (e.g. tetrakis(triphenylphoshine)palladium(0) or palladium acetate), in a suitable solvent (e.g. THF, dimethoxyethane, acetone, ethanol or toluene) at room temperature under an inert atmosphere (argon, nitrogen). The mixture is then treated with an aryl or heteroaryl boronic acid or boronic acid ester and a base (sodium carbonate, triethylamine, potassium phosphate) in water or fluoride source (cesium fluoride) under anhydrous conditions, and the reaction may then be heated to the boiling point of the solvent. The required product 24 is then isolated and purified by standard means.
Compound 24 may then be de-protected under the conditions prescribed by the nature of the protecting group. For example if the protecting group is a benzyl ether then treatment with boron tribromide or trimethylsilyl iodide in a suitable solvent (dichloromethane for example) would afford the compound 18. Other methods to remove the benzyl ether would involve hydrogenation (hydrogen gas or other hydrogen source such as cyclohexadiene or ammonium formate) in the presence of a palladium catalyst. Solvents suitable for such a process include methanol, ethanol, THF, ethyl acetate and dioxane, at a temperature between room temperature and the boiling point of the solvent. If the protecting group was an acetal derivative (tetrahydropyranyl or methoxymethyl ethers) then hydrolysis could be effected under acidic conditions (hydrochloric acid, sulfuric acid, p-toluene sulfonic acid or acidic ion exchange resin) in a solvent such as methanol, ethanol, THF dioxane or acetonitrile. If the protecting group was an acyl derivative (acetate, or benzoate for example) then hydrolysis could be effected under acidic conditions as described above or under basic conditions (lithium, sodium or potassium hydroxide) in a solvent such as an alcohol, THF dioxane or acetonitrile at a temperature between room temperature and the boiling point of the solvent. If the protecting group was a silyl ether then compound 18 may be prepared by hydrolysing intermediate 24 under the acidic conditions described above or alternately by exposing compound 24 to a fluoride source (eg potassium fluoride, cesium fluoride or tetra butyl ammonium fluoride) in a solvent such as an alcohol, THF dioxane or acetonitrile at a temperature between room temperature and the boiling point of the solvent. An inert atmosphere of nitrogen or argon may be necessary.
Another method of synthesizing compound 18 would be to convert the protected N-hydroxy amidine 23 into a boronic acid or boronic acid ester (by lithium halogen exchange followed by quench with tri-isopropyl borate, or palladium catalyzed coupling with diboron pinacolate) and then couple this boronic acid or ester derivative with an aryl chloride, bromide, iodide or triflate under a suitable palladium catalysis system as described previously. Subsequent deprotection as described for Scheme 8 would afford the desired compounds 18.
R '~.n Ar ~ R2 ~
Ar ~ R2 ~NH
H ~ H ~ ~ N
H
R~
Ar \ RZ
~N
~GN
Scheme 9 According to Scheme 9, treatment of the N-hydroxyamidine 18 under reducing conditions (e.g. catalytic hydrogenation, iron in acetic acid or hydrazine-raney nickel) would then afford intermediate 25. Solvents suitable for such a process include methanol, ethanol, THF, ethyl acetate and dioxane, at a temperature between room temperature and the boiling point of the solvent. Protection of the secondary nitrogen (a tertiary butyl carbamate is shown as a non-limiting example) under standard conditions would then give compound 26. Reaction of compound 26 with an electrophilic cyanating agent (e.g. cyanogen bromide, N-cyanobenzotriazole or cyanogen bromide/ 4-dimethylaminopyridine complex) in a suitable solvent (THF
acetonitrile or DMF, optionally in the presence of a base such as pyridine or sodium hydride or potassium tert-butoxide) may then afford the desired compound 27.
In some cases the cyanation step may occur with concomitant removal of the secondary nitrogen protecting group, if this deprotection does not occur in-situ then a further hydrolysis step would be required.
An alternate synthesis of compound 27 may follow that of compound 18, Scheme 8, where an N-cyanoamidine bromide 28, prepared from compound 22 adopting a similar strategy to the reactions shown in scheme 9, could be coupled with a suitable functionalised aryl boronic acid or boronic acid ester to give compound 27.
In another strategy intermediate 28 may be converted into the corresponding boronic 1 S acid or boronic acid ester and coupled in a Suzuki or Suzuki type palladium coupling with a suitable functionalised aryl bromide.
N
The compounds of the present invention can be used in the form of salts derived from pharmaceutically or physiologically acceptable acids or bases.
These salts include, but are not limited to, the following salts with inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid and, as the case may be, such organic acids as acetic acid, oxalic acid, succinic acid, and malefic acid. Other salts include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium in the form of esters, carbamates and other conventional "pro-drug" forms, which, when administered in such form, convert to the active moiety in vivo.
This invention includes pharmaceutical compositions and treatments which comprise administering to a mammal a pharmaceutically effective amount of one or more compounds as described above, or a pharmaceutically acceptable salt thereof, as agonists of the progesterone receptor.
The progesterone receptor agonists of this invention, used alone or in combination, can be utilized in methods of contraception and the treatment and/or prevention of dysfunctional bleeding, uterine leiomyomata, endometriosis;
polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate. Additional uses of the invention include stimulation of food intake.
When the compounds are employed for the above utilities, they may be combined with one or more pharmaceutically acceptable Garners or excipients, for example, solvents, diluents and the like, and may be administered orally in such forms as tablets, capsules, dispersible powders, granules, or suspensions containing, for example, from about 0.05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% of sugar, and elixirs containing, for example, from about 20 to 50% ethanol, and the like, or parenterally in the form of sterile injectable solutions or suspensions containing from about 0.05 to 5% suspending agent in an isotonic medium. Such pharmaceutical preparations may contain, for example, from about 25 to about 90% of the active ingredient in combination with the carrier, more usually between about 5% and 60% by weight.
The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration and the severity of the condition being treated. However, in general, satisfactory results are obtained when the compounds of the invention are administered at a daily dosage of from about 0.5 to about 500 mg/kg of animal body weight, preferably given in divided doses two to four times a day, or in a sustained release form. For most large mammals, the total daily dosage is from about 1 to 100 mg, preferably from about 2 to 80 mg.
Dosage forms suitable for internal use comprise from about 0.5 to 500 mg of the active compound in intimate admixture with a solid or liquid pharmaceutically acceptable carrier. This dosage regimen may be adjusted to provide the optimal therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
These active compounds may be administered orally as well as by intravenous, intramuscular, or subcutaneous routes. Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene glycols, non-ionic surfactants and edible oils such as corn, peanut and sesame oils, as are appropriate to the nature of the active ingredient and the particular form of administration desired. Adjuvents customarily employed in the preparation of pharmaceutical compositions may be advantageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA.
The preferred pharmaceutical compositions from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard-filled or liquid-filled capsules. Oral administration of the compounds is preferred.
These active compounds may also be administered parenterally or intraperitoneally. Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid, polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringe ability exits. It must be stable under conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacterial and fungi. The Garner can be a solvent or dispersion medium containing, for example, water, ethanol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oil.
This invention is further understood by the following non-limiting examples.
5'-(3-Chlorophenyl)spiro(cyclohexane-1,3'-]3H]indolel-2'(1'H)-thione biro[cyclohexane-1,3'-[3Hlindol]-2'-( 1'H)one A solution of oxindole (25 g, 0.19 mol) in anhydrous tetrahydrofuran (800 cm3) was cooled to -20°C, then n-butyllithium (2.SM in hexanes, 152 cm', 0.38 mol) was added slowly followed by N,N,N',N'-tetramethylethylenediamine (51 cm', 0.38 mol,). After 15 min. 1,5-diiodopentane (174 g, 0.54 mol) was added slowly and the mixture was allowed to warm to room temperature. After stirring for 16 h.
saturated aqueous ammonium chloride solution ( 1 L) and EtOAc ( 1 L) were added. After min., the layers were separated and the aqueous phase was extracted with EtOAc (x2). The combined organic layers were extracted with hydrochloric acid (1N), then washed with brine (500 cm3), dried (MgS04), and concentrated to obtain an oil.
The oil was triturated with hexane (200 cm') and benzene (20 cm'). The precipitate was collected and dried in vacuo to obtain the subtitled compound (26.3g, 69.6%) as colorless crystals: mp 110-114°C;'H NMR (DMSO-d6) 8 1.67 (m, lOH), 6.84 (d, 1H, J = 8 Hz) 6.94 (t, 1 H, J = 8 Hz), 7.17 (t, 1 H, J = 8 Hz), 7.44 (d, 1 H, J =
8 Hz), 10.3 (S, 1H).
5'-Bromospiro[cyclohexane-1,3'-[3H] indoll-2'(1'H)-one To a solution of spiro[cyclohexane-1,3'-[3H]indol]-2' (1'H)-one (17.6 g, 0.09 mol) in acetic acid (300 cm3) was added sodium acetate (8.0 g, 0.1 mol) and bromine ( 14.6g, 0.091 mol) with stirring. After 30 min. at room temperature, the reaction mixture was partitioned between water and EtOAc. The aqueous phase was extracted twice with EtOAc. The combined organic layers were washed with water, dried (MgS04) and evaporated and the residue was triturated with hexane. The precipitate was collected, and dried in vacuo to obtain the subtitled compound (l6.Sg, 67%) as off white crystals: mp 196 -199 °C; 'H NMR (DMSO-d6) 8 1.62 (m, l OH), 6.8 (d, 1H, J = 6.8 Hz), 7.36 (d, 1H, J= 8.2, 1.8 Hz), 7.58 (dd, 1H, J= 8.2, 1.8 Hz), 10.44 (S, 1 H).
5 ~3-chlorophenyl)spiro [cyclohexane-1,3-[3H~indoll-2( 1 H)-one A solution of 5'-bromospiro[cyclohexane-1,3'-[3H] indol]-2'(1'H)-one (0.32 g, 1.14 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.14 g, 0.12 mmol) in dimethoxyethane (6 cm3) was stirred under Nz for 20 min.. To this mixture was then added 3-chlorophenylboronic acid (0.21 g, 1.37 mmol) and sodium carbonate (0.36 g, 3.4 mmol) in water (3 cm3). The solution was brought to reflux for 6 h then cooled to RT, poured into water and extracted with EtOAc (x 3). The combined organic extracts were washed with water, brine, dried (MgS04), and evaporated. The residue was purified by column chromatography (Si02, ethyl acetate: hexane 1:3) to afford the subtitled compound (0.28 g, 0.89 mmol, 80%) as a yellow solid: mp. 164-165 °C , 1H NMR (CDC13) 8 1.60-1.78 (m, 6H), 1.81-1.99 (m, 4H), 7.04 (d, J= 8.1 Hz, 1H), 7.22-7.47 (m, 4H), 7.53 (s, 1H), 7.61 (s, 1H), 9.28 (br s, 1H);'3C-NMR
((CDC13) 20.17, 24.12, 31.92 (t), 47.22 (s), 109.21, 121.94, 124.06, 125.50, 125.79, 125.97, 126.38, 128.96 (d), 132.88, 133.59, 135.60, 139.14, 142.17, 182.89 (s); MS
(EI) m/z 310, 312 (M-H)+; Anal. (C,9H,8C1N0) C, H, N.
To a solution of 5'-(3-Chlorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'(1'H)-one (0.63 g, 2.0 mmol) in dry xylene (20 cm3) under nitrogen was added 2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide (0.89 g, 2.2 mmol) and the mixture heated under reflux. After 72h, the mixture was evaporated and the residue subjected to column chromatography (Si02, EtOAc: hexane, gradient elution) to afford a solid which was re-crystallized from di-iso-propylether/ hexane to afford the title compound as yellow crystals (0.17g, 0.51 mmol, 26%): mp. 223 - 227 C; d (CDC13) 1.53 - 1.66 (m, 8H), 1.83 - 2.05 (m, 4H), 2.07 - 2.17 (m, 2H), 7.11 (d, 1H, J
= 8.0 Hz) 7.31 - 7.53 (m, 3H), 7.54 (s, 1H), 7.86 (S, 1H), 9.93 (s, 1H, br):
MS
((+APCI) m/z 328 (M + H)+.
3-(1',2'-Dihydro-2'-thioxospiro f cyclohexane-1,3'-f3H~indol-5'-yl) benzonitrile To a solution of 5'-bromospiro[cyclohexane-1,3'-[3H] indol]-2'(1'H)-one (1.00 g, 3.57 mmol) in dimethoxyethane (20 cm3) was added tetrakis(triphenylphosphine)palladium (0.20 g, 0.17 mmol). After 15 min. 3-formylphenylboronic acid ( 1.00 g, 6.93 g) was added followed by potassium carbonate (2.90 g, 21 mmol) in water ( 10 cm3). After 20h at reflux, the mixture was cooled poured into water and extracted with EtOAc (x3). The combined organic extract was washed with saturated brine, dried (MgS04) and evaporated. The residue was purified by column chromatography (SiOz, EtOAc: hexane, gradient elution) to afford the title compound (0.66 g, 2.15 mmol, 60%) as a white solid, 'H NMR
(CDC13) 8 1.65 - 1.85 (m, 6H), 1.86 - 2.08 (m, 4H), 7.22 (d, 1 H, J = 8 Hz), 7.48 (dd, 1 H, J = 8, 2 Hz), 7.61 (t, 1 H, J = 8 Hz), 7.66 (d, 1 H, J = 2 Hz), 7.81 - 7.
8 8 ( m, 2H), 8.06 (t, 1H, J= 2 Hz), 8.30 (s , 1H, br); MS ((+)ESI) mlz 306 (M + H)+.
3-(1',2'-Dihydro-2'-oxospiro[cyclohexane-1,3'-[3H]indol-5'-yl) benzaldehyde oxime To a solution of 3-(1',2'-dihydro-2'-oxospirocyclohexane-1,3'-[3H]indol-5'-yl) benzaldehyde (0.59 g, 1.95 mmol) in EtOH: H20 (10 cm3, 8:2) was added hydroxylamine hydrochloride (0.17 g, 2.5 mmol) and sodium acetate (0.20 g, 2.5 mmol). After 20 min. the mixture was concentrated water was added and the product extracted with EtOAc (x2). The combined organic layers were washed with sat.
sodium hydrogen carbonate solution, water, sat. brine, dried (MgS04) and evaporated to afford the subtitled oxime (0.63 g, 1.95 mmol, 100%) which was used without further purification, 'H NMR (CDC13) 8 1.60 - 1.84 (m, 6H), 1.85 - 2.00 (m, 4H), 6.86 (d, 1 H, J = 8 Hz), 7.36 (dd, 1 H, J = 8, 2 Hz), 7.43 - 7.50 (m, 1 H), 7.57 -7.67 (m, 2H), 7.85 (s, 1H, br), 8.25 (s, 1H), 8.68 (s, 1H, br), 8.94 (s, 1H, br); MS ((-)ESI) m/z 319 (M - H)'.
3-(1',2'-Dihydro-2'-oxospirofcyclohexane-1,3'~3H]indol-5'-yl) benzonitrile A solution of 3-(1',2'-Dihydro-2'-oxospiro[cyclohexane-1,3'-[3H]indol-5'-yl) benzaldehyde oxime (0.48 g, 1.49 mmol) in chloroform ( 10 cm3) was treated with selenium dioxide (0.38 g, 3.50 mmol) and heated under reflux. After 16 h, the mixture was concentrated and the residue purified by column chromatography (SiOZ, EtOAc: hexane 1:4) and the product re-crystallized from EtOAc-hexane to afford the subtitled compound (0.161 g, 0.53 mmol, 35%) as a white solid: mp. 190 - 191 °C; 'H
NMR (CDC13) 8 1.59 - 1.87 (m, 6H), 1.88 - 2.09 (m, 4H), 7.03 (d, 1H, J= 8 Hz), 7.42 (dd, 1H, J= 8, 2 Hz), 7.54 (t, 1H, J= 8 Hz), 7.58 - 7.65 (m, 2H), 7.78 (dt, 1H, J= 7, 2 Hz), 7.83 (m, 1H), 8.26 (s, 1H, br); MS ((+) ESI) m/z 303 (M + H)+.
Reaction of 3-(1',2'-Dihydro-2'-oxospiro[cyclohexane-1,3'-[3H]indol-5'-yl) benzonitrile and Lawesson's reagent according to the procedure in example 1 gave the title compound: mp. >231 °C (decomp.);'H NMR (DMSO-db) 8 1.38 -1.55 (m, 3H), 1.82 - 1.99 (m, 7H), 7.16 (d, 1H, J= 8.1 Hz), 7.63 - 7.69 (m, 2H), 7.80 (d, 1H, J
= 7.7 Hz), 8.01 (d, 1 H, J = 8 Hz) and 12.76 (s, 1 H); MS ((-)-APCI) m/z 317 [M-H]-.
4-(1',2'-Dihydro-2'-thioxospirofcyclohexane-1,3'-[3H~indoll-5'-yl)-2-thiophenecarbonitrile 3-(Trimeth ls~yl)-2-thiophenecarbonitrile. A solution of 3-bromo-2-thiophenecarbonitrile (0.8 g, 4.3 mmol), tetrakis(triphenylphosphine)palladium(0) (0.25 g, 0.2 mmol) and hexamethylditin ( 1.4 g, 4.3 mmol) in dimethoxyethane (5 cm') was heated under reflux for 14 h then cooled to RT. The reaction mixture was absorbed onto florisil and purified by column chromatography (Si02, methylene chloride: hexane 1:9) to afford the subtitled compound ( 1.04 g, 3.8 mmol, 90%) as a clear viscous oil: 'H NMR (CDCl3) 8 0.35 (s, 9H), 7.56 (d, J= 0.9 Hz, 1H), 7.66 (d, J
= 0.9 Hz, 1 H).
4-( 1,2-Dihydro-2-oxospiroCcyclohexane-1,3-(3H]indol]-5-yl)-2-thiophenecarbonitrile A solution of the 5'-bromospiro[cyclohexane-1,3'-[3H] indol]-2'(1'H)-one (0.53 g, 1.9 mmol), dichlorobis(triphenylphosphine) palladium(II) (0.1 g, 0.14 mmol) and triphenylarsine (0.14 g, 0.47 mmol) in dimethoxyethane (8 cm3) was stirred under Nz for 20 minutes. To this mixture was then added 3-(trimethylstannyl)-2-thiophenecarbonitrile (0.64 g, 2.35 mmol). The solution was brought to reflux for 32 h. After cooling to room temperature the reaction mixture was absorbed onto florisil and purified by column chromatography (SiOz, ethyl acetate: hexane 2:3) to afford the subtitled compound (0.43 g, 1.39 mmol, 74%) as an off white solid: 'H NMR
(CDC13) 8 1.56-2.1 (m, lOH), 6.97 (d, J= 8.0 Hz, 1H), 7.39 (dd, J = 8.03, 1.45 Hz, 1H), 7.57 (d, J= 1.45 Hz, 1H), 7.59 (d, J= 1.4 Hz, 1H), 7.84 (d, J= 1.4 Hz, 1H), 8.32 (br s, 1H); '3C-NMR (CDC13) 8 22.07, 26.56, 34.4 (t), 48.13 (s), 110.18 (d), 111.3, 114.75 (s), 122.92, 126.76 (d), 128.44 (s), 137.55 (d), 138.11, 142.71, 144.49, 182.13 (s); MS (EI) m/z 307 (M-H)+; Anal. (C,8H,6NZOS) C, H, N.
A solution of4-(1,2-dihydro-2-oxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-2-thiophenecarbonitrile ( 1.0 g, 3.2 mmol) and Lawesson's Reagent ( 1.3 g, 3.2 mmol) in o-xylene (20 mL) was heated for two and a half hours. The reaction mixture was washed with distilled water (5x100 mL), dried over MgS04, and evaporated. The product was purified by column chromatography (Si02, EtOAc:Hexane 1:5) to afford the title compound (0.2 g, 20%) as a pale-yellow solid: m.p. 230-232 °C; 'H-NMR
(DMSO-db) 8 12.72 (s, 1H), 8.52 (d, 1H, J = 1.5 Hz), 8.36 (d, IH, J = 1.5 Hz), 8.00 (d, 1 H, J = 1.5 Hz), 7.69 (dd, 1 H, J = 6.4, 1.8 Hz), 7.10 (d, 1 H, J = 8.3 Hz), 1.98 - 1.77 (m, 7H), 1.43 - 1.33 (m, 3H); MS (EI) M+ @ m/z 324.
3-(1,2-Dihydro-2-thioxospirolcyclohexane-1,3-l3Hlindoll-5-yl)-5-fluorobenzonitrile To a solution of 5'-bromospiro [cyclohexane-1,3'-[3H]indol]-2'-(1'H)-one (1 lg, 0.04 mol) in dry tetrahydrofuran (200 cm3) was added sodium hydride (60%
dispersion in mineral oil, 1.6 g, 0.04 mol). After 30 min. stirnng at room temperature, the mixture was cooled to -78°C and butyl lithium (1.7M in hexanes, 23.2 cm', 0.04 mol) was added slowly. After 30 min. di-iso-propylborate (25 cm3, 0.11 mol) was added and the mixture was allowed to warm to room temperature.
After 2 hrs. hydrochloric acid (1N, 500 cm3) and ethylacetate (S00 cm3) were added.
The aqueous phase was extracted with ethylacetate, then the combined organic layers were washed with water, brine, dried (MgS04) and evaporated. The residue was triturated with hexane and the precipitate dried in vacuo to obtain (2'-oxo-2, dihydrospiro[cyclohexane-1, 3'- [3H] indol] -5'-yl) boronic acid (8.3 g, 86%) as an off white solid that was used without further purification. A sample that was further triturated with ethyl acetate had the following properties: mp. 255-260°C dec.; 'H
NMR (DMSO-d6) 8 1.50 (m, 2H), 1.73 (m, 8H), 6.82 (d, 1H, J= 7.72 Hz) 7.66 (d, 1H, J= 7.72 Hz) 7.91 (s, 3H, br), 10.36 (s, 1H);MS ((-)ESI) m/z 244 [M-H].
3-( 1,2-Dihydro-2-oxospiro[cyclohexane-1,3-[3H]indoll-5-yl)-5-fluorobenzonitrile.
To a solution of 3,5-dibromofluorobenzene in diethyl ether ( 100 cm3) at -78 °C was added n-butyl lithium (2.5 M, 8 cm', 20 mmol) dropwise. After 30 min. the mixture was treated with DMF (20 cm3) in diethyl ether (10 cm3) and stirring was continued at -78 °C. After 30 min. the mixture was quenched with dilute HCl aq., separated and the aqueous layer was extracted with EtOAc. The combined organic layers were combined, washed with water, brine, dried (MgS04) and evaporated to give 3-fluoro-S-bromobenzaldehyde (4.0 g, 19.7 mmol, 100%) as an oil: 'H NMR
(CDC13) 8 inter alia 7.50 - 7.53 (m, 2H), 7.82 (s, 1H) and 9.93 (m, 1H); MS
(EI) mlz 202, 204 [M+]
To a solution of the last cited compound (4.0 g, 19.7 mmol) in ethanol:water (8:2, 50 cm3), was added sodium acetate (1.72 g, 21 mmol) and hydroxylamine hydrochloride (1.45 g, 21 mmol), and the mixture was heated under reflux.
After 30 min., the mixture was cooled, evaporated and the residue partitioned between water and EtOAc. The aqueous layer was re-extracted with EtOAc and the combined organic layers were washed with water, saturated sodium hydrogen carbonate solution, brine, dried (MgS04) and evaporated to give 3-fluoro-5-bromobenzaldehyde oxime (3.76 g, 17.24 mmol, 87%) which was used without further purification:
'H
NMR (CDCI3) 8 7.24 - 7.27 (m, 2H), 7.50 (s, 1H), 7.68 (s, 1H) and 8.04 (s, 1H); MS
(EI) m/z 217 [M+].
The above oxime (3.76 g, 17.24 mmol) and copper (II) acetate (370 mg) were dissolved in acetonitrile (100 cm') under nitrogen and heated under reflux.
After Sh, the mixture was evaporated, the residue taken into EtOAc, washed with sulfuric acid (1N), water, brine, dried (MgS04) and evaporated to give 3-fluoro-5-bromobenzonitrile (3.08 g, 15.39 mmol, 89%) which was used without further purification.
The above bromide (3.0 g, 15 mmol) and tetrakis(triphenylphosphine)palladium (0) (0.86 g, 0.75 mmol) were dissolved in dimethoxyethane (130 cm3) under nitrogen. After 15 min. (2'-oxo-2, 3-dihydrospiro[cyclohexane-l, 3'- [3H] indol] -5'-yl) boronic acid (2.82 g, 11.5 mmol) and sodium carbonate (3.1 g, 29.3 mmol) dissolved in water (40 cm3) were added, and the mixture heated under reflux. After 8h the mixture was cooled, poured into water and extracted with EtOAc (x3). The combined organic layers were then washed with water, dried (MgS04) and evaporated. The residue was then purified by column chromatography (EtOAc: hexane, gradient elution), and the product recrystallized from methanol to give 3-(1,2-Dihydro-2-oxospiro[cyclohexane-1,3-[3H]indol]-S-yl)-5-fluorobenzonitrile (1.78 g, 5.55 mmol, 48%): mp 199 - 205 °C; 'H
NMR (CDC13) 8 1.64 -2.03 (m, lOH), 7.03 (d, 1H, J= 8 Hz), 7.31 (dt, 1H, J= 7.7 and 1.6 Hz), 7.41 (dd, 1 H, J = 8, 1.7 Hz), 7.49 (dt, 1 H, J = 9.6, 2 Hz), 7.5 8 (d, 1 H, J = 2 Hz), 7.64 (s, 1H) and 8.37 (s, 1H): MS (EI) m/z 320 [M+].
To a solution of 3-(1,2-Dihydro-2-oxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-5-fluorobenzonitrile (0.32 g, 1.0 mmol) in xylenes (10 cm3) under nitrogen was added Lawesson's reagent (0.89 g, 2.22 mmol) and the reaction was heated under reflux. After 4h., the mixture was cooled, evaporated and the residue subjected to column chromatography (Si02, EtOAc: hexane, gradient elution) to afford (0.143 g, 0.42 mmol, 42%) as a white solid: mp. 236-250 °C; 'H NMR (CDCl3) 8 1.54 - 1.66 (m, 3H), 1.86 - 2,18 (m,7H), 7.16 (d, 1H, J= 8.1 Hz), 7.33 - 7.36 (m, 1H), 7.46 - 7.52 (m, 2H), 7.65 (s, 1H), 7.85 (d, 1H, J= 1Hz), 10.05 (s, 1H); MS ((+)-APCI) mlz [M+H]+.
4-Methyl-5-(1,2-dihydro-2-thioxospiro(cyclohexane-1,3-(3Hl-indoll-5-xl)-2-thiophene thioamide 2'-oxo-2',3'-dihydrospiro [cyclohexane-1,3'-[3H]indol]-5'-yl)boronic acid (2.45 g, 10 mmol), 2-bromo-S-cyano-3-methylthiophene (2.4 g, 12 mmol), potassium (4 g, 29 mmol), and tetrakis(triphenylphosphine)palladium(0) (0.6 g, 0.5 mmol) in dimethoxyethane: water: ethanol (130 cm3, 10:2:1) was heated to 80°C
for 16 h., then poured into 1 L of water, and extracted with EtOAc. The organic layer was washed with brine, dried (MgS04) and concentrated. The crude product was subjected to column chromatography (Si02, EtOAc:hexane,l:l) to obtain the title compound (0.9 g, 28%): m.p. 200-203°C; 'H NMR (DMSO-d6) 8 1.63 (m, 8H), 1.87 (m, 2H), 2.27 (s, 3H), 6.95 (d, 1 H, J = 8.13 Hz), 7.34 (dd, 1 H, J = 8.13, 1.98 Hz) 7.54 (d, 1 H, J = 1.98 Hz), 7.82 (S, 1H) 10.50 (S, 1H); MS ((+)APC1) m/z 323 [M + H] +.
A solution of 4-methyl-5-[2'-oxo-2'3'-dihydrospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-2-thiophenecarbonitrile (0.61 g, 1.9 mmol) and phosphorous pentasulfide (0.92 g, 2.1 mmol) in dioxane (17 mL) was heated to 85 °C
for 30 minutes. The reaction mixture was poured into distilled water, and washed with aqueous NaHC03, distilled water, dried over MgS04, and evaporated to dryness.
The residue was purified with column chromatography (2.5% MeOH/CHzCl2) to afford the title compound (O.OSg, 8%) as a orange-brown solid: m.p. 244-249 °C; 'H-NMR
(DMSO-db) b 12.75 (s, 1H), 9.54 (s, 1H), 9.34 (s, 1H), 7.76 (d, 1H, J = 1.5 Hz), 7.58 (s, 1H), 7.45 (dd, 1H, J = 6.4, 1.8 Hz), 7.14 (d, 1H, J = 7.9 Hz), 2.26 (s, 3H), 1.98 -1.89 (m, 7H), 1.83 - 1.81 (m, 3H); MS ((+)APCI) [M+H]+ @ m/z 373.
EXAMPLE 6 - Pharmacology The progestational activity for the compounds of the current invention was evaluated in the in-vitro and in-vivo assays described below. In-vitro potencies lie in the range 0.01 nM - 10,000 nM, and in-vivo potencies in the range 1 ug/kg to mg/kg.
A. In-vitro biology The in-vitro biology is determined by ( 1 ) competitive Radioligand Binding: using the A-form of the human progesterone receptor with progesterone as the radioligand; (2) co-transfection assay, which provides functional activity expressed as agonist ECSO and Antagonist IC50 values; (3) a T47D cell proliferation, which is a further functional assay which also provides agonist and antagonist data;
and (4) T47D cell alkaline phosphatase assay, which is a further functional assay which also provides agonist and antagonist data.
1. hPR Binding a~ssay - This assay is carried out in accordance with: Pathirana, C.; Stein, R.B.; Bergen T.S.; Fenical, W.; Ianiro, T.;
Mais, D.E.; Tones, A.; Glodman, M.E., Nonsteroidal human progesterone receptor modulators from the marine alga cymoplia barbata, J. Steroid Biochem. Mol.
Biol., 1992, 41, 733-738.
2. PRE-luciferase assay in CV-1 cells The object of this assay is to determine a compound's progestational or antiprogestational potency based on its effect on PRE-luciferase reporter activity in CV-1 cells co-transfected with human PR and PRE-luciferase plasmids. The materials methods used in the assay are as follows.
a. Growth medium: DMEM (BioWhittaker) containing 10% (v/v) fetal bovine serum (heat inactivated), 0.1 mM MEM non-essential amino acids, 100U/ml penicillin, 100mg/ml streptomycin, and 2 mM
GlutaMax (GIBCO, BRL). Experimental medium: DMEM (BioWhittaker), phenol red-free, containing 10% (v/v) charcoal-stripped fetal bovine serum (heat-inactivated), 0.1 mM MEM non-essential amino acids, 100U/ml penicillin, 100mg/ml streptomycin, and 2 mM GlutaMax (GIBCO, BRL).
b. Cell culture, transfection, treatment, and luciferase as_ say Stock CV-1 cells are maintained in growth medium.
Co-transfection is done using 1.2x10' cells, 5 mg pLEM plasmid with hPR-B
inserted at Sphl and BamHl sites, 10 mg pGL3 plasmid with two PREs upstream of the luciferase sequence, and 50 mg sonicated calf thymus DNA as carrier DNA in 250 ml. Electroporation is carried out at 260 V and 1,000 mF in a Biorad Gene Pulser II.
After electroporation, cells are resuspended in growth medium and plated in 96-well plate at 40,000 cells/well in 200 ~1. Following overnight incubation, the medium is changed to experimental medium. Cells are then treated with reference or test compounds in experimental medium. Compounds are tested for antiprogestational activity in the presence of 3 nM progesterone. Twenty-four hr. after treatment, the medium is discarded, cells are washed three times with D-PBS (GIBCO, BRL).
Fifty ~1 of cell lysis buffer (Promega, Madison, WI) is added to each well and the plates are shaken for 15 min in a Titer Plate Shaker (Lab Line Instrument, Inc.).
Luciferase activity is measured using luciferase reagents from Promega.
c. Analysis of Results:
Each treatment consists of at least 4 replicates. Log transformed data are used for analysis of variance and nonlinear dose response curve fitting for both agonist and antagonist modes. Huber weighting is used to downweight the effects of outliers. ECSo or ICSO values are calculated from the retransformed values. JMP software (SAS Institute, Inc.) is used for both one-way analysis of variance and non-linear response analyses.
d. Reference Compounds:
Progesterone and trimegestone are reference progestins and RU486 is the reference antiprogestin. All reference compounds are run in full dose-response curves and the ECSO or ICSo values are calculated.
Table 1. Estimated ECSp, standard error (SE), and 95% confidence intervals (CI) for reference progestins from three individual studies EC50 95% CI
Compound Exp. (nM) SE lower upper Progesterone 1 0.616 0.026 0.509 0.746 2 0.402 0.019 0.323 0.501 3 0.486 0.028 0.371 0.637 Trimegestone 1 0.0075 0.0002 0.0066 0.0085 2 0.0081 0.0003 0.0070 0.0094 3 0.0067 0.0003 0.0055 0.0082 Table 2. Estimated ICS°, standard error (SE), and 95% confident interval (CI) for the antiprogestin, RU486 from three individual studies IC 50 95%
CI
Compound Exp. (nM) SE lower upper RU486 1 0.028 0.002 0.019 0.042 2 0.037 0.002 0.029 0.048 3 0.019 0.001 0.013 0.027 Progestational activity: Compounds that increase PRE-luciferase activity significantly (p<0.05) compared to vehicle control are considered active.
Antiprogestational activity: Compounds that decrease 3 nM progesterone induced PRE-luciferase activity significantly (p<0.05) ECS°: Concentration of a compound that gives half maximal increase PRE-luciferase activity (default-nM) with SE.
ICS°: Concentration of a compound that gives half maximal decrease in 3 nM
progesterone induced PRE-luciferase activity (default-nM) with SE.
3. T47D cell proliferation assay The objective of this assay is the determination of progestational and antiprogestational potency by using a cell proliferation assay in T47D cells. A compound's effect on DNA synthesis in T47D cells is measured.
The materials and methods used in this assay are as follows.
a. Growth medium: DMEM: F I 2 ( 1:1 ) (GIBCO, BRL) supplemented with 10% (v/v) fetal bovine serum (not heat-inactivated), 100U/ml penicillin, 100mg/ml streptomycin, and 2 mM GlutaMax (GIBCO, BRL).
b. Treatment medium: Minimum Essential Medium (MEM) (#51200-038GIBC0, BRL) phenol red-free supplemented with 0.5%
charcoal stripped fetal bovine serum, 100U/ml penicillin, 200 mg/ml streptomycin, and 2 mM GlutaMax (GIBCO, BRL).
c. Cell culture Stock T47 D cells are maintained in growth medium. For BrdU incorporation assay, cells are plated in 96-well plates (Falcon, Becton Dickinson Labware) at 10,000 cells/well in growth medium. After overnight incubation, the medium is changed to treatment medium and cells are cultured for an additional 24 hr before treatment. Stock compounds are dissolved in appropriate vehicle (100% ethanol or 50% ethanol/50% DMSO), subsequently diluted in treatment medium and added to the cells. Progestin and antiprogestin reference compounds are run in full dose-response curves. The final concentration of vehicle is 0.1 %. In control wells, cells receive vehicle only. Antiprogestins are tested in the presence of 0.03 nM trimegestone, the reference progestin agonist. Twenty-four hours after treatment, the medium is discarded and cells are labeled with 10 mM
BrdU (Amersham Life Science, Arlington Heights, IL) in treatment medium for 4 hr.
d. Cell Proliferation Assay At the end of BrdU labeling, the medium is removed and BrdU incorporation is measured using a cell proliferation ELISA
kit (#RPN 250, Amersham Life Science) according to manufacturer's instructions.
Briefly, cells are fixed in an ethanol containing fixative for 30 min, followed by incubation in a blocking buffer for 30 min to reduce background. Peroxidase-labeled anti-BrdU antibody is added to the wells and incubated for 60 min. The cells are rinsed three times with PBS and incubated with 3,3'5,5'-tetramethylbenzidine (TMB) substrate for 10-20 min depending upon the potency of tested compounds. Then ~1 of 1 M sulfuric acid is added to each well to stop color reaction and optical density is read in a plate reader at 450 nm within 5 min.
e. Analysis of Results:
Square root-transformed data are used for analysis of variance and nonlinear dose response curve fitting for both agonist and antagonist modes. Huber weighting is used to downweight the effects of outliers.
ECS° or ICS° values are calculated from the retransformed values. JMP software (SAS
Institute, Inc.) is used for both one-way analysis of variance and non-linear dose response analyses in both single dose and dose response studies.
f. Reference Compounds:
Trimegestone and medroxyprogesterone acetate (MPA) are reference progestins and RU486 is the reference antiprogestin. All reference compounds are run in full dose-response curves and the ECS°
or ICS° values are calculated.
Table 3. Estimated ECSp, standard error (SE), and 95% confidence intervals (CI) for individual studies ECS° 95% CI
Compound Exp (nM) SE lower upper Trimegestone 1 0.017 0.003 0.007 0.040 2 0.014 0.001 0.011 0.017 3 0.019 0.001 0.016 0.024 MPA 1 0.019 0.001 0.013 0.027 2 0.017 0.001 0.011 0.024 Table 4. Estimated ICS°, standard error, and 95% confident interval for the antiprogestin, RU486 ICS° 95% CI
Compound Exp (nMl SE lower upper RU486 1 0.011 0.001 0.008 0.014 2 0.016 0.001 0.014 0.020 3 0.018 0.001 0.014 0.022 ECS°: Concentration of a compound that gives half maximal increase in BrdU
incorporation with SE; ICS°: Concentration of a compound that gives half maximal decrease in 0.1 trimegestone induced BrdU incorporation with SE
4. T47D cell alkaline phosphatase assay The purpose of this assay is to identify progestins or antiprogestins by determining a compound's effect on alkaline phosphatase activity in T47D
cells. The materials and methods used in this assay are as follows.
a. Culture medium: DMEM:F 12 ( 1:1 ) (GIBCO, BRL) supplemented with 5% (v/v) charcoal stripped fetal bovine serum (not heat-inactivated), 100U/ml penicillin, 100 pg/ml streptomycin, and 2 mM GlutaMax (GIBCO, BRL).
b. Alkaline php osnhatase assay buffer:
I. 0.1 M Tris-HCI, pH 9.8, containing 0.2% Triton X-100; II. 0.1 M Tris-HCI, pH 9.8 containing 4 mM p-nitrophenyl phosphate (Sigma).
c. Cell Culture and Treatment:
Frozen T47D cells were thawed in a 37°C water bath and diluted to 280,000 cells/ml in culture medium. To each well in a 96-well plate (Falcon, Becton Dickinson Labware), 180 pl of diluted cell suspension was added.
Twenty pl of reference or test compounds diluted in the culture medium was then added to each well. When testing for progestin antagonist activity, reference antiprogestins or test compounds were added in the presence of 1 nM
progesterone.
The cells were incubated at 37°C in a 5% COz/humidified atmosphere for 24 hr.
d. Alkaline Phosphatase Enzyme Assay:
At the end of treatment, the medium was removed from the plate and fifty ~l of assay buffer I was added to each well. The plates were shaken in a titer plate shaker for 15 min. Then 150 ~1 of assay buffer II was added to each well. Optical density measurements were taken at 5 min intervals for 30 min at a test wavelength of 405 nM.
e. Analysis of Results: Analysis of dose-response data For reference and test compounds, a dose response curve is generated for dose (X-axis) vs. the rate of enzyme reaction (slope) (Y-axis).
Square root-transformed data are used for analysis of variance and nonlinear dose response curve fitting for both agonist and antagonist modes. Huber weighting is used to downweight the effects of outliers. ECso or ICSO values are calculated from the retransformed values. JMP software (SAS Institute, Inc.) is used for both one-way analysis of variance and non-linear dose response analyses in both single dose and dose response studies.
f. Reference Compounds:
Progesterone and trimegestone are reference progestins and RU486 is the reference antiprogestin. All reference compounds are run in full dose response curves and the ECso or ICSO values are calculated.
Table 5. Estimated ECSp, standard error (SE), and 95% confidence intervals (CI) for reference progestins from three independent experiments EC50 95% CI
Compound Exp (nM) SE lower upper Progesterone 1 0.839 0.030 0.706 0.996 2 0.639 0.006 0.611 0.669 3 1.286 0.029 1.158 1.429 Trimegestone 1 0.084 0.002 0.076 0.091 2 0.076 0.001 0.072 0.080 3 0.160 0.004 0.141 0.181 Table 6. Estimated ICSp, standard error, and 95% confident interval for the reference antiprogestin RU486 from three independent experiments IC SO 95% CI
Compound Exp (nM) SE lower ~uer RU486 1 0.103 0.002 0.092 0.11 S
2 0.120 0.001 0.115 0.126 3 0.094 0.007 0.066 0.134 B. In-vivo Biology The primary in-vivo assay is the rat decidualization model which may be used to determine progestational effects of both agonists and antagonists. The secondary in-vivo assay is the rat ovulation inhibition model which is under development and hence the protocol is un-available.
1. Rat decidualization assay: The objective of this procedure is used to evaluate the effect of progestins and antiprogestins on rat uterine decidualization and compare the relative potencies of various test compounds.
The materials and methods used in this assay are as follows.
a. Methods: Test compounds are dissolved in 100%
ethanol and mixed with corn oil (vehicle). Stock solutions of the test compounds in oil (MazolaTM) are then prepared by heating (~80 oC) the mixture to evaporate ethanol. Test compounds are subsequently diluted with 100% corn oil or 10%
ethanol in corn oil prior to the treatment of animals. No difference in decidual response was found when these two vehicles were compared.
b. Animals (RACUC protocol #5002 Ovariectomized mature female Sprague-Dawley rats (~60-day old and 230g) are obtained from Taconic (Taconic Farms, NY) following surgery. Ovariectomy is performed at least 10 days prior to treatment to reduce circulating sex steroids.
Animals are housed under 12 hr light/dark cycle and given standard rat chow and water ad libitum.
c. Treatment Rats are weighed and randomly assigned to groups of 4 or 5 before treatment. Test compounds in 0.2 ml vehicle are administered by subcutaneous injection in the nape of the neck or by gavage using 0.5 ml. The animals are treated once daily for seven days. For testing antiprogestins, animals are given the test compounds and a EC50 dose of progesterone (5.6 mg/kg) during the first three days of treatment. Following decidual stimulation, animals continue to receive progesterone until necropsy four days later.
d. Dosing Doses are prepared based upon mg/kg mean group body weight. In all studies, a control group receiving vehicle is included.
Determination of dose-response curves is carried out using doses with half log increases (e.g.
0.1, 0.3, 1.0, 3.0 mg/kg...).
e. Decidual induction Approximately 24 hr after the third injection, decidualization is induced in one of the uterine horns by scratching the antimesometrial luminal epithelium with a blunt 21 G needle. The contralateral horn is not scratched and serves as an unstimulated control. Approximately 24 hr following the final treatment, rats are sacrificed by C02 asphyxiation and body weight measured. Uteri are removed and trimmed of fat. Decidualized (D-horn) and control (C-horn) uterine horns are weighed separately.
f. Analysis of Results:
The increase in weight of the decidualized uterine horn is calculated by D-horn/C-horn and logarithmic transformation is used to maximize normality and homogeneity of variance. The Huber M-estimator is used to down weight the outlying transformed observations for both dose-response curve fitting and one-way analysis of variance. JMP software (SAS Institute, Inc.) is used for both one-way ANOVA and non-linear dose-response analyses.
g. Reference Compounds:
All progestin reference compounds were run in full dose-response curves and the ECSO for uterine wet weight were calculated.
Table 7. Estimated ECSO, standard error (SE), and 95% confidence intervals for individual studies ECS° 95% CI
Compound Exp (m,~/k~, s.c.) SE lower upper Progesterone 1 5.50 0.77 4.21 7.20 2 6.21 1.12 4.41 8.76 3-Ketodesogestrel 0.11 0.02 0.07 0.16 2 0.10 0.05 0.11 0.25 3 0.06 0.03 0.03 0.14 Levonorgestrel 1 0.08 0.03 0.04 0.16 2 0.12 0.02 0.09 0.17 3 0.09 0.02 0.06 0.13 4 0.09 0.02 0.06 0.14 MPA 1 0.42 0.03 0.29 0.60 2 0.39 0.05 0.22 0.67 3 0.39 0.04 0.25 0.61 Table 8. Estimated average ECso~ standard error, and 95% confidence intervals for dose-response curves of 3 reference compounds EC50 95% CI
Compound (m /g-kg SE lower upper s.c.) Progesterone 5.62 0.62 4.55 7.00 3-Ketodesogestrel0.10 0.02 0.07 0.14 Levonorgestrel 0.10 0.01 0.08 0.12 Table 9. Estimated ICSO, standard error, and 95% confident interval for the antiprogestin, RU 486 ICS° 95% CI
Compound Exp. (m~~p.o.) SE lower upper RU 486 1 0.21 0.07 0.05 0.96 1 S 2 0.14 0.02 0.08 0.27 Concentration: Compound concentration in assay(default-mg/kg body weight) Route of administration: Route the compound is administered to the animals Body weight: Mean total animal body weight (default-kg) D-horn: Wet weight of decidualized uterine horn (default-mg) C-horn: Wet weight of control uterine horn (default-mg) Decidual response: [(D-C)/C]x100%
Progestational activity: Compounds that induce decidualization significantly (p<0.05) compared to vehicle control are considered active Antiprogestational activity: Compounds that decrease ECS°
progesterone induced decidualization significantly (p<0.05) ECS° for uterine weight: Concentration of compound that gives half maximal increase in decidual response (default-mg/kg) ICS° for uterine weight: Concentration of compound that gives half maximal decrease in ECSO progesterone induced decidual response (default-mg/kg) Table 10. Data for Representative Compounds Example Ki/nM CV-1 EC50/nM Ovulation #
inhibition mg/kg S 0.3 3 0.1 0.2 1 0.2 0.8 4 0.06 0.1 0.1 Example 7 5-(1,2-Dihydro-2-thioxospirolcyclopentane-1,3-(3Hlindoll-5'-yl)-1H-pyrrole-2 carbonitrile 5-(2'-Oxo-2',3'-dihydrospiro[cyclopentane-1 3'-[3HJindol]-5'-yl-2-cyanopyrrole: A solution of 5'-bromospiro[cyclopentane-1,3'-[3HJ indolJ-2'(1'H)-one (2.0 g, 7.5 mmol) and tetrakis(triphenylphosphine)palladium(0) (430 mg, 0.3 mmol) in ethylene glycol dimethyl ether (50 mL) was stirred under a flow of nitrogen for 15 min. To the solution was added sequentially 1-t-butoxycarbonylpyrrole-2-boronic acid (2.1 g, 9.7 mmol) and potassium carbonate (2.4 g, 17 mmol) in water (10 mL). The mixture was heated to 80 °C for 3 h and allowed to cool. The reaction mixture was poured into water (50 mL) and extracted with ethyl acetate (3 x SO
mL).
The organic layers were combined, washed with brine (30 mL) and dried over magnesium sulfate. The solution was filtered and concentrated in vacuo.
Crystallization from 20% ethyl acetate/hexane gave 2-( 1',2'-dihydro-2'-oxospiro[cyclopentane-1,3'-[3HJindolJ-5'-yl)-1H-pyrrole-1-carboxylic acid, tert-butyl ester (2.2 g, 83%) as a white powder, mp 179-180.5 °C. 'H NMR (DMSO-d6, MHz) 8 1.30 (s, 9H), 1.75-1.98 (m, 8 H), 6.16 (dd, 1 H, J= 1.8, 3.3 Hz), 6.22 ('t', 1 H, J= 3.3, 3.3 Hz), 6.79 (d, 1 H, J= 7.9 Hz), 7.08 (dd, 1 H, J= 1.8, 7.9 Hz), 7.14 ('d', 1 H, J= 1.5 Hz), 7.28 (dd, J= 1.9, 3.3 Hz),10.30 (s, 1 H). MS (EI) mlz [M+]. Anal. Calcd for CZ,HZqN203: C, 71.57; H, 6.86; N, 7.95. Found: C, 71.08;
H, 6.83; N, 7.74.
To a solution of 2-(1',2'-dihydro-2'-oxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-1H-pyrrole-1-carboxylic acid, tert-butyl ester (2.2 g, 6.0 mmol) in THF
(anhydrous, 25 mL) was added at -78 °C chlorosulfonyl isocyanate (0.63 mL, 7.0 mmol). After 90 min, dimethylformamide ( 11 mL, 140 mmol) was added and the reaction was allowed to warm to room temperature. The reaction mixture was poured into water (50 mL) and extracted with ethyl acetate (2 x 50 mL). The organic layers were combined, washed with brine (50 mL), dried over magnesium sulfate, filtered and concentrated in vacuo. Purification via flash column chromatography on silica gel (30% ethyl acetate/hexane) gave 5-(2'-oxo-2',3'-dihydrospiro[cyclopentane-1,3'-[3H]indol]-5'-yl-2-cyanopyrrole-1-carboxylic acid, tert-butyl ester (1.7 g, 75%) as white crystals, mp 167-9 °C. 'H NMR (DMSO-db, 400 MHz) 8 1.34 (s, 9H), 1.75-1.98 (m, 8 H), 6.39 (d, 1 H, J= 3.7 Hz), 6.84 (d, 1 H, J= 7.9 Hz), 7.17 (dd, 1 H, J=
1.8, 7.9 Hz), 7.28 ('t', 2 H), 10.41 (s, 1 H). MS (ESI) m/z 376 [M-H]-. Anal.
Calcd.
for CZZH23N3O3: C, 70.01; H, 6.14; N, 11.13. Found: C, 69.67; H, 6.38; N, 11.04.
5-(2'-Oxo-2',3'-dihydrospiro[cyclopentane-1,3'-[3H]indol]-5'-yl-2 cyanopyrrole-1-carboxylic acid, tert-butyl ester (1 g, 2.7 mmol) was placed in a 25 mL round bottomed flask stoppered with a rubber septum and equipped with nitrogen inlet and a needle to allow gaseous outflow. A vigorous flow of nitrogen was maintained as the flask was placed in an oil bath and heated to 165 °C.
After 20 min at this temperature, the flask was removed from the oil bath and allowed to cool.
Crystallization from ethyl ether gave the title compound (600 mg, 79%) as a yellow powder, mp 285-286 °C. 'H NMR (DMSO-db, 400 MHz) 8 1.75-2.03 (m, 8 H), 6.60 (dd, 1 H, J= 2.4, 3.7 Hz), 6.84 (d, 1 H, J= 8.1 Hz), 6.94 (dd, 1 H, J= 2.4, 3.7 Hz), 7.52 (dd, 1 H, J= 1.8, 8.1 Hz), 7.60 (d, 1 H, J= 1.8 Hz), 10.38 (s, 1 H), 12.45 (s, 1 H). MS (ESI) m/z 276 [M-H]-. Anal. Calcd. For C"H,SN30: C, 73.63; H, 5.45; N, 15.15. Found: C, 73.24; H, 5.34; N, 14.96.
To 5-(1,2-Dihydro-2-oxospiro[cyclopentane-1,3-[3H]indol]-5'-yl)-1H-pyrrole-2-carbonitrile (0.18 g, 0.7 mmol, 1 eq) in p-xylene (20 mL) was added Lawesson's reagent (0.14 g, 0.36 mmol, 0.5 eq) and the reaction was heated to reflux for 1 hour. The reaction was cooled to room temperature and adsorbed onto silica gel. Purification by flash column chromatography (20% ethyl acetate/hexane) on silica gel gave the product as an orange powder. Further purification by HPLC
gave the title compound as a green solid (0.144 g, 70%), mp 275-276 °C
(dec.). 'H NMR
(db-DMSO, 300 MHz) 8 1.81-2.16 (m, 8 H), 6.69 (dd, 1 H, J= 2.3, 3.7 Hz), 6.98 (dd, 1 H, J = 1.8, 3.7 Hz), 7.04 (d, 1 H, J = 8.2 Hz), 7.63 (dd, 1 H, J = 1.6, 8.2 Hz), 7.72 (d, 1 H, J= 1.3 Hz), 12.57 (s, 1 H), 12.65 (s, 1 H). MS (ESI) [M-H)-= 292.
Anal.
Calculated (cald.) for C"H,SN3S: C, 69.6; H, 5.15; N, 14.32. Found: C, 69; H, 5.31;
N, 13.81.
Example 8 5-(1,2-DihYdro-2-thioxospirolcyclohexane-1,3-f3Hlindoll-5-yl)-1-(tert-butoxycarbon~)-pyrrole-2-carbonitrile To a solution of 5'-bromo-spiro[cyclohexane-1,3'-indolin]-2'-one (3.4 g, 12 mmol) in 1,2-DME (100 mL) under a nitrogen atmosphere was added tetrakis(triphenylphospine)palladium(0) (70 mg, S mol%). After 15 min, 2-borono-1H-pyrrole-1-carboxylic acid, 1-tert butyl ester (1.3 eq, 3.31 g, 15.6 mmol) and a solution of KZC03 (2.3 eq, 3.83 g, 27.6 mmol) in water (5 mL) were added sequentially. The solution was heated to 80 °C for 3 h and allowed to cool. The reaction mixture was poured into water (200 mL) and extracted with EtOAc (2 x mL). The organic layers were combined, washed with brine (150 mL) and dried over MgS04. The solution was filtered, concentrated in vacuo, and the residue was purified by flash column chromatography on silica gel (eluting with 30%
EtOAc/hexane) to give 2-(1',2'-dihydro-2'-oxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-1H-pyrrole-1-carboxylic acid, tert-butyl ester (3.4 g, 76%) as a white powder, mp 177 °C. 'H NMR (CDC13; 300 MHz) 8 1.38 (s, 9 H), 1.59-1.93 (m, 10 H), 6.18 (m, 1 H), 6.23 ('t', 1H, 3 Hz), 6.91 (d, 1 H, J--8 Hz), 7.21 (d, 1 H, J--8 Hz), 7.34 (m, 1 H), 7.44 (s, 1 H), 8.33 (br s, 1 H, DZOex). MS ((+)-APCI) m/z 367 [(M+H)+]. Anal.
Calcd for Cz2H26N2~3~ C~ 72.11; H, 7.15; N, 7.64. Found: C, 71.7; H, 7.16; N, 7.5.
To a solution of 2-(1',2'-dihydro-2'-oxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-1H-pyrrole-1-carboxylic acid, tert-butyl ester (0.75 g, 2 mmol) in THF
(anhydrous, 20 mL) at -78 °C was added chlorosulfonyl isocyanate (1.15 eq, 0.23 mL, 2.3 mmol). After 90 min, DMF (20 eq, 3.6 mL, 46 mmol) was added and the reaction was allowed to warm to room temperature. The reaction mixture was poured into water (50 mL) and extracted with ethyl acetate (2 x 50 mL). The organic layers were combined, washed with brine (50 mL), dried over magnesium sulfate, filtered and concentrated in vacuo. Purification via flash column chromatography on silica gel (30% ethyl acetate/hexane) gave 5-(2'-oxo-2',3'-dihydrospiro[cyclohexane-1,3'-[3H]indol]-5'-yl-2-cyanopyrrole-1-carboxylic acid, tert-butyl ester (0.5 g, 63%) as an oil which crystallized from acetone to give white crystals, mp 156 °C.
'H NMR (db DMSO, 400 MHz) 8 1.32 (s, 9H), 1.50 (m, 3 H), 1.60-1.70 (m, 5 H), 1.75-1.85 (m, 2 H), 6.38 (d, 1 H, J= 3.7 Hz), 6.87 (d, 1 H, J= 7.9 Hz), 7.18 (dd, 1 H, J= 1.5, 7.9 Hz), 7.27 (d, 1 H, J= 3.7 Hz), 7.48 (d, 1 H, J= 1.8 Hz), 10.42 (bs, 1 H). MS (EI) m/z 391 (M+). Anal. Calcd for CZ3HZSN3O3: C, 70.57; H, 6.44; N, 10.73. Found: C, 69.82; H, 6.46; N, 10.43.
To a solution oft-Cyano-5-(1,2-Dihydro-2-oxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-1H-pyrrole-1-carboxylic acid, tert-butyl ester (0.7 g, 1.8 mmol, 1 eq) in toluene (70 mL) was added Lawesson's reagent (0.47 g, 1.1 mmol, 0.65 eq) and the reaction was heated to reflux for 1 hour. The reaction was cooled to room temperature, poured into water (100 mL) and extracted with ethyl acetate (2 x mL). The organic layers were combined, washed with brine (50 mL), dried over magnesium sulfate, filtered and concentrated in vacuo. Purification by flash column chromatography (20-30% ethyl acetate/hexane) on silica gel gave title compound as a yellow solid (0.7 g, 96 %). 'H NMR (db-DMSO, 500 MHz) 8 1.30-1.98 (m, 19 H), 6.45 (d, 1 H, J= 3.7 Hz), 7.09 (d, 1 H, J= 7.9 Hz), 7.31-7.34 (m, 2 H), 7.81 (d, 1 H, J
= 1.4 Hz), 12.74 (s, 1 H). MS (ESI) [M-H]- = 406. Anal. calcd. for Cz3HzsN3OzS: C, 67.79; H, 6.18; N, 10.31. Found: C, 67.86; H, 5.99; N, 10.25.
Example 9 5-~-Dihydro-2-thioxospiro[cyclohexane-1,3-[3Hlindol]-S~r~-1-H-pyrrole-2-rarhnnitrilP
To a solution of 5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-1-(tert-butoxycarbonyl)-pyrrole-2-carbonitrile (0.5 g, 1.2 mmol, 1 eq) in THF (5 mL) was added NaOEt (0.25 g, 3.6 mmol, 3 eq) in EtOH (5 mL) and the reaction was heated to 80°C for 24 h. The solvents were removed in vacuo and the residue partitioned between ethyl acetate (50 mL) and water (50 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (50 mL). The organic layers were combined, washed with brine (50 mL), dried over magnesium sulfate, filtered and concentrated in vacuo. Purification by flash column chromatography (30% ethyl acetate/hexane) on silica gel gave the title compound (0.27g, 68%) as a yellow powder. 'H NMR (db-DMSO, 500 MHz) 8 1.32-1.99 (m, 10 H), 6.71 (d, 1 H, J= 3.7 Hz), 7.00 (d, 1 H, J= 3.7 Hz), 7.09 (d, 1 H, J= 8.4 Hz), 7.70 (dd, 1 H, J= 1.6, 8.4 Hz), 8.05 (d, 1 H, J= 1.1 Hz), 12.67 (s, 1 H), 12.73 (s, 1 H). MS
(ESI) [M-H]-= 306. Anal. calcd. for C,BH"N3S: C, 70.33; H, 5.57; N, 13.67.
Found:
C, 69.64; H, 5.79; N, 13.04.
Example 10 5-(2'-thioxospiro[cyclohexane-1,3'-(3Hlindoll-5'-yl~ 1-meth,~pyrrole-2-carbonitrile To a solution of 5-(2'-oxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-1-methyl-pyrrole-2-carbonitrile (0.55 g, 1.8 mmol, 1 eq) in toluene (50 mL) was added Lawesson's reagent (0.47 g, 1.1 mmol, 0.65 eq) and the reaction was heated to 80 °C
for 1 hour. The reaction was cooled to room temperature, poured into water (100 mL) and extracted with ethyl acetate (2 x 100 mL). The organic layers were combined, washed with brine (50 mL), dried over magnesium sulfate, filtered and concentrated in vacuo. Purification by flash column chromatography on silica gel gave the product as a white solid (0.32 g, 55 %). 'H NMR (d6-DMSO, 500 MHz) 8 1.36-1.99 (m, 10 H), 3.7 (s, 3 H), 6.35 (d, 1 H, J= 4.2 Hz), 7.05 (d, 1 H, J= 4.2 Hz), 7.16 (d, 1 H, J=
7.9 Hz), 7.44 (dd, 1 H, J= 1.6, 8.1 Hz), 7.83 (d, 1 H, J= 1.6 Hz), 12.75 (s, 1 H). MS
(ESI) [M-H]-= 320. Anal. calcd. for C,9H,9N3S: C, 70.99; H, 5.96; N, 13.07.
Found:
C, 68.69; H, 5.36; N, 12.27.
Example 11 5-(1,2-Dihydro-2-thioxospirolc~lopentane-1,3-f3Hlindoll-5-vl)-3-thiophenecarbonitrile 5-Bromo-2-thiophenecarbonitrile: A mixture of S-bromo-2-thiophenecarboxaldehyde (96.Og, 500 mmol), hydroxylamine hydrochloride ( 111.9 g, S00 mmol), pyridine (500 mL), and ethanol (500 mL) was heated under nitrogen at reflux for two hours. The reaction mixture was cooled to ambient temperature and concentrated in vacuo to give an oil. The crude product was triturated twice with ice water and the solid obtained was collected on a filter. A mixture of a portion of the above solid (44.31 g, 215 mmol), copper (II) acetate monohydrate (4.2 g, 21 mmol) in acetonitrile ( 1.4L) was heated at reflux for three hours. The solvent was removed in vacuo and the residue was dissolved in ethyl acetate. The solution was washed with 5% aqueous sulfuric acid (2X30 mL), water (2X30 mL), brine (20 mL), and dried (MgS04). The solvent was removed in vacuo and the residue was dissolved in a minimum amount of chloroform ( 1 L) and allowed to crystallize. The crystal obtained was collected on a filter and the filtrate was concentrated and purified by a chromatography (silica gel, chloroform) to give the subtitled compound as an off white solid (3l.Sg combined, 58%). IR (film) cm' 2200. 'H-NMR (CDCI3) 8 7.39-7.38 (d, 1H, J= 4. 1 Hz), 7.10 (d, 1H, J= 4.0 Hz); MS (EI) mlz 187 (M+, 98%) 189(M+, 100%).
5-( 1,2 -dihydro-2-oxospiro[ cyclopentane-1,3-[ 3H]indole]-5-yl)-3-thiophenecarbonitrile was prepared according to the procedure for Example 5 using 5-bromo-2-thiophenecarbonitrile and (2'-oxo-2',3'-dihydrospiro[cyclohexane-1,3'-[3H]indol]-5'-yl) boronic acid: mp. 225-228°C; 'H NMR (DMSO-db) 8 1.63 (m, 8H), 1.90 (m, 2H) 6.91 (d, 1H, J= 8.13 Hz), 7.55 (dd, 1H, J= 8.13 , 1.76Hz), 7.60 (d, 1H, J= 4.17 Hz), 7.75 (d, 1H, J= 1.76 Hz), 7.93 (d, 1H, J= 4.17 Hz), 10.51 (s, 1H); MS
((+)APC1) m/z 309 [M + H]+.
A solution of 5-( 1,2 -dihydro-2-oxospiro[ cyclopentane-1,3-[ 3H]indole]-5-yl)-3-thiophenecarbonitrile (0.66 g, 2.4 mmol ), and 2,4-bis (4-methoxyphenyl )-1,3-dithia-2,4-diphosphetane-2,4-disulfide ( 0.97 g, 2.4 mmol ) in toluene (250 ml) was stirred at 80°C for 2 hours. The solution was concentrated in vacuo.
The residue was extracted with ethylacetate, the ethylacetate solution was washed with water, dried over magnesium sulfate, and concentrated. The residue was purified by column chromatography (silica gel, ethylacetate, hexane 20/80) to afford the title compound, m.p. 269-272 °C (0.24 g, 32% ). 'H-NMR ( DMSO-db ) 8 2.09 ( m, 8H ), 7.05 (d, J--8.1 Hz, 1H ), 7.55 ( dd, J--8.1, 1.7 Hz, 1H ), 7.7 (d, J--1.7 Hz, 1H ), 7.95 (d, J--1.3 Hz,IH ),8.49 ( d, J--1.3 Hz, 1H ), 8.49 (d, J--1.3 Hz, 1H ), 12.68 (s, 1H );
MS ( EI
NEG ) m/z 309 ( M-H )-.
Example 12 1,2-Dihydro - thioxos~ro ( cyclopentane - 1,3-f3 H lindol) - 5- 1 thiophenecarbonitrile The title compound was prepared from 5- (1,2-dihydro-oxospiro(cyclopentane - 1,3- [3 H ] indol )-5 yl ~2-thiophenecarbonitrile (2 g ,6.8 mmol ) and Lawesson's reagent (3.32 g ,8.2 mmol ) heated to reflux in toluene ( 150 mL ) for 3 hours. Yield 1.5 g (48.3 % ).m.p. 250-253~C.'H NMR (DMSO-d6) 8 12.75 ( S,1H),7.98-7.97(d, 1 H,J=3.9Hz),7.71-7.70(d, 1 H,J=5.2Hz),7.65-7.62( d, 1 HJ--8.1 Hz),7.09-7.07(d, 1 H,J=8.1 Hz)2.132.08(m, 6H), 1.99-1.85( m, 2 H ); MS. [ M-H]- = 309 .IR ( SP ATR ) 1430,1620,2220 crri'.Anal.C"H,4NzSz.
calc C,65.77;H,4.55; N , 9.02. obs'd C65.27; H,4.41 ; N , 8.84.
Example 13 5-I 3-Fluoro-4-methoxyphen~piro[cYClohexane-1,3-f3Hlindolel-2(1H)-thione 5-(3-Fluoro-4-methoxyphen~)spiro[cyclohexane-1,3-[3H]indol]-2( 1 H)-one:
Prepared from 4-bromo-2-fluoroanisole and (2'-oxo-2',3'-dihydrospiro[cyclohexane-1,3'-[3H]indol]-5'-yl) boronic acid according to the procedure for example 5 to afford the subtitled compound as a white solid, mp. 178 - 180 °C; 'H-NMR (DMSO
- db) 8 10.4 (s, 1H), 7.65 (d, 1H, J= 1.1 Hz), 7.5 - 7.4 (m, 3H), 7.2 (t, 1H, J= d J=
8.8 Hz), 3.9 (s, 3H), 1.9 (m, 2H) 1.7 - 1.6 (m, 8H); MS (APCI (-)) m/z 324 [M-H]~;
Anal.
Calc. For CzoHz°FNOz. : C, 73.83, H, 6.20, N, 4.30. Found: C, 73.55, H, 6.23, N, 4.40.
The title compound was prepared by refluxing overnight a mixture of 5-(3-Fluoro-4-methoxyphenyl)spiro[cyclohexane-1,3-[3H]indole]-2(1H)-one and an equal weight of phosphorus pentasulfide in pyridine. Removal of the pyridine in vacuo followed by treatment of the residue with 5N hydrochloric acid solution and subsequent recrystallization in ethanol gave a grey solid, mp 228-229°C; 'H-NMR
(DMSO-d6) 8 12.7 (s, 1H), 7.9 (s, 1H), 7.6 - 7.5 (m, 2H), 7.5 - 7.4 (m, 1H), 7.2 (t, 1H, J= 8.8 Hz), 7.1 (d, 1H, J= 8.1 Hz), 3.9 (s, 3H), 1.9 - 1.8 (m, 7H), 1.4 - 1.3 (m, 3H);
MS (APCI (-)) [M-H]-m/z 324. Anal. Cal. for CzoHzoFNOS. 0.25 H20 C, 69.44; H, 5.97; N, 4.05. Found: C, 69.43; H, 5.75; N, 4.32.
Example 14 5-(2-Amino-5-pyrimidin~piro[cyclohexane-1,3-[3Hl indole]-2(1H)-thione Prepared by refluxing overnight a mixture of 5-(2-amino-5-pyrimidinyl)spiro[cyclohexane-1,3-[3H]-indole]-2(1H)-one and an equal weight of phosphorus pentasulfide in pyridine. Removal of the pyridine in vacuo followed by treatment of the residue with 5N hydrochloric acid solution and subsequent recrystallization in ethanol gave a grey solid; mp 274 - 277 °C (dec.);
'H-NMR
(DMSO-db) 8 12.7 (s, 1H), 8.6 (s, 2H), 7.9 (s, 1H), 7.5 (d,lH, J= 8.1 Hz), 7.1 (d, 1H, J= 8.1 Hz), 6.8 (s, 2H), 1.9 -1.8 (m, 7H), 1.4 - 1.3 (m, 3H). MS (APCI (-)) [M-H]~ m/z 309.
Example 15 3-(1,2-Dihydro-2-thioxospirofcyclopentane-1,3-[3Hjindoll-5-X1L
fluorobenzonitrile Spiro(cyclopentane-1,3'-[3H]indol]-2'(1'H)-one To a -25 °C solution of oxindole (2.0 g, 15.0 mmol) in 40 (cm3) of anhydrous THF under NZ was added n-butyllithium ( 1.6 M in hexanes, 19.7 cm3, 31.5 mmol) drop-wise. To the resulting milky solution was added N,N,N',N'-tetramethylethylenediamine (4.75 cm3, 31.5 mmol). After 30 min. a solution of 1,4-diiodobutane (21.9 g, 70.6 mmol) in THF (3 cm3) was added and the reaction mixture was allowed to warm to RT and stirred for 14 h. The reaction mixture was poured into water, extracted with EtOAc (x 2), the combined organic layers were washed with dilute HCl (pH 1) and water (x 2), dried (MgS04) and evaporated. The residue was purified by column chromatography (Si02, EtOAc: hexane 1:4) to afford the subtitled compound (1.4 g, 7.5 mmol, 50%) as a tan solid: 'H NMR (CDCI3) 8 1.8-2.2 (m, 8H), 6.94 (dd, J= 7.5, 1.0 Hz, 1H), 7.01 (dd, J7.5, 1.0 Hz, 1H), 7.14-7.25 (m, 2H), 9.30 (br s, 1 H).
S-Bromo-spiro[cyclopentane-1,3'-(3H]indol]-2'( 1'H)-one A solution of spiro[cyclopentane-1,3'-[3H]indol]-2'(1'H)-one (0.27 g, 1.4 mmol) and sodium acetate (0.12 g, 1.46 mmol) in acetic acid ( 10 cm3) was treated with bromine (0.24 g, 1.51 mmol) in acetic acid (2 cm3). After 30 min. the mixture was poured into sat. sodium hydrogen carbonate solution and extracted with EtOAc (x 2), the combined organic layers were washed with water, sat. sodium hydrogen carbonate solution, water, dried (MgS04), and evaporated to give the subtitled compound (0.37 g, 1.47 mmol, 96 %) as an off white solid which was used without further purification: 'H NMR (CDC13) 8 1.8-2.27 (m, 8H), 6.79 (d, J= 8 Hz, 1H), 7.30-7.39 (m, 2H), 8.63 (br s, 1H).
5'-(3-Cyano-5-fluorophenyl)-spiro [cyclopentane-1,3'-[3H]indol]-2'( 1'H)-one:
A solution of 3-cyano-5-fluoro-bromobenzene (0.5 g, 2.6 mmol), and tetrakis (triphenylphosphine) palladium(0) (0.2 g) in ethylene glycol dimethyl ether (20 cm3) was stirred under Nz for 20 minutes. To this mixture was then (spiro[cyclopentane-1,3'-[3H]indol]-2'(1'H)-one-5-yl) boronic acid (0.9 g, 3.9 mmol) and sodium carbonate (0.8 g, 7.8 mmol) in water (5 cm3). The solution was brought to reflux for 18 hours and then cooled to room temperature, poured into 2N NaOH and extracted with EtOAc (x 3). The combined extracts were washed with water, brine, dried (MgS04), and evaporated. The residue was purified by column chromatography (Si02, EtOAc, hexane) to afford the subtitled compound (0.35 g, 44%) as white needles. mp: 235 - 237 °C; 'H NMR (DMSO-db) 8 10.5 (s, 1H), 8.1 (s, 1H), 8.0 (dt, 1 H, J = 1.7, 2.0, 7.0 Hz), 7.8 - 7.7 (m, 2H), 7.6 (dd, 1 H, J = 1.8, 6.4 Hz), 6.9 (d, 1 H, J
= 8.1 Hz), 2.0 - 1.9 (m, 8H); MS (EI) M+ @ m/z 306.
General Procedure A
The title compound was prepared from S'-(3-Cyano-5-fluorophenyl)-spiro[cyclopentane-1,3'-[3H]indol]-2'(1'H)-one (40 mg) and Lawesson's reagent (50 mg) in toluene ( 10 ml) at reflux in a sealed tube for 16 h. The mixture was concentrated and the residue dissolved in a minimal amount of THF, then purified by HPLC (SiOZ, 30 cm x 2.5 cm, EtOAc-Hexane 2:8 at 20 ml/min.) to afford the title compound (0.022 g) as an off white solid: mp. 236 - 238 °C; 'H NMR
(DMSO-db) 8 12.66 (br s, 1H), 8.11 (s, 1H), 7.97 (dt, 1H, J= 10.1 and 2.2 Hz), 7.79 - 7.76 (m, 2H), 7.68 (dd, 1H, J= 8.1 and 1.7 Hz), 7.07 (d, 1H, J= 8.1 Hz), 2.10 - 2.05 (m, 6H) and 1.97 - 1.88 (m, 2H); MS (EI) m/z 322 [M]+.
Example 16 5-(3-chloropheny_l~l-3,3-dimethyl-1,3-dihydro-2H-indole-2-thione 5-(3-Chloro-phenyl)-3,3-dimethyl-1,3-dihydro-indol-2-one. 5-bromo-1,3-dihydro-3,3-dimethyl-2H-indol-2-one (0.98 g, 4.07 mol) and tetrakis(triphenylphosphine)palladium(0) (0.239 g) were stirred under an atmosphere of nitrogen in dimethoxyethane (35 cm'). After 1 S min., 3-chlorophenylboronic acid (1.27 g, 8.13 mol) was added, followed by potassium carbonate (3.40 g, 45 mmol) in water (15 cm3). The reaction was heated to reflux for 2 hours and then stirred at room temperature overnight. The mixture was diluted with sat. ammonium chloride and extracted with EtOAc (x3). The combined organic layers were dried (MgS04), filtered, and evaporated. The residue was purified by column chromatography (Si02, EtOAc: hexane, 1:3) to afford the subtitled compound (0.284 g, 25%): mp 188 -°C; 'H NMR (DMSO-db) 8 3.34 (s, 6 H), 6.93 (d, 1 H, J= 8.04 Hz), 7.38-7.35 (m, 1 H), 7.53-7.43 (m, 2 H), 7.61 (d, 1 H, J= 7.68 Hz), 7.70 (s, 2 H), 10.40 (s, 1 H); IR
(KBr) 3420, 3150, 3050, 1700 cm'; MS (EI) m/z 270 (M-H)-; CHN calculated for C,6H,4C1N0 + O.1C4H80z: C, 70.21; H, 5.32; N, 4.99; Found: C, 70.3; H, 5.44;
N, 4.93.
The title compound was prepared from 5-(3-Chloro-phenyl)-3,3-dimethyl-1,3-dihydro-indol-2-one ( 100 mg) and Lawesson's reagent ( 120 mg) in toluene ( 10 ml) at reflux, according to General Procedure A, to afford the title compound (0.031 g) as an off white solid: mp. 158 - 160 °C;'H NMR (CDC13) 8 9.67 (br s, 1H), 7.55 (s, 1H), 7.47 - 7.43 (m, 3H), 7.40 - 7.30 (m, 2H), 7.08 (d, 1H, J= 8.7 Hz) and 1.50 (s, 6H);
MS (EI) m/z 287/289 [M]+.
Example 17 3-Benzyl-5-(3-chlorophenyl~-3-methyl-1,3-dihydro-2H-indole-2-thione The title compound was prepared from 3-benzyl-5-(3-chloro-phenyl)-3-methyl-1,3-dihydro-indol-2-one (100 mg) and Lawesson's reagent (120 mg) in toluene (10 ml) at reflux, according to General Procedure A, to afford the title compound (0.022 g) as an off white solid: mp. 168 - 170 °C; 'H NMR
(CDC13) 8 9.23 (br s, 1H), 7.49 (s, 1H), 7.49 - 7.30 (m, 4H), 7.21 (s, 1H), 7.15 - 7.09 (m, 3H), 6.96 - 6.94 (m, 2H), 6.89 (d, 1H, J= 8.0 Hz), 3.19 (dd, 2H, J= 40.5 and 13 Hz) and 1.57 (s, 3H); MS (EI) m/z 363/365 [M]+.
Example 18 4-(3,3-dimethvl-2-thioxo-2,3-dihydro-1H-indol-5-yl)-2-furonitrile 4-(3,3-Dimethyl-2-oxo-2,3-dihydro-1 H-indol-5-yl)-furan-2-carbonitrile.
Prepared according to the procedure for Example 5 using (2'-oxo-[2, 3-dihydro-3,3-dimethyl -l, 3'- [3H] indol] -5'-yl) boronic acid (354 mg, 1.7 mmol) and 4-bromo-furan-2-carbonitrile (200 mg, 1.2 mmol) to afford the subtitled compound (76 mg, 0.3 mmol, 26 %) as a white solid: mp.199.6-201.4 °C , 'H NMR (DMSO-db) 8 1.28 (s, 6H), 6.89 (d, J= 8.0 Hz, 1H), 7.48 (dd, J= 8.0, 1.8 Hz, 1H), 7.65 (d, J= 1.5 Hz, 1H), 8.1 (s, 1H), 8.5 (s, 1H), 10.46 (s, 1H); MS (ESI) m/z 251 (M-H)-; Anal.
C, SH, ZN202Ø6 H20 The title compound was prepared from 4-(3,3-Dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-furan-2-carbonitrile (73 mg) and Lawesson's reagent (120 mg) in toluene ( 10 ml) at reflux, according to General Procedure A, to afford the title compound (0.003 g) as an off white solid: mp. 188 - 191 °C; 'H NMR
(CDC13) b 9.63 (br s, 1H), 7.83 (s, 1H), 7.36 - 7.33 (m, 3H), 7.06 (d, 1H, J= 7.9 Hz) and 1.48 (s, 6H); MS (EI) m/z 268 [M]+.
Example 19 5-(3-methoxYphenyl)-3,3-dimethyl-1,3-dihydro-2H-indole-2-thione 5-bromo-1.3-dihydro-3,3-dimethyl-2H-indol-2-one: 3,3-dimethyl-indol-2-one (0.65 g, 4.03 mmol) and sodium acetate (0.33 g, 4.07 mmol) were stirred in acetic acid (5 cm3) then bromine (0.66 g, 4.13 mmol) in acetic acid (S cm3) was added drop-wise to the reaction mixture. The reaction was stirred for SO min., then poured into water. The mixture was basified with sodium carbonate, extracted with ethyl acetate (x3), dried (MgS04), filtered, and evaporated to give the subtitled compound (0.89 g, 92%)'H NMR (DMSO-db) 8 1.21 (s, 6 H), 6.76 (d, 1 H, J= 8.22 Hz), 7.29 (dd, 1 H, J
= 2.12 Hz, 8.23 Hz), 7.49 (d, 1 H, J= 2.03 Hz), 10.4 (s, 1H).
5-bromo-1,3-dihydro-3,3-dimethyl-2H-indol-2-one (0.33 g, 1.38 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.094 g) were stirred under an atmosphere of nitrogen in dimethoxyethane ( 12 cm3). After 1 S minutes, 3-methoxyphenylboronic acid (0.42 g, 2.76 mmol) was added, followed by potassium carbonate ( 1.15 g, 8.34 mmol) in water (5 cm3). The reaction was heated to reflux for S hours, and then cooled to room temperature. Saturated aqueous ammonium chloride and EtOAc were added and the mixture was filtered. The aqueous layer was extracted with EtOAc (x2), and the combined organic layers were dried (MgS04), filtered, and evaporated. The residue was purified by column chromatography (SiOz, EtOAc: hexane 1:3) to afford 5-(3-methoxy-phenyl)-3,3-dimethyl-1,3-dihydro-indol-2-one (0.1 lg, 31%), mp = 157-158 °C; 'H NMR
(DMSO-db) 8 3.34 (s, 6 H), 3.82 (s, 3 H), 6.87 - 6.93 (m, 2 H), 7.20-7.15 (m, 2 H), 7.37-7.32 (m, 1 H), 7.49-7.46 (m, 1 H), 7.63 (d, 1 H, J= 1.14 Hz), 10.4 (s, 1 H); MS
(EI) mlz 266 (M-H)-; CHN calculated for C"H"NO2: C, 76.38; H, 6.41; N, 5.24; Found: C, 76.02; H, 6.49; N, 5.02.
The title compound was prepared from 5-(3-methoxy-phenyl)-3,3-dimethyl-1,3-dihydro-indol-2-one ( 100 mg) and Lawesson's reagent ( 120 mg) in toluene ( 10 ml) at reflux, according to General Procedure A, to afford the title compound (0.022 g) as an off white solid: mp. 149 - 150 °C; 'H NMR (CDC13) 8 9.69 (br s, 1H), 7.49 -7.46 (m, 2H), 7.37 (t, 1H, J= 8.0 Hz), 7.16 (d, 1H, J= 7.7 Hz), 7.09- 7.06 (m, 2H), 6.90 (dd, 1H, J= 8.2 and 2.3 Hz) 3.88 (s, 3H) and 1.50 (s, 6H); MS (EI) mlz [M]+.
Example 20 3-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-l3Hlindol]'-5-yl~-4-tluorobenzonitrile 3-( 1,2-Dihydro-2-oxospirof cyclohexane-1,3-[3H]indol]-5-yl)-4-fluorobenzonitrile Prepared according to the procedure for Example 5: m.p. 205 - 206 °C. 'H
NMR (DMSO-db) 8 10.47 (s,lH), 8.08 - 8.06 (dd, 1H), 7.89 - 7.85 (m, 1H), 7.65 (s, 1 H), 7.54 -7.49 (m, 1 H), 7.43 - 7.40 (tt, 1 H), 6.95 - 6.93 (d, 1 H J = 7.9 Hz), 1.97 -1.83 (m, 2H), 1.69 - 1.55 (m, 8H); MS (EI) m/z 320 (M+).
The title compound was prepared from 3-(1,2-Dihydro-2-oxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-4-fluorobenzonitrile (100 mg) and Lawesson's reagent ( 120 mg) in toluene ( 10 ml) at reflux, according to General Procedure A, to afford the title compound (0.037 g) as an off white solid: mp.
233 °C; 'H NMR (CDCl3) 8 9.82 (br s, 1H), 7.86 (s, 1H), 7.77 (dd, 1H, J= 7.0 and 1.8 Hz), 7.68 - 7.63 (m, 1 H), 7.45 (d, 1 H, J = 8.0 Hz), 7.31 (d, 1 H, J =
9.0 Hz), 7.15 (d, 1H, J= 8.1 Hz), 2.17 - 1.84 (m, 7 H) and 1.60 - 1.54 (m, 3H); MS (EI) mlz [M]+.
Example 21 5-(1,2-Dihydro-2-thioxospirofcyclohexane-1,3-l3Hlindoll-5-yl)-3 pyridinecarbonitrile A solution of 3-bromopyridine-5-carbonitrile (2.79 g, 15.26 mmol), hexamethylditin (5.00 g, 15.26 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.20 g, 0.17 mmol) in anhydrous dimethoxyethane (30 cm3) under Nz was heated under reflux.. After 16 h the mixture was concentrated and purified by column chromatography (Si02, EtOAc: hexane 5:95) to afford 3-cyanopyridine-5-trimethylstannane (2.82 g, 10.55 mmol, 69%): 'H NMR (CDC13) 8 0.40 (s, 9H), 8.01 (m, 1H), 8.80 (m, 2H); MS ((+) APCI) m/z 269 (M + H)+.
A solution of 5'-bromospiro[cyclohexane-1,3'-[3H] indol]-2'(1'H)-one (1.97 g, 7.05 mmol), 3-cyanopyridine-5-trimethylstannane (2.26 g, 8.46 mmol), bis(triphenylphosphine)palladium(II)chloride (0.33 g, 0.47 mmol) and lithium chloride (1.48 g, 35 mmol) in anhydrous toluene (30 cm3) was heated under reflux.
After 16h the mixture was cooled, partitioned between EtOAc and water, the aqueous layer was re-extracted with EtOAc (x 2), the combined organic extracts were washed with water, dried (MgS04) and evaporated. The residue was subjected to column chromatography (Si02, EtOAc: hexane, 1:2) and then further purified by preparative LC (Primesphere C18, 10 micron, 50 x 250 mm, MeCN: H20 1:1, 100 cm3/min., RT
7.92 min.) to afford 3-(1',2'-dihydro-2'-oxospiro[cyclohexane-1,3'-[3H]indol-5'-yl)pyridine carbonitrile. as white crystals (0.56 g, 1.84 mmol, 26%): mp. 232 -°C, 'H NMR (CDC13) 8 1.68 - 1.89 (m, 6H), 1.93 - 2.13 (m, 4H), 7.12 (d, 1H, J= 8 Hz), 7.49 (dd, 1 H, J = 8, 2 Hz), 7.66 (d, 1 H, 2 Hz), 8.15 (t, 1 H, J = 2 Hz), 8.39 (s, 1 H, br), 8.89 (d, 1 H, J = 2 Hz), 9.06 (d, 1 H, J = 2 Hz); MS ((+)-ESI) m/z 304 (M
+ H)+;
Anal. C,9H"N30 CHN.
The title compound was prepared from 3-( 1',2'-Dihydro-2'-oxospiro[cyclohexane-1,3'-[3H]indol-5'-yl)pyridine carbonitrile (100 mg) and Lawesson's reagent (120 mg) in toluene (10 ml) at reflux, according to General Procedure A, to afford the title compound (0.004 g) as a yellow solid: mp. 237 °C; 'H NMR (CDC13) 8 9.56 (br s, 1 H), 9.03 (d, 1 H, J = 1.9 Hz), 8.87 (d, 1 H, J = 1.4 _76_ Hz), 8.12 (s, 1H), 7.87 (s, 1H), 7.50 (d, 1H, J= 8.1 Hz), 7.17 (d, 1H, J= 8.1 Hz), 2.19 - 1.85 (m, 7H) and 1.59 - 1.54 (m, 3H); MS ((-)-APCI) m/z 318 [M-H]-.
Example 22 5-(3,4-Difluorophenyl)spirofcyclohexane-1,3-[3Hlindolej-2(1H)-thione 5'-(3,5-DifluorophenylZspirojcyclohexane-1,3'-(3H] indolj-2' ( 1'H)-one:
Prepared according to the procedure for Example 5: mp 180-183 °C;
'H-NMR
(CDCl3) 8 8.35 (s, 1H), 7.59 (d, IH, J= 2.0 Hz), 7.40 (dd, 1H, J= 6.2, 2.0 Hz), 7.10 -7.03 (m, 2H), 6.99 (d, IH, J= 8.1 Hz), 7.76 (tt, 1 H, J= 4.3, 2.3 Hz), 2.05 -1.62 (m, l OH); MS ((+)APCI) m/z 314 [M+H]+.
The title compound was prepared from 5'-(3,5-difluorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'(I'H)-one (100 mg) and Lawesson's reagent (120 mg) in toluene (10 ml) at reflux, according to General Procedure A, to afford the product (0.020 g) as a yellow solid: mp. 232 - 233 °C; 'H
1 S NMR (CDCl3) 8 10.05 (br s, 1 H), 7.83 (s, 1 H), 7.44 (dd, 1 H, J = 8.1 and 1.4 Hz), 7.3 8 - 7.30 (m, 1 H), 7.26 - 7. I 9 (m, 3H), 7.11 (d, 1 H, J = 8.1 Hz), 2.17 -1.82 (m, 7H) and 1.66 - 1.53 (m, 3H); MS ((-)-APCI) m/z 328 [M-H]-.
Example 23 5-(5-Chloro-2-thien~)spirolcyclohexane-1,3-f3Hlindolej-2(1H)-thione 5-(S-Chloro-2-thienyl)spirofcyclohexane-1,3-[3Hl indol)-2(1H)-one:
Prepared according to the procedure for Example 5: m.p. 191-192°C , 'H NMR
(CDC13) 8 1.6-2.1 (m, lOH), 6.85-6.95 (m, 2H), 6.98 (d, J= 4.0 Hz, 1H), 7.36 (dd, J=
7.5, 1.6 Hz, 1H), 7.53 (d, J= 0.9 Hz, 1H), 7.80 (br s, 1H);'3C-NMR (THF-d8) 8 21.35, 25.33, 33.12 (t), 48.32 (s), 110.40, 121.66, 121.96, 125.44, 127.25 (d), 128.17, 128.43, 136.92, 140.20, 143.43, 183.72 (s); MS (EI) m/z 318 (M+H)+; Anal.
(C"H,6C1NOS) C, H, N.
The title compound was prepared from 5-(5-Chloro-2-thienyl)spiro [cyclohexane-1,3-[3H] indol]-2(1H)-one (100 mg) and Lawesson's reagent (120 mg) in toluene (10 ml) at reflux, according to General Procedure A, to afford the product _77_ (0.041 g) as a yellow solid: mp. 231 - 232 °C; 'H NMR (CDCl3) 8 9.75 (br s, 1H), 7.82 (d, 1H, J= 1.2 Hz), 7.43 (dd, 1H, J= 8.1 and 1.6 Hz), 7.04 - 7.02 (m, 2H), 6.89 (d, 1H, J= 3.8), 2.15 - 1.84 (m, 7H) and 1.59 - 1.52 (m, 3H); MS ((-)-APCI) mlz 332/334 [M-H]-.
Example 24 5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3Hlindoll-5-~)-3-furancarbonitrile 5-( 1',2'-Dihydro-2'-oxospiro[cyclohexane-1,3'-[3H] indol]-5'-yl)-3-furancarbonitrile:
Prepared according to the procedure for Example 5: m.p. 243 - 245 °C. 'H-NMR (DMSO-d6) 8 10.48 (s, 1H), 8.62 (d, 1H J= 0.7 Hz), 7.76 (d, 1H J= 1.5 Hz), 7.58 -7.55 (dd, 1H), 7.33 (d, 1H J= 0.7 Hz), 6.92 - 6.90 (d, 1H J= 8.1 Hz), 1.87 -1.83 (m, 2H), 1.73 - 1.53 (m, 8H). MS ((+)EI) m/z 292 (M+).
The title compound was prepared from 5-(1',2'-dihydro-2'-oxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-3-furancarbonitrile (100 mg) and Lawesson's reagent ( 120 mg) in toluene ( 10 ml) at reflux, according to General Procedure A, to afford the product (0.020 g) as a yellow solid: mp. 264 - 268 °C; 'H
NMR (CDC13) 8 9.66 (br s, 1H), 7.98 (s, 2H), 7.59 (dd, 1H, J= 8.2 and 1.5 Hz), 7.08 (d, 1H, J= 8.2 Hz), 6.78 (s, 1H), 2.16 - 1.85 (m, 7H) and 1.56 - 1.52 (m, 2H):
MS ((--APCI) m/z 307 [M-H]~.
Example 25 5-(3-Chloro-4-fluorophenyl)spiro f cyclohexane-1,3-f 3H1 indolel-2(1H)- thione 5'-(3-Chloro-4-fluorophen~pirojcyclohexane-1,3'-[3Hlindol]-2'(1'H)-one.
Prepared according to the procedure for Example 5: mp 188-189 °C;
'H-NMR
(CDC13) 8 7.97 (s, 1H), 7.57 - 7.54 (m, 2H), 7.41 - 7.34 (m, 2H), 7.20 (t, 1H, J= 8.7 Hz), 9.96 (d, 1H, J= 8.1 Hz), 2.04 - 1.65 (m, lOH); MS ((+)APCI) mlz 330 [M+H]+.
The title compound was prepared from 5'-(3-Chloro-4-fluorophenyl) _78_ spiro[cyclohexane-1,3'-[3H]indol]-2'(1'H)-one (100 mg) and Lawesson's reagent ( 100 mg) in toluene ( 10 ml) at reflux, according to General Procedure A, to afford the product (0.036 g) as an off white solid: 'H NMR (DMSO-db) 8 12.74 (br s, 1H), 7.92 (d, 1 H, J = 1.4 Hz), 7.87 (dd, 1 H, J = 7.1 and 2.3 Hz), 7.70 - 7.65 (m, 1 H), 7.61 (dd, 1H, J= 7.1 and 1.5 Hz), 7.49 (t, 1H, J= 8.9 Hz), 7.14 (d, 1H, J= 8.1 Hz), 1.99 - 1.82 (m, 7H) and 1.40 - 1.37 (m, 3H): MS ((-)-APCI) mlz 344/346 [M-H]-.
Example 26 ~3-Chloro-5-lluorophenylLpiro[cyclohexane-1,3-f3Hlindolel-2(1H)-thione 5'-(3-Chloro-5-fluorophenyl)spiro[cyclohexane-1,3'-f3H]indol]-2'(1'H)-one:
Prepared according to the procedure for Example 5: mp 178-180 °C;
'H-NMR
(CDC13) 8 8.50 (s, 1H), 7.57 (d, 1H, J= 1.8 Hz), 7.39 (dd, 1H, J= 6.2, 1.9 Hz), 7.33 -7.32 (m, 1 H), 7.15 (dq, 1H, J= 5.7, 1.7, 0.7 Hz), 7.06 (dq, 1 H, J= 4.2, 1.9, 0.4 Hz), 7.00 (d, 1H, J= 8.1 Hz), 2.05 - 1.64 (m, lOH); MS ((-)ESI) [M-H]- @ m/z 328.
The title compound was prepared from 5'-(3-chloro-S-fluorophenyl)spiro [cyclohexane-1,3'-[3H]indol]-2'(1'H)-one (100 mg) and Lawesson's reagent (100 mg) in toluene ( 10 ml) at reflux, according to General Procedure A, to afford the product (0.039 g) as an off white solid: 'H NMR (DMSO-db) 8 12.76 (br s, 1 H), 7.97 (d, 1H, J= 1.1 Hz), 7.67 (dd, 1H, J= 8.1 and 1.4 Hz), 7.60 - 7.54 (m, 2H), 7.40 (dt, 1H, J= 8.65 and 2.0 Hz), 7.14 (d, 1H, J= 8.1 Hz), 1.99 - 1.83 (m, 7H) and 1.41 -1.38 (m, 3H): MS ((-)-APCI) m/z 344/346 [M-H]-.
Example 27 5-(3,5-Difluorophenyl~lspirofcyclohexane-1,3-[3H)indolel-2(1H~I-thione 5'-(3,5-Difluorophenyl)spiro[c~rclohexane-1,3'-[3H]indol]-2'(1'H)-one:
Prepared according to the procedure for Example 5: mp 180-183 °C;
'H-NMR
(CDC13) 8 8.35 (s, 1 H), 7.59 (d, 1 H, J = 2.0 Hz), 7.40 (dd, 1 H, J = 6.2, 2.0 Hz), 7.10 -7.03 (m, 2H), 6.99 (d, 1H, J= 8.1 Hz), 7.76 (tt, 1 H, J= 4.3, 2.3 Hz), 2.05 -1.62 (m, l OH); MS ((+)APCI) mlz 314 [M+H]+.
The title compound was prepared from 5'-(3,5-difluorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'(1'H)-one (100 mg) and Lawesson's reagent (100 mg) in toluene (10 ml) at reflux, according to General Procedure A, to afford the title compound 0.029 g as an off white solid: 'H
NMR
(DMSO-db) 8 12.76 (br s, 1H), 7.84 (s, 1H), 7.64 - 7.56 (m, 1H), 7.46 (d, 1H, J= 8.1 Hz), 7.40 - 7.32 (m, 1H), 7.22 - 7.15 (m, 2H), 1.99 - 1.80 (m, 7H) and 1.38 -1.35 (m, 3H); MS ((-)-APCI) m/z 328 [M-H]-.
Example 28 5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-l3Hlindoll-5-ylLpropyl-2-thiophenecarbonitrile 5-(1,2-Dihydro-2-oxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-4-propyl- 2-thiophenecarbonitrile. The title compound was prepared in a manner similar to Example 5 from 5-bromo-4-n-propyl thiophene-2-carbonitrile ( 1.17 g, 5 mmol ), (1,2-dihydro-2-oxospiro[cyclohexane-1,3-[3H] indol)-5-boronic acid ( 1.24 g, 5 mmol ), tetrakis(triphenylphosphine) palladium, potassium carbonate ( 2.75 g,21 mmol), water ( 10 mL ), and dimethoxyethane (50 mL) heated at reflux over night, to afford the product (0.7 g, 40%): m.p.168-171 °C;'H NMR ( DMSO-db) 8 10.56 ( s,lH ), 7.93 ( s, 1 H ) 7.52-7.51 (d, 1 H, J = 1.5 Hz), 7.33 - 7.29 (dd, 1 H, J = 1.6 Hz), 7.00-6.96 (d, 1H, J= 8.0 Hz), 2.62-2.57 (t, 2H), 1.86 (m, 2H), 1.70-1.56 (m, 11 H), 0.88-0.84 (t, H); MS m/z (APCI (+)) 351 [M+H)+. IR (KBr) 1620,1700,2200 crri'..-.Anal.
Cz,H22N20S~1/2 Hz0 calc. C,70.2; H, 6.39; N, 7.79. Observed. C,70.67; H,6.34;
N,7.62.
The title compound was prepared from 5-(1,2-dihydro-2-oxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-4-propyl- 2-thiophenecarbonitrile (90 mg) and Lawesson's reagent (90 mg) in toluene (10 ml) at reflux, according to General Procedure A, to afford the title compound (0.037 g) as an orange solid: 'H NMR
(DMSO-db) b 12.83 (br s, 1H), 7.96 (s, 1H), 7.77 (s, 1H), 7.44 (d, 1H, J= 7.7 Hz), 7.19 (d, 1H, J= 8.0 Hz), 2.60 (t, 2H, J= 8.0 Hz), 1.98 - 1.79 (m, 7H), 1.64 -1.56 (m, 2H), 1.39 - 1.35 (m, 2H) and 0.87 (t, 3H, J= 7.3 Hz):MS ((-)-APCI) mlz 365 [M-H]-.
Example 29 5-(3-Fluoro-4-nitrophen~piro ~ cyclohexane-1,3-f 3Hl indolel-2(1 H)-thione 5-(3-Fluoro-4-nitrophenyl)spirofcyclohexane-1,3-[3H]indol]-2(1H -one:
Prepared from (2'-oxo-2,3-dihydrospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)boronic acid (3.2 g, 12.5 mmol) and 4-bromo-2-fluoro-nitrobenzene (3 g, 13.6 mmol) as described for example 5, to afford the title compound (0.7 g, 16%) as a yellow solid:
mp. 213-215 °C; 'H NMR (DMSO-db) 8 1.5 - 1.8 (m, 8H), 1.8 - 2.0 (m, 2H), 6.96 (d, 1H, J = 8.13 Hz), 7.68 (dd, 1H, J= 8.13, 1.76 Hz), 7.74 (dd, 1 H, J= 8.68, 1.76 Hz), 7.86 (d, 1 H, J = 1.98 Hz), 7.92 (dd, 1 H, J = 13.4, 1.76 Hz), 8.18 (t, 1 H, J
= 8.46 Hz) and 10.52 (s, 1H); MS (EI) m/z = 340 (M+) The title compound was prepared from 5-(3-fluoro-4-nitrophenyl)spiro [cyclohexane-1,3-[3H]indol]-2(1H)-one (90 mg) and Lawesson's reagent (90 mg) in toluene ( 10 ml) at reflux, according to General Procedure A, to afford the product (0.021 g) as a yellow solid: 'H NMR (DMSO-db) 8 12.82 (br s, 1H), 8.21 (t, 1H, J=
8.4 Hz), 8.07 (d, 1 H, J = 1 Hz), 7.98 (dd, 1 H, J = 13.1 Hz), 7.79 (dt, 1 H, J = 8.1 and 2.6 Hz), 7.19 (1H, J= 8.2 Hz), 1.99 - 1.83 (m, 7H) and 1.42 - 1.39 (m, 3H): MS
((-)-APCI) m/z 355 [M-H]-.
Example 30 X1,2-Dihydro-2-thioxospiro cyclohexane-1,3-f3Hlindol]-5-yll-2-furancarbonitrile 4-( 1,2-Dihydro-2-oxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-2-furancarbonitrile: A solution of 3-bromo-5-cyano-furan (0.75 g, 4.4 mmol), and tetrakis(triphenylphosphine) palladium(0) (0.4 g) in ethylene glycol dimethyl ether (20 cm3) was stirred under NZ for 20 minutes. To this mixture was then added (spiro[cyclohexane-1,3'-[3H]indol]-2'(1'H)-one-5-yl) boronic acid (1.6 g, 6.5 mmol) and sodium acetate ( 1.4 g, 13.1 mmol) in water (5 cm3). The solution was brought to reflux for 18 hours and then cooled to room temperature, poured into 2N NaOH
and extracted with EtOAc (x 3). The combined extracts were washed with water, brine, dried (MgS04), and evaporated. The residue was purified by column chromatography (SiOZ, EtOAc, hexane) to afford the product (0.45 g, 36%) as an off white solid. mp:
240 - 242 °C; 'H NMR (DMSO-db) 8 10.4 (s, 1H), 8.5 (s, 1H), 8.2 (s, 1H), 7.7 (s, 1H), 7.5 (dd, 1H, J= 1.5 6.5 Hz), 6.9 (d, 1H, J= 8.0 Hz), 2.0 - 1.6 (m, lOH); MS
(EI) M+
@ m/z 292.
The title compound was prepared from 4-(1,2-dihydro-2-oxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-2- furancarbonitrile (67 mg) and Lawesson's reagent (67 mg) in toluene (10 ml) at reflux, according to General Procedure A, to afford the title compound (0.018 g) as a yellow solid: 'H NMR
(DMSO-db) 8 12.74 (s, 1H), 8.68 (s, 1H), 8.26 (s, 1H), 7.96 (s, 1H), 7.62 (dd, 1H, J=
8.0 and 1.0 Hz), 7.10 (s, 1H, J= 8.1 Hz), 1.94 - 1.78 (m, 7H) and 1.35 - 1.32 (m, 3H): MS ((-)-APCI) m/z 307 [M-H]-.
Example 31 5"-(3-Chlorophenyl)spirofcyclobutane-1,3"-f3Hlindolel-Z"(1"H?-thione 5-Bromospirojcyclobutane-1,3-[3Hlindoll-2(1H)-one: To a stirred solution of spiro[cyclobutane-1,3'-[3H]indol]-2'(1'I~-one (J. Med. Chem. 1987, 824-9) (1.0 g, 6 mmol) in glacial acetic acid ( 10 mL) was added dropwise at room temperature a solution of bromine (0.30 mL, 6 mmol) in glacial acetic acid (6 mL). After stirnng for 10 min, anhydrous sodium acetate (0.47 g, 6 mmol) was added and the solution was concentrated in vacuo. The residue was dissolved in ethyl ether (50 mL) and washed sequentially with water (50 mL), aqueous saturated sodium bicarbonate solution (50 mL), water (50 mL) and brine (30 mL). The organic layer was dried over magnesium sulfate, filtered and concentrated in vacuo. Crystallization from ethyl ether yielded the product as a white fluffy solid (1.1 g, 73%), mp 235-7 °C. 'H NMR
(DMSO-d6, 300 MHz) 2.15-2.41 (m, 6 H), 6.74 (d, 1 H, J= 8.2 Hz), 7.33 (dd, 1 H, J
= 2, 8.2 Hz), 7.75 (d, 1 H, J = 2 Hz), 10.36 (bs, 1 H). MS (EI) m/z 251 [M+].
Anal.
Calcd for C"H,oBrNO: C, 52.41; H, 4.00; N, 5.56. Found: C, 51.98; H, 4.24; N, 5.42.
To a solution of 5-bromospiro[cyclobutane-1,3-[3H]indol]-2(1H)-one (0.6 g, 2 mmol) in ethylene glycol dimethyl ether (50 mL) under a nitrogen atmosphere was added tetrakis(triphenylphosphine)palladium(0) (140 mg, 0.1 mmol). To the solution was added sequentially 3-chlorophenyl boronic acid (0.48 g, 3 mmol) and potassium carbonate (0.76 g, 5 mmol) in water (5 mL). The mixture was heated to 80 °C for 3 h and allowed to cool. The reaction mixture was poured into water ( 100 mL) and extracted with ethyl acetate (3 x 100 mL). The organic layers were combined, washed with brine (50 mL) and dried over magnesium sulfate. The solution was filtered, concentrated in vacuo, and the residue was purified by HPLC (Zorbax PRO, C18, 10u, 15A, 50 X 250mm; 35% Water/65% AcCN; 254NM; AMB. temp.) to give 5-(3-chlorophenyl)spiro[cyclobutane-1,3-[3H]indole]-2(1H)-one (200 mg, 35%) as a white powder, mp 199.5-201 °C. 'H NMR (DMSO-d6, 300 MHz) 2.21-2.28m, 2 H), 2.40-2.45 (m, 4 H), 6.87 (d, 1 H, J= 8.1 Hz), 7.37 ('d', 1 H), 7.44-7.52 (m, 2 H), 7.65 (bd, 1 H, J= 7.8 Hz), 7.76 (bs, 1 H), 7.92 (bs, 1 H), 10.35 (s, 1 H). MS (EI) mlz 283 [M+]. Anal. Calcd for C"H,QC1N0: C, 71.96; H, 4.97; N, 4.94. Found: C, 70.75;
H, 5.07; N, 4.68.
The title compound was prepared from 5-(3-Chlorophenyl)spiro[cyclobutane-1,3-[3H]indole]-2(1H)-one (55 mg) and Lawesson's reagent (55 mg) in toluene (10 ml) at reflux, according to General Procedure A, to afford the title compound 0.016 g as an orange solid: 'H NMR (DMSO-db) 8 12.58 (br s, 1H), 8.07 (d, 1H, J= 1.5 Hz), 7.82 (t, 1 H, J = 1.7 Hz), 7.70 (d, 1 H, J = 7.74 Hz), 7.60 (dd, 1 H, J = 8.12 and 1.71 Hz), 7.49 (t, 1 H, 7.9 Hz), 7.41 (d, 1 H, J = 8.32 Hz), 7.05 (d, 1 H, J = 8.14 Hz) and 2.57 - 2.27 (m, 6H); MS ((-)-APCI) m/z 298/300 [M-H]-.
Example 32 5"-(2-Chlorophenyl)spirofcyclohexane-1,3"-[3Hlindole]-2"(1"H]-thione The title compound was prepared from 5"-(2-Chlorophenyl)spiro[cyclohexane-1,3"-[3H]indole]-2"(1"H)-thione (90 mg) and Lawesson's reagent (90 mg) in toluene (10 ml) at reflux, according to General Procedure A, to afford the product 0.042 g as an off white solid: 'H NMR (DMSO-db) 8 12.75 (br s, 1H), 7.80 (d, 1H, J= 1.1 Hz) 7.58 - 7.55 (m, 1H), 7.48 - 7.36 (m, 4H), 7.16 (d, 1H, J= 8.0 Hz) ; MS ((-)-APCI) mlz 326/328 [M-H]-.
Exam lp a 33 5"-(4-Chlorophenyl)spirofcyclohexane-1,3"-f3Hlindole-2"(1"H)-thione The title compound was prepared from 5-(4-chlorophenyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-one (90 mg) and Lawesson's reagent (90 mg) in toluene (10 ml) at reflux, according to General Procedure A, to afford the product 0.035 g as an off white solid: 'H NMR (DMSO-db) 8 12.74 (br s, 1H), 7.91 (d, 1H, J= 1.3 Hz), 7.69 (d, 2H, J= 5.5 Hz), 7.60 (dd, 1H, J= 8.1 and 1.4 Hz), 7.50 (d, 2H, J= 8.5 Hz), 7.15 (d, 1H, J= 8.1 Hz), 1.99 - 1.83 (m, 7H) and 1.50 - 1.36 (m, 3H); MS ((-)-APCI) m/z 326/328 [M-H]~.
Example 34 5-(1",2"-Dihydro-2"-thioxospiro[cyclohexane-1,3"-f3HJindoll-5"-xl)- 4-methyl-2-thiophenecarbonitrile 5-Bromo-4-methyl-2-thiophene carboxaldehyde: To a solution of diethylamine (28g, 0.383 mol) in anhydrous THF (400 mL) was added at -40 °C
under nitrogen a solution of n-BuLi (2.5 M, 153 mL, 0.383 mol) in hexane.
After addition, the solution was stirred at -40 °C under nitrogen for 30 minutes, cooled to -78 °C and treated dropwise with a solution of 2-bromo-3-methylthiophene (45g, 0.254 mol) in anhydrous THF (450 mL). The reaction solution was stirred at -78 °C
for 30 minutes and treated with anhydrous DMF (100 mL). The mixture was allowed to warm to ambient temperature and was quenched with 1N aqueous hydrochloride solution (1L). The solution was extracted with ethyl acetate (3x450 mL) and the extracts washed with water, brine and dried (MgS04). After removal of solvent in vacuo, the title compound was obtained as a white solid (46g, 88.3%). A sample of the product was crystallized from hexane: mp 63-65 °C; IR (KBr) 1654 cm-'. 'H-NMR (CDCI3) 8 9.75 (S, 1H), 7.45 (S, 1H), 2.26 (S, 3H); MS (EI) m/z 204/206 (M+).
Anal. Calc. For C6HSBrOS: C, 35.14; H, 2.46. Found: C, 35.00; H, 2.44.
5-Bromo-4-methyl-2-thiophenecarbonitrile: Prepared from 5-bromo-4-methyl-2-thiophene carboxaldehyde using the procedure of Example 5. White solid:
mp 40-42 °C; IR (KBr) 2200 cm'; 'H-NMR (CDC13) 8 7.29 (S, 1H), 2.21 (S, 3H).
MS (EI) m/z 201/203 (M+, 98%/100%); Anal. Calc. For C6H4BrNS: C, 35.66; H, 1.99; N, 6.93. Found: C, 36.00; H, 2.14; N, 6.76.
Prepared according to the procedure for Example 5 using (2'-oxo-[2, 3-dihydro-3,3-dimethyl -l, 3'- [3H] indol] -5'-yl) boronic acid (357 mg, 1.7 mmol) and 5-bromo-4-methylthiophene-2-carbonitrile (295 mg, 1.5 mmol) to afford 5-(3,3-Dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-4-methyl thiophene-2-carbonitrile (227 mg, 0.8 mmol, 55 %) as a white solid: mp. 192.3-193 °C , 'H NMR (DMSO-db) b 1.29 (s, 6H), 2.29 (s, 3H), 6.97 (d, J= 8.0 Hz, 1H), 7.34 (dd, J= 8.0, 1.8 Hz, 1H), 7.49 (d, J= 1.7 Hz, 1H), 7.84 (s, 1H), 10.57 (s, 1H); MS (EI) mlz 282 (m)+; Anal.
C,6H,4NZOS.
The title compound was prepared from 5-(3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-4-methyl thiophene-2-carbonitrile (0.77 g, 2.39 mmol) and phosphorous pentasulfide (0.42 g, 0.96 mmol) in toluene (20 ml) at reflux.
After 3 h, the reaction was cooled and partitioned between water and EtOAc, the organic layer was separated, dried (MgS04) and evaporated. The residue was purified by column chromatography (Si02, EtOAc- hexane gradient elution) to afford the product (0.25 g, 0.73 mmol, 30%) as an orange solid: 'H NMR (DMSO-db) 8 12.82 (br s, 1H), 7.88 (s, 1 H), 7.82 (d, 1 H, 2 Hz), 7.49 (dd, 1 H, J = 8.1, 1.6 Hz), 7.18 (d, 1 H, J =
8.1 Hz), 1.99 - 1.80 (m, 7H) and 1.40 - 1.36 (m, 3H); MS ((-)-APCI) m/z 321 [M-H]-.
Example 35 5-(1",2"-Dihydro-2"-thioxospirofcyclohexane-1,3"-l3Hlindoll-5"- 1~)- 2-thiophenecarbonitrile 5-Bromo-2-thiophenecarbonitrile: A mixture of 5-bromo-2-thiophenecarboxaldehyde (96.Og, 500 mmol), hydroxylamine hydrochloride ( 111.9 g, 500 mmol), pyridine (500 mL), and ethanol (500 mL) was heated under nitrogen at reflux for two hours. The reaction mixture was cooled to ambient temperature and concentrated in vacuo to give an oil. The crude product was triturated twice with ice water and the solid obtained was collected on a filter. A mixture of a portion of the above solid (44.31 g, 215 mmol), copper (II) acetate monohydrate (4.2 g, 21 mmol) in acetonitrile ( 1.4L) was heated at reflux for three hours. The solvent was removed in vacuo and the residue was dissolved in ethyl acetate. The solution was washed with S% aqueous sulfuric acid (2X30 mL), water (2X30 mL), brine (20 mL), and dried (MgS04). The solvent was removed in vacuo and the residue was dissolved in a minimum amount of chloroform ( 1 L) and allowed to crystallize. The crystals obtained was collected on a filter and the filtrate was concentrated and purified by a chromatography (silica gel, chloroform) to give the subtitled compound as an off white solid (3l.Sg combined, 58%). IR (film) cm' 2200. 'H-NMR (CDC13) 8 7.39-7.38 (d, 1H, J= 4. 1 Hz), 7.10 (d, 1H, J= 4.0 Hz); MS (EI) mlz 187 (M+, 98%) 189(M+, 100%).
5-(2'-Oxo-2',3'-dihydrospiro[cyclohexane-1,3'-[3H]indol]-5'yl-2-thiophenecarbonitrile was prepared according to the procedure for Example 5 using 5-bromo-2-thiophenecarbonitrile and (2'-oxo-2',3'-dihydrospiro[cyclohexane-1,3'-[3H]indol]-5'-yl) boronic acid: mp. 225-228°C;'H NMR (DMSO-db) 8 1.63 (m, 8H), 1.90 (m, 2H) 6.91 (d, 1H, J= 8.13 Hz), 7.55 (dd, 1H, J= 8.13 , 1.76Hz), 7.60 (d, 1H, J = 4.17 Hz), 7.75 (d, 1 H, J = 1.76 Hz), 7.93 (d, 1 H, J = 4.17 Hz), 10.51 (s, 1 H); MS
((+)APC 1 ) m/z 309 [M + H]+.
The title compound was prepared from 5-(2'-oxo-2',3'-dihydrospiro[cyclohexane-1,3'-[3H]indol]-5'yl-2-thiophenecarbonitrile (0.69 g) and phosphorous pentasulfide (0.4 g) in toluene (20 ml) at reflux. After 3 h. the reaction was cooled, poured into sat. aqueous sodium hydrogen carbonate solution, and extracted with EtOAc. The organic layer was separated, dried (MgS04) and evaporated. The residue was purified by column chromatography (Si02, EtOAc-hexane gradient elution) to afford the title compound (0.215 g) as an orange solid: 'H
NMR (DMSO-db) 8 12.82 (br s, 1H), 8.00 - 7.98 (m, 2H), 7.74 (d, 1H, J= 4.1 Hz), 7.69 (dd, 1H, J= 8.2 and 1.6 Hz), 7.14 (d, 1H, J= 8.1 Hz), 1.99 - 1.83 (m, 7H) and 1.40 - 1.37 (m, 3H); MS ((-)-APCI) m/z 323 [M-H]-.
Example 36 5"-(3-Fluorophen~piro(cyclohexane-1,3"-(3Hlindolel-2"(1 "H)-thione 5'-(3-Fluorophenyl)spiro(cyclohexane-1 3'-(3H]indol]-2'(1'H)-one' Prepared according to the procedure for Example 5: mp 171-172 °C; 'H-NMR (CDCl3) 8 8.43 (s, 1 H), 7.62 (d, 1 H, J = 1.8 Hz), 7.42 (dt, 1 H, J = 6.2, 2.0 Hz), 7.3 9 -7.3 7 (m, 1 H), 7.33 (dt, 1H, J= 5.1, 1.3 Hz), 7.26 (dq, 1 H, J= 5.9, 2.1 Hz), 7.05 - 6.99 (m, 2H), 2.03 - 1.64 (m, lOH); MS ((+)APCI) m/z 296 [M+H]+.
The title compound was prepared from 5'-(3-fluorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'(1'H)-one (0.70 g) and phosphorous pentasulfide (0.4 g) in toluene (20 ml) at reflux. After 3 h. the reaction was cooled, poured into sat.
aqueous sodium hydrogen carbonate solution, and extracted with EtOAc, the organic layer was separated, dried (MgS04) and evaporated. The residue was purified by column chromatography (SiOz, EtOAc-hexane gradient elution) to afford the product (0.42 g) as an off white solid: 'H NMR (DMSO-db) 8 12.75 (br s, 1H), 7.95 (d, 1H, J=
1.5 Hz), 7.64 (dd, 1H, J= 8.13 and 1.5 Hz), 7.53 - 7.48 (m, 3H), 7.21 - 7.14 (m, 2H), 1.99 - 1.83 (m, 7H) and 1.40 - 1.37 (m, 3H); MS ((-)-APCI) m/z 310 [M-H]-.
Example 37 5-(3-Hydroxyphenyl)spiro(cyclohexane-1,3-(3Hjindole]-2(1H)-thione 5'-(3-Hydroxyphenyl)spiro[cyclohexane-1 3'~3H]indol)-2'(1'H)-one' Prepared according to the procedure for example 5: mp. 213 - 216 °C; 'H NMR
(CDCl3) 8 1.60-1.96 (m, lOH), 6.78 - 6.82 (m, 1H), 6.94 (d, 1H, J= 8 Hz), 7.01 - 7.04 (m, 2H), 7.23 (t, 1 H, J = 7.7 Hz), 7.3 8 (d, 1 H, J = 8 Hz), 7.61 (s, 1 H), 8.91 (s, 1 H) and 9.73 (s, 1 H, br); MS ((+)-APCI) m/z 294 [M+H]+.
The title compound was prepared from 5'-(3-hydroxyphenyl)spiro[cyclohexane-1,3'-[3H]indol)-2'(1'H)-one (100 mg) and Lawesson's reagent (110 mg) in toluene (10 ml) at reflux, according to General Procedure A, to afford the title compound (0.0045 g) as an off white solid: 'H
NMR
(CDC13) 8 9.59 (br s, 1H), 7.89 (s, 1H), 7.49 (dd, 1H, J= 8.1 and 1.5 Hz), 7.33 (t, 1H, _87_ J= 7.9 Hz), 7.15 - 7.10 (m, 3H), 6.84 (dd, 1H, J= 8.0 and 2.2 Hz), 2.17 - 2.05 (m, 2H), 1.98 - 1.88 (m, 5H) and 1.57 - 1.53 (m, 3H): MS ((-)-APCI) m/z 308 [M-H]-.
Example 38 5-(3-chlorophenyl)-3,3-diethyl-1 3-dih~dro-2H-indole-2-thione A solution of oxindole (40 g, 0.3 mol) in dry THF (400 ml) under Nz was cooled to -25 °C and treated drop wise with n-butyl lithium (2.SM in hexanes, 240 ml, 0.6 mol). To the resulting solution was added N,N,N',N'-tetramethylethylenediamine (90.4 ml, 0.6 mol). After 30 min. iodoethane (48 ml, 0.6 mol) was added and the reaction mixture was allowed to warm to room temperature and stirred over night.
The reaction mixture was poured into aqueous NH4C1 solution, extracted with EtOAc (2x) and the combined organic layers were washed with dil. HCI, water, brine, dried (MgS04) and concentrated. The residual oil was triturated with hexane to afford the crude product (24.5 g, 51 %). A sample (3 g) was recrystallized from EtOAc/hexane to obtain 3-ethyl-indol-2-one (1.4 g), m.p. 100 - 101 °C; 'H-NMR (DMSO-db) 8 0.76 (t, 3H, J = 7.5 Hz), 1.8 - 2.0 (m, 2H), 3.38 (t, 3H, J = 5.7 Hz), 6.8 (dt, 1 H, J = 7.69, 0.45 Hz), 6.93 (dt, 1 H, J = 7.45, 1.10 Hz), 7.15 (m, 1 H), 7.22 (m, 1 H), 10.3 (s, 1 H);
MS (ESI) m/z 270 [M+H].
A solution of 3-ethyl-indol-2-one (16 g, 0.1 mol) in dry THF (200 ml) under Nz was cooled to -25 °C and treated drop wise with n-butyllithium (2.5M
in hexanes, 80 ml, 0.2 mol). To the resulting solution was added N,N,N',N' tetramethylethylenediamine (30 ml, 0.2 mol). After 30 min. iodoethane (8 ml, 0.1 mol) was added and the reaction mixture was allowed to warm to RT and stirred over night. The reaction mixture was poured into an aqueous NH4C1 solution, extracted with EtOAc (2x) and the combined organic layers were washed with dil. HCI, water, brine, dried (MgS04) and concentrated. The residual oil was triturated with hexane to afford 3,3-diethylindol-2-one (9 g, 45%), m.p. 156 - 159 °C; 'H NMR
(DMSO-db) 8 10.44 (s, l H), 7.70 - 7.69 (t, l H), 7.62 - 7.59 (m, 1 H), 7.58 (d, l H J--1.7Hz), 7.53-7.50 (m, 1H), 7.45 - 7.41 (t,lH), 7.36 - 7.35 (m,lH), 7.34 - 7.33 (m,lH), 6.91 -6.89 (d,lH
_88_ J--8.2Hz), 1.87 - 1.80 (m,2H), 1.77 - 1.70 (m, 2H), 0.54 - 0.50 (t, 6H); MS
(+ESI) m/z 190 (M+H).
A solution of 3,3-diethylindol-2-one (8 g, 40 mmol) and sodium acetate (4 g, 48 mmol) in acetic acid (100 ml) was treated with bromine (6.4 g, 40 mmol).
After 30 min. the mixture was diluted with water and extracted with EtOAc (2x); the combined organic layers were washed with water, sat. sodium hydrogen carbonate solution, then brine, dried (MgS04) and evaporated to afford the crude product (7.6 g, 75%). A sample was recrystallized from EtOAc/hexane to obtain 5-bromo-1,3-dihydro-3,3-diethyl-[2H]-indol-2-one, m. p. 164 - 165 °C; 'H-NMR (DMSO-db) 8 10.45 (s, 1 H), 7.41-7.40(d, 1 H, J = 2.2Hz), 7.34 - 7.31 (m, 1 H), 6.78 -6.76 (d, 1 H J =
8.2 Hz), 1.78-1.65 (m, 4H), 0.50 - 0.46 (m, 6H); MS (-ESI) m/z 266/268 (M-H).
A solution of 5-bromo-1,3-dihydro-3,3-diethyl-[2H]-indol-2-one (2.7 g, 10 mmol), 3-chlorophenylboronic acid (1.6 g, 10 mmol), potassium carbonate (4 g, mmol) and tetrakis(triphenylphosphine)palladium(0) (0.5 g, 0.4 mmol) in dimethoxyethane ( 100 ml), ethanol (25 ml), and water (25 ml) was heated to reflux for 6 hours. After cooling to room temperature, the mixture was diluted with water and extracted with EtOAc (2x). The combined organic extracts were washed with water, then brine, dried (MgS04) and evaporated. The residue was purified by column chromatography (Si02, EtOAc:hexane 1:3) to afford 5-(3-chloro-phenyl)-3,3-diethyl-1,3-dihydro-indol-2-onecompound (0.8 g, 27%), m.p. 195 - 197 °C; 'H-NMR
(DMSO-db) 8 7.70 (t, 1H, J= 2 Hz), 7.62 - 7.60 (m, 1H), 7.58 (d, 1H, J= 1.7 Hz), 7.52, (dd, 1H, J= 8.1, 2 Hz), 7.43 (t, 1H, 7.9 Hz), 7.36 - 7.33 (m, 1H), 6.90 (d, 1H, J
= 8.1 Hz), 1.87 - 1.70 (m, 4H) and 0.52 (t, 6H, J= 7.4 Hz); MS (+APCI) mlz (M-H).
The title compound was prepared from 5-(3-chloro-phenyl)-3,3-diethyl-1,3-dihydro-indol-2-onecompound (100 mg) and Lawesson's reagent (100 mg) in toluene ( 10 ml) at reflux, according to General Procedure A, to afford the product (0.023 g) as a yellow solid: 'H NMR (DMSO-db) 8 12.73 (br s, 1H), 7.77 (t, 1H, J= 1.8 Hz), 7.75 (d, 1 H, J = 1.6 Hz), 7.68 - 7.62 (m, 2H), 7.48 (t, 1 H, J = 7.9 Hz), 7.40 (d, 1 H, J = 8.3 Hz), 7.09 (d, 1H, J= 8.1 Hz), 2.07 - 2.00 (m, 2H), 1.86 - 1.79 (m, 2H) and 0.37 (t, 6H, J= 7.3 Hz): MS ((-)-APCI) mlz 314/316 [M-H]-.
Examine 39 S 5-f4-Fluoro-3-(trifluoromethyl?phenyl)spirofcYClohexane-1,3- [3Hlindoll 2(1H) thione 5-[4-Fluoro-3-(trifluoromethyl)phenyl]spiro[cyclohexane-1,3- [3H]indol]-2(1H)-one was prepared from (2'-oxo-2,3-dihydrospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)boronic acid (2.5 g, 10 mmol) and 5-bromo-2-fluoro-trifluoromethylbenzene (2 g, 8 mmol) as described for Example 5, to afford the title compound (0.87 g, 30%) as a solid: mp. 222 °C; 'H NMR (DMSO-db) 8 1.5 - 1.8 (m, 8 H), 1.8 - 2.0 (m, 2 H), 6.92 (d, 1 H, J = 8.13 Hz), 7.51 (dd, 1 H, J = 8.13, 1.76 Hz), 7.55 (dd, 1 H, J =
10.54, 9.01 Hz) 7.72 (d, 1 H, J = 1.76 Hz), 7.90 (dd, 1 H, J = 7.03, 2.20 Hz), 7.98 (m, 1 H) and 10.39 (s, 1 H); MS (EI) m/z 363 (M+) The title compound was prepared from 5-[4-Fluoro-3-(trifluoromethyl)phenyl]
spiro[cyclohexane-1,3- [3H]indol]-2(1H)-one (90 mg) and Lawesson's reagent (90 mg) in toluene (10 ml) at reflux, according to General Procedure A, to afford the product (0.016 g) as a yellow solid: 'H NMR (DMSO-db) 8 12.75 (br s, 1H), 8.06 -8.00 (m, 1H), 7.96 - 7.92 (m, 2H), 7.66 - 7.56 (m, 2H), 7.16 (d, 1H, J= 8.1 Hz), 1.99 - 1.83 (m, 7H) and 1.41 - 1.38 (m, 3H): MS ((-)-APCI) m/z 378 [M-H]-.
Example 40 4-(1,2-Dihydro-2-thioxospiro f cyclohexane-1,3-l3Hl indoll-5-y1L
lluorobenzonitrile The title compound was prepared from 4-(1,2-dihydro-2-oxospiro[cyclohexane-1,3-[3H]indol]-S-yl)-2-fluorobenzonitrile (90 mg) and Lawesson's reagent (90 mg) in toluene ( 10 ml) at reflux, according to General Procedure A, to afford the title compound (0.050 g) as an orange solid: 'H NMR
(DMSO-db) 8 12.80 (br s, 1H), 8.04 (d, 1H, J= 1.3 Hz), 7.98 (t, 1H, J= 7.5 Hz), 7.92 (dd, 1 H, J = 1 I .3 and 1.3 Hz), 7.76 (d, 2H, J = 8.0 Hz), 7.18 (d, I H, J =
8.2 Hz), 1.99 - I .82 (m, 7H) and 1.40 - 1.38 (m, 3H); MS ((-)-APCI) m/z 335 [M-H]-.
Example 41 5-( 1,2-Dihydro-2-thioxospiro(cyclohexane-1,3-[3Hl indolj-5-yl) 4-n-but thiophenecarbonitrile The title compound was prepared in a manner similar to Example 5 from 5-bromo-4-n-butyl thiophenecarbonitrile (1.24 g, 5.1 mmol), (1,2-dihydro -2-oxospiro[cyclohexane-1,3-[3H] indol)-5-boronic acid (1.24 g, 5.05 mmol), tetrakis(triphenylphosphine) palladium (0.25 g), potassium carbonate (2.75 g, mmol), water ( 10 mL),and dimethoxyethane (50 mL) heated at reflux for 5 hours to afford 5-( 1,2-dihydro-2-oxospiro[cyclohexane-1,3-[3H] indol]-5-yl) 4-n-butyl-thiophenecarbonitrile (1 g, 54%), m.p.130-132° C. 'H NMR ( DMSO-db ) 8 10.56 (s, IH), 7.92 (s, 1H) , 7.52-7.51 (d, 1H, J= 1.2 Hz ), 7.32-7.29 (dd, 1H, J= 1.5 Hz), 6.98 - 6.96 (d, IH, J= 8.0 Hz), 2.64 - 2.59 (t, 2H), 1.99 - 1.86 (m, 2H), 1.70 -1.50 (m, 11 H), 1.32 - 1.22 (m, 2H) , 0.86 - 0.82 (t, 3H ); MS (APCI (+)) m/z 365 [M+H]+;
IR
(KBr) 1620,1700;2200 cm'; Anal. Cz2Hz4NzOS~1/4 H20. calc. C, 71.61; H, 6.69; N
7.59. observed C, 71.13; H, 6.61; N, 6.91.
The title compound was prepared from S-( 1,2-dihydro-2-oxospiro[cyclohexane-1,3-[3H] indol]-5-yl) 4-n-butyl-2-thiophenecarbonitrile (90 mg) and Lawesson's reagent (90 mg) in toluene (10 ml) at reflux, according to General Procedure A, to afford the product (0.050 g) as an orange solid: 'H
NMR
(DMSO-db) 8 12.83 (br s, 1 H), 7.95 (s, 1 H), 7.77 (s, I H), 7.44 (d, 1 H, J =
8.1 Hz), 7.18 (d, 1 H, J = 8. I Hz), 2.63 (t, 1 H, J .79= 8.0 Hz), 1.99 - 1.77 (m, 7H), I .60 - 1.50 (m, 2H), 1.39 - 1.35 (m, 3 H), 1.29 - 1.22 (m, 2H) and 0.81 (t, 3H, 7.3 Hz):
MS ((-)-APCI) m/z 379 [M-H]-.
Example 42 5-(3-Fluoro-5-methoxyphen~)spirolcyclohexane-1,3-f3Hlindolel-2(1H)-thione The title compound was prepared from 5-(3-Fluoro-5-methoxyphenyl)spiro [cyclohexane-1,3-[3H]indole]-2(1H)-one (90 mg) and Lawesson's reagent (90 mg) in toluene ( 10 ml) at reflux, according to General Procedure A, to afford the product (0.043 g) as an off white solid: 'H NMR (DMSO-d6) 8 12.74 (br s, 1H), 7.90 (s, 1H), 7.63 (dd, 1 H, J = 8.1 and 1.2 Hz), 7.13 (d, 1 H, J = 8.1 Hz), 7.08 (d, 1 H, J
= 10 Hz), S 7.01 (s, 1H), 6.83 (dt, 1H, J= 11 and 2.0 Hz), 1.99 - 1.83 (m, 7H) and 1.40 -1.37 (m, 3H): MS ((-)-APCI) m/z 340 [M-H]~.
Example 43 5-(3-Chlorophenyl)-N-hydroxyspiro(cyclohexane-1,3'-(3Hlindoll-2-amine To a solution of 5'-(3-Chlorophenyl)spiro[cyclohexane-1,3'-[3H]indole]-2'(1'H)-thione (0.74 g, 2.25 mmol) in dry THF (15 ml) was added sodium hydride (60% in oil, 0.1 g, 2.5 mmol) at room temperature. After 15 min., methyl iodide (0.18 ml, 2.88 mmol) was added. After lh, the reaction mixture was partitioned between water and EtOAc, the organic layer was washed with brine, dried (MgS04) and evaporated to give 5-(3-chlorophenyl)-2-(methylthio)spiro[cyclohexane-1,3' [3H]indole] (0.80 g, 100%) which was used without further purification:
To a solution of the last cited compound (1.96 g, 5.73 mmol) in DMSO (20 ml) was added hydroxylamine (60% in water, 5 ml) and the mixture was heated to 120 oC. After lh., the reaction was cooled, partitioned between diethyl ether and saturated aqueous ammonium chloride solution. The organic layer was washed with water and brine and then dried (MgS04) and evaporated. The crude product was then crystallized from MeOH to afford the title compound ( 1.67 g, 5.08 mmol, 89%) as a white solid: 'H NMR (CDCl3) 8 7.52 (t, 1H, J= 1.7 Hz), 7.43 - 7.28 (m, 7H), 6.83 (d, 1H, J= 8 Hz) and 1.98 - 1.51 (m, lOH); MS (ESI (+)) mlz 327/329 [M+H]+.
Example 44 N-(Acetyloxy)-5'-(3-chlorophenvl)spiro(cyclohexane-1,3'-(3Hlindoll-2"amine To a solution of 5-(3-Chlorophenyl)-N-hydroxyspiro[cyclohexane-1,3' [3H]indol]-2-amine (0.23 g, 0.71 mmol) in methylene chloride-methanol (9:1, 10 ml) was added acetic anhydride (0.08 ml, 0.8 mmol) and 4-dimethylaminopyridine (catalytic amount) under a nitrogen atmosphere. After 20 min., the reaction was evaporated and the product purified by column chromatography (Si02, methanol:
methylene chloride 5:95). The product was then triturated with di-iso-propylether to afford the title compound (0.12 g, 0.32 mmol, 45%): 'H NMR (CDC13) 8 7.52 -7.51 (m, 2H), 7.43 - 7.27 (m, SH), 6.88 (d, 1H, J = 8 Hz), 2.27 (s, 3H), 2.04 -1.92 (m, 4H), 1.84 - 1.74 (m, 4H) and 1.72 - 1.57 (m, 2H); MS (ESI (+)) m/z 369/371 [M+H]+; C21 H21 C1N2O2. 0.5 H20 requires C 66.98: H 5.64: N 7.34. Found C
66.74:
H 5.86: N 7.41.
Example 45 5'-(3-Fluorophenyl)spirofcyclohexane-1,3'-f3Hlindol-2'(1'H)-one oxime Prepared according to the method for Example 43 from 5'-(3-fluorophenyl) spiro[cyclohexane-1,3'-[3H]indole]-2'(1'H)-thione (0.59 g, 1.90 mmol) to afford the title compound (0.053 g, 0.17 mmol, 10%): 'H NMR (DMSO-d6) 8 9.59 (s, 1H), 9.40 (s, 1H), 7.57 (d, 1H, J = 1.5 Hz), 7.46 - 7.39 (m, 4H), 7.11 - 7.05 (m, 1H), 6.80 (d, 1H, J = 8.1 Hz), 2.04 -1.97 (m, 2H), 1.82 - 1.74 (m, 2H) and 1.66 - 1.42 (m, 6H):
MS (ESI (-)) m/z 309 [M-H]', C19H19FN20 requires C: 73.53, H: 6.17, N: 9.03.
Found C: 73.33, H: 6.07, N: 8.83.
Exam Ip a 46 5'-(2-Fluorophenyl)spiro[cyclohexane-1,3'-f3H]iindol-2'(1'H)-one oxime 5'-bromospiro{cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O- benzyloxime).
5'-Bromo-2'-(methylthio)spiro[cyclohexane-1,3'-[3H]indole] (9.0 g, 28.98 mmol) and O-benzylhydroxylamine hydrochloride (13.8 g, 86.9 mmol) were combined in methanol ( 150 mL) and heated to 45°C for 6 hours. Methanol was evaporated in vacuo. Ethyl acetate was added to the residue and this mixture was washed with ammonium chloride solution. Ethyl acetate was dried over magnesium sulfate, ethyl acetate collected evaporated in vacuo and the residue was flash chromatographed on alumina 90 (9:1 Hexane/EtOAc) to the desired product (6.5 g, 60%).
1H NMR (DMSO-db, 300 MHz) b 1.38-1.70 (m, 8H), 1.92-2.06 (m, 2H), 5.06 (s, 2H), 6.71 (d, 1 H, J = 8.26 Hz), 7.22-7.43 (m, 7H), 9.62 (s, 1 H).
Procedure A
5'-(2-Fluorophenyl)-spiro[cyclohexane-1,3'-[3H]indol}-2'(1H)-one 2(O-benzyloxime). 5'-Bromospiro{cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O-benzyloxime) (1.0 g, 2.6 mmol), and tetrakistriphenyl phosphine Pd (0) (0.14 g, 0.12 mmol) were stirred under an atmosphere of nitrogen in ethylene glycol dimethyl ether (23 mL). After 15 minutes, 2-flurophenyl boronic acid (0.72 mg, 5.2 mmol) was added, followed by sodium carbonate ( 1.6 g, 15.6 mmol) in water (6.0 mL). The reaction was heated to reflux overnight, cooled to room temperature and filtered through a Celite plug. Saturated ammonium chloride was added. The water layer was extracted with ethyl acetate (3 X 100 mL). The combined organic layers were dried (MgS04), filtered, and the solvent removed in vacuo. The product was purified by flash silica gel chromatography; (eluant: 10:0.5 hexane: ethyl acetate) to give the desired target compound (0.75 g, 1.8 mmol, 72%) as a viscous oil. 'H NMR (500 MHz, DMSO-db) 8 1.44 - 1.73 (8H, m) 1.93 - 2.06 ( 2H, q) 5.00 (2H, s) 6.88 (1H, d, J-- 8.1 Hz) 7.24 - 7.38 (6H, m) 7.44 - 7.56 (5H, m) 9.64 (1H, s); MS (ESI(+
ve)) mlz 399 (M-H)'.
Procedure B
A solution of 5'-(2-Fluorophenyl)-spiro[cyclohexane-1,3'-[3H]indol}-2'(1H)-one 2(O-benzyloxime) (0.55 g, 1.37 mmol) in ethanol(15 mL) was added to Palladium on carbon ( 10%, 0.11 g) in ethanol ( 10 mL). The mixture was stirred under an atmosphere of hydrogen (balloon) for 24 h at room temperature. The reaction mixture was filtered through a Celite plug and the filtrate was concentrated in vacuo.
The product was purified by flash silica gel chromatography (hexane: ethyl acetate, gradient elutions) to give the title compound (0.45 g, 1.12 mmol, 82%), mp.
203 °C; 'H NMR (500 MHz, DMSO-db) 8 1.45 - 1.73 (8H, m) 1.96 - 2.00 (2H, q) 6.83 (1H, d, J-- 7.9) 7.23 - 7.50 (6H, m) 9.42 (1H, s) 9.58 (1H, s); MS (ESI(+ ve)) m/z 311 (M+H)+.
Example 47 5'-(4-Fluorophenyl)spirofcyclohexane-1,3' [3H~'indol 2' 1'H) one oxime 5'-(4-Fluorophenyl)-spiro[cyclohexane-1,3'-[3H)indol}-2' (1'H)-one 2'(O-benzyloxime). Prepared from 5'-bromospiro{cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O- benzyloxime) ( 1.0 g, 2.6 mmol), and 4-fluorophenyl boronic acid (0.72 g, 5.2 mmol) according to Example 46 procedure A. The product was purified by flash silica gel chromatography; (eluant: 10:0.5 hexane: ethyl acetate) to give the desired product (0.70 g, 1.7 mmol, 67 %) as a viscous oil. 'H NMR (500 MHz, DMSO-db) 8 1.42 - 1.77 (8H, m) 1.95 - 1.99 (2H, q) 5.00 (2H, s) 6.84 (1H, d, J-- 8.1 Hz) 7.21 -7.63 (1H, m) 9.58 (1H, s); MS (ESI(- ve)) m/z 399 (M-H)-.
The product was synthesized using 5'-(4-Fluorophenyl)-spiro[cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O-benzyloxime) (0.70 g, 1.74 mmol), according to Example 45 procedure B. The product was purified by flash silica gel chromatography; (hexane: ethyl acetate, gradient elution) to give the title compound (0.44 g, 1.4 mmol, 81 %), Mp. 205 - 208°C; 'H NMR (500 MHz, DMSO-db) 8 1.43 -1.77 (8H, m) 2.00 - 2.05 (2H, q) 6.80 (1H, d, J-- 8.2 Hz) 7.21 - 7.24 (2H, m) 7.33 -7.35 (1H, dd, J-- 1.9 Hz) 7.49 (1H, s) 7.60 - 7.63 (2H, m) 9.35 (1H, s) 9.56 (1H, s);
MS (ESI(+ ve)) m/z 311 (M+H)+.
Example 48 5'-(3 4-difluorophenyl)spiro[cyclohexane-1,3' [3Hlindol 2'(1'H) one oxime 5'-(3,4-Difluorophenyl)-spiro[cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O-benzyloxime). Prepared from 5'-bromospiro{cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O- benzyloxime) ( 1.0 g, 2.6 mmol) and 3,4 -diflurophenyl boronic acid ( 1.6 g, 5.2 mmol of a 50 % solution of acid in THF/water) according to Example 46 procedure A. The product was purified by flash silica gel chromatography (eluant: 10:
0.5 hexane: ethyl acetate) to give the desired product (0.75 g, 1.7 mmol, 69 %) as a viscous oil. 'H NMR (500 MHz, DMSO-db) 8 1.41 - 1.78 (8H, m) 1.95 - 1.99 (2H, q) 5.00 (2H, s) 6.82 ( 1 H, d) 7.28 - 7.46 (8H, m) 7.58 ( 1 H, q) 7.67 - 7.71 ( 1 H, m) 9.61 (1H, s); MS (ESI(- ve)) m/z 417 (M-H)-.
Reaction of the last cited compound (0.70 g, 1.6 mmol) according to Example 45 procedure B, afforded the title compound (0.44 g, 1.3 mmol, 80 % ), 'H NMR
(500 MHz, DMSO-db) 8 1.42 - 1.79 (8H, m) 2.01 - 2.05 (2H, q) 6.78 - 6.80 (1H, d) 7.39 - 7.46 (3H, m) 7.55 (1H, s) 7.70 (1H, m) 9.10 (1H, s) 9.59 (1H, s); MS
(ESI(+
ve)) m/z 329 (M+H)+.
Exam In a 49 5'-(3-methoxyphenYlLpirolcyclohexane-1,3'-f3Hlindol-2'(1'H)-one oxime 5'-(3-Methoxyphenyl)-spiro[cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O-benzyloxime). Prepared from 5'-bromospiro{cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O- benzyloxime) ( 1.0 g, 2.6 mmol) and 3-methoxyphenyl boronic acid (0.79 g, 5.2 mmol) according to Example 46 procedure A. The product was purified by flash silica gel chromatography; (eluant: 10:0.5 hexane: ethyl acetate) to give the desired product (0.80 g, 1.9 mmol, 75 %) as a viscous oil. 'H NMR (500 MHz, DMSO-db) 8 1.43 - 1.78 (8H, m) 1.95 - 2.00 (2H, q) 3.80 (3H, s) 5.00 (2H, s) 6.82 - 6.86 (2H, m) 7.10 - 7.16 (2H, m) 7.28 - 7.53 (IOH, m) 9.57 (1H, s); MS (ESI(- ve)) m/z 411 (M-H)-Reaction of the last cited compound (0.80 g, 1.9 mmol) according to Example 46 procedure B, afforded the title compound (0.48 g, 1.4 mmol, 77 %), as a white solid. Mp. 101 - 104°C; 'H NMR (500 MHz, DMSO-db) 8 1.44 - 1.78 (8H, m) 1.99 -2.03 (2H, q) 3.81 (3H, s) 6.78 (1H, d) 6.85 (1H, d) 7.10 - 7.16 (2H, m) 7.30 -7.38 (2H, m) 7.50 (1H, d) 9.35 (1H, s) 9.56 (1H, s); MS (ESI(+ ve)) m/z 323 (M+H)+.
Example 50 5'-(3-nitrophenyl)spirofcyclohexane-1,3'-l3Hlindol-2'(1'H)-one oxime 5'-(3-Nitrophenyl)-spiro[cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O-benzyloxime). Prepared from 5'-bromospiro{cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O- benzyloxime) ( 1.0 g, 2.6 mmol) and 3-Nitrophenyl boronic acid (0.86 g, 5.2 mmol) according to Example 46 procedure A. Purification by flash silica gel chromatography (eluant : 10:0.5 hexane: ethyl acetate) afforded the desired compound (0.60 g, 1.4 mmol, 55 %) as a viscous oil. 'H NMR (500 MHz, DMSO-db) 8 1.42 - 1.82 (8H, m) 2.02 - 2.04 (2H, q) 5.01 (2H, s) 6.88 (1H, d) 7.28-7.71 (8H, m) 8.08 - 8.13 (2H, m ) 8.38 (1H, d) 9.69 (1H, s); MS (ESI(- ve)) m/z 426 (M-H) -.
Procedure C
The last cited compound (0.54 g, 1.26 mmol) was dissolved in dry methylene chloride (25 mL) and cooled to -78 °C under nitrogen. Boron tribromide (3.8 mL, 3.8 mmol, 1.0 M in methylene chloride) was added drop-wise over 5 minutes. After minutes the reaction was quenched with saturated sodium bicarbonate (5 mL).
The reaction mixture was allowed to warm to room temperature, the layers were separated and the aqueous layer was extracted with methylene chloride. The combined organic layers were dried (NazS04), filtered, and the solvent removed in vacuo. The product was purified by flash silica gel chromatography (eluant: 8:1 hexane: ethyl acetate) to give afford the title compound (0.33 g, 0.9 mmol, 78 %). Mp. 221 - 224 °C; 'H
NMR (500 MHz, DMSO-db) 8 1.42 - 1.83 (8H, m) 1.99 - 2.07 (2H, q) 6.84 - 6.85 (1H, dd) 7.50 - 7.52 (1H, m) 7.67 - 7.71 (2H, m) 8.08 - 8.12 (2H, m) 8.37 -8.38 (1H, d) 9.48 (1H, s) 9.64 (1H, s); MS (ESI(+ ve)) m/z 338 (M+H)+.
Example 51 5'-( 3-c,~phen~l?spiro[cyclohexane-1,3'-[3Hlindol-2'(1'H)-one oxime 3-Lpiro Lcyclohexane-1 3'-f 3H]indol]-( 1'H)-one-2'-(O-benzyloxime)lbenzonitrile f3H]indol]-5-yllbenzonitrile. Prepared from 5'-bromospiro{cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O- benzyloxime) (1.0 g, 2.6 mmol) and 3-cyanophenyl boronic acid (0.76 g, 5.2 mmol) according to Example procedure A. The product was purified by flash silica gel chromatography (eluant: 10:
0.5 hexane: ethyl acetate) to give the desired product (0.75 g, 1.8 mmol, 71 %) as a viscous oil.'H NMR (500 MHz, DMSO-db) 8 1.41 - 1.81 (8H, m) 1.96 - 2.03 (2H, q) 5.01 (2H,s)6.86(lH,d)7.28-7.33(9H,m)7.95-7.97(lH,d)8.12(lH,s)9.65 (1H, s); MS (ESI(- ve)) mlz 406 (M-H)-.
Reaction of the last cited compound (0.17 g, 0.43 mmol) and boron tribromide (1.2 mL, 1.2 mmol) according to Example SO procedure C afforded the title compound (0.06 g, 0.2 mmol, 47 %) as a white solid, Mp. 198 - 200°C; 'H
NMR
(500 MHz, DMSO-db) 8 1.41 - 1.80 (8H, m) 1.97 - 2.04 (2H, q) 6.80 (1H, q) 7.45 -7.69 (4H, m) 7.93 - 7.95 ( 1 H, dd) 8.10 ( 1 H, s) 9.42 ( 1 H, s) 9.59 ( 1 H, s); (ESI(+ ve)) mlz 318 (M+H)+.
Example 52 3-11',2'-Dihydro-2'-(hydrox 'mino)spiro[cyclohexane-1,3'-f3H]indoll-5'x11-5-fluorobenzonitrile To a solution of 3-fluoro-5-cyano-bromobenzene (0.4 g, 2.0 mmol) in dry DMF ( 10 ml) was added diboron pinacolate ester (0.63 g, 2.5 mmol), potassium acetate (0.65 g, 6.7 mmol) and PdClz (dppf) (0.2. g) and the reaction was heated to 80 °C under a nitrogen atmosphere. After 8 h. from 5'-bromospiro{cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O- benzyloxime) (0.2 g, 0.5 mmol), PdCl2 (dppf) (0.05 g) and sodium carbonate (1.30 g, 12.5 mmol) were added and heating at 80 °C was continued. After 8h. the reaction was cooled and partitioned between water and ethyl acetate, the organic layer was washed with brine, dried (MgS04) and evaporated. The residue was purified by column chromatography (Si02, EtOAc:hexane 1:20) to give the desired product (0.14 g, 0.33 mmol, 66%).
Reaction of the last cited compound (0.14 g, 0.33 mmol) and boron tribromide ( 1.0 ml, 1.0 mmol) according to Example 50 procedure C afforded the title compound (0.019 g, 0.05 mmol, 17%): 'H NMR (300 MHz, DMSO-db) 8 9.65 (s, 1H), 9.49 (s, 1 H), 8.04 (m, 1 H), 7.89 (dt, 1 H, J = 10.5 and 2 Hz), 7.72 - 7.68 (m, 2H), 7.54 (d, 1 H, J= 8.1 Hz), 6.80 (d, 1H, J= 8.1 Hz), 2.05 - 1.99 (m, 2H), 1.84 - 1.76 (m, 2H) and 1.65 - 1.44 (m, 6H): MS (ESI(+ ve)) m/z 336 (M+H)+.
Examine 53 5-(Spiro f cyclohexane-1,3'-(3Hl indoll-2'-(hvdroxvimino)-5'-yl)-4-methyl-2 thiophenecarbonitrile 4-Methyl-5-trimethylstannanyl-thiophene-2-carbonitrile Prepared from 5-bromo-4-methyl-thiophene-2-carbonitrile (3.08 g, 15.2 mmol), tetrakistriphenyl phosphine Pd (0) (0.82 g, 0.71 mmol), hexamethylditin (5.0 g, 15.2 mmol) and ethylene glycol dimethyl ether (20 mL) under nitrogen. The mixture was heated to reflux for 14 hours. The reaction mixture was concentrated in vacuo and purified using flash silica gel chromatography (eluant: 2% MeOH: methylene chloride) to recover the desired roduct (2.8 g, 0.01 mmol, 67 %) as a runny oil. 1H NMR
(300 MHz, DMSO-db) 8 0.41 (9H, s), 2.28 (3H, s), 7.83 (1H, s).
The last cited compound (0.20 g, 0.50 mmol), dichlorobis (triphenylphosphine) palladium(II) (0.02 g, 0.03 mmol) and triphenylarsine (0.03 g, 0.13 mmol) in DME (8.0 mL) were stirred under nitrogen for 20 minutes. 5'-Bromospiro{cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O- benzyloxime) (0.18 g, 0.64 mmol) was added in a solution of DME (2.0 mL). The solution was heated to reflux overnight. The reaction solution was concentrated in vacuo and purified by flash silica gel chromatography (eluant 12:1 hexane : ethyl acetate) to give the crude product(0.10 g, 0.25 mmol, 50%) which was used without further purification Boron tribromide (2.6 mL, 2.6 mmol of a 1.0 M solution in methylene chloride) was added to a solution of the last product (0.37 g, 0.86 mmol) in dry methylene chloride ( 1.7 mL) at -78°C. The solution was stirred for 30 minutes and quenched with saturated sodium bicarbonate (10 mL). The mixture was allowed to warm to room temperature and the layers were separated. The organic layer was dried (NazS04), filtered and concentrated in vacuo to give crude product which was purified by flash silica gel chromatography (eluant: 6:1 hexane: ethyl acetate) to give the title compound (0.02 g, 24 %): Mp. 173-176 °C; 'H NMR (500 MHz, DMSO-db) 8 1.44 -1.73 (8H, m), 1.96 - 2.00 (2H, m), 2.28 (3H, s), 6.82 - 6.84 (1H, m), 7.24 -7.26 (1H, dd, J-- 1.7 Hz), 7.3 8 ( 1 H, m) 7.82 ( 1 H, m) 9.51 ( 1 H, m) 9.66 ( 1 H, m);
MS (ESI(+ ve)) m/z 338 (M+H)+.
Example 54 5-(Spiro[cyclohexane-1,3'-f3Hlindole]-2'(hydroxyimino)-5'-yl)-2-thiophenecarbonitrile To a solution of 2-cyanothiophene ( 1.0 g, 9.16 mmol) and tri-iso-propylborate (2.3 ml, 10 mmol) in dry THF (30 ml) under nitrogen at -78 °C was added, dropwise, lithium hexamethyldisilazide (1M in THF, 10 ml, 10 mmol). After 30 min., the reaction was quenched with 1N HCI, then extracted with ethyl acetate, the organic layer was washed with water, dried (Na2S04) and evaporated to the product (1.25g, 8.17 mmol, 89%) which was used without further purification: 'H NMR (500 MHz, DMSO-db) 8 8.75 (br s, 2H), 7.97 (d, 1H, J= 8 Hz) and 7.73 (d, 1H, J= 8 Hz):
MS
(ESI(- ve)) m/z 152 (M-H)-.
Prepared from the last cited product (0.91 g, 5.95 mmol) and 5'-bromospiro{cyclohexane-1,3'-[3H)indol}-2' (1'H)-one 2'(O- benzyloxime) (1.53 g, 3.97 mmol) according to Example 46 procedure A. Purification by flash silica gel chromatography (eluant: 5: 1 hexane: THF) gave the desired product (0.66 g, 1.59 mmol) which was used without further purification: MS (ESI(- ve)) m/z 412 (M-H)-.
Reaction of the last cited compound (0.60 g, 1.45 mmol) and boron tribromide (1M in dichloromethane, S mL, 5 mmol) according to Example 50 procedure C afforded the title compound (0.036 g, 0.11 mmol, 8 %): 'H NMR (300 MHz, DMSO-db) 8 9.71 (s, 1H), 9.62 (s, 1H), 7.92 (d, 1H, J= 3.9 Hz), 7.63 (d, 1H, J
= 1.5 Hz), 7.54 (d, 1H, J = 3.9 Hz), 7.47 (dd, 1H, J= 8.1 and 1.6 Hz), 6.78 (d, 1H, J
= 8.1 Hz), 2.13 - 1.90 (m, 2H) and 1.78 - 1.60 (m, 6H): MS (ESI(+ ve)) m/z 324 (M+H)+.
Example 55 4-(Spiro(cyclohexane-1,3'-l3Hlindole)-2'(h~yimino~l-5'-y1L
thiophenecarbonitrile 4-(Trimethylstann~)-2-thiophenecarbonitrile A solution of 3-bromo-2-thiophenecarbonitrile (0.8 g, 4.3 mmol), tetrakis(triphenylphosphine)palladium(0) (0.25 g, 0.2 mmol) and hexamethylditin (1.4 g, 4.3 mmol) in dimethoxyethane (5 cm3) was heated under reflux for 14 h then cooled to RT. The reaction mixture was absorbed onto florisil and purified by column chromatography (Si02, methylene chloride: hexane 1:9) to afford the subtitled compound ( 1.04 g, 3.8 mmol, 90%) as a clear viscous oil: 1H NMR (CDC13) 8 0.35 (s, 9H), 7.56 (d, J= 0.9 Hz, 1H), 7.66 (d, J
= 0.9 Hz, 1 H).
To a solution of 5'-bromospiro{cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O- benzyloxime) (1.65 g, 4.28 mmol), 4-(trimethylstannyl)-2-thiophenecarbonitrile (1.48 g, 5.44 mmol), triphenylarsine (330 mg) in dry dimethoxy ethane (20 ml), under 1 S a nitrogen atmosphere was added bis(triphenylphosphine)palladium (II) chloride, and the mixture was heated under reflux for 16 h. After cooling to room temperature the mixture was evaporated, and the residue purified by column chromatography (Si02, EtOAc:hexane, gradient elution) to afford the desired product (0.61 g, 1.47 mmol, 56%).
Reaction of the last cited compound (0.61 g, 1.47 mmol) and boron tribromide (1M in dichloromethane, 4.5 mL, 4.5 mmol) according to Example 50 procedure C afforded the title compound (0.084 g, 0.26 mmol, 18 %): 'H NMR
(300 MHz, DMSO-db) 8 9.61 (s, 1H), 9.42 (s, 1H), 8.41 (s, 1H), 8.18 (s, 1H), 7.65 (s, 1H), 7.48 (dd, 1 H, J = 8.1 and 0.9 Hz), 6.76 (d, 1 H, J = 8.1 Hz), 2.03 - 1.96 (m, 2H) and 1.78 - 1.42 (m, 6H): MS (ESI(+ ve)) m/z 324 (M+H)+.
Example 56 5-(Spirolcyclohexane-1,3'-l3Hlindolel-2'(h~yimino)-5'-yl)- 1H-pyrrole-1-methyl-2-carbonitrile 2- {S'[spiro[cyclohexane-1,3'-[3H]indol]-( 1'H)-one-2'(O-benzyloxime)] } -1 H-pyrrole-1-carboxylic acid, tert-butyl ester. A solution of S'-bromospiro{cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O- benzyloxime) (7.4 g, 19.17 mmol) and tetrakis (triphenylphosphine)palladium (0) (2.5 g, 2.00 mmol) in DME ( 100 ml) was stirred under nitrogen for 15 minutes. To the solution was added 1-tert-butoxycarbonylpyrrole boronic acid (5.5 g, 26 mmol) and 1M sodium carbonate (50 ml). The mixture was heated to 80° C for 6 hours and allowed to cool.
The reaction mixture was poured into water and extracted with ethyl acetate (3 x 100 ml).
The organic layers were combined and dried over magnesium sulfate. The solution was filtered, concentrated in vacuo, and the residue was purified by flash chromatography on silica gel (4.5:1 Hexane/ ethylacetate) to give the product (7.7 g, 88 %) as a white solid. 'H NMR (DMSO-d6, 300 MHz) 8 1.28 (s, 9H), 1.55 - 1.66 (m, 8H), 1.83 - 1.98 (m, 2H), 4.99 (s, 2H), 6.12 - 6.14 (m, 1H), 6.22 (t, 1H, J= 3.26 Hz), 6.76 (d, 1H, J= 7.9 Hz), 7.02 (dd, 1H, J= 7.98, 1.4 Hz), 7.19 (s, 1H) 7.27 -7.31 (m, 2H) , 7.35 (t, 1H, J-- 6.8 Hz), 7.43 (d, 1H, J= 8 Hz ), 9.55 (s, 1H).
5'-( 1-tert-Butoxycarbonyl-1 H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-(1'H)one-2'-(O-benzyloxime)-1'-carboxylic acid, tert-butyl ester. To a solution of 2- {5'[spiro[cyclohexane-1,3'-[3H]indol]-( 1'H)-one-2'(O-benzyloxime)] } -1 H-pyrrole-1-carboxylic acid, tert-butyl ester (7.7 g, 16.38 mmol) in THF (anhydrous, 100 mL) was added sodium hydride (0.665 g, 17 mmol) after hydrogen evolution ceased di-tert-butyldicarbonate (10.9 g, 50 mmol) and DMAP( 0.20 g) was added and the reaction stirred at 65 °C for 18 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layers were combined, and dried over magnesium sulfate. The solution was filtered , concentrated in vacuo, to give the product ( 9.0 g, 15.76 mmol) which was taken directly to the next step.
To a solution of 5'-(1-tert-Butoxycarbonyl-1H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-(1'H)one-2'-(O-benzyloxime)-1'-carboxylic acid, tert-butyl ester (9.0 g, 15.76 mmol) in THF (anhydrous, 75 mL) at -78° C was added chlorosulfonyl isocyanate (l.SSmL, 17.54 mmol). After 90 minutes, DMF (21 mL, 275 mmol) was added and the reaction was allowed to warm to room temperature. The reaction was poured into water (200 mL) and extracted with ethyl acetate (2 X 100 mL). The organic layers combined and dried over magnesium sulfate, filtered and concentrated in vacuo. Purification by flash column chromatography on silica gel (10% ethyl acetate/ Hexane) gave 5'-(5-cyano-1-tert-butoxycarbonyl-1H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'( 1'H)one-2'(O-benzyloxime)-1'-carboxylic acid, tert-butyl ester (7.6 g, 82%) as a white powder. 'H NMR (DMSO-dy, 300MHz) 8 1.30 (s, 9H), 1.38 (s, 9H), 1.58-1.83 (m, 8H), 1.72-1.73 (m, 2H), 5.0 (s, 2H), 6.44-6.45 (d, 1H, J= 3.76), 7.25-1.46 (m, lOH).
5'-(5-Cyano-1 H-pyrrol-2-yl)spiro[cylohexane-1,3'-[3H]indol]-2'( 1'H)one-2'-(O-benzyloxime)-1'-carboxylic acid, tert-butyl ester. To a solution of 5'-(5-cyano-1-tert-butoxycarbonyl-1 H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'( 1'H)one-2'(O-benzyloxime)-1'-carboxylic acid, tent-butyl ester (7.6 g, 3.25 g, 48 mmol) in THF (anhydrous, 30 mL) was added a solution of sodium ethoxide in ethanol (120 mL). The reaction mixture was heated to 80° C and stirred overnight.
The mixture was cooled to room temperature and concentrated in vacuo. The residue was dissolved in ethyl acetate and washed with water, brine, and dried over magnesium sulfate. The solvent was evaporated in vacuo to afford the product (6.1 g, 95%). 'H
NMR (DMSO, 500 MHz ) 8 1.38 (s, 9H), 1.63-1.74 (m, 8H), 1.88-1.97 (m, 2H), 5.08 (s, 2H) 6.69-6.7 (d, 1H, J= .BHz), 6.98-6.99 (d, 1H, J= .7 Hz), 7.29-7.37 (m, 1H), 7.35 (m, 2H), 7.42 (m, 3H), 7.63 (dd, 1H, J= 1.8, .3 Hz), 7.76 (d, 1H, J= .4 Hz).
5'-(5-Cyano-1-methyl-1 H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-(O-benzyloxime)-1'-carboxylic acid, tent-butyl ester. To 5'-(5-cyano-1H-pyrrol-yl)spiro[cylohexane-1,3'-[3H]indol]-2'( 1'H)one-2'-(O-benzyloxime)-1'-carboxylic acid, tert-butyl ester (6.1 g, 12.29 mmol) in DMF (75 mL) was added potassium carbonate (6.5 g, 47 mmol) and MeI ( 1 mL, 15.4 mmol) and the reaction mixture was stirred at room temperature for 2.5 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with brine and the solvent was concentrated in vacuo. To give the desired product (6.1 g, 12.29 mmol) which was carried on to the next step without further purification. 'H
NMR
DMSO, 300 MHz) 8 1.38 (s, 9H), 1.62-1.98 (m,IOH), 3.71 (s, 3H), 5.08 (s, 2H), 6.34 (d, 1 H, J = 4.1 ), 7.03 (d, 1 H, J = 3.99), 7.30-7.53 (m, 8H).
5-{5'-Spiro[cyclohexane-1,3'-[3H]indol]-(1'H)-one-2'-(O-benzyloxime)]}-1H-pyrrole-1-methyl-2-carbonitrile. 5'-(5-Cyano-1-methyl-1 H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-(O-benzyloxime)-1'-carboxylic acid, tert-butyl ester (6.1 g,12.29 mmol) was dissolved in dioxane (5 mL) and 4 M HCl in dioxane ( 10 mL) was added and the reaction heated to 45 °C for 3.5 hours. The mixture was carefully neutralized with sodium bicarbonate (sat.). The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with brine and dried over magnesium sulfate. The solvent was evaporated in vacuo. Purification by column chromatography on silica gel (5%
ethyl acetate/hexane) gave the product (4.36 g, 94%). 'H NMR (DMSO-d6, 300MHz) 8 1.57-1.7 (m, 8H), 1.9-2.05 (m, 2H), 3.68 (s, 3H), 5.00 (s, 2H), 6.25 (d, 1H, J= 3.92), 6.85 (d,lH, J= 8.03), 7.00 (d, 1H, J= 4.08), 7.2-7.44 (m, 7H), 9.7 (s, 1H) To 5-{5'-spiro[cyclohexane-1,3'-[3H]indol]-(1'H)-one-2'-(O-benzyloxime)]}-1H-pyrrole-1-methyl-2-carbonitrile (4.36g, 10.6 mmol) in methylene chloride (50 mL) was added 1M boron tribromide (35 mL, in methylene chloride) at -78° C. The reaction mixture was allowed to warm to room temperature. After 4 hours, the reaction mixture was quenched with saturated sodium bicarbonate ( 100 mL). The organic layer was collected and the aqueous layer was extracted with ethyl acetate (2X 100 mL), organic layers combined, washed with brine, dried over magnesium sulfate, and the solvent evaporated in vacuo. The residue was purified by flashed chromatography on silica gel (7:3 hexane/ethylacetate) to give the title compound (1.35g, 40%) as a white solid. 'H NMR (DMSO-d6, 300 MHz) 8 1.58 - 1.71 (m, 8H), 1.99 - 2.00 (m, 2H), 3.69 (s, 3H) 6.24 (d, 1H, J= 4.07 Hz), 6.8 (d, 1H, J=
8.05 Hz), 6.99 (d, 1H, J= 4.01 Hz), 7.20 (dd, 1H, J= 8.04, 1.57 Hz), 7.36 (d, 1H, J=
1.12 Hz), 9.48 (s, 1H), 9.62 (s, 1H).
Example 57 ~spiro f cyclohexane-1,3'-[3H] indoll-2'-(hvdroxyimino)-5'-yl)-1H-pyrrole-2 carbonitrile 5-(spiro[cyclohexane-1,3'-[3]indole]-2' ( 1 H)-(O-benyloxime))-1 H-pyrrole-2-carbonitrile. Prepared from 5'-(5-Cyano-1H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'(1'H)one-2'-(O-benzyloxime)-1'-carboxylic acid, tert-butyl ester (0.395 g, 0.796 mmol) dissolved in 2mL of THF and 4M HCl Dioxane/water (10 mL) following the procedure used to prepare 5-{5'-spiro[cyclohexane-1,3'-[3H]indol]-(1'H)-one-2'-(O-benzyloxime)]}-1H-pyrrole-1-methyl-2-carbonitrile the desired product was obtained (0.220 g, 0.745 mmol, 95%). ' H NMR (DMSO-d6, 500 MHz) 8 1.44 - 1.50 (m, 1H), 1.61 - 1.70 (m, 7H), 1.94 - 1.99 (m, 2H), S.0 (s, 2H), 6.55 (d, 1 H, J = 4 Hz), 6.79 (d, 1 H, J = 8.0 Hz), 6.95 (d, 1 H, J = 4 Hz), 7.27 -7.31 (m, 1 H), 7.34 - 7.37 (m, 2H), 7.42 - 7.43 (m, 2H), 7.47 (dd, 1H, J = 8.0 , 1.4 Hz), 7.65 (d, 1H, J = 1.5 Hz), 9.65 (s, 1 H), 12.4 (s, 1 H).
The title compound was prepared from 5-(spiro[cyclohexane-1,3'-[3]indole]-2'(IH)-(O-benyloxime))-1H-pyrrole-2-carbonitrile (0.325 g, 0.82mmol) and 1M
Boron tribromide (6mL in methylene chloride), following the procedure for 5-(spiro[cyclohexane-1,3'-[3H]indole]-2'-(hydroxyimino)-5'-yl)- IH-pyrrole-1-methyl-2-carbonitrile, to obtain the product as an off white solid (0.110 g, 0.326 mmol, 44%).
' H NMR (DMSO-d6, 500 MHz) 8 1.46 - I.5 (m, 1H), 1.62 - 1.71 (m, 7H), 1.95 -2.05 (m, 2H), 6.55 (d, 1 H, J = 4.0 Hz), 6.75 (d, 1 H, J = 8.0 Hz), 6.94 (d, l H, J
= 3.47 Hz), 7.45 (dd, 1H, J= 8.1, 1.73 Hz), 7.63 (d, 1H, J= 1.73), 9.42 (s, 1H), 9.59 (s, IH), 12.39 (s, 1H).
Examele 58 4-(Spiro(cYclohexane-1,3'-(3Hlindolel-2'(acetoxyimino)-5'-Xl)-2-thiophenecarbonitrile S
To a solution of 4-(Spiro[cyclohexane-1,3'-[3H]indole]-2'(hydroxyimino)-5'-yl)-2-thiophenecarbonitrile (2.21 g, 6.83 mmol) and acetic anhydride ( 1 ml) in dichloromethane-pyridine (30 ml, 9:1 ) was added 4-dimethylaminopyridine (250 mg) at room temperature. After 3h., the mixture was diluted with dichloromethane, washed with water, dil. Hydrochloric acid, water, dried (MgS04), and evaporated.
The residue was purified by column chromatography (EtOAc: hexane, gradient elution) to afford the title compound (0.84 g, 2.29 mmol, 33%) as a white solid: MS
(ESI (+ ve)) m/z 366 [M+H]+.
Example 59 3-Fluoro-N'-hydroxy-5-(2'-(hydrox a~)spiro(cyclohexane-1,3'-(3Hlindoll-5'-benzenecarboximidamide 5'-(3-Cyano-5-fluorophenyl)-2-(methylthio)spiro[cyclohexane-1,3'-[3H]indole]. Prepared from 3-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-5-fluorobenzonitrile (0.451 g, 1.34 mmol) according to the procedure described in Example 43 to afford the desired product (0.316 g, 0.90 mmol, 67%): 'H NMR (DMSO, 300 MHz) 8 7.74 (d, 1H, J= 1.7 Hz), 7.68 (t, 1H, J= 1.4 Hz), 7.5 8 (d, 1 H, J = 8.0 Hz), 7.54 (t, 1 H, J = 2.3 Hz), 7.50 (dd, 1 H, J =
8.0 and 1.9 Hz), 7.33 - 7.29 (m, 1H), 2.67 (s, 3H), 2.04 - 1.78 (m, 7H) and 1.58 - 1.50 (m, 3H);
MS (ESI(+ ve)) m/z 351 (M+H)+.
To a solution of the last cited product (0.30 g, 0.88 mmol) in DMSO ( 10 ml) was added hydroxylamine (SO% aqueous solution, 1 ml), and the reaction was heated to 120 °C. After lh., the mixture was cooled, partitioned between saturated aqueous ammonium chloride and ethylacetate. The organic layer was washed with water, brine, dried (MgS04) and evaporated. The residue was purified by column chromatography (Si02, 5% MeOH in dichloromethane) to afford the title compound (0.079 g, 0.23 mmol, 26%) as a white foam: 'H NMR (DMSO, 300 MHz) 8 9.79 (s, 1H), 9.61 (s, 1H), 9.42 (s, 1H), 7.73 (s, 1H), 7.61 (d, 1H, J= 1.3 Hz), 7.46 (dd, 1H, J
= 8.3 and 1.5 Hz), 7.34 (d, 1H, J= 10 Hz), 6.81 (d, 1H, J= 8.0 Hz), 6.01 (s, 2H), 2.11 - 2.02 (m, 2H) and 1.81 - 1.56 (m, 8H): MS (ESI(+ ve)) m/z 369 (M+H)+.
Example 60 N'-Hydroxy-5-(suiro(cyclohexane-1,3'-(3Hlindolel-2'(hydroxyimino)-5'- lyl)-4-methyl-2-thiophenecarboximidamide 4-Methyl-5-(spiro[cyclohexane-1,3'[3H]indol] 2'-(methylthio)-5'-yl]-2-thiophenecarbonitrile. To potassium tert-butoxide (0.32g, 2.6 mmol) in THF was added 5-(1',2'-Dihydro-2'-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-4-methyl-2-thiophenecarbonitrile (0.84 g, 2.5 mmol). After 15 minutes, methyl iodide (0.50 g, 3.48 mmol) was added. After 3 hours, reaction was poured into ammonium chloride (sat.) and extracted with ethylacetate. The organic layers were combined and dried over magnesium sulfate. The solution was filtered, concentrated in vacuo, and the residue was purified by flash chromatography on silica gel (4:1 Hexane/ethyl acetate) to give the desired product (0.530 g, 85%). (DMSO, 300 MHz) 8 1.48 (m, 3H), 1.70 (m, 2H), 1.81 (m, 5H), 2.32 (s, 3H), 2.62 (s, 3H), 7.48 (dd, 1H, J= 7.87 Hz, 1.46 Hz), 7.5 (d, 1H, J= 8.05 Hz), 7.77 (d, 1H, J= 1.46 Hz), 7.88 (s, 1H).
To 4-methyl-5-(spiro[cyclohexane-1,3'[3H] indol]2'-(methylthio)-5'-yl]-2-thiophenecarbonitrile (.450 g, 1.3 mmol) in DMSO (1 mL) was added hydroxylamine hydrochloride (2 mL, 50% sol. in water) and heated to 100° C for 2.5 hours. Water added until solution became slightly turbid, allowed the mixture to cool to room temperature. The white solid was filtered, collected and dissolved in ethyl acetate and dried over magnesium sulfate. The solution was filtered, concentrated in vacuo, giving (0.320 g, 69%). (DMSO-d6, 500 MHz) 8 1.4-1.74 (m, 8H), 1.94-2.4 9m, 2H), 2.54 (s, 3H), 5.8 (s, 1H), 6.79 (d, 1H, J = 8.0), 7.16 (dd, 1H, J= 8.12, 1.83), 7.39 (m, 2H), 9.42 (s, 1H), 9.56 (s, 1H), 9.58 (s, 1H).
Example 61 N'-Hydroxy-4-(spiro[~cyclohexane-1,3'-f3Hlindole]-2' 9hydroxyimino)-5'-yl-2-thiophenecarboximidamide 4-(Spiro[cyclohexane-1,3'-[3H]indol]-2'-(methylthio)-5'-yl]-2-thiophenecarbonitrile (0.077 g, .237 mmol) was reacted with 50% solution of hydroxylamine ( 1 mL) following the procedure for Example 60 to afford the title compound (0.016g, 0.044 mmol, 20 %). MS (ESI, (+VE)) m/z 357 [M+H]+.
Example 62 N'-Hey-~spirolcyclohexane-1,3'-(3Hjindoll-2'-(hydrox~mino)-5'-ylj-2-thiophenecarboxidamide The title compound was prepared from 5-(spiro[cyclohexane-1,3'-[3H]indol]2'-(methylthio)-5'-yl]-2-thiophenecarbonitrile (0.500 g, 1.5 mmol) and a 50% solution of hydroxylamine (2 mL, excess) following the procedure for Example 60, to afford the product (0.200 g, 0.56 mmol, 56%). 'H NMR (DMSO-d6, S00 MHz) 8 1.45-1.75 (m, 8H), 1.97-2.06 (m, 2H), 5.89 (s,lH), 6.74 (d, 1H, J = 8 Hz), 7.3 (d, 1H, J= 3.9 Hz), 7.34 (dd, 1H, J= 8.06, 1.46 Hz), 7.4 (d, 1H, J= 8.0 Hz), 7.5 (d, 1 H, 1.95 Hz), 9.44 (s, l H), 9.58 (s, 1 H), 9.6 (s, 1 H).
Example 63 5'-(3-Chlorophen~piro f cyclohexane-1,3'-(3Hl indoll-2'-cyanamide 5'-(3-Chlorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'-amine. To a turbid solution of S'-(3-Chlorophenyl)-N-hydroxyspiro[cyclohexane-1,3-[3H]indol]-2-amine ( 0.500 g; 1.53 mmol) in 25 mL of ethanol was added hydrazine hydrate (0.600 mL; 12.24 mmol). The solution was warmed to 55° C, where Raney-nickel (50% in water) was added to the reaction to keep a constant evolution of gas. After 45 minutes, the hot reaction mixture was filtered through a Celite plug and rinsed with a copious amount of hot methanol. The filtrate was concentrated in vacuo to give 0.890 g of an opaque solid. The product was purified by flash silica gel chromatography;
(eluant, 2% to 8 % methanol-methylene chloride with 0.1 % ammonium hydroxide) to afford 0.310 g (65%) of the desired product as a white solid. Mp. 118-120° C. 'H
NMR 8 (300 MHz, DMSO-db) 1.31-1.46 (m, 2H), 1.70-1.93 (m, 8H), 7.0 (d, 1H), 7.1 (br, 2H, 2NH), 7.31-7.34 (dt, 1H, J= 8 Hz), 7.41-7.46 (t, 2H), 7.55-7.58 (d, 1H), 7.62 (s, 1H), 7.72 (s, 1H); MS (ECI(+ve)) m/z 311 (M+H)+.
1-tert-butoxycarbonyl-5'-(3-chlorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'-amine. To a solution of 5'-(3-chlorophenyl)spiro[cyclohexane-1,3-[3H]indol]-2'-amine (0.310 g; 0.96 mmol) in dry methylene chloride at 0° C was added Di-tert-butyl dicarbonate (0.252 g; 1.15 mmol) and 4-dimethylaminopyridine (0.117 g; 0.96 mmol). The solution was allowed to warm to room temperature and stir 24 h. The reaction solution was diluted with water(SO mL) and the layers were separated.
The organic layer was dried over Na2S04 , filtered and concentrated in vacuo to give 0.355 g of a yellow oil. The product was purified by flash silica gel chromatography;
(eluant, 1 %to 3 % methanol- methylene chloride) to afford the desired product (0.081 g, 20%) as a white solid. 'H NMR 8 (300 MHz, DMSO-db) 1.58 (m, 2H), 1.63 (s, 9H, Boc), 1.77-1.79 (m, 8H), 7.42-7.48 (m, 2H), 7.64-7.68 (m, 3H), 7.70-7.80(m, 2H), 9.72 (s, 1H, NH). MS (ECI(+ve)) m/z 411 (M+H)+.
1'-tent-Butoxycarbonyl-5'-(3-chlorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'-amine (0.120 g; 0.29 mmol) in 2.0 mL of dry DMF was added to a solution of 4- dimethylaminopyridine (0.089 g; 0.73 mmol) and cyanogen bromide (0.077 g; 0.73 mmol) in 4.0 mL of dry DMF at 0° C. The yellow solution was heated to 40° C for 16 h. Work-up included pouring the reaction solution into 0.1 N NaHC03 (50 mL) and extracting with ethyl acetate (3 x 50 mL). The combined organic layers were dried over anhydrous NaZS04, filtered and concentrated in vacuo to give 0.091 g of a yellow residue. The product was purified by flash silica gel chromatography;
(stepwise gradient of 5:1 to 3:1 hexane : ethyl acetate) to afford 0.031 g (32%) of the product as a bright yellow solid. Mp. 225°C (dec.). 'H NMR 8 (500 MHz, DMSO-db) 1.46-1.73 (m, 8H), 1.89-1.90 (m, 2H), 7.13-7.16 (d, 1H), 7.38-7.41 (dt, 1H, J=
8Hz), 7.45-7.50 (m, 1H), 7.60-7.63 (dd, 2H, J= 6.4 Hz), 7.71 (s, 1H), 7.85 (s, 1H), 12.1 (s, 1H, NH); MS (ECI(-ve)) m/z 336 (M-H)-.
Other desirable compounds, which can be made according to the methods described herein, include 5'-(3-Cyano-5-fluorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'-cyanamide, S'-(5-Cyano-1H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2-cyanamide, 5'-(5-Cyano-1-methyl-1H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-cyanamide cyanamide, 5'-(S-Cyano-thiophen-2-yl) spiro[cyclohexane-1,3'-[3H]indol]-2'-cyanamide, 5'-(5-Cyano-3-methyl-thiophen-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-cyanamide, 5'-(5-Cyano-thiophen-3-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-cyanamide, 3-(2'-Cyanomethylene-spiro[cyclohexane-1,3'-[3H]indol-5'-yl])-5-fluoro-benzonitrile, 5-(2'-Cyanomethylene-spiro[cyclohexane-1,3'-[3H]indol-5'-yl])-1H-pyrrole-2-carbonitrile, 5-(2'-Cyanomethylene-spiro[cyclohexane-1,3'-[3H]indol-5'-yl])-1-methyl-1 H-pyrrole-2-carbonitrile, 5-(2'-Cyanomethylene-spiro[cyclohexane-1,3'-[3H]indol-5'-yl])-thiophene-2-carbonitrile, 5-(2'-Cyanomethylene-spiro[cyclohexane-1,3'-[3H]indol-5'-yl])-4-methyl-thiophene-2-carbonitrile, 4-(2'-Cyanomethylene-spiro[cyclohexane-1,3'-[3H]indol-5'-yl])-thiophene-2-carbonitrile.
All publications cited in this specification are incorporated herein by reference herein. While the invention has been described with reference to a particularly preferred embodiment, it will be appreciated that modifications can be made without departing from the spirit of the invention. Such modifications are intended to fall within the scope of the appended claims.
R
Ar Ar O
'N H
H
g 11 R
Nu O ~~ ~ O
N ~ N
H H
g 12 Reaction of the indoline-2-one derivative 6 with either Lawessen's reagent or phosphorous pentasulfide in a suitable organic solvent (pyridine, THF, dioxane, dimethoxyethane, dichloromethane, benzene, toluene, xylene) at a temperature between room temperature and the reflux temperature of the solvent provides access to the thiocarbonyl derivative 7. An additive such as sodium hydrogen carbonate may also be useful.
Scheme 4 (HO
R' ~S
N
H
An alternative mode of preparation is to react compound 5 with either Lawessen's reagent or phosphorous pentasulfide in a suitable organic solvent (pyridine, THF, dioxane, dimethoxyethane, dichloromethane, benzene, toluene, xylene) at a temperature between room temperature and the reflux temperature of the solvent, under an inert atmosphere (nitrogen or argon) providing access to the thiocarbonyl derivative 13. Then reaction of bromide 13 in an anhydrous solvent (e.g.
THF, EtzO) with a strong base (sodium hydride preferred, sodium hexamethyldisilazide, potassium hydride) followed by reaction at reduced temperature (-50 to -20 °C) with n-butyllithium and N,N,N,N'-tetramethylethylenediamine followed after a suitable period of time by a trialkylborate (trimethyl or triisopropylborate) gives after acidic work-up the boronic acid 14 (scheme 4). Compound 14 may then be reacted under palladium catalyzed conditions (tetrakis(triphenylphosphine)palladium(0) or palladium acetate, base (NaHC03, Na2C03, KZC03, triethylamine, CsF) solvent (toluene/EtOH/water, THF/water, dimethoxyethane/water, anhydrous dimethoxyethane) with an aryl or heteroaryl bromide, aryl or heteroaryl iodide, aryl or heteroaryl trifluoromethane sulfonate or aryl or heteroaryl fluorosulfonate, to provide the desired compounds 7.
Alternatively reaction of compound 13 under palladium catalyzed conditions (tetrakis(triphenylphosphine)palladium(0) or palladium acetate, base (NaHC03, NazC03, KzC03, triethylamine, CsF) solvent (acetone/water, toluene/EtOH/water, THF/water, dimethoxyethane/water, anhydrous dimethoxyethane) with an aryl or heteroaryl bromide, aryl or heteroaryl iodide, aryl or heteroaryl trifluoromethane sulfonate or aryl or heteroaryl fluorosulfonate, to provide the desired compounds 7.
Scheme 5 R :~ ;.
Rz ~~H~B Rz ~o > I ~ ~O
N ~N
H H
R.~' R:
Rz ~ Rz ~O ~S
N ~ N
H H
Treatment of the bromide 5 in an anhydrous solvent (e.g. THF, Et20) with a strong base (sodium hydride preferred, sodium hexamethyldisilazide, potassium hydride) followed by reaction at reduced temperature (-50 to -20 °C) with n-butyllithium and N,N,N,N'-tetramethylethylenediamine followed after a suitable period of time by a trialkylborate (trimethyl or triisopropylborate) gives after acidic work-up the boronic acid 15 (scheme 5). Compound 15 may then be reacted under palladium catalyzed conditions (tetrakis(triphenylphosphine)palladium(0), base (NaHC03, NaZC03, KZC03, triethylamine, CsF) solvent (toluene/EtOH/water, THF/water, dimethoxyethane/water, anhydrous dimethoxyethane) with an aryl or heteroaryl bromide, aryl or heteroaryl iodide, aryl or heteroaryl trifluoromethane sulfonate or aryl or heteroaryl fluorosulfonate, to provide the desired compounds 6.
An alternative strategy would be to prepare an organo zinc or magnesium reagent from compound 5 and react it in-situ with an aryl or heteroaryl bromide, aryl or heteroaryl iodide, aryl or heteroaryl trifluoromethane sulfonate of aryl or heteroaryl fluorosulfonate, under palladium catalyzed conditions to afford compound 6.
Such an organo zinc or magnesium species could be prepared by treatment of the bromide in an anhydrous solvent (e.g. THF, EtzO) with a strong base (sodium hydride preferred, sodium hexamethyldisilazide, potassium hydride) followed by reaction at reduced temperature (-50 to -20 °C) with n-butyllithium and N,N,N',N'-tetramethylethylenediamine followed after a suitable period of time by reaction with anhydrous zinc chloride or magnesium bromide.
Reaction of the indoline-2-one derivative 6 with either Lawesson's reagent or phosphorous pentasulfide in a suitable organic solvent (pyridine, THF, dioxane, dimethoxyethane, dichloromethane, benzene, toluene, xylene) at a temperature between room temperature and the reflux temperature of the solvent, under an inert atmosphere (nitrogen or argon) provides access to the thiocarbonyl derivative 15. An additive such as sodium hydrogen carbonate may also be useful.
Scheme 6 R~ R' Rz B ~ R2 S > I ~ ~Y
N N
H H
Y = CHN4z = NCN
= NSOzCF3 _ o Me Me O
O
According to scheme 6 thioamide derivatives 7 may be converted into enamine derivatives 16 (Wrobel, et al, J. Med. Chem., 1989, 2493).
Thus reaction of thioamide 7 (Pg = H, 2-(trimethylsilyl)-ethoxymethyl, benzyl, etc) with triethyloxonium tetrafluoroborate followed by reaction with a nucleophile (nitromethane, cyanamide, trifluoromethanesulfonamide, Meldrum's acid, etc) followed by removal of the protecting group under appropriate conditions (e.g. tetrabutylammonium fluoride in THF for Pg = 2-(trimethylsilyl)-ethoxymethyl) then gives the enamine derivatives 16. Appropriate solvents for the two steps are selected from dichloromethane, THF, dioxane, 1,2-dichloroethane, and the reaction is conducted at a temperature from -78 °C to the boiling point of the solvent under an inert atmosphere (nitrogen or argon).
Ar R ~~wynu.~ A ~ Rp. nrk7 ~ / ~~~~m / H aM
y.. Rn..
Ar \ ~z hydroxylamine Ar \ kz -N
~aky1 H OH
17 Ig '~. yuy EWG~R \ R ~ ~ R ~ \ R ~anrunuR H
g decarboxylat'ron EWG ~ H EWG
a<N
Scheme 7 According to Scheme 7, treatment of intermediate 7 with an alkylating agent, e.g., methyl iodide, ethyl iodide, 2,4-dinitrofluoro benzene, or 4-nitro fluorobenzene, in the presence of a suitable base (e.g. an amine base such as pyridine, triethylamine or di-iso-propylethylamine or lithium, sodium, potassium or cesium carbonate) in a suitable organic solvent (e.g. DMF, THF, DMSO, dioxane or acetonitrile) at a temperature between -78 °C and the boiling point of the solvent, would then afford thioimino ethers 17. Subsequent reaction of intermediates 17 with hydroxylamine or an acid salt of hydroxylamine (e.g. the hydrochloride) in a suitable solvent (for example but not limited to pyridine methanol, ethanol, iso-propanol, DMF, THF
or DMSO and optionally in the presence of an additive such as a tertiary amine base or sodium or potassium acetate) at a temperature between -78 °C and the boiling point of the solvent would then afford the N hydroxyamidines 18.
Similarly treatment of intermediates 17 with a carbon nucleophile such as a malonate derivative (e.g., malononitrile, a cyano acetate ester, a nitro acetate ester or a malonate) in the presence of a suitable base (e.g. an amine base such as pyridine, triethylamine or di-iso-propylethylamine or lithium, sodium, potassium or cesium carbonate) or a Lewis acid (e.g. boron trifluoride etherate, a lead II salt, titanium tetrachloride, a magnesium II salt, or a silver salt) in a solvent compatible with the chosen base or Lewis acid (e.g. DMF, THF, DMSO, dioxane or acetonitrile, chloroform, benzene, toluene or dichloromethane) would then afford the adduct 19. If the group R3 in adduct 19 is an ester of a carboxylic acid, then it may be decarboxylated directly to give the enamine derivative 20 by treatment with, e.g.
sodium iodide in DMSO at a temperature between room temperature and thee boiling point of the solvent. Alternatively the ester may be first hydrolysed to the carboxylic acid (by treatment with an aqueous base (e.g. lithium, sodium, or potassium hydroxide) in a suitable solvent (e.g. THF, dioxane acetonitrile, methanol or ethanol), followed by decarboxylation in the presence of an acid (e.g. hydrochloric or sulfuric acid) in a suitable solvent (e.g. acetonitrile, THF, dioxane) to afford the derivatives 20. Alternatively the xanthate ester of the carboxylic acid may be prepared by reaction with a base such as sodium or potassium hydride in THF, followed by treatment with carbon disulfide. Subsequent reaction with tributyl tin hydride at elevated temperatures in a solvent such as benzene or toluene under an inert nitrogen or argon atmosphere in the presence of a radical initiator such as benzoyl peroxide or azo-bis-iso-butyronitrile would then give the product 20.
Rn.' ftn Br Rz Br ~ Rz S ~ ~ ~ S
N V N ~ kN
H a aryl Rt c R1 - '' 3 Br '\ Ra hydroxylamine Br \ RZ R' __ _ Br ~ Rz S~ rkN ~ ~ H N OH / N N OProrectirg aryl H 9~uD
Rn Rn.' Ar ~ Rz lv ~ Rz N '' N
~mbceng ~ ~ N~ ~ H
H gmuG N
Scheme 8 An alternative strategy for synthesizing the product 18 is illustrated by Scheme 8. Thus the bromide 13 (the corresponding chloride, iodide or triflate ester may also be employed) is treated with an alkylating agent, eg methyl iodide, ethyl iodide, 2,4-dinitrofluoro benzene, or 4-nitro fluorobenzene, in the presence of a suitable base (e.g. an amine base such as pyridine, triethylamine or di-iso-propylethylamine or lithium, sodium, potassium or cesium carbonate) in a suitable organic solvent (e.g. DMF, THF, DMSO, dioxane or acetonitrile) at a temperature between -78 °C and the boiling point of the solvent, would then afford thioimino ethers 21. Subsequent reaction of intermediate 21 with hydroxylamine or an acid salt of hydroxylamine (e.g. the hydrochloride, hydrobromide) in a suitable solvent (for example but not limited to pyridine methanol, ethanol, iso-propanol, DMF, THF
or DMSO and optionally in the presence of an additive such as a tertiary amine base or sodium or potassium acetate) at a temperature between -78 °C and the boiling point of the solvent, would then afford the N hydroxyamidine 22. Intermediate 22 could then be protected with a compatible group (e.g. benzyl ether, acyl derivative, _38_ tetrahydropyranyl ether, methoxy methyl ether, silyl ether) to give the derivative 23.
Alternately compound 21 could be reacted directly with a protected hydroxlamine derivative (chosen, but not limited to the protecting groups described above) to directly afford derivative 23. Compound 23 may then be reacted with a palladium salt (e.g. tetrakis(triphenylphoshine)palladium(0) or palladium acetate), in a suitable solvent (e.g. THF, dimethoxyethane, acetone, ethanol or toluene) at room temperature under an inert atmosphere (argon, nitrogen). The mixture is then treated with an aryl or heteroaryl boronic acid or boronic acid ester and a base (sodium carbonate, triethylamine, potassium phosphate) in water or fluoride source (cesium fluoride) under anhydrous conditions, and the reaction may then be heated to the boiling point of the solvent. The required product 24 is then isolated and purified by standard means.
Compound 24 may then be de-protected under the conditions prescribed by the nature of the protecting group. For example if the protecting group is a benzyl ether then treatment with boron tribromide or trimethylsilyl iodide in a suitable solvent (dichloromethane for example) would afford the compound 18. Other methods to remove the benzyl ether would involve hydrogenation (hydrogen gas or other hydrogen source such as cyclohexadiene or ammonium formate) in the presence of a palladium catalyst. Solvents suitable for such a process include methanol, ethanol, THF, ethyl acetate and dioxane, at a temperature between room temperature and the boiling point of the solvent. If the protecting group was an acetal derivative (tetrahydropyranyl or methoxymethyl ethers) then hydrolysis could be effected under acidic conditions (hydrochloric acid, sulfuric acid, p-toluene sulfonic acid or acidic ion exchange resin) in a solvent such as methanol, ethanol, THF dioxane or acetonitrile. If the protecting group was an acyl derivative (acetate, or benzoate for example) then hydrolysis could be effected under acidic conditions as described above or under basic conditions (lithium, sodium or potassium hydroxide) in a solvent such as an alcohol, THF dioxane or acetonitrile at a temperature between room temperature and the boiling point of the solvent. If the protecting group was a silyl ether then compound 18 may be prepared by hydrolysing intermediate 24 under the acidic conditions described above or alternately by exposing compound 24 to a fluoride source (eg potassium fluoride, cesium fluoride or tetra butyl ammonium fluoride) in a solvent such as an alcohol, THF dioxane or acetonitrile at a temperature between room temperature and the boiling point of the solvent. An inert atmosphere of nitrogen or argon may be necessary.
Another method of synthesizing compound 18 would be to convert the protected N-hydroxy amidine 23 into a boronic acid or boronic acid ester (by lithium halogen exchange followed by quench with tri-isopropyl borate, or palladium catalyzed coupling with diboron pinacolate) and then couple this boronic acid or ester derivative with an aryl chloride, bromide, iodide or triflate under a suitable palladium catalysis system as described previously. Subsequent deprotection as described for Scheme 8 would afford the desired compounds 18.
R '~.n Ar ~ R2 ~
Ar ~ R2 ~NH
H ~ H ~ ~ N
H
R~
Ar \ RZ
~N
~GN
Scheme 9 According to Scheme 9, treatment of the N-hydroxyamidine 18 under reducing conditions (e.g. catalytic hydrogenation, iron in acetic acid or hydrazine-raney nickel) would then afford intermediate 25. Solvents suitable for such a process include methanol, ethanol, THF, ethyl acetate and dioxane, at a temperature between room temperature and the boiling point of the solvent. Protection of the secondary nitrogen (a tertiary butyl carbamate is shown as a non-limiting example) under standard conditions would then give compound 26. Reaction of compound 26 with an electrophilic cyanating agent (e.g. cyanogen bromide, N-cyanobenzotriazole or cyanogen bromide/ 4-dimethylaminopyridine complex) in a suitable solvent (THF
acetonitrile or DMF, optionally in the presence of a base such as pyridine or sodium hydride or potassium tert-butoxide) may then afford the desired compound 27.
In some cases the cyanation step may occur with concomitant removal of the secondary nitrogen protecting group, if this deprotection does not occur in-situ then a further hydrolysis step would be required.
An alternate synthesis of compound 27 may follow that of compound 18, Scheme 8, where an N-cyanoamidine bromide 28, prepared from compound 22 adopting a similar strategy to the reactions shown in scheme 9, could be coupled with a suitable functionalised aryl boronic acid or boronic acid ester to give compound 27.
In another strategy intermediate 28 may be converted into the corresponding boronic 1 S acid or boronic acid ester and coupled in a Suzuki or Suzuki type palladium coupling with a suitable functionalised aryl bromide.
N
The compounds of the present invention can be used in the form of salts derived from pharmaceutically or physiologically acceptable acids or bases.
These salts include, but are not limited to, the following salts with inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid and, as the case may be, such organic acids as acetic acid, oxalic acid, succinic acid, and malefic acid. Other salts include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium in the form of esters, carbamates and other conventional "pro-drug" forms, which, when administered in such form, convert to the active moiety in vivo.
This invention includes pharmaceutical compositions and treatments which comprise administering to a mammal a pharmaceutically effective amount of one or more compounds as described above, or a pharmaceutically acceptable salt thereof, as agonists of the progesterone receptor.
The progesterone receptor agonists of this invention, used alone or in combination, can be utilized in methods of contraception and the treatment and/or prevention of dysfunctional bleeding, uterine leiomyomata, endometriosis;
polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate. Additional uses of the invention include stimulation of food intake.
When the compounds are employed for the above utilities, they may be combined with one or more pharmaceutically acceptable Garners or excipients, for example, solvents, diluents and the like, and may be administered orally in such forms as tablets, capsules, dispersible powders, granules, or suspensions containing, for example, from about 0.05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% of sugar, and elixirs containing, for example, from about 20 to 50% ethanol, and the like, or parenterally in the form of sterile injectable solutions or suspensions containing from about 0.05 to 5% suspending agent in an isotonic medium. Such pharmaceutical preparations may contain, for example, from about 25 to about 90% of the active ingredient in combination with the carrier, more usually between about 5% and 60% by weight.
The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration and the severity of the condition being treated. However, in general, satisfactory results are obtained when the compounds of the invention are administered at a daily dosage of from about 0.5 to about 500 mg/kg of animal body weight, preferably given in divided doses two to four times a day, or in a sustained release form. For most large mammals, the total daily dosage is from about 1 to 100 mg, preferably from about 2 to 80 mg.
Dosage forms suitable for internal use comprise from about 0.5 to 500 mg of the active compound in intimate admixture with a solid or liquid pharmaceutically acceptable carrier. This dosage regimen may be adjusted to provide the optimal therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
These active compounds may be administered orally as well as by intravenous, intramuscular, or subcutaneous routes. Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene glycols, non-ionic surfactants and edible oils such as corn, peanut and sesame oils, as are appropriate to the nature of the active ingredient and the particular form of administration desired. Adjuvents customarily employed in the preparation of pharmaceutical compositions may be advantageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA.
The preferred pharmaceutical compositions from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard-filled or liquid-filled capsules. Oral administration of the compounds is preferred.
These active compounds may also be administered parenterally or intraperitoneally. Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid, polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringe ability exits. It must be stable under conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacterial and fungi. The Garner can be a solvent or dispersion medium containing, for example, water, ethanol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oil.
This invention is further understood by the following non-limiting examples.
5'-(3-Chlorophenyl)spiro(cyclohexane-1,3'-]3H]indolel-2'(1'H)-thione biro[cyclohexane-1,3'-[3Hlindol]-2'-( 1'H)one A solution of oxindole (25 g, 0.19 mol) in anhydrous tetrahydrofuran (800 cm3) was cooled to -20°C, then n-butyllithium (2.SM in hexanes, 152 cm', 0.38 mol) was added slowly followed by N,N,N',N'-tetramethylethylenediamine (51 cm', 0.38 mol,). After 15 min. 1,5-diiodopentane (174 g, 0.54 mol) was added slowly and the mixture was allowed to warm to room temperature. After stirring for 16 h.
saturated aqueous ammonium chloride solution ( 1 L) and EtOAc ( 1 L) were added. After min., the layers were separated and the aqueous phase was extracted with EtOAc (x2). The combined organic layers were extracted with hydrochloric acid (1N), then washed with brine (500 cm3), dried (MgS04), and concentrated to obtain an oil.
The oil was triturated with hexane (200 cm') and benzene (20 cm'). The precipitate was collected and dried in vacuo to obtain the subtitled compound (26.3g, 69.6%) as colorless crystals: mp 110-114°C;'H NMR (DMSO-d6) 8 1.67 (m, lOH), 6.84 (d, 1H, J = 8 Hz) 6.94 (t, 1 H, J = 8 Hz), 7.17 (t, 1 H, J = 8 Hz), 7.44 (d, 1 H, J =
8 Hz), 10.3 (S, 1H).
5'-Bromospiro[cyclohexane-1,3'-[3H] indoll-2'(1'H)-one To a solution of spiro[cyclohexane-1,3'-[3H]indol]-2' (1'H)-one (17.6 g, 0.09 mol) in acetic acid (300 cm3) was added sodium acetate (8.0 g, 0.1 mol) and bromine ( 14.6g, 0.091 mol) with stirring. After 30 min. at room temperature, the reaction mixture was partitioned between water and EtOAc. The aqueous phase was extracted twice with EtOAc. The combined organic layers were washed with water, dried (MgS04) and evaporated and the residue was triturated with hexane. The precipitate was collected, and dried in vacuo to obtain the subtitled compound (l6.Sg, 67%) as off white crystals: mp 196 -199 °C; 'H NMR (DMSO-d6) 8 1.62 (m, l OH), 6.8 (d, 1H, J = 6.8 Hz), 7.36 (d, 1H, J= 8.2, 1.8 Hz), 7.58 (dd, 1H, J= 8.2, 1.8 Hz), 10.44 (S, 1 H).
5 ~3-chlorophenyl)spiro [cyclohexane-1,3-[3H~indoll-2( 1 H)-one A solution of 5'-bromospiro[cyclohexane-1,3'-[3H] indol]-2'(1'H)-one (0.32 g, 1.14 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.14 g, 0.12 mmol) in dimethoxyethane (6 cm3) was stirred under Nz for 20 min.. To this mixture was then added 3-chlorophenylboronic acid (0.21 g, 1.37 mmol) and sodium carbonate (0.36 g, 3.4 mmol) in water (3 cm3). The solution was brought to reflux for 6 h then cooled to RT, poured into water and extracted with EtOAc (x 3). The combined organic extracts were washed with water, brine, dried (MgS04), and evaporated. The residue was purified by column chromatography (Si02, ethyl acetate: hexane 1:3) to afford the subtitled compound (0.28 g, 0.89 mmol, 80%) as a yellow solid: mp. 164-165 °C , 1H NMR (CDC13) 8 1.60-1.78 (m, 6H), 1.81-1.99 (m, 4H), 7.04 (d, J= 8.1 Hz, 1H), 7.22-7.47 (m, 4H), 7.53 (s, 1H), 7.61 (s, 1H), 9.28 (br s, 1H);'3C-NMR
((CDC13) 20.17, 24.12, 31.92 (t), 47.22 (s), 109.21, 121.94, 124.06, 125.50, 125.79, 125.97, 126.38, 128.96 (d), 132.88, 133.59, 135.60, 139.14, 142.17, 182.89 (s); MS
(EI) m/z 310, 312 (M-H)+; Anal. (C,9H,8C1N0) C, H, N.
To a solution of 5'-(3-Chlorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'(1'H)-one (0.63 g, 2.0 mmol) in dry xylene (20 cm3) under nitrogen was added 2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide (0.89 g, 2.2 mmol) and the mixture heated under reflux. After 72h, the mixture was evaporated and the residue subjected to column chromatography (Si02, EtOAc: hexane, gradient elution) to afford a solid which was re-crystallized from di-iso-propylether/ hexane to afford the title compound as yellow crystals (0.17g, 0.51 mmol, 26%): mp. 223 - 227 C; d (CDC13) 1.53 - 1.66 (m, 8H), 1.83 - 2.05 (m, 4H), 2.07 - 2.17 (m, 2H), 7.11 (d, 1H, J
= 8.0 Hz) 7.31 - 7.53 (m, 3H), 7.54 (s, 1H), 7.86 (S, 1H), 9.93 (s, 1H, br):
MS
((+APCI) m/z 328 (M + H)+.
3-(1',2'-Dihydro-2'-thioxospiro f cyclohexane-1,3'-f3H~indol-5'-yl) benzonitrile To a solution of 5'-bromospiro[cyclohexane-1,3'-[3H] indol]-2'(1'H)-one (1.00 g, 3.57 mmol) in dimethoxyethane (20 cm3) was added tetrakis(triphenylphosphine)palladium (0.20 g, 0.17 mmol). After 15 min. 3-formylphenylboronic acid ( 1.00 g, 6.93 g) was added followed by potassium carbonate (2.90 g, 21 mmol) in water ( 10 cm3). After 20h at reflux, the mixture was cooled poured into water and extracted with EtOAc (x3). The combined organic extract was washed with saturated brine, dried (MgS04) and evaporated. The residue was purified by column chromatography (SiOz, EtOAc: hexane, gradient elution) to afford the title compound (0.66 g, 2.15 mmol, 60%) as a white solid, 'H NMR
(CDC13) 8 1.65 - 1.85 (m, 6H), 1.86 - 2.08 (m, 4H), 7.22 (d, 1 H, J = 8 Hz), 7.48 (dd, 1 H, J = 8, 2 Hz), 7.61 (t, 1 H, J = 8 Hz), 7.66 (d, 1 H, J = 2 Hz), 7.81 - 7.
8 8 ( m, 2H), 8.06 (t, 1H, J= 2 Hz), 8.30 (s , 1H, br); MS ((+)ESI) mlz 306 (M + H)+.
3-(1',2'-Dihydro-2'-oxospiro[cyclohexane-1,3'-[3H]indol-5'-yl) benzaldehyde oxime To a solution of 3-(1',2'-dihydro-2'-oxospirocyclohexane-1,3'-[3H]indol-5'-yl) benzaldehyde (0.59 g, 1.95 mmol) in EtOH: H20 (10 cm3, 8:2) was added hydroxylamine hydrochloride (0.17 g, 2.5 mmol) and sodium acetate (0.20 g, 2.5 mmol). After 20 min. the mixture was concentrated water was added and the product extracted with EtOAc (x2). The combined organic layers were washed with sat.
sodium hydrogen carbonate solution, water, sat. brine, dried (MgS04) and evaporated to afford the subtitled oxime (0.63 g, 1.95 mmol, 100%) which was used without further purification, 'H NMR (CDC13) 8 1.60 - 1.84 (m, 6H), 1.85 - 2.00 (m, 4H), 6.86 (d, 1 H, J = 8 Hz), 7.36 (dd, 1 H, J = 8, 2 Hz), 7.43 - 7.50 (m, 1 H), 7.57 -7.67 (m, 2H), 7.85 (s, 1H, br), 8.25 (s, 1H), 8.68 (s, 1H, br), 8.94 (s, 1H, br); MS ((-)ESI) m/z 319 (M - H)'.
3-(1',2'-Dihydro-2'-oxospirofcyclohexane-1,3'~3H]indol-5'-yl) benzonitrile A solution of 3-(1',2'-Dihydro-2'-oxospiro[cyclohexane-1,3'-[3H]indol-5'-yl) benzaldehyde oxime (0.48 g, 1.49 mmol) in chloroform ( 10 cm3) was treated with selenium dioxide (0.38 g, 3.50 mmol) and heated under reflux. After 16 h, the mixture was concentrated and the residue purified by column chromatography (SiOZ, EtOAc: hexane 1:4) and the product re-crystallized from EtOAc-hexane to afford the subtitled compound (0.161 g, 0.53 mmol, 35%) as a white solid: mp. 190 - 191 °C; 'H
NMR (CDC13) 8 1.59 - 1.87 (m, 6H), 1.88 - 2.09 (m, 4H), 7.03 (d, 1H, J= 8 Hz), 7.42 (dd, 1H, J= 8, 2 Hz), 7.54 (t, 1H, J= 8 Hz), 7.58 - 7.65 (m, 2H), 7.78 (dt, 1H, J= 7, 2 Hz), 7.83 (m, 1H), 8.26 (s, 1H, br); MS ((+) ESI) m/z 303 (M + H)+.
Reaction of 3-(1',2'-Dihydro-2'-oxospiro[cyclohexane-1,3'-[3H]indol-5'-yl) benzonitrile and Lawesson's reagent according to the procedure in example 1 gave the title compound: mp. >231 °C (decomp.);'H NMR (DMSO-db) 8 1.38 -1.55 (m, 3H), 1.82 - 1.99 (m, 7H), 7.16 (d, 1H, J= 8.1 Hz), 7.63 - 7.69 (m, 2H), 7.80 (d, 1H, J
= 7.7 Hz), 8.01 (d, 1 H, J = 8 Hz) and 12.76 (s, 1 H); MS ((-)-APCI) m/z 317 [M-H]-.
4-(1',2'-Dihydro-2'-thioxospirofcyclohexane-1,3'-[3H~indoll-5'-yl)-2-thiophenecarbonitrile 3-(Trimeth ls~yl)-2-thiophenecarbonitrile. A solution of 3-bromo-2-thiophenecarbonitrile (0.8 g, 4.3 mmol), tetrakis(triphenylphosphine)palladium(0) (0.25 g, 0.2 mmol) and hexamethylditin ( 1.4 g, 4.3 mmol) in dimethoxyethane (5 cm') was heated under reflux for 14 h then cooled to RT. The reaction mixture was absorbed onto florisil and purified by column chromatography (Si02, methylene chloride: hexane 1:9) to afford the subtitled compound ( 1.04 g, 3.8 mmol, 90%) as a clear viscous oil: 'H NMR (CDCl3) 8 0.35 (s, 9H), 7.56 (d, J= 0.9 Hz, 1H), 7.66 (d, J
= 0.9 Hz, 1 H).
4-( 1,2-Dihydro-2-oxospiroCcyclohexane-1,3-(3H]indol]-5-yl)-2-thiophenecarbonitrile A solution of the 5'-bromospiro[cyclohexane-1,3'-[3H] indol]-2'(1'H)-one (0.53 g, 1.9 mmol), dichlorobis(triphenylphosphine) palladium(II) (0.1 g, 0.14 mmol) and triphenylarsine (0.14 g, 0.47 mmol) in dimethoxyethane (8 cm3) was stirred under Nz for 20 minutes. To this mixture was then added 3-(trimethylstannyl)-2-thiophenecarbonitrile (0.64 g, 2.35 mmol). The solution was brought to reflux for 32 h. After cooling to room temperature the reaction mixture was absorbed onto florisil and purified by column chromatography (SiOz, ethyl acetate: hexane 2:3) to afford the subtitled compound (0.43 g, 1.39 mmol, 74%) as an off white solid: 'H NMR
(CDC13) 8 1.56-2.1 (m, lOH), 6.97 (d, J= 8.0 Hz, 1H), 7.39 (dd, J = 8.03, 1.45 Hz, 1H), 7.57 (d, J= 1.45 Hz, 1H), 7.59 (d, J= 1.4 Hz, 1H), 7.84 (d, J= 1.4 Hz, 1H), 8.32 (br s, 1H); '3C-NMR (CDC13) 8 22.07, 26.56, 34.4 (t), 48.13 (s), 110.18 (d), 111.3, 114.75 (s), 122.92, 126.76 (d), 128.44 (s), 137.55 (d), 138.11, 142.71, 144.49, 182.13 (s); MS (EI) m/z 307 (M-H)+; Anal. (C,8H,6NZOS) C, H, N.
A solution of4-(1,2-dihydro-2-oxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-2-thiophenecarbonitrile ( 1.0 g, 3.2 mmol) and Lawesson's Reagent ( 1.3 g, 3.2 mmol) in o-xylene (20 mL) was heated for two and a half hours. The reaction mixture was washed with distilled water (5x100 mL), dried over MgS04, and evaporated. The product was purified by column chromatography (Si02, EtOAc:Hexane 1:5) to afford the title compound (0.2 g, 20%) as a pale-yellow solid: m.p. 230-232 °C; 'H-NMR
(DMSO-db) 8 12.72 (s, 1H), 8.52 (d, 1H, J = 1.5 Hz), 8.36 (d, IH, J = 1.5 Hz), 8.00 (d, 1 H, J = 1.5 Hz), 7.69 (dd, 1 H, J = 6.4, 1.8 Hz), 7.10 (d, 1 H, J = 8.3 Hz), 1.98 - 1.77 (m, 7H), 1.43 - 1.33 (m, 3H); MS (EI) M+ @ m/z 324.
3-(1,2-Dihydro-2-thioxospirolcyclohexane-1,3-l3Hlindoll-5-yl)-5-fluorobenzonitrile To a solution of 5'-bromospiro [cyclohexane-1,3'-[3H]indol]-2'-(1'H)-one (1 lg, 0.04 mol) in dry tetrahydrofuran (200 cm3) was added sodium hydride (60%
dispersion in mineral oil, 1.6 g, 0.04 mol). After 30 min. stirnng at room temperature, the mixture was cooled to -78°C and butyl lithium (1.7M in hexanes, 23.2 cm', 0.04 mol) was added slowly. After 30 min. di-iso-propylborate (25 cm3, 0.11 mol) was added and the mixture was allowed to warm to room temperature.
After 2 hrs. hydrochloric acid (1N, 500 cm3) and ethylacetate (S00 cm3) were added.
The aqueous phase was extracted with ethylacetate, then the combined organic layers were washed with water, brine, dried (MgS04) and evaporated. The residue was triturated with hexane and the precipitate dried in vacuo to obtain (2'-oxo-2, dihydrospiro[cyclohexane-1, 3'- [3H] indol] -5'-yl) boronic acid (8.3 g, 86%) as an off white solid that was used without further purification. A sample that was further triturated with ethyl acetate had the following properties: mp. 255-260°C dec.; 'H
NMR (DMSO-d6) 8 1.50 (m, 2H), 1.73 (m, 8H), 6.82 (d, 1H, J= 7.72 Hz) 7.66 (d, 1H, J= 7.72 Hz) 7.91 (s, 3H, br), 10.36 (s, 1H);MS ((-)ESI) m/z 244 [M-H].
3-( 1,2-Dihydro-2-oxospiro[cyclohexane-1,3-[3H]indoll-5-yl)-5-fluorobenzonitrile.
To a solution of 3,5-dibromofluorobenzene in diethyl ether ( 100 cm3) at -78 °C was added n-butyl lithium (2.5 M, 8 cm', 20 mmol) dropwise. After 30 min. the mixture was treated with DMF (20 cm3) in diethyl ether (10 cm3) and stirring was continued at -78 °C. After 30 min. the mixture was quenched with dilute HCl aq., separated and the aqueous layer was extracted with EtOAc. The combined organic layers were combined, washed with water, brine, dried (MgS04) and evaporated to give 3-fluoro-S-bromobenzaldehyde (4.0 g, 19.7 mmol, 100%) as an oil: 'H NMR
(CDC13) 8 inter alia 7.50 - 7.53 (m, 2H), 7.82 (s, 1H) and 9.93 (m, 1H); MS
(EI) mlz 202, 204 [M+]
To a solution of the last cited compound (4.0 g, 19.7 mmol) in ethanol:water (8:2, 50 cm3), was added sodium acetate (1.72 g, 21 mmol) and hydroxylamine hydrochloride (1.45 g, 21 mmol), and the mixture was heated under reflux.
After 30 min., the mixture was cooled, evaporated and the residue partitioned between water and EtOAc. The aqueous layer was re-extracted with EtOAc and the combined organic layers were washed with water, saturated sodium hydrogen carbonate solution, brine, dried (MgS04) and evaporated to give 3-fluoro-5-bromobenzaldehyde oxime (3.76 g, 17.24 mmol, 87%) which was used without further purification:
'H
NMR (CDCI3) 8 7.24 - 7.27 (m, 2H), 7.50 (s, 1H), 7.68 (s, 1H) and 8.04 (s, 1H); MS
(EI) m/z 217 [M+].
The above oxime (3.76 g, 17.24 mmol) and copper (II) acetate (370 mg) were dissolved in acetonitrile (100 cm') under nitrogen and heated under reflux.
After Sh, the mixture was evaporated, the residue taken into EtOAc, washed with sulfuric acid (1N), water, brine, dried (MgS04) and evaporated to give 3-fluoro-5-bromobenzonitrile (3.08 g, 15.39 mmol, 89%) which was used without further purification.
The above bromide (3.0 g, 15 mmol) and tetrakis(triphenylphosphine)palladium (0) (0.86 g, 0.75 mmol) were dissolved in dimethoxyethane (130 cm3) under nitrogen. After 15 min. (2'-oxo-2, 3-dihydrospiro[cyclohexane-l, 3'- [3H] indol] -5'-yl) boronic acid (2.82 g, 11.5 mmol) and sodium carbonate (3.1 g, 29.3 mmol) dissolved in water (40 cm3) were added, and the mixture heated under reflux. After 8h the mixture was cooled, poured into water and extracted with EtOAc (x3). The combined organic layers were then washed with water, dried (MgS04) and evaporated. The residue was then purified by column chromatography (EtOAc: hexane, gradient elution), and the product recrystallized from methanol to give 3-(1,2-Dihydro-2-oxospiro[cyclohexane-1,3-[3H]indol]-S-yl)-5-fluorobenzonitrile (1.78 g, 5.55 mmol, 48%): mp 199 - 205 °C; 'H
NMR (CDC13) 8 1.64 -2.03 (m, lOH), 7.03 (d, 1H, J= 8 Hz), 7.31 (dt, 1H, J= 7.7 and 1.6 Hz), 7.41 (dd, 1 H, J = 8, 1.7 Hz), 7.49 (dt, 1 H, J = 9.6, 2 Hz), 7.5 8 (d, 1 H, J = 2 Hz), 7.64 (s, 1H) and 8.37 (s, 1H): MS (EI) m/z 320 [M+].
To a solution of 3-(1,2-Dihydro-2-oxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-5-fluorobenzonitrile (0.32 g, 1.0 mmol) in xylenes (10 cm3) under nitrogen was added Lawesson's reagent (0.89 g, 2.22 mmol) and the reaction was heated under reflux. After 4h., the mixture was cooled, evaporated and the residue subjected to column chromatography (Si02, EtOAc: hexane, gradient elution) to afford (0.143 g, 0.42 mmol, 42%) as a white solid: mp. 236-250 °C; 'H NMR (CDCl3) 8 1.54 - 1.66 (m, 3H), 1.86 - 2,18 (m,7H), 7.16 (d, 1H, J= 8.1 Hz), 7.33 - 7.36 (m, 1H), 7.46 - 7.52 (m, 2H), 7.65 (s, 1H), 7.85 (d, 1H, J= 1Hz), 10.05 (s, 1H); MS ((+)-APCI) mlz [M+H]+.
4-Methyl-5-(1,2-dihydro-2-thioxospiro(cyclohexane-1,3-(3Hl-indoll-5-xl)-2-thiophene thioamide 2'-oxo-2',3'-dihydrospiro [cyclohexane-1,3'-[3H]indol]-5'-yl)boronic acid (2.45 g, 10 mmol), 2-bromo-S-cyano-3-methylthiophene (2.4 g, 12 mmol), potassium (4 g, 29 mmol), and tetrakis(triphenylphosphine)palladium(0) (0.6 g, 0.5 mmol) in dimethoxyethane: water: ethanol (130 cm3, 10:2:1) was heated to 80°C
for 16 h., then poured into 1 L of water, and extracted with EtOAc. The organic layer was washed with brine, dried (MgS04) and concentrated. The crude product was subjected to column chromatography (Si02, EtOAc:hexane,l:l) to obtain the title compound (0.9 g, 28%): m.p. 200-203°C; 'H NMR (DMSO-d6) 8 1.63 (m, 8H), 1.87 (m, 2H), 2.27 (s, 3H), 6.95 (d, 1 H, J = 8.13 Hz), 7.34 (dd, 1 H, J = 8.13, 1.98 Hz) 7.54 (d, 1 H, J = 1.98 Hz), 7.82 (S, 1H) 10.50 (S, 1H); MS ((+)APC1) m/z 323 [M + H] +.
A solution of 4-methyl-5-[2'-oxo-2'3'-dihydrospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-2-thiophenecarbonitrile (0.61 g, 1.9 mmol) and phosphorous pentasulfide (0.92 g, 2.1 mmol) in dioxane (17 mL) was heated to 85 °C
for 30 minutes. The reaction mixture was poured into distilled water, and washed with aqueous NaHC03, distilled water, dried over MgS04, and evaporated to dryness.
The residue was purified with column chromatography (2.5% MeOH/CHzCl2) to afford the title compound (O.OSg, 8%) as a orange-brown solid: m.p. 244-249 °C; 'H-NMR
(DMSO-db) b 12.75 (s, 1H), 9.54 (s, 1H), 9.34 (s, 1H), 7.76 (d, 1H, J = 1.5 Hz), 7.58 (s, 1H), 7.45 (dd, 1H, J = 6.4, 1.8 Hz), 7.14 (d, 1H, J = 7.9 Hz), 2.26 (s, 3H), 1.98 -1.89 (m, 7H), 1.83 - 1.81 (m, 3H); MS ((+)APCI) [M+H]+ @ m/z 373.
EXAMPLE 6 - Pharmacology The progestational activity for the compounds of the current invention was evaluated in the in-vitro and in-vivo assays described below. In-vitro potencies lie in the range 0.01 nM - 10,000 nM, and in-vivo potencies in the range 1 ug/kg to mg/kg.
A. In-vitro biology The in-vitro biology is determined by ( 1 ) competitive Radioligand Binding: using the A-form of the human progesterone receptor with progesterone as the radioligand; (2) co-transfection assay, which provides functional activity expressed as agonist ECSO and Antagonist IC50 values; (3) a T47D cell proliferation, which is a further functional assay which also provides agonist and antagonist data;
and (4) T47D cell alkaline phosphatase assay, which is a further functional assay which also provides agonist and antagonist data.
1. hPR Binding a~ssay - This assay is carried out in accordance with: Pathirana, C.; Stein, R.B.; Bergen T.S.; Fenical, W.; Ianiro, T.;
Mais, D.E.; Tones, A.; Glodman, M.E., Nonsteroidal human progesterone receptor modulators from the marine alga cymoplia barbata, J. Steroid Biochem. Mol.
Biol., 1992, 41, 733-738.
2. PRE-luciferase assay in CV-1 cells The object of this assay is to determine a compound's progestational or antiprogestational potency based on its effect on PRE-luciferase reporter activity in CV-1 cells co-transfected with human PR and PRE-luciferase plasmids. The materials methods used in the assay are as follows.
a. Growth medium: DMEM (BioWhittaker) containing 10% (v/v) fetal bovine serum (heat inactivated), 0.1 mM MEM non-essential amino acids, 100U/ml penicillin, 100mg/ml streptomycin, and 2 mM
GlutaMax (GIBCO, BRL). Experimental medium: DMEM (BioWhittaker), phenol red-free, containing 10% (v/v) charcoal-stripped fetal bovine serum (heat-inactivated), 0.1 mM MEM non-essential amino acids, 100U/ml penicillin, 100mg/ml streptomycin, and 2 mM GlutaMax (GIBCO, BRL).
b. Cell culture, transfection, treatment, and luciferase as_ say Stock CV-1 cells are maintained in growth medium.
Co-transfection is done using 1.2x10' cells, 5 mg pLEM plasmid with hPR-B
inserted at Sphl and BamHl sites, 10 mg pGL3 plasmid with two PREs upstream of the luciferase sequence, and 50 mg sonicated calf thymus DNA as carrier DNA in 250 ml. Electroporation is carried out at 260 V and 1,000 mF in a Biorad Gene Pulser II.
After electroporation, cells are resuspended in growth medium and plated in 96-well plate at 40,000 cells/well in 200 ~1. Following overnight incubation, the medium is changed to experimental medium. Cells are then treated with reference or test compounds in experimental medium. Compounds are tested for antiprogestational activity in the presence of 3 nM progesterone. Twenty-four hr. after treatment, the medium is discarded, cells are washed three times with D-PBS (GIBCO, BRL).
Fifty ~1 of cell lysis buffer (Promega, Madison, WI) is added to each well and the plates are shaken for 15 min in a Titer Plate Shaker (Lab Line Instrument, Inc.).
Luciferase activity is measured using luciferase reagents from Promega.
c. Analysis of Results:
Each treatment consists of at least 4 replicates. Log transformed data are used for analysis of variance and nonlinear dose response curve fitting for both agonist and antagonist modes. Huber weighting is used to downweight the effects of outliers. ECSo or ICSO values are calculated from the retransformed values. JMP software (SAS Institute, Inc.) is used for both one-way analysis of variance and non-linear response analyses.
d. Reference Compounds:
Progesterone and trimegestone are reference progestins and RU486 is the reference antiprogestin. All reference compounds are run in full dose-response curves and the ECSO or ICSo values are calculated.
Table 1. Estimated ECSp, standard error (SE), and 95% confidence intervals (CI) for reference progestins from three individual studies EC50 95% CI
Compound Exp. (nM) SE lower upper Progesterone 1 0.616 0.026 0.509 0.746 2 0.402 0.019 0.323 0.501 3 0.486 0.028 0.371 0.637 Trimegestone 1 0.0075 0.0002 0.0066 0.0085 2 0.0081 0.0003 0.0070 0.0094 3 0.0067 0.0003 0.0055 0.0082 Table 2. Estimated ICS°, standard error (SE), and 95% confident interval (CI) for the antiprogestin, RU486 from three individual studies IC 50 95%
CI
Compound Exp. (nM) SE lower upper RU486 1 0.028 0.002 0.019 0.042 2 0.037 0.002 0.029 0.048 3 0.019 0.001 0.013 0.027 Progestational activity: Compounds that increase PRE-luciferase activity significantly (p<0.05) compared to vehicle control are considered active.
Antiprogestational activity: Compounds that decrease 3 nM progesterone induced PRE-luciferase activity significantly (p<0.05) ECS°: Concentration of a compound that gives half maximal increase PRE-luciferase activity (default-nM) with SE.
ICS°: Concentration of a compound that gives half maximal decrease in 3 nM
progesterone induced PRE-luciferase activity (default-nM) with SE.
3. T47D cell proliferation assay The objective of this assay is the determination of progestational and antiprogestational potency by using a cell proliferation assay in T47D cells. A compound's effect on DNA synthesis in T47D cells is measured.
The materials and methods used in this assay are as follows.
a. Growth medium: DMEM: F I 2 ( 1:1 ) (GIBCO, BRL) supplemented with 10% (v/v) fetal bovine serum (not heat-inactivated), 100U/ml penicillin, 100mg/ml streptomycin, and 2 mM GlutaMax (GIBCO, BRL).
b. Treatment medium: Minimum Essential Medium (MEM) (#51200-038GIBC0, BRL) phenol red-free supplemented with 0.5%
charcoal stripped fetal bovine serum, 100U/ml penicillin, 200 mg/ml streptomycin, and 2 mM GlutaMax (GIBCO, BRL).
c. Cell culture Stock T47 D cells are maintained in growth medium. For BrdU incorporation assay, cells are plated in 96-well plates (Falcon, Becton Dickinson Labware) at 10,000 cells/well in growth medium. After overnight incubation, the medium is changed to treatment medium and cells are cultured for an additional 24 hr before treatment. Stock compounds are dissolved in appropriate vehicle (100% ethanol or 50% ethanol/50% DMSO), subsequently diluted in treatment medium and added to the cells. Progestin and antiprogestin reference compounds are run in full dose-response curves. The final concentration of vehicle is 0.1 %. In control wells, cells receive vehicle only. Antiprogestins are tested in the presence of 0.03 nM trimegestone, the reference progestin agonist. Twenty-four hours after treatment, the medium is discarded and cells are labeled with 10 mM
BrdU (Amersham Life Science, Arlington Heights, IL) in treatment medium for 4 hr.
d. Cell Proliferation Assay At the end of BrdU labeling, the medium is removed and BrdU incorporation is measured using a cell proliferation ELISA
kit (#RPN 250, Amersham Life Science) according to manufacturer's instructions.
Briefly, cells are fixed in an ethanol containing fixative for 30 min, followed by incubation in a blocking buffer for 30 min to reduce background. Peroxidase-labeled anti-BrdU antibody is added to the wells and incubated for 60 min. The cells are rinsed three times with PBS and incubated with 3,3'5,5'-tetramethylbenzidine (TMB) substrate for 10-20 min depending upon the potency of tested compounds. Then ~1 of 1 M sulfuric acid is added to each well to stop color reaction and optical density is read in a plate reader at 450 nm within 5 min.
e. Analysis of Results:
Square root-transformed data are used for analysis of variance and nonlinear dose response curve fitting for both agonist and antagonist modes. Huber weighting is used to downweight the effects of outliers.
ECS° or ICS° values are calculated from the retransformed values. JMP software (SAS
Institute, Inc.) is used for both one-way analysis of variance and non-linear dose response analyses in both single dose and dose response studies.
f. Reference Compounds:
Trimegestone and medroxyprogesterone acetate (MPA) are reference progestins and RU486 is the reference antiprogestin. All reference compounds are run in full dose-response curves and the ECS°
or ICS° values are calculated.
Table 3. Estimated ECSp, standard error (SE), and 95% confidence intervals (CI) for individual studies ECS° 95% CI
Compound Exp (nM) SE lower upper Trimegestone 1 0.017 0.003 0.007 0.040 2 0.014 0.001 0.011 0.017 3 0.019 0.001 0.016 0.024 MPA 1 0.019 0.001 0.013 0.027 2 0.017 0.001 0.011 0.024 Table 4. Estimated ICS°, standard error, and 95% confident interval for the antiprogestin, RU486 ICS° 95% CI
Compound Exp (nMl SE lower upper RU486 1 0.011 0.001 0.008 0.014 2 0.016 0.001 0.014 0.020 3 0.018 0.001 0.014 0.022 ECS°: Concentration of a compound that gives half maximal increase in BrdU
incorporation with SE; ICS°: Concentration of a compound that gives half maximal decrease in 0.1 trimegestone induced BrdU incorporation with SE
4. T47D cell alkaline phosphatase assay The purpose of this assay is to identify progestins or antiprogestins by determining a compound's effect on alkaline phosphatase activity in T47D
cells. The materials and methods used in this assay are as follows.
a. Culture medium: DMEM:F 12 ( 1:1 ) (GIBCO, BRL) supplemented with 5% (v/v) charcoal stripped fetal bovine serum (not heat-inactivated), 100U/ml penicillin, 100 pg/ml streptomycin, and 2 mM GlutaMax (GIBCO, BRL).
b. Alkaline php osnhatase assay buffer:
I. 0.1 M Tris-HCI, pH 9.8, containing 0.2% Triton X-100; II. 0.1 M Tris-HCI, pH 9.8 containing 4 mM p-nitrophenyl phosphate (Sigma).
c. Cell Culture and Treatment:
Frozen T47D cells were thawed in a 37°C water bath and diluted to 280,000 cells/ml in culture medium. To each well in a 96-well plate (Falcon, Becton Dickinson Labware), 180 pl of diluted cell suspension was added.
Twenty pl of reference or test compounds diluted in the culture medium was then added to each well. When testing for progestin antagonist activity, reference antiprogestins or test compounds were added in the presence of 1 nM
progesterone.
The cells were incubated at 37°C in a 5% COz/humidified atmosphere for 24 hr.
d. Alkaline Phosphatase Enzyme Assay:
At the end of treatment, the medium was removed from the plate and fifty ~l of assay buffer I was added to each well. The plates were shaken in a titer plate shaker for 15 min. Then 150 ~1 of assay buffer II was added to each well. Optical density measurements were taken at 5 min intervals for 30 min at a test wavelength of 405 nM.
e. Analysis of Results: Analysis of dose-response data For reference and test compounds, a dose response curve is generated for dose (X-axis) vs. the rate of enzyme reaction (slope) (Y-axis).
Square root-transformed data are used for analysis of variance and nonlinear dose response curve fitting for both agonist and antagonist modes. Huber weighting is used to downweight the effects of outliers. ECso or ICSO values are calculated from the retransformed values. JMP software (SAS Institute, Inc.) is used for both one-way analysis of variance and non-linear dose response analyses in both single dose and dose response studies.
f. Reference Compounds:
Progesterone and trimegestone are reference progestins and RU486 is the reference antiprogestin. All reference compounds are run in full dose response curves and the ECso or ICSO values are calculated.
Table 5. Estimated ECSp, standard error (SE), and 95% confidence intervals (CI) for reference progestins from three independent experiments EC50 95% CI
Compound Exp (nM) SE lower upper Progesterone 1 0.839 0.030 0.706 0.996 2 0.639 0.006 0.611 0.669 3 1.286 0.029 1.158 1.429 Trimegestone 1 0.084 0.002 0.076 0.091 2 0.076 0.001 0.072 0.080 3 0.160 0.004 0.141 0.181 Table 6. Estimated ICSp, standard error, and 95% confident interval for the reference antiprogestin RU486 from three independent experiments IC SO 95% CI
Compound Exp (nM) SE lower ~uer RU486 1 0.103 0.002 0.092 0.11 S
2 0.120 0.001 0.115 0.126 3 0.094 0.007 0.066 0.134 B. In-vivo Biology The primary in-vivo assay is the rat decidualization model which may be used to determine progestational effects of both agonists and antagonists. The secondary in-vivo assay is the rat ovulation inhibition model which is under development and hence the protocol is un-available.
1. Rat decidualization assay: The objective of this procedure is used to evaluate the effect of progestins and antiprogestins on rat uterine decidualization and compare the relative potencies of various test compounds.
The materials and methods used in this assay are as follows.
a. Methods: Test compounds are dissolved in 100%
ethanol and mixed with corn oil (vehicle). Stock solutions of the test compounds in oil (MazolaTM) are then prepared by heating (~80 oC) the mixture to evaporate ethanol. Test compounds are subsequently diluted with 100% corn oil or 10%
ethanol in corn oil prior to the treatment of animals. No difference in decidual response was found when these two vehicles were compared.
b. Animals (RACUC protocol #5002 Ovariectomized mature female Sprague-Dawley rats (~60-day old and 230g) are obtained from Taconic (Taconic Farms, NY) following surgery. Ovariectomy is performed at least 10 days prior to treatment to reduce circulating sex steroids.
Animals are housed under 12 hr light/dark cycle and given standard rat chow and water ad libitum.
c. Treatment Rats are weighed and randomly assigned to groups of 4 or 5 before treatment. Test compounds in 0.2 ml vehicle are administered by subcutaneous injection in the nape of the neck or by gavage using 0.5 ml. The animals are treated once daily for seven days. For testing antiprogestins, animals are given the test compounds and a EC50 dose of progesterone (5.6 mg/kg) during the first three days of treatment. Following decidual stimulation, animals continue to receive progesterone until necropsy four days later.
d. Dosing Doses are prepared based upon mg/kg mean group body weight. In all studies, a control group receiving vehicle is included.
Determination of dose-response curves is carried out using doses with half log increases (e.g.
0.1, 0.3, 1.0, 3.0 mg/kg...).
e. Decidual induction Approximately 24 hr after the third injection, decidualization is induced in one of the uterine horns by scratching the antimesometrial luminal epithelium with a blunt 21 G needle. The contralateral horn is not scratched and serves as an unstimulated control. Approximately 24 hr following the final treatment, rats are sacrificed by C02 asphyxiation and body weight measured. Uteri are removed and trimmed of fat. Decidualized (D-horn) and control (C-horn) uterine horns are weighed separately.
f. Analysis of Results:
The increase in weight of the decidualized uterine horn is calculated by D-horn/C-horn and logarithmic transformation is used to maximize normality and homogeneity of variance. The Huber M-estimator is used to down weight the outlying transformed observations for both dose-response curve fitting and one-way analysis of variance. JMP software (SAS Institute, Inc.) is used for both one-way ANOVA and non-linear dose-response analyses.
g. Reference Compounds:
All progestin reference compounds were run in full dose-response curves and the ECSO for uterine wet weight were calculated.
Table 7. Estimated ECSO, standard error (SE), and 95% confidence intervals for individual studies ECS° 95% CI
Compound Exp (m,~/k~, s.c.) SE lower upper Progesterone 1 5.50 0.77 4.21 7.20 2 6.21 1.12 4.41 8.76 3-Ketodesogestrel 0.11 0.02 0.07 0.16 2 0.10 0.05 0.11 0.25 3 0.06 0.03 0.03 0.14 Levonorgestrel 1 0.08 0.03 0.04 0.16 2 0.12 0.02 0.09 0.17 3 0.09 0.02 0.06 0.13 4 0.09 0.02 0.06 0.14 MPA 1 0.42 0.03 0.29 0.60 2 0.39 0.05 0.22 0.67 3 0.39 0.04 0.25 0.61 Table 8. Estimated average ECso~ standard error, and 95% confidence intervals for dose-response curves of 3 reference compounds EC50 95% CI
Compound (m /g-kg SE lower upper s.c.) Progesterone 5.62 0.62 4.55 7.00 3-Ketodesogestrel0.10 0.02 0.07 0.14 Levonorgestrel 0.10 0.01 0.08 0.12 Table 9. Estimated ICSO, standard error, and 95% confident interval for the antiprogestin, RU 486 ICS° 95% CI
Compound Exp. (m~~p.o.) SE lower upper RU 486 1 0.21 0.07 0.05 0.96 1 S 2 0.14 0.02 0.08 0.27 Concentration: Compound concentration in assay(default-mg/kg body weight) Route of administration: Route the compound is administered to the animals Body weight: Mean total animal body weight (default-kg) D-horn: Wet weight of decidualized uterine horn (default-mg) C-horn: Wet weight of control uterine horn (default-mg) Decidual response: [(D-C)/C]x100%
Progestational activity: Compounds that induce decidualization significantly (p<0.05) compared to vehicle control are considered active Antiprogestational activity: Compounds that decrease ECS°
progesterone induced decidualization significantly (p<0.05) ECS° for uterine weight: Concentration of compound that gives half maximal increase in decidual response (default-mg/kg) ICS° for uterine weight: Concentration of compound that gives half maximal decrease in ECSO progesterone induced decidual response (default-mg/kg) Table 10. Data for Representative Compounds Example Ki/nM CV-1 EC50/nM Ovulation #
inhibition mg/kg S 0.3 3 0.1 0.2 1 0.2 0.8 4 0.06 0.1 0.1 Example 7 5-(1,2-Dihydro-2-thioxospirolcyclopentane-1,3-(3Hlindoll-5'-yl)-1H-pyrrole-2 carbonitrile 5-(2'-Oxo-2',3'-dihydrospiro[cyclopentane-1 3'-[3HJindol]-5'-yl-2-cyanopyrrole: A solution of 5'-bromospiro[cyclopentane-1,3'-[3HJ indolJ-2'(1'H)-one (2.0 g, 7.5 mmol) and tetrakis(triphenylphosphine)palladium(0) (430 mg, 0.3 mmol) in ethylene glycol dimethyl ether (50 mL) was stirred under a flow of nitrogen for 15 min. To the solution was added sequentially 1-t-butoxycarbonylpyrrole-2-boronic acid (2.1 g, 9.7 mmol) and potassium carbonate (2.4 g, 17 mmol) in water (10 mL). The mixture was heated to 80 °C for 3 h and allowed to cool. The reaction mixture was poured into water (50 mL) and extracted with ethyl acetate (3 x SO
mL).
The organic layers were combined, washed with brine (30 mL) and dried over magnesium sulfate. The solution was filtered and concentrated in vacuo.
Crystallization from 20% ethyl acetate/hexane gave 2-( 1',2'-dihydro-2'-oxospiro[cyclopentane-1,3'-[3HJindolJ-5'-yl)-1H-pyrrole-1-carboxylic acid, tert-butyl ester (2.2 g, 83%) as a white powder, mp 179-180.5 °C. 'H NMR (DMSO-d6, MHz) 8 1.30 (s, 9H), 1.75-1.98 (m, 8 H), 6.16 (dd, 1 H, J= 1.8, 3.3 Hz), 6.22 ('t', 1 H, J= 3.3, 3.3 Hz), 6.79 (d, 1 H, J= 7.9 Hz), 7.08 (dd, 1 H, J= 1.8, 7.9 Hz), 7.14 ('d', 1 H, J= 1.5 Hz), 7.28 (dd, J= 1.9, 3.3 Hz),10.30 (s, 1 H). MS (EI) mlz [M+]. Anal. Calcd for CZ,HZqN203: C, 71.57; H, 6.86; N, 7.95. Found: C, 71.08;
H, 6.83; N, 7.74.
To a solution of 2-(1',2'-dihydro-2'-oxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-1H-pyrrole-1-carboxylic acid, tert-butyl ester (2.2 g, 6.0 mmol) in THF
(anhydrous, 25 mL) was added at -78 °C chlorosulfonyl isocyanate (0.63 mL, 7.0 mmol). After 90 min, dimethylformamide ( 11 mL, 140 mmol) was added and the reaction was allowed to warm to room temperature. The reaction mixture was poured into water (50 mL) and extracted with ethyl acetate (2 x 50 mL). The organic layers were combined, washed with brine (50 mL), dried over magnesium sulfate, filtered and concentrated in vacuo. Purification via flash column chromatography on silica gel (30% ethyl acetate/hexane) gave 5-(2'-oxo-2',3'-dihydrospiro[cyclopentane-1,3'-[3H]indol]-5'-yl-2-cyanopyrrole-1-carboxylic acid, tert-butyl ester (1.7 g, 75%) as white crystals, mp 167-9 °C. 'H NMR (DMSO-db, 400 MHz) 8 1.34 (s, 9H), 1.75-1.98 (m, 8 H), 6.39 (d, 1 H, J= 3.7 Hz), 6.84 (d, 1 H, J= 7.9 Hz), 7.17 (dd, 1 H, J=
1.8, 7.9 Hz), 7.28 ('t', 2 H), 10.41 (s, 1 H). MS (ESI) m/z 376 [M-H]-. Anal.
Calcd.
for CZZH23N3O3: C, 70.01; H, 6.14; N, 11.13. Found: C, 69.67; H, 6.38; N, 11.04.
5-(2'-Oxo-2',3'-dihydrospiro[cyclopentane-1,3'-[3H]indol]-5'-yl-2 cyanopyrrole-1-carboxylic acid, tert-butyl ester (1 g, 2.7 mmol) was placed in a 25 mL round bottomed flask stoppered with a rubber septum and equipped with nitrogen inlet and a needle to allow gaseous outflow. A vigorous flow of nitrogen was maintained as the flask was placed in an oil bath and heated to 165 °C.
After 20 min at this temperature, the flask was removed from the oil bath and allowed to cool.
Crystallization from ethyl ether gave the title compound (600 mg, 79%) as a yellow powder, mp 285-286 °C. 'H NMR (DMSO-db, 400 MHz) 8 1.75-2.03 (m, 8 H), 6.60 (dd, 1 H, J= 2.4, 3.7 Hz), 6.84 (d, 1 H, J= 8.1 Hz), 6.94 (dd, 1 H, J= 2.4, 3.7 Hz), 7.52 (dd, 1 H, J= 1.8, 8.1 Hz), 7.60 (d, 1 H, J= 1.8 Hz), 10.38 (s, 1 H), 12.45 (s, 1 H). MS (ESI) m/z 276 [M-H]-. Anal. Calcd. For C"H,SN30: C, 73.63; H, 5.45; N, 15.15. Found: C, 73.24; H, 5.34; N, 14.96.
To 5-(1,2-Dihydro-2-oxospiro[cyclopentane-1,3-[3H]indol]-5'-yl)-1H-pyrrole-2-carbonitrile (0.18 g, 0.7 mmol, 1 eq) in p-xylene (20 mL) was added Lawesson's reagent (0.14 g, 0.36 mmol, 0.5 eq) and the reaction was heated to reflux for 1 hour. The reaction was cooled to room temperature and adsorbed onto silica gel. Purification by flash column chromatography (20% ethyl acetate/hexane) on silica gel gave the product as an orange powder. Further purification by HPLC
gave the title compound as a green solid (0.144 g, 70%), mp 275-276 °C
(dec.). 'H NMR
(db-DMSO, 300 MHz) 8 1.81-2.16 (m, 8 H), 6.69 (dd, 1 H, J= 2.3, 3.7 Hz), 6.98 (dd, 1 H, J = 1.8, 3.7 Hz), 7.04 (d, 1 H, J = 8.2 Hz), 7.63 (dd, 1 H, J = 1.6, 8.2 Hz), 7.72 (d, 1 H, J= 1.3 Hz), 12.57 (s, 1 H), 12.65 (s, 1 H). MS (ESI) [M-H)-= 292.
Anal.
Calculated (cald.) for C"H,SN3S: C, 69.6; H, 5.15; N, 14.32. Found: C, 69; H, 5.31;
N, 13.81.
Example 8 5-(1,2-DihYdro-2-thioxospirolcyclohexane-1,3-f3Hlindoll-5-yl)-1-(tert-butoxycarbon~)-pyrrole-2-carbonitrile To a solution of 5'-bromo-spiro[cyclohexane-1,3'-indolin]-2'-one (3.4 g, 12 mmol) in 1,2-DME (100 mL) under a nitrogen atmosphere was added tetrakis(triphenylphospine)palladium(0) (70 mg, S mol%). After 15 min, 2-borono-1H-pyrrole-1-carboxylic acid, 1-tert butyl ester (1.3 eq, 3.31 g, 15.6 mmol) and a solution of KZC03 (2.3 eq, 3.83 g, 27.6 mmol) in water (5 mL) were added sequentially. The solution was heated to 80 °C for 3 h and allowed to cool. The reaction mixture was poured into water (200 mL) and extracted with EtOAc (2 x mL). The organic layers were combined, washed with brine (150 mL) and dried over MgS04. The solution was filtered, concentrated in vacuo, and the residue was purified by flash column chromatography on silica gel (eluting with 30%
EtOAc/hexane) to give 2-(1',2'-dihydro-2'-oxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-1H-pyrrole-1-carboxylic acid, tert-butyl ester (3.4 g, 76%) as a white powder, mp 177 °C. 'H NMR (CDC13; 300 MHz) 8 1.38 (s, 9 H), 1.59-1.93 (m, 10 H), 6.18 (m, 1 H), 6.23 ('t', 1H, 3 Hz), 6.91 (d, 1 H, J--8 Hz), 7.21 (d, 1 H, J--8 Hz), 7.34 (m, 1 H), 7.44 (s, 1 H), 8.33 (br s, 1 H, DZOex). MS ((+)-APCI) m/z 367 [(M+H)+]. Anal.
Calcd for Cz2H26N2~3~ C~ 72.11; H, 7.15; N, 7.64. Found: C, 71.7; H, 7.16; N, 7.5.
To a solution of 2-(1',2'-dihydro-2'-oxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-1H-pyrrole-1-carboxylic acid, tert-butyl ester (0.75 g, 2 mmol) in THF
(anhydrous, 20 mL) at -78 °C was added chlorosulfonyl isocyanate (1.15 eq, 0.23 mL, 2.3 mmol). After 90 min, DMF (20 eq, 3.6 mL, 46 mmol) was added and the reaction was allowed to warm to room temperature. The reaction mixture was poured into water (50 mL) and extracted with ethyl acetate (2 x 50 mL). The organic layers were combined, washed with brine (50 mL), dried over magnesium sulfate, filtered and concentrated in vacuo. Purification via flash column chromatography on silica gel (30% ethyl acetate/hexane) gave 5-(2'-oxo-2',3'-dihydrospiro[cyclohexane-1,3'-[3H]indol]-5'-yl-2-cyanopyrrole-1-carboxylic acid, tert-butyl ester (0.5 g, 63%) as an oil which crystallized from acetone to give white crystals, mp 156 °C.
'H NMR (db DMSO, 400 MHz) 8 1.32 (s, 9H), 1.50 (m, 3 H), 1.60-1.70 (m, 5 H), 1.75-1.85 (m, 2 H), 6.38 (d, 1 H, J= 3.7 Hz), 6.87 (d, 1 H, J= 7.9 Hz), 7.18 (dd, 1 H, J= 1.5, 7.9 Hz), 7.27 (d, 1 H, J= 3.7 Hz), 7.48 (d, 1 H, J= 1.8 Hz), 10.42 (bs, 1 H). MS (EI) m/z 391 (M+). Anal. Calcd for CZ3HZSN3O3: C, 70.57; H, 6.44; N, 10.73. Found: C, 69.82; H, 6.46; N, 10.43.
To a solution oft-Cyano-5-(1,2-Dihydro-2-oxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-1H-pyrrole-1-carboxylic acid, tert-butyl ester (0.7 g, 1.8 mmol, 1 eq) in toluene (70 mL) was added Lawesson's reagent (0.47 g, 1.1 mmol, 0.65 eq) and the reaction was heated to reflux for 1 hour. The reaction was cooled to room temperature, poured into water (100 mL) and extracted with ethyl acetate (2 x mL). The organic layers were combined, washed with brine (50 mL), dried over magnesium sulfate, filtered and concentrated in vacuo. Purification by flash column chromatography (20-30% ethyl acetate/hexane) on silica gel gave title compound as a yellow solid (0.7 g, 96 %). 'H NMR (db-DMSO, 500 MHz) 8 1.30-1.98 (m, 19 H), 6.45 (d, 1 H, J= 3.7 Hz), 7.09 (d, 1 H, J= 7.9 Hz), 7.31-7.34 (m, 2 H), 7.81 (d, 1 H, J
= 1.4 Hz), 12.74 (s, 1 H). MS (ESI) [M-H]- = 406. Anal. calcd. for Cz3HzsN3OzS: C, 67.79; H, 6.18; N, 10.31. Found: C, 67.86; H, 5.99; N, 10.25.
Example 9 5-~-Dihydro-2-thioxospiro[cyclohexane-1,3-[3Hlindol]-S~r~-1-H-pyrrole-2-rarhnnitrilP
To a solution of 5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-1-(tert-butoxycarbonyl)-pyrrole-2-carbonitrile (0.5 g, 1.2 mmol, 1 eq) in THF (5 mL) was added NaOEt (0.25 g, 3.6 mmol, 3 eq) in EtOH (5 mL) and the reaction was heated to 80°C for 24 h. The solvents were removed in vacuo and the residue partitioned between ethyl acetate (50 mL) and water (50 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (50 mL). The organic layers were combined, washed with brine (50 mL), dried over magnesium sulfate, filtered and concentrated in vacuo. Purification by flash column chromatography (30% ethyl acetate/hexane) on silica gel gave the title compound (0.27g, 68%) as a yellow powder. 'H NMR (db-DMSO, 500 MHz) 8 1.32-1.99 (m, 10 H), 6.71 (d, 1 H, J= 3.7 Hz), 7.00 (d, 1 H, J= 3.7 Hz), 7.09 (d, 1 H, J= 8.4 Hz), 7.70 (dd, 1 H, J= 1.6, 8.4 Hz), 8.05 (d, 1 H, J= 1.1 Hz), 12.67 (s, 1 H), 12.73 (s, 1 H). MS
(ESI) [M-H]-= 306. Anal. calcd. for C,BH"N3S: C, 70.33; H, 5.57; N, 13.67.
Found:
C, 69.64; H, 5.79; N, 13.04.
Example 10 5-(2'-thioxospiro[cyclohexane-1,3'-(3Hlindoll-5'-yl~ 1-meth,~pyrrole-2-carbonitrile To a solution of 5-(2'-oxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-1-methyl-pyrrole-2-carbonitrile (0.55 g, 1.8 mmol, 1 eq) in toluene (50 mL) was added Lawesson's reagent (0.47 g, 1.1 mmol, 0.65 eq) and the reaction was heated to 80 °C
for 1 hour. The reaction was cooled to room temperature, poured into water (100 mL) and extracted with ethyl acetate (2 x 100 mL). The organic layers were combined, washed with brine (50 mL), dried over magnesium sulfate, filtered and concentrated in vacuo. Purification by flash column chromatography on silica gel gave the product as a white solid (0.32 g, 55 %). 'H NMR (d6-DMSO, 500 MHz) 8 1.36-1.99 (m, 10 H), 3.7 (s, 3 H), 6.35 (d, 1 H, J= 4.2 Hz), 7.05 (d, 1 H, J= 4.2 Hz), 7.16 (d, 1 H, J=
7.9 Hz), 7.44 (dd, 1 H, J= 1.6, 8.1 Hz), 7.83 (d, 1 H, J= 1.6 Hz), 12.75 (s, 1 H). MS
(ESI) [M-H]-= 320. Anal. calcd. for C,9H,9N3S: C, 70.99; H, 5.96; N, 13.07.
Found:
C, 68.69; H, 5.36; N, 12.27.
Example 11 5-(1,2-Dihydro-2-thioxospirolc~lopentane-1,3-f3Hlindoll-5-vl)-3-thiophenecarbonitrile 5-Bromo-2-thiophenecarbonitrile: A mixture of S-bromo-2-thiophenecarboxaldehyde (96.Og, 500 mmol), hydroxylamine hydrochloride ( 111.9 g, S00 mmol), pyridine (500 mL), and ethanol (500 mL) was heated under nitrogen at reflux for two hours. The reaction mixture was cooled to ambient temperature and concentrated in vacuo to give an oil. The crude product was triturated twice with ice water and the solid obtained was collected on a filter. A mixture of a portion of the above solid (44.31 g, 215 mmol), copper (II) acetate monohydrate (4.2 g, 21 mmol) in acetonitrile ( 1.4L) was heated at reflux for three hours. The solvent was removed in vacuo and the residue was dissolved in ethyl acetate. The solution was washed with 5% aqueous sulfuric acid (2X30 mL), water (2X30 mL), brine (20 mL), and dried (MgS04). The solvent was removed in vacuo and the residue was dissolved in a minimum amount of chloroform ( 1 L) and allowed to crystallize. The crystal obtained was collected on a filter and the filtrate was concentrated and purified by a chromatography (silica gel, chloroform) to give the subtitled compound as an off white solid (3l.Sg combined, 58%). IR (film) cm' 2200. 'H-NMR (CDCI3) 8 7.39-7.38 (d, 1H, J= 4. 1 Hz), 7.10 (d, 1H, J= 4.0 Hz); MS (EI) mlz 187 (M+, 98%) 189(M+, 100%).
5-( 1,2 -dihydro-2-oxospiro[ cyclopentane-1,3-[ 3H]indole]-5-yl)-3-thiophenecarbonitrile was prepared according to the procedure for Example 5 using 5-bromo-2-thiophenecarbonitrile and (2'-oxo-2',3'-dihydrospiro[cyclohexane-1,3'-[3H]indol]-5'-yl) boronic acid: mp. 225-228°C; 'H NMR (DMSO-db) 8 1.63 (m, 8H), 1.90 (m, 2H) 6.91 (d, 1H, J= 8.13 Hz), 7.55 (dd, 1H, J= 8.13 , 1.76Hz), 7.60 (d, 1H, J= 4.17 Hz), 7.75 (d, 1H, J= 1.76 Hz), 7.93 (d, 1H, J= 4.17 Hz), 10.51 (s, 1H); MS
((+)APC1) m/z 309 [M + H]+.
A solution of 5-( 1,2 -dihydro-2-oxospiro[ cyclopentane-1,3-[ 3H]indole]-5-yl)-3-thiophenecarbonitrile (0.66 g, 2.4 mmol ), and 2,4-bis (4-methoxyphenyl )-1,3-dithia-2,4-diphosphetane-2,4-disulfide ( 0.97 g, 2.4 mmol ) in toluene (250 ml) was stirred at 80°C for 2 hours. The solution was concentrated in vacuo.
The residue was extracted with ethylacetate, the ethylacetate solution was washed with water, dried over magnesium sulfate, and concentrated. The residue was purified by column chromatography (silica gel, ethylacetate, hexane 20/80) to afford the title compound, m.p. 269-272 °C (0.24 g, 32% ). 'H-NMR ( DMSO-db ) 8 2.09 ( m, 8H ), 7.05 (d, J--8.1 Hz, 1H ), 7.55 ( dd, J--8.1, 1.7 Hz, 1H ), 7.7 (d, J--1.7 Hz, 1H ), 7.95 (d, J--1.3 Hz,IH ),8.49 ( d, J--1.3 Hz, 1H ), 8.49 (d, J--1.3 Hz, 1H ), 12.68 (s, 1H );
MS ( EI
NEG ) m/z 309 ( M-H )-.
Example 12 1,2-Dihydro - thioxos~ro ( cyclopentane - 1,3-f3 H lindol) - 5- 1 thiophenecarbonitrile The title compound was prepared from 5- (1,2-dihydro-oxospiro(cyclopentane - 1,3- [3 H ] indol )-5 yl ~2-thiophenecarbonitrile (2 g ,6.8 mmol ) and Lawesson's reagent (3.32 g ,8.2 mmol ) heated to reflux in toluene ( 150 mL ) for 3 hours. Yield 1.5 g (48.3 % ).m.p. 250-253~C.'H NMR (DMSO-d6) 8 12.75 ( S,1H),7.98-7.97(d, 1 H,J=3.9Hz),7.71-7.70(d, 1 H,J=5.2Hz),7.65-7.62( d, 1 HJ--8.1 Hz),7.09-7.07(d, 1 H,J=8.1 Hz)2.132.08(m, 6H), 1.99-1.85( m, 2 H ); MS. [ M-H]- = 309 .IR ( SP ATR ) 1430,1620,2220 crri'.Anal.C"H,4NzSz.
calc C,65.77;H,4.55; N , 9.02. obs'd C65.27; H,4.41 ; N , 8.84.
Example 13 5-I 3-Fluoro-4-methoxyphen~piro[cYClohexane-1,3-f3Hlindolel-2(1H)-thione 5-(3-Fluoro-4-methoxyphen~)spiro[cyclohexane-1,3-[3H]indol]-2( 1 H)-one:
Prepared from 4-bromo-2-fluoroanisole and (2'-oxo-2',3'-dihydrospiro[cyclohexane-1,3'-[3H]indol]-5'-yl) boronic acid according to the procedure for example 5 to afford the subtitled compound as a white solid, mp. 178 - 180 °C; 'H-NMR (DMSO
- db) 8 10.4 (s, 1H), 7.65 (d, 1H, J= 1.1 Hz), 7.5 - 7.4 (m, 3H), 7.2 (t, 1H, J= d J=
8.8 Hz), 3.9 (s, 3H), 1.9 (m, 2H) 1.7 - 1.6 (m, 8H); MS (APCI (-)) m/z 324 [M-H]~;
Anal.
Calc. For CzoHz°FNOz. : C, 73.83, H, 6.20, N, 4.30. Found: C, 73.55, H, 6.23, N, 4.40.
The title compound was prepared by refluxing overnight a mixture of 5-(3-Fluoro-4-methoxyphenyl)spiro[cyclohexane-1,3-[3H]indole]-2(1H)-one and an equal weight of phosphorus pentasulfide in pyridine. Removal of the pyridine in vacuo followed by treatment of the residue with 5N hydrochloric acid solution and subsequent recrystallization in ethanol gave a grey solid, mp 228-229°C; 'H-NMR
(DMSO-d6) 8 12.7 (s, 1H), 7.9 (s, 1H), 7.6 - 7.5 (m, 2H), 7.5 - 7.4 (m, 1H), 7.2 (t, 1H, J= 8.8 Hz), 7.1 (d, 1H, J= 8.1 Hz), 3.9 (s, 3H), 1.9 - 1.8 (m, 7H), 1.4 - 1.3 (m, 3H);
MS (APCI (-)) [M-H]-m/z 324. Anal. Cal. for CzoHzoFNOS. 0.25 H20 C, 69.44; H, 5.97; N, 4.05. Found: C, 69.43; H, 5.75; N, 4.32.
Example 14 5-(2-Amino-5-pyrimidin~piro[cyclohexane-1,3-[3Hl indole]-2(1H)-thione Prepared by refluxing overnight a mixture of 5-(2-amino-5-pyrimidinyl)spiro[cyclohexane-1,3-[3H]-indole]-2(1H)-one and an equal weight of phosphorus pentasulfide in pyridine. Removal of the pyridine in vacuo followed by treatment of the residue with 5N hydrochloric acid solution and subsequent recrystallization in ethanol gave a grey solid; mp 274 - 277 °C (dec.);
'H-NMR
(DMSO-db) 8 12.7 (s, 1H), 8.6 (s, 2H), 7.9 (s, 1H), 7.5 (d,lH, J= 8.1 Hz), 7.1 (d, 1H, J= 8.1 Hz), 6.8 (s, 2H), 1.9 -1.8 (m, 7H), 1.4 - 1.3 (m, 3H). MS (APCI (-)) [M-H]~ m/z 309.
Example 15 3-(1,2-Dihydro-2-thioxospirofcyclopentane-1,3-[3Hjindoll-5-X1L
fluorobenzonitrile Spiro(cyclopentane-1,3'-[3H]indol]-2'(1'H)-one To a -25 °C solution of oxindole (2.0 g, 15.0 mmol) in 40 (cm3) of anhydrous THF under NZ was added n-butyllithium ( 1.6 M in hexanes, 19.7 cm3, 31.5 mmol) drop-wise. To the resulting milky solution was added N,N,N',N'-tetramethylethylenediamine (4.75 cm3, 31.5 mmol). After 30 min. a solution of 1,4-diiodobutane (21.9 g, 70.6 mmol) in THF (3 cm3) was added and the reaction mixture was allowed to warm to RT and stirred for 14 h. The reaction mixture was poured into water, extracted with EtOAc (x 2), the combined organic layers were washed with dilute HCl (pH 1) and water (x 2), dried (MgS04) and evaporated. The residue was purified by column chromatography (Si02, EtOAc: hexane 1:4) to afford the subtitled compound (1.4 g, 7.5 mmol, 50%) as a tan solid: 'H NMR (CDCI3) 8 1.8-2.2 (m, 8H), 6.94 (dd, J= 7.5, 1.0 Hz, 1H), 7.01 (dd, J7.5, 1.0 Hz, 1H), 7.14-7.25 (m, 2H), 9.30 (br s, 1 H).
S-Bromo-spiro[cyclopentane-1,3'-(3H]indol]-2'( 1'H)-one A solution of spiro[cyclopentane-1,3'-[3H]indol]-2'(1'H)-one (0.27 g, 1.4 mmol) and sodium acetate (0.12 g, 1.46 mmol) in acetic acid ( 10 cm3) was treated with bromine (0.24 g, 1.51 mmol) in acetic acid (2 cm3). After 30 min. the mixture was poured into sat. sodium hydrogen carbonate solution and extracted with EtOAc (x 2), the combined organic layers were washed with water, sat. sodium hydrogen carbonate solution, water, dried (MgS04), and evaporated to give the subtitled compound (0.37 g, 1.47 mmol, 96 %) as an off white solid which was used without further purification: 'H NMR (CDC13) 8 1.8-2.27 (m, 8H), 6.79 (d, J= 8 Hz, 1H), 7.30-7.39 (m, 2H), 8.63 (br s, 1H).
5'-(3-Cyano-5-fluorophenyl)-spiro [cyclopentane-1,3'-[3H]indol]-2'( 1'H)-one:
A solution of 3-cyano-5-fluoro-bromobenzene (0.5 g, 2.6 mmol), and tetrakis (triphenylphosphine) palladium(0) (0.2 g) in ethylene glycol dimethyl ether (20 cm3) was stirred under Nz for 20 minutes. To this mixture was then (spiro[cyclopentane-1,3'-[3H]indol]-2'(1'H)-one-5-yl) boronic acid (0.9 g, 3.9 mmol) and sodium carbonate (0.8 g, 7.8 mmol) in water (5 cm3). The solution was brought to reflux for 18 hours and then cooled to room temperature, poured into 2N NaOH and extracted with EtOAc (x 3). The combined extracts were washed with water, brine, dried (MgS04), and evaporated. The residue was purified by column chromatography (Si02, EtOAc, hexane) to afford the subtitled compound (0.35 g, 44%) as white needles. mp: 235 - 237 °C; 'H NMR (DMSO-db) 8 10.5 (s, 1H), 8.1 (s, 1H), 8.0 (dt, 1 H, J = 1.7, 2.0, 7.0 Hz), 7.8 - 7.7 (m, 2H), 7.6 (dd, 1 H, J = 1.8, 6.4 Hz), 6.9 (d, 1 H, J
= 8.1 Hz), 2.0 - 1.9 (m, 8H); MS (EI) M+ @ m/z 306.
General Procedure A
The title compound was prepared from S'-(3-Cyano-5-fluorophenyl)-spiro[cyclopentane-1,3'-[3H]indol]-2'(1'H)-one (40 mg) and Lawesson's reagent (50 mg) in toluene ( 10 ml) at reflux in a sealed tube for 16 h. The mixture was concentrated and the residue dissolved in a minimal amount of THF, then purified by HPLC (SiOZ, 30 cm x 2.5 cm, EtOAc-Hexane 2:8 at 20 ml/min.) to afford the title compound (0.022 g) as an off white solid: mp. 236 - 238 °C; 'H NMR
(DMSO-db) 8 12.66 (br s, 1H), 8.11 (s, 1H), 7.97 (dt, 1H, J= 10.1 and 2.2 Hz), 7.79 - 7.76 (m, 2H), 7.68 (dd, 1H, J= 8.1 and 1.7 Hz), 7.07 (d, 1H, J= 8.1 Hz), 2.10 - 2.05 (m, 6H) and 1.97 - 1.88 (m, 2H); MS (EI) m/z 322 [M]+.
Example 16 5-(3-chloropheny_l~l-3,3-dimethyl-1,3-dihydro-2H-indole-2-thione 5-(3-Chloro-phenyl)-3,3-dimethyl-1,3-dihydro-indol-2-one. 5-bromo-1,3-dihydro-3,3-dimethyl-2H-indol-2-one (0.98 g, 4.07 mol) and tetrakis(triphenylphosphine)palladium(0) (0.239 g) were stirred under an atmosphere of nitrogen in dimethoxyethane (35 cm'). After 1 S min., 3-chlorophenylboronic acid (1.27 g, 8.13 mol) was added, followed by potassium carbonate (3.40 g, 45 mmol) in water (15 cm3). The reaction was heated to reflux for 2 hours and then stirred at room temperature overnight. The mixture was diluted with sat. ammonium chloride and extracted with EtOAc (x3). The combined organic layers were dried (MgS04), filtered, and evaporated. The residue was purified by column chromatography (Si02, EtOAc: hexane, 1:3) to afford the subtitled compound (0.284 g, 25%): mp 188 -°C; 'H NMR (DMSO-db) 8 3.34 (s, 6 H), 6.93 (d, 1 H, J= 8.04 Hz), 7.38-7.35 (m, 1 H), 7.53-7.43 (m, 2 H), 7.61 (d, 1 H, J= 7.68 Hz), 7.70 (s, 2 H), 10.40 (s, 1 H); IR
(KBr) 3420, 3150, 3050, 1700 cm'; MS (EI) m/z 270 (M-H)-; CHN calculated for C,6H,4C1N0 + O.1C4H80z: C, 70.21; H, 5.32; N, 4.99; Found: C, 70.3; H, 5.44;
N, 4.93.
The title compound was prepared from 5-(3-Chloro-phenyl)-3,3-dimethyl-1,3-dihydro-indol-2-one ( 100 mg) and Lawesson's reagent ( 120 mg) in toluene ( 10 ml) at reflux, according to General Procedure A, to afford the title compound (0.031 g) as an off white solid: mp. 158 - 160 °C;'H NMR (CDC13) 8 9.67 (br s, 1H), 7.55 (s, 1H), 7.47 - 7.43 (m, 3H), 7.40 - 7.30 (m, 2H), 7.08 (d, 1H, J= 8.7 Hz) and 1.50 (s, 6H);
MS (EI) m/z 287/289 [M]+.
Example 17 3-Benzyl-5-(3-chlorophenyl~-3-methyl-1,3-dihydro-2H-indole-2-thione The title compound was prepared from 3-benzyl-5-(3-chloro-phenyl)-3-methyl-1,3-dihydro-indol-2-one (100 mg) and Lawesson's reagent (120 mg) in toluene (10 ml) at reflux, according to General Procedure A, to afford the title compound (0.022 g) as an off white solid: mp. 168 - 170 °C; 'H NMR
(CDC13) 8 9.23 (br s, 1H), 7.49 (s, 1H), 7.49 - 7.30 (m, 4H), 7.21 (s, 1H), 7.15 - 7.09 (m, 3H), 6.96 - 6.94 (m, 2H), 6.89 (d, 1H, J= 8.0 Hz), 3.19 (dd, 2H, J= 40.5 and 13 Hz) and 1.57 (s, 3H); MS (EI) m/z 363/365 [M]+.
Example 18 4-(3,3-dimethvl-2-thioxo-2,3-dihydro-1H-indol-5-yl)-2-furonitrile 4-(3,3-Dimethyl-2-oxo-2,3-dihydro-1 H-indol-5-yl)-furan-2-carbonitrile.
Prepared according to the procedure for Example 5 using (2'-oxo-[2, 3-dihydro-3,3-dimethyl -l, 3'- [3H] indol] -5'-yl) boronic acid (354 mg, 1.7 mmol) and 4-bromo-furan-2-carbonitrile (200 mg, 1.2 mmol) to afford the subtitled compound (76 mg, 0.3 mmol, 26 %) as a white solid: mp.199.6-201.4 °C , 'H NMR (DMSO-db) 8 1.28 (s, 6H), 6.89 (d, J= 8.0 Hz, 1H), 7.48 (dd, J= 8.0, 1.8 Hz, 1H), 7.65 (d, J= 1.5 Hz, 1H), 8.1 (s, 1H), 8.5 (s, 1H), 10.46 (s, 1H); MS (ESI) m/z 251 (M-H)-; Anal.
C, SH, ZN202Ø6 H20 The title compound was prepared from 4-(3,3-Dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-furan-2-carbonitrile (73 mg) and Lawesson's reagent (120 mg) in toluene ( 10 ml) at reflux, according to General Procedure A, to afford the title compound (0.003 g) as an off white solid: mp. 188 - 191 °C; 'H NMR
(CDC13) b 9.63 (br s, 1H), 7.83 (s, 1H), 7.36 - 7.33 (m, 3H), 7.06 (d, 1H, J= 7.9 Hz) and 1.48 (s, 6H); MS (EI) m/z 268 [M]+.
Example 19 5-(3-methoxYphenyl)-3,3-dimethyl-1,3-dihydro-2H-indole-2-thione 5-bromo-1.3-dihydro-3,3-dimethyl-2H-indol-2-one: 3,3-dimethyl-indol-2-one (0.65 g, 4.03 mmol) and sodium acetate (0.33 g, 4.07 mmol) were stirred in acetic acid (5 cm3) then bromine (0.66 g, 4.13 mmol) in acetic acid (S cm3) was added drop-wise to the reaction mixture. The reaction was stirred for SO min., then poured into water. The mixture was basified with sodium carbonate, extracted with ethyl acetate (x3), dried (MgS04), filtered, and evaporated to give the subtitled compound (0.89 g, 92%)'H NMR (DMSO-db) 8 1.21 (s, 6 H), 6.76 (d, 1 H, J= 8.22 Hz), 7.29 (dd, 1 H, J
= 2.12 Hz, 8.23 Hz), 7.49 (d, 1 H, J= 2.03 Hz), 10.4 (s, 1H).
5-bromo-1,3-dihydro-3,3-dimethyl-2H-indol-2-one (0.33 g, 1.38 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.094 g) were stirred under an atmosphere of nitrogen in dimethoxyethane ( 12 cm3). After 1 S minutes, 3-methoxyphenylboronic acid (0.42 g, 2.76 mmol) was added, followed by potassium carbonate ( 1.15 g, 8.34 mmol) in water (5 cm3). The reaction was heated to reflux for S hours, and then cooled to room temperature. Saturated aqueous ammonium chloride and EtOAc were added and the mixture was filtered. The aqueous layer was extracted with EtOAc (x2), and the combined organic layers were dried (MgS04), filtered, and evaporated. The residue was purified by column chromatography (SiOz, EtOAc: hexane 1:3) to afford 5-(3-methoxy-phenyl)-3,3-dimethyl-1,3-dihydro-indol-2-one (0.1 lg, 31%), mp = 157-158 °C; 'H NMR
(DMSO-db) 8 3.34 (s, 6 H), 3.82 (s, 3 H), 6.87 - 6.93 (m, 2 H), 7.20-7.15 (m, 2 H), 7.37-7.32 (m, 1 H), 7.49-7.46 (m, 1 H), 7.63 (d, 1 H, J= 1.14 Hz), 10.4 (s, 1 H); MS
(EI) mlz 266 (M-H)-; CHN calculated for C"H"NO2: C, 76.38; H, 6.41; N, 5.24; Found: C, 76.02; H, 6.49; N, 5.02.
The title compound was prepared from 5-(3-methoxy-phenyl)-3,3-dimethyl-1,3-dihydro-indol-2-one ( 100 mg) and Lawesson's reagent ( 120 mg) in toluene ( 10 ml) at reflux, according to General Procedure A, to afford the title compound (0.022 g) as an off white solid: mp. 149 - 150 °C; 'H NMR (CDC13) 8 9.69 (br s, 1H), 7.49 -7.46 (m, 2H), 7.37 (t, 1H, J= 8.0 Hz), 7.16 (d, 1H, J= 7.7 Hz), 7.09- 7.06 (m, 2H), 6.90 (dd, 1H, J= 8.2 and 2.3 Hz) 3.88 (s, 3H) and 1.50 (s, 6H); MS (EI) mlz [M]+.
Example 20 3-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-l3Hlindol]'-5-yl~-4-tluorobenzonitrile 3-( 1,2-Dihydro-2-oxospirof cyclohexane-1,3-[3H]indol]-5-yl)-4-fluorobenzonitrile Prepared according to the procedure for Example 5: m.p. 205 - 206 °C. 'H
NMR (DMSO-db) 8 10.47 (s,lH), 8.08 - 8.06 (dd, 1H), 7.89 - 7.85 (m, 1H), 7.65 (s, 1 H), 7.54 -7.49 (m, 1 H), 7.43 - 7.40 (tt, 1 H), 6.95 - 6.93 (d, 1 H J = 7.9 Hz), 1.97 -1.83 (m, 2H), 1.69 - 1.55 (m, 8H); MS (EI) m/z 320 (M+).
The title compound was prepared from 3-(1,2-Dihydro-2-oxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-4-fluorobenzonitrile (100 mg) and Lawesson's reagent ( 120 mg) in toluene ( 10 ml) at reflux, according to General Procedure A, to afford the title compound (0.037 g) as an off white solid: mp.
233 °C; 'H NMR (CDCl3) 8 9.82 (br s, 1H), 7.86 (s, 1H), 7.77 (dd, 1H, J= 7.0 and 1.8 Hz), 7.68 - 7.63 (m, 1 H), 7.45 (d, 1 H, J = 8.0 Hz), 7.31 (d, 1 H, J =
9.0 Hz), 7.15 (d, 1H, J= 8.1 Hz), 2.17 - 1.84 (m, 7 H) and 1.60 - 1.54 (m, 3H); MS (EI) mlz [M]+.
Example 21 5-(1,2-Dihydro-2-thioxospirofcyclohexane-1,3-l3Hlindoll-5-yl)-3 pyridinecarbonitrile A solution of 3-bromopyridine-5-carbonitrile (2.79 g, 15.26 mmol), hexamethylditin (5.00 g, 15.26 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.20 g, 0.17 mmol) in anhydrous dimethoxyethane (30 cm3) under Nz was heated under reflux.. After 16 h the mixture was concentrated and purified by column chromatography (Si02, EtOAc: hexane 5:95) to afford 3-cyanopyridine-5-trimethylstannane (2.82 g, 10.55 mmol, 69%): 'H NMR (CDC13) 8 0.40 (s, 9H), 8.01 (m, 1H), 8.80 (m, 2H); MS ((+) APCI) m/z 269 (M + H)+.
A solution of 5'-bromospiro[cyclohexane-1,3'-[3H] indol]-2'(1'H)-one (1.97 g, 7.05 mmol), 3-cyanopyridine-5-trimethylstannane (2.26 g, 8.46 mmol), bis(triphenylphosphine)palladium(II)chloride (0.33 g, 0.47 mmol) and lithium chloride (1.48 g, 35 mmol) in anhydrous toluene (30 cm3) was heated under reflux.
After 16h the mixture was cooled, partitioned between EtOAc and water, the aqueous layer was re-extracted with EtOAc (x 2), the combined organic extracts were washed with water, dried (MgS04) and evaporated. The residue was subjected to column chromatography (Si02, EtOAc: hexane, 1:2) and then further purified by preparative LC (Primesphere C18, 10 micron, 50 x 250 mm, MeCN: H20 1:1, 100 cm3/min., RT
7.92 min.) to afford 3-(1',2'-dihydro-2'-oxospiro[cyclohexane-1,3'-[3H]indol-5'-yl)pyridine carbonitrile. as white crystals (0.56 g, 1.84 mmol, 26%): mp. 232 -°C, 'H NMR (CDC13) 8 1.68 - 1.89 (m, 6H), 1.93 - 2.13 (m, 4H), 7.12 (d, 1H, J= 8 Hz), 7.49 (dd, 1 H, J = 8, 2 Hz), 7.66 (d, 1 H, 2 Hz), 8.15 (t, 1 H, J = 2 Hz), 8.39 (s, 1 H, br), 8.89 (d, 1 H, J = 2 Hz), 9.06 (d, 1 H, J = 2 Hz); MS ((+)-ESI) m/z 304 (M
+ H)+;
Anal. C,9H"N30 CHN.
The title compound was prepared from 3-( 1',2'-Dihydro-2'-oxospiro[cyclohexane-1,3'-[3H]indol-5'-yl)pyridine carbonitrile (100 mg) and Lawesson's reagent (120 mg) in toluene (10 ml) at reflux, according to General Procedure A, to afford the title compound (0.004 g) as a yellow solid: mp. 237 °C; 'H NMR (CDC13) 8 9.56 (br s, 1 H), 9.03 (d, 1 H, J = 1.9 Hz), 8.87 (d, 1 H, J = 1.4 _76_ Hz), 8.12 (s, 1H), 7.87 (s, 1H), 7.50 (d, 1H, J= 8.1 Hz), 7.17 (d, 1H, J= 8.1 Hz), 2.19 - 1.85 (m, 7H) and 1.59 - 1.54 (m, 3H); MS ((-)-APCI) m/z 318 [M-H]-.
Example 22 5-(3,4-Difluorophenyl)spirofcyclohexane-1,3-[3Hlindolej-2(1H)-thione 5'-(3,5-DifluorophenylZspirojcyclohexane-1,3'-(3H] indolj-2' ( 1'H)-one:
Prepared according to the procedure for Example 5: mp 180-183 °C;
'H-NMR
(CDCl3) 8 8.35 (s, 1H), 7.59 (d, IH, J= 2.0 Hz), 7.40 (dd, 1H, J= 6.2, 2.0 Hz), 7.10 -7.03 (m, 2H), 6.99 (d, IH, J= 8.1 Hz), 7.76 (tt, 1 H, J= 4.3, 2.3 Hz), 2.05 -1.62 (m, l OH); MS ((+)APCI) m/z 314 [M+H]+.
The title compound was prepared from 5'-(3,5-difluorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'(I'H)-one (100 mg) and Lawesson's reagent (120 mg) in toluene (10 ml) at reflux, according to General Procedure A, to afford the product (0.020 g) as a yellow solid: mp. 232 - 233 °C; 'H
1 S NMR (CDCl3) 8 10.05 (br s, 1 H), 7.83 (s, 1 H), 7.44 (dd, 1 H, J = 8.1 and 1.4 Hz), 7.3 8 - 7.30 (m, 1 H), 7.26 - 7. I 9 (m, 3H), 7.11 (d, 1 H, J = 8.1 Hz), 2.17 -1.82 (m, 7H) and 1.66 - 1.53 (m, 3H); MS ((-)-APCI) m/z 328 [M-H]-.
Example 23 5-(5-Chloro-2-thien~)spirolcyclohexane-1,3-f3Hlindolej-2(1H)-thione 5-(S-Chloro-2-thienyl)spirofcyclohexane-1,3-[3Hl indol)-2(1H)-one:
Prepared according to the procedure for Example 5: m.p. 191-192°C , 'H NMR
(CDC13) 8 1.6-2.1 (m, lOH), 6.85-6.95 (m, 2H), 6.98 (d, J= 4.0 Hz, 1H), 7.36 (dd, J=
7.5, 1.6 Hz, 1H), 7.53 (d, J= 0.9 Hz, 1H), 7.80 (br s, 1H);'3C-NMR (THF-d8) 8 21.35, 25.33, 33.12 (t), 48.32 (s), 110.40, 121.66, 121.96, 125.44, 127.25 (d), 128.17, 128.43, 136.92, 140.20, 143.43, 183.72 (s); MS (EI) m/z 318 (M+H)+; Anal.
(C"H,6C1NOS) C, H, N.
The title compound was prepared from 5-(5-Chloro-2-thienyl)spiro [cyclohexane-1,3-[3H] indol]-2(1H)-one (100 mg) and Lawesson's reagent (120 mg) in toluene (10 ml) at reflux, according to General Procedure A, to afford the product _77_ (0.041 g) as a yellow solid: mp. 231 - 232 °C; 'H NMR (CDCl3) 8 9.75 (br s, 1H), 7.82 (d, 1H, J= 1.2 Hz), 7.43 (dd, 1H, J= 8.1 and 1.6 Hz), 7.04 - 7.02 (m, 2H), 6.89 (d, 1H, J= 3.8), 2.15 - 1.84 (m, 7H) and 1.59 - 1.52 (m, 3H); MS ((-)-APCI) mlz 332/334 [M-H]-.
Example 24 5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3Hlindoll-5-~)-3-furancarbonitrile 5-( 1',2'-Dihydro-2'-oxospiro[cyclohexane-1,3'-[3H] indol]-5'-yl)-3-furancarbonitrile:
Prepared according to the procedure for Example 5: m.p. 243 - 245 °C. 'H-NMR (DMSO-d6) 8 10.48 (s, 1H), 8.62 (d, 1H J= 0.7 Hz), 7.76 (d, 1H J= 1.5 Hz), 7.58 -7.55 (dd, 1H), 7.33 (d, 1H J= 0.7 Hz), 6.92 - 6.90 (d, 1H J= 8.1 Hz), 1.87 -1.83 (m, 2H), 1.73 - 1.53 (m, 8H). MS ((+)EI) m/z 292 (M+).
The title compound was prepared from 5-(1',2'-dihydro-2'-oxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-3-furancarbonitrile (100 mg) and Lawesson's reagent ( 120 mg) in toluene ( 10 ml) at reflux, according to General Procedure A, to afford the product (0.020 g) as a yellow solid: mp. 264 - 268 °C; 'H
NMR (CDC13) 8 9.66 (br s, 1H), 7.98 (s, 2H), 7.59 (dd, 1H, J= 8.2 and 1.5 Hz), 7.08 (d, 1H, J= 8.2 Hz), 6.78 (s, 1H), 2.16 - 1.85 (m, 7H) and 1.56 - 1.52 (m, 2H):
MS ((--APCI) m/z 307 [M-H]~.
Example 25 5-(3-Chloro-4-fluorophenyl)spiro f cyclohexane-1,3-f 3H1 indolel-2(1H)- thione 5'-(3-Chloro-4-fluorophen~pirojcyclohexane-1,3'-[3Hlindol]-2'(1'H)-one.
Prepared according to the procedure for Example 5: mp 188-189 °C;
'H-NMR
(CDC13) 8 7.97 (s, 1H), 7.57 - 7.54 (m, 2H), 7.41 - 7.34 (m, 2H), 7.20 (t, 1H, J= 8.7 Hz), 9.96 (d, 1H, J= 8.1 Hz), 2.04 - 1.65 (m, lOH); MS ((+)APCI) mlz 330 [M+H]+.
The title compound was prepared from 5'-(3-Chloro-4-fluorophenyl) _78_ spiro[cyclohexane-1,3'-[3H]indol]-2'(1'H)-one (100 mg) and Lawesson's reagent ( 100 mg) in toluene ( 10 ml) at reflux, according to General Procedure A, to afford the product (0.036 g) as an off white solid: 'H NMR (DMSO-db) 8 12.74 (br s, 1H), 7.92 (d, 1 H, J = 1.4 Hz), 7.87 (dd, 1 H, J = 7.1 and 2.3 Hz), 7.70 - 7.65 (m, 1 H), 7.61 (dd, 1H, J= 7.1 and 1.5 Hz), 7.49 (t, 1H, J= 8.9 Hz), 7.14 (d, 1H, J= 8.1 Hz), 1.99 - 1.82 (m, 7H) and 1.40 - 1.37 (m, 3H): MS ((-)-APCI) mlz 344/346 [M-H]-.
Example 26 ~3-Chloro-5-lluorophenylLpiro[cyclohexane-1,3-f3Hlindolel-2(1H)-thione 5'-(3-Chloro-5-fluorophenyl)spiro[cyclohexane-1,3'-f3H]indol]-2'(1'H)-one:
Prepared according to the procedure for Example 5: mp 178-180 °C;
'H-NMR
(CDC13) 8 8.50 (s, 1H), 7.57 (d, 1H, J= 1.8 Hz), 7.39 (dd, 1H, J= 6.2, 1.9 Hz), 7.33 -7.32 (m, 1 H), 7.15 (dq, 1H, J= 5.7, 1.7, 0.7 Hz), 7.06 (dq, 1 H, J= 4.2, 1.9, 0.4 Hz), 7.00 (d, 1H, J= 8.1 Hz), 2.05 - 1.64 (m, lOH); MS ((-)ESI) [M-H]- @ m/z 328.
The title compound was prepared from 5'-(3-chloro-S-fluorophenyl)spiro [cyclohexane-1,3'-[3H]indol]-2'(1'H)-one (100 mg) and Lawesson's reagent (100 mg) in toluene ( 10 ml) at reflux, according to General Procedure A, to afford the product (0.039 g) as an off white solid: 'H NMR (DMSO-db) 8 12.76 (br s, 1 H), 7.97 (d, 1H, J= 1.1 Hz), 7.67 (dd, 1H, J= 8.1 and 1.4 Hz), 7.60 - 7.54 (m, 2H), 7.40 (dt, 1H, J= 8.65 and 2.0 Hz), 7.14 (d, 1H, J= 8.1 Hz), 1.99 - 1.83 (m, 7H) and 1.41 -1.38 (m, 3H): MS ((-)-APCI) m/z 344/346 [M-H]-.
Example 27 5-(3,5-Difluorophenyl~lspirofcyclohexane-1,3-[3H)indolel-2(1H~I-thione 5'-(3,5-Difluorophenyl)spiro[c~rclohexane-1,3'-[3H]indol]-2'(1'H)-one:
Prepared according to the procedure for Example 5: mp 180-183 °C;
'H-NMR
(CDC13) 8 8.35 (s, 1 H), 7.59 (d, 1 H, J = 2.0 Hz), 7.40 (dd, 1 H, J = 6.2, 2.0 Hz), 7.10 -7.03 (m, 2H), 6.99 (d, 1H, J= 8.1 Hz), 7.76 (tt, 1 H, J= 4.3, 2.3 Hz), 2.05 -1.62 (m, l OH); MS ((+)APCI) mlz 314 [M+H]+.
The title compound was prepared from 5'-(3,5-difluorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'(1'H)-one (100 mg) and Lawesson's reagent (100 mg) in toluene (10 ml) at reflux, according to General Procedure A, to afford the title compound 0.029 g as an off white solid: 'H
NMR
(DMSO-db) 8 12.76 (br s, 1H), 7.84 (s, 1H), 7.64 - 7.56 (m, 1H), 7.46 (d, 1H, J= 8.1 Hz), 7.40 - 7.32 (m, 1H), 7.22 - 7.15 (m, 2H), 1.99 - 1.80 (m, 7H) and 1.38 -1.35 (m, 3H); MS ((-)-APCI) m/z 328 [M-H]-.
Example 28 5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-l3Hlindoll-5-ylLpropyl-2-thiophenecarbonitrile 5-(1,2-Dihydro-2-oxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-4-propyl- 2-thiophenecarbonitrile. The title compound was prepared in a manner similar to Example 5 from 5-bromo-4-n-propyl thiophene-2-carbonitrile ( 1.17 g, 5 mmol ), (1,2-dihydro-2-oxospiro[cyclohexane-1,3-[3H] indol)-5-boronic acid ( 1.24 g, 5 mmol ), tetrakis(triphenylphosphine) palladium, potassium carbonate ( 2.75 g,21 mmol), water ( 10 mL ), and dimethoxyethane (50 mL) heated at reflux over night, to afford the product (0.7 g, 40%): m.p.168-171 °C;'H NMR ( DMSO-db) 8 10.56 ( s,lH ), 7.93 ( s, 1 H ) 7.52-7.51 (d, 1 H, J = 1.5 Hz), 7.33 - 7.29 (dd, 1 H, J = 1.6 Hz), 7.00-6.96 (d, 1H, J= 8.0 Hz), 2.62-2.57 (t, 2H), 1.86 (m, 2H), 1.70-1.56 (m, 11 H), 0.88-0.84 (t, H); MS m/z (APCI (+)) 351 [M+H)+. IR (KBr) 1620,1700,2200 crri'..-.Anal.
Cz,H22N20S~1/2 Hz0 calc. C,70.2; H, 6.39; N, 7.79. Observed. C,70.67; H,6.34;
N,7.62.
The title compound was prepared from 5-(1,2-dihydro-2-oxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-4-propyl- 2-thiophenecarbonitrile (90 mg) and Lawesson's reagent (90 mg) in toluene (10 ml) at reflux, according to General Procedure A, to afford the title compound (0.037 g) as an orange solid: 'H NMR
(DMSO-db) b 12.83 (br s, 1H), 7.96 (s, 1H), 7.77 (s, 1H), 7.44 (d, 1H, J= 7.7 Hz), 7.19 (d, 1H, J= 8.0 Hz), 2.60 (t, 2H, J= 8.0 Hz), 1.98 - 1.79 (m, 7H), 1.64 -1.56 (m, 2H), 1.39 - 1.35 (m, 2H) and 0.87 (t, 3H, J= 7.3 Hz):MS ((-)-APCI) mlz 365 [M-H]-.
Example 29 5-(3-Fluoro-4-nitrophen~piro ~ cyclohexane-1,3-f 3Hl indolel-2(1 H)-thione 5-(3-Fluoro-4-nitrophenyl)spirofcyclohexane-1,3-[3H]indol]-2(1H -one:
Prepared from (2'-oxo-2,3-dihydrospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)boronic acid (3.2 g, 12.5 mmol) and 4-bromo-2-fluoro-nitrobenzene (3 g, 13.6 mmol) as described for example 5, to afford the title compound (0.7 g, 16%) as a yellow solid:
mp. 213-215 °C; 'H NMR (DMSO-db) 8 1.5 - 1.8 (m, 8H), 1.8 - 2.0 (m, 2H), 6.96 (d, 1H, J = 8.13 Hz), 7.68 (dd, 1H, J= 8.13, 1.76 Hz), 7.74 (dd, 1 H, J= 8.68, 1.76 Hz), 7.86 (d, 1 H, J = 1.98 Hz), 7.92 (dd, 1 H, J = 13.4, 1.76 Hz), 8.18 (t, 1 H, J
= 8.46 Hz) and 10.52 (s, 1H); MS (EI) m/z = 340 (M+) The title compound was prepared from 5-(3-fluoro-4-nitrophenyl)spiro [cyclohexane-1,3-[3H]indol]-2(1H)-one (90 mg) and Lawesson's reagent (90 mg) in toluene ( 10 ml) at reflux, according to General Procedure A, to afford the product (0.021 g) as a yellow solid: 'H NMR (DMSO-db) 8 12.82 (br s, 1H), 8.21 (t, 1H, J=
8.4 Hz), 8.07 (d, 1 H, J = 1 Hz), 7.98 (dd, 1 H, J = 13.1 Hz), 7.79 (dt, 1 H, J = 8.1 and 2.6 Hz), 7.19 (1H, J= 8.2 Hz), 1.99 - 1.83 (m, 7H) and 1.42 - 1.39 (m, 3H): MS
((-)-APCI) m/z 355 [M-H]-.
Example 30 X1,2-Dihydro-2-thioxospiro cyclohexane-1,3-f3Hlindol]-5-yll-2-furancarbonitrile 4-( 1,2-Dihydro-2-oxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-2-furancarbonitrile: A solution of 3-bromo-5-cyano-furan (0.75 g, 4.4 mmol), and tetrakis(triphenylphosphine) palladium(0) (0.4 g) in ethylene glycol dimethyl ether (20 cm3) was stirred under NZ for 20 minutes. To this mixture was then added (spiro[cyclohexane-1,3'-[3H]indol]-2'(1'H)-one-5-yl) boronic acid (1.6 g, 6.5 mmol) and sodium acetate ( 1.4 g, 13.1 mmol) in water (5 cm3). The solution was brought to reflux for 18 hours and then cooled to room temperature, poured into 2N NaOH
and extracted with EtOAc (x 3). The combined extracts were washed with water, brine, dried (MgS04), and evaporated. The residue was purified by column chromatography (SiOZ, EtOAc, hexane) to afford the product (0.45 g, 36%) as an off white solid. mp:
240 - 242 °C; 'H NMR (DMSO-db) 8 10.4 (s, 1H), 8.5 (s, 1H), 8.2 (s, 1H), 7.7 (s, 1H), 7.5 (dd, 1H, J= 1.5 6.5 Hz), 6.9 (d, 1H, J= 8.0 Hz), 2.0 - 1.6 (m, lOH); MS
(EI) M+
@ m/z 292.
The title compound was prepared from 4-(1,2-dihydro-2-oxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-2- furancarbonitrile (67 mg) and Lawesson's reagent (67 mg) in toluene (10 ml) at reflux, according to General Procedure A, to afford the title compound (0.018 g) as a yellow solid: 'H NMR
(DMSO-db) 8 12.74 (s, 1H), 8.68 (s, 1H), 8.26 (s, 1H), 7.96 (s, 1H), 7.62 (dd, 1H, J=
8.0 and 1.0 Hz), 7.10 (s, 1H, J= 8.1 Hz), 1.94 - 1.78 (m, 7H) and 1.35 - 1.32 (m, 3H): MS ((-)-APCI) m/z 307 [M-H]-.
Example 31 5"-(3-Chlorophenyl)spirofcyclobutane-1,3"-f3Hlindolel-Z"(1"H?-thione 5-Bromospirojcyclobutane-1,3-[3Hlindoll-2(1H)-one: To a stirred solution of spiro[cyclobutane-1,3'-[3H]indol]-2'(1'I~-one (J. Med. Chem. 1987, 824-9) (1.0 g, 6 mmol) in glacial acetic acid ( 10 mL) was added dropwise at room temperature a solution of bromine (0.30 mL, 6 mmol) in glacial acetic acid (6 mL). After stirnng for 10 min, anhydrous sodium acetate (0.47 g, 6 mmol) was added and the solution was concentrated in vacuo. The residue was dissolved in ethyl ether (50 mL) and washed sequentially with water (50 mL), aqueous saturated sodium bicarbonate solution (50 mL), water (50 mL) and brine (30 mL). The organic layer was dried over magnesium sulfate, filtered and concentrated in vacuo. Crystallization from ethyl ether yielded the product as a white fluffy solid (1.1 g, 73%), mp 235-7 °C. 'H NMR
(DMSO-d6, 300 MHz) 2.15-2.41 (m, 6 H), 6.74 (d, 1 H, J= 8.2 Hz), 7.33 (dd, 1 H, J
= 2, 8.2 Hz), 7.75 (d, 1 H, J = 2 Hz), 10.36 (bs, 1 H). MS (EI) m/z 251 [M+].
Anal.
Calcd for C"H,oBrNO: C, 52.41; H, 4.00; N, 5.56. Found: C, 51.98; H, 4.24; N, 5.42.
To a solution of 5-bromospiro[cyclobutane-1,3-[3H]indol]-2(1H)-one (0.6 g, 2 mmol) in ethylene glycol dimethyl ether (50 mL) under a nitrogen atmosphere was added tetrakis(triphenylphosphine)palladium(0) (140 mg, 0.1 mmol). To the solution was added sequentially 3-chlorophenyl boronic acid (0.48 g, 3 mmol) and potassium carbonate (0.76 g, 5 mmol) in water (5 mL). The mixture was heated to 80 °C for 3 h and allowed to cool. The reaction mixture was poured into water ( 100 mL) and extracted with ethyl acetate (3 x 100 mL). The organic layers were combined, washed with brine (50 mL) and dried over magnesium sulfate. The solution was filtered, concentrated in vacuo, and the residue was purified by HPLC (Zorbax PRO, C18, 10u, 15A, 50 X 250mm; 35% Water/65% AcCN; 254NM; AMB. temp.) to give 5-(3-chlorophenyl)spiro[cyclobutane-1,3-[3H]indole]-2(1H)-one (200 mg, 35%) as a white powder, mp 199.5-201 °C. 'H NMR (DMSO-d6, 300 MHz) 2.21-2.28m, 2 H), 2.40-2.45 (m, 4 H), 6.87 (d, 1 H, J= 8.1 Hz), 7.37 ('d', 1 H), 7.44-7.52 (m, 2 H), 7.65 (bd, 1 H, J= 7.8 Hz), 7.76 (bs, 1 H), 7.92 (bs, 1 H), 10.35 (s, 1 H). MS (EI) mlz 283 [M+]. Anal. Calcd for C"H,QC1N0: C, 71.96; H, 4.97; N, 4.94. Found: C, 70.75;
H, 5.07; N, 4.68.
The title compound was prepared from 5-(3-Chlorophenyl)spiro[cyclobutane-1,3-[3H]indole]-2(1H)-one (55 mg) and Lawesson's reagent (55 mg) in toluene (10 ml) at reflux, according to General Procedure A, to afford the title compound 0.016 g as an orange solid: 'H NMR (DMSO-db) 8 12.58 (br s, 1H), 8.07 (d, 1H, J= 1.5 Hz), 7.82 (t, 1 H, J = 1.7 Hz), 7.70 (d, 1 H, J = 7.74 Hz), 7.60 (dd, 1 H, J = 8.12 and 1.71 Hz), 7.49 (t, 1 H, 7.9 Hz), 7.41 (d, 1 H, J = 8.32 Hz), 7.05 (d, 1 H, J = 8.14 Hz) and 2.57 - 2.27 (m, 6H); MS ((-)-APCI) m/z 298/300 [M-H]-.
Example 32 5"-(2-Chlorophenyl)spirofcyclohexane-1,3"-[3Hlindole]-2"(1"H]-thione The title compound was prepared from 5"-(2-Chlorophenyl)spiro[cyclohexane-1,3"-[3H]indole]-2"(1"H)-thione (90 mg) and Lawesson's reagent (90 mg) in toluene (10 ml) at reflux, according to General Procedure A, to afford the product 0.042 g as an off white solid: 'H NMR (DMSO-db) 8 12.75 (br s, 1H), 7.80 (d, 1H, J= 1.1 Hz) 7.58 - 7.55 (m, 1H), 7.48 - 7.36 (m, 4H), 7.16 (d, 1H, J= 8.0 Hz) ; MS ((-)-APCI) mlz 326/328 [M-H]-.
Exam lp a 33 5"-(4-Chlorophenyl)spirofcyclohexane-1,3"-f3Hlindole-2"(1"H)-thione The title compound was prepared from 5-(4-chlorophenyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-one (90 mg) and Lawesson's reagent (90 mg) in toluene (10 ml) at reflux, according to General Procedure A, to afford the product 0.035 g as an off white solid: 'H NMR (DMSO-db) 8 12.74 (br s, 1H), 7.91 (d, 1H, J= 1.3 Hz), 7.69 (d, 2H, J= 5.5 Hz), 7.60 (dd, 1H, J= 8.1 and 1.4 Hz), 7.50 (d, 2H, J= 8.5 Hz), 7.15 (d, 1H, J= 8.1 Hz), 1.99 - 1.83 (m, 7H) and 1.50 - 1.36 (m, 3H); MS ((-)-APCI) m/z 326/328 [M-H]~.
Example 34 5-(1",2"-Dihydro-2"-thioxospiro[cyclohexane-1,3"-f3HJindoll-5"-xl)- 4-methyl-2-thiophenecarbonitrile 5-Bromo-4-methyl-2-thiophene carboxaldehyde: To a solution of diethylamine (28g, 0.383 mol) in anhydrous THF (400 mL) was added at -40 °C
under nitrogen a solution of n-BuLi (2.5 M, 153 mL, 0.383 mol) in hexane.
After addition, the solution was stirred at -40 °C under nitrogen for 30 minutes, cooled to -78 °C and treated dropwise with a solution of 2-bromo-3-methylthiophene (45g, 0.254 mol) in anhydrous THF (450 mL). The reaction solution was stirred at -78 °C
for 30 minutes and treated with anhydrous DMF (100 mL). The mixture was allowed to warm to ambient temperature and was quenched with 1N aqueous hydrochloride solution (1L). The solution was extracted with ethyl acetate (3x450 mL) and the extracts washed with water, brine and dried (MgS04). After removal of solvent in vacuo, the title compound was obtained as a white solid (46g, 88.3%). A sample of the product was crystallized from hexane: mp 63-65 °C; IR (KBr) 1654 cm-'. 'H-NMR (CDCI3) 8 9.75 (S, 1H), 7.45 (S, 1H), 2.26 (S, 3H); MS (EI) m/z 204/206 (M+).
Anal. Calc. For C6HSBrOS: C, 35.14; H, 2.46. Found: C, 35.00; H, 2.44.
5-Bromo-4-methyl-2-thiophenecarbonitrile: Prepared from 5-bromo-4-methyl-2-thiophene carboxaldehyde using the procedure of Example 5. White solid:
mp 40-42 °C; IR (KBr) 2200 cm'; 'H-NMR (CDC13) 8 7.29 (S, 1H), 2.21 (S, 3H).
MS (EI) m/z 201/203 (M+, 98%/100%); Anal. Calc. For C6H4BrNS: C, 35.66; H, 1.99; N, 6.93. Found: C, 36.00; H, 2.14; N, 6.76.
Prepared according to the procedure for Example 5 using (2'-oxo-[2, 3-dihydro-3,3-dimethyl -l, 3'- [3H] indol] -5'-yl) boronic acid (357 mg, 1.7 mmol) and 5-bromo-4-methylthiophene-2-carbonitrile (295 mg, 1.5 mmol) to afford 5-(3,3-Dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-4-methyl thiophene-2-carbonitrile (227 mg, 0.8 mmol, 55 %) as a white solid: mp. 192.3-193 °C , 'H NMR (DMSO-db) b 1.29 (s, 6H), 2.29 (s, 3H), 6.97 (d, J= 8.0 Hz, 1H), 7.34 (dd, J= 8.0, 1.8 Hz, 1H), 7.49 (d, J= 1.7 Hz, 1H), 7.84 (s, 1H), 10.57 (s, 1H); MS (EI) mlz 282 (m)+; Anal.
C,6H,4NZOS.
The title compound was prepared from 5-(3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-4-methyl thiophene-2-carbonitrile (0.77 g, 2.39 mmol) and phosphorous pentasulfide (0.42 g, 0.96 mmol) in toluene (20 ml) at reflux.
After 3 h, the reaction was cooled and partitioned between water and EtOAc, the organic layer was separated, dried (MgS04) and evaporated. The residue was purified by column chromatography (Si02, EtOAc- hexane gradient elution) to afford the product (0.25 g, 0.73 mmol, 30%) as an orange solid: 'H NMR (DMSO-db) 8 12.82 (br s, 1H), 7.88 (s, 1 H), 7.82 (d, 1 H, 2 Hz), 7.49 (dd, 1 H, J = 8.1, 1.6 Hz), 7.18 (d, 1 H, J =
8.1 Hz), 1.99 - 1.80 (m, 7H) and 1.40 - 1.36 (m, 3H); MS ((-)-APCI) m/z 321 [M-H]-.
Example 35 5-(1",2"-Dihydro-2"-thioxospirofcyclohexane-1,3"-l3Hlindoll-5"- 1~)- 2-thiophenecarbonitrile 5-Bromo-2-thiophenecarbonitrile: A mixture of 5-bromo-2-thiophenecarboxaldehyde (96.Og, 500 mmol), hydroxylamine hydrochloride ( 111.9 g, 500 mmol), pyridine (500 mL), and ethanol (500 mL) was heated under nitrogen at reflux for two hours. The reaction mixture was cooled to ambient temperature and concentrated in vacuo to give an oil. The crude product was triturated twice with ice water and the solid obtained was collected on a filter. A mixture of a portion of the above solid (44.31 g, 215 mmol), copper (II) acetate monohydrate (4.2 g, 21 mmol) in acetonitrile ( 1.4L) was heated at reflux for three hours. The solvent was removed in vacuo and the residue was dissolved in ethyl acetate. The solution was washed with S% aqueous sulfuric acid (2X30 mL), water (2X30 mL), brine (20 mL), and dried (MgS04). The solvent was removed in vacuo and the residue was dissolved in a minimum amount of chloroform ( 1 L) and allowed to crystallize. The crystals obtained was collected on a filter and the filtrate was concentrated and purified by a chromatography (silica gel, chloroform) to give the subtitled compound as an off white solid (3l.Sg combined, 58%). IR (film) cm' 2200. 'H-NMR (CDC13) 8 7.39-7.38 (d, 1H, J= 4. 1 Hz), 7.10 (d, 1H, J= 4.0 Hz); MS (EI) mlz 187 (M+, 98%) 189(M+, 100%).
5-(2'-Oxo-2',3'-dihydrospiro[cyclohexane-1,3'-[3H]indol]-5'yl-2-thiophenecarbonitrile was prepared according to the procedure for Example 5 using 5-bromo-2-thiophenecarbonitrile and (2'-oxo-2',3'-dihydrospiro[cyclohexane-1,3'-[3H]indol]-5'-yl) boronic acid: mp. 225-228°C;'H NMR (DMSO-db) 8 1.63 (m, 8H), 1.90 (m, 2H) 6.91 (d, 1H, J= 8.13 Hz), 7.55 (dd, 1H, J= 8.13 , 1.76Hz), 7.60 (d, 1H, J = 4.17 Hz), 7.75 (d, 1 H, J = 1.76 Hz), 7.93 (d, 1 H, J = 4.17 Hz), 10.51 (s, 1 H); MS
((+)APC 1 ) m/z 309 [M + H]+.
The title compound was prepared from 5-(2'-oxo-2',3'-dihydrospiro[cyclohexane-1,3'-[3H]indol]-5'yl-2-thiophenecarbonitrile (0.69 g) and phosphorous pentasulfide (0.4 g) in toluene (20 ml) at reflux. After 3 h. the reaction was cooled, poured into sat. aqueous sodium hydrogen carbonate solution, and extracted with EtOAc. The organic layer was separated, dried (MgS04) and evaporated. The residue was purified by column chromatography (Si02, EtOAc-hexane gradient elution) to afford the title compound (0.215 g) as an orange solid: 'H
NMR (DMSO-db) 8 12.82 (br s, 1H), 8.00 - 7.98 (m, 2H), 7.74 (d, 1H, J= 4.1 Hz), 7.69 (dd, 1H, J= 8.2 and 1.6 Hz), 7.14 (d, 1H, J= 8.1 Hz), 1.99 - 1.83 (m, 7H) and 1.40 - 1.37 (m, 3H); MS ((-)-APCI) m/z 323 [M-H]-.
Example 36 5"-(3-Fluorophen~piro(cyclohexane-1,3"-(3Hlindolel-2"(1 "H)-thione 5'-(3-Fluorophenyl)spiro(cyclohexane-1 3'-(3H]indol]-2'(1'H)-one' Prepared according to the procedure for Example 5: mp 171-172 °C; 'H-NMR (CDCl3) 8 8.43 (s, 1 H), 7.62 (d, 1 H, J = 1.8 Hz), 7.42 (dt, 1 H, J = 6.2, 2.0 Hz), 7.3 9 -7.3 7 (m, 1 H), 7.33 (dt, 1H, J= 5.1, 1.3 Hz), 7.26 (dq, 1 H, J= 5.9, 2.1 Hz), 7.05 - 6.99 (m, 2H), 2.03 - 1.64 (m, lOH); MS ((+)APCI) m/z 296 [M+H]+.
The title compound was prepared from 5'-(3-fluorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'(1'H)-one (0.70 g) and phosphorous pentasulfide (0.4 g) in toluene (20 ml) at reflux. After 3 h. the reaction was cooled, poured into sat.
aqueous sodium hydrogen carbonate solution, and extracted with EtOAc, the organic layer was separated, dried (MgS04) and evaporated. The residue was purified by column chromatography (SiOz, EtOAc-hexane gradient elution) to afford the product (0.42 g) as an off white solid: 'H NMR (DMSO-db) 8 12.75 (br s, 1H), 7.95 (d, 1H, J=
1.5 Hz), 7.64 (dd, 1H, J= 8.13 and 1.5 Hz), 7.53 - 7.48 (m, 3H), 7.21 - 7.14 (m, 2H), 1.99 - 1.83 (m, 7H) and 1.40 - 1.37 (m, 3H); MS ((-)-APCI) m/z 310 [M-H]-.
Example 37 5-(3-Hydroxyphenyl)spiro(cyclohexane-1,3-(3Hjindole]-2(1H)-thione 5'-(3-Hydroxyphenyl)spiro[cyclohexane-1 3'~3H]indol)-2'(1'H)-one' Prepared according to the procedure for example 5: mp. 213 - 216 °C; 'H NMR
(CDCl3) 8 1.60-1.96 (m, lOH), 6.78 - 6.82 (m, 1H), 6.94 (d, 1H, J= 8 Hz), 7.01 - 7.04 (m, 2H), 7.23 (t, 1 H, J = 7.7 Hz), 7.3 8 (d, 1 H, J = 8 Hz), 7.61 (s, 1 H), 8.91 (s, 1 H) and 9.73 (s, 1 H, br); MS ((+)-APCI) m/z 294 [M+H]+.
The title compound was prepared from 5'-(3-hydroxyphenyl)spiro[cyclohexane-1,3'-[3H]indol)-2'(1'H)-one (100 mg) and Lawesson's reagent (110 mg) in toluene (10 ml) at reflux, according to General Procedure A, to afford the title compound (0.0045 g) as an off white solid: 'H
NMR
(CDC13) 8 9.59 (br s, 1H), 7.89 (s, 1H), 7.49 (dd, 1H, J= 8.1 and 1.5 Hz), 7.33 (t, 1H, _87_ J= 7.9 Hz), 7.15 - 7.10 (m, 3H), 6.84 (dd, 1H, J= 8.0 and 2.2 Hz), 2.17 - 2.05 (m, 2H), 1.98 - 1.88 (m, 5H) and 1.57 - 1.53 (m, 3H): MS ((-)-APCI) m/z 308 [M-H]-.
Example 38 5-(3-chlorophenyl)-3,3-diethyl-1 3-dih~dro-2H-indole-2-thione A solution of oxindole (40 g, 0.3 mol) in dry THF (400 ml) under Nz was cooled to -25 °C and treated drop wise with n-butyl lithium (2.SM in hexanes, 240 ml, 0.6 mol). To the resulting solution was added N,N,N',N'-tetramethylethylenediamine (90.4 ml, 0.6 mol). After 30 min. iodoethane (48 ml, 0.6 mol) was added and the reaction mixture was allowed to warm to room temperature and stirred over night.
The reaction mixture was poured into aqueous NH4C1 solution, extracted with EtOAc (2x) and the combined organic layers were washed with dil. HCI, water, brine, dried (MgS04) and concentrated. The residual oil was triturated with hexane to afford the crude product (24.5 g, 51 %). A sample (3 g) was recrystallized from EtOAc/hexane to obtain 3-ethyl-indol-2-one (1.4 g), m.p. 100 - 101 °C; 'H-NMR (DMSO-db) 8 0.76 (t, 3H, J = 7.5 Hz), 1.8 - 2.0 (m, 2H), 3.38 (t, 3H, J = 5.7 Hz), 6.8 (dt, 1 H, J = 7.69, 0.45 Hz), 6.93 (dt, 1 H, J = 7.45, 1.10 Hz), 7.15 (m, 1 H), 7.22 (m, 1 H), 10.3 (s, 1 H);
MS (ESI) m/z 270 [M+H].
A solution of 3-ethyl-indol-2-one (16 g, 0.1 mol) in dry THF (200 ml) under Nz was cooled to -25 °C and treated drop wise with n-butyllithium (2.5M
in hexanes, 80 ml, 0.2 mol). To the resulting solution was added N,N,N',N' tetramethylethylenediamine (30 ml, 0.2 mol). After 30 min. iodoethane (8 ml, 0.1 mol) was added and the reaction mixture was allowed to warm to RT and stirred over night. The reaction mixture was poured into an aqueous NH4C1 solution, extracted with EtOAc (2x) and the combined organic layers were washed with dil. HCI, water, brine, dried (MgS04) and concentrated. The residual oil was triturated with hexane to afford 3,3-diethylindol-2-one (9 g, 45%), m.p. 156 - 159 °C; 'H NMR
(DMSO-db) 8 10.44 (s, l H), 7.70 - 7.69 (t, l H), 7.62 - 7.59 (m, 1 H), 7.58 (d, l H J--1.7Hz), 7.53-7.50 (m, 1H), 7.45 - 7.41 (t,lH), 7.36 - 7.35 (m,lH), 7.34 - 7.33 (m,lH), 6.91 -6.89 (d,lH
_88_ J--8.2Hz), 1.87 - 1.80 (m,2H), 1.77 - 1.70 (m, 2H), 0.54 - 0.50 (t, 6H); MS
(+ESI) m/z 190 (M+H).
A solution of 3,3-diethylindol-2-one (8 g, 40 mmol) and sodium acetate (4 g, 48 mmol) in acetic acid (100 ml) was treated with bromine (6.4 g, 40 mmol).
After 30 min. the mixture was diluted with water and extracted with EtOAc (2x); the combined organic layers were washed with water, sat. sodium hydrogen carbonate solution, then brine, dried (MgS04) and evaporated to afford the crude product (7.6 g, 75%). A sample was recrystallized from EtOAc/hexane to obtain 5-bromo-1,3-dihydro-3,3-diethyl-[2H]-indol-2-one, m. p. 164 - 165 °C; 'H-NMR (DMSO-db) 8 10.45 (s, 1 H), 7.41-7.40(d, 1 H, J = 2.2Hz), 7.34 - 7.31 (m, 1 H), 6.78 -6.76 (d, 1 H J =
8.2 Hz), 1.78-1.65 (m, 4H), 0.50 - 0.46 (m, 6H); MS (-ESI) m/z 266/268 (M-H).
A solution of 5-bromo-1,3-dihydro-3,3-diethyl-[2H]-indol-2-one (2.7 g, 10 mmol), 3-chlorophenylboronic acid (1.6 g, 10 mmol), potassium carbonate (4 g, mmol) and tetrakis(triphenylphosphine)palladium(0) (0.5 g, 0.4 mmol) in dimethoxyethane ( 100 ml), ethanol (25 ml), and water (25 ml) was heated to reflux for 6 hours. After cooling to room temperature, the mixture was diluted with water and extracted with EtOAc (2x). The combined organic extracts were washed with water, then brine, dried (MgS04) and evaporated. The residue was purified by column chromatography (Si02, EtOAc:hexane 1:3) to afford 5-(3-chloro-phenyl)-3,3-diethyl-1,3-dihydro-indol-2-onecompound (0.8 g, 27%), m.p. 195 - 197 °C; 'H-NMR
(DMSO-db) 8 7.70 (t, 1H, J= 2 Hz), 7.62 - 7.60 (m, 1H), 7.58 (d, 1H, J= 1.7 Hz), 7.52, (dd, 1H, J= 8.1, 2 Hz), 7.43 (t, 1H, 7.9 Hz), 7.36 - 7.33 (m, 1H), 6.90 (d, 1H, J
= 8.1 Hz), 1.87 - 1.70 (m, 4H) and 0.52 (t, 6H, J= 7.4 Hz); MS (+APCI) mlz (M-H).
The title compound was prepared from 5-(3-chloro-phenyl)-3,3-diethyl-1,3-dihydro-indol-2-onecompound (100 mg) and Lawesson's reagent (100 mg) in toluene ( 10 ml) at reflux, according to General Procedure A, to afford the product (0.023 g) as a yellow solid: 'H NMR (DMSO-db) 8 12.73 (br s, 1H), 7.77 (t, 1H, J= 1.8 Hz), 7.75 (d, 1 H, J = 1.6 Hz), 7.68 - 7.62 (m, 2H), 7.48 (t, 1 H, J = 7.9 Hz), 7.40 (d, 1 H, J = 8.3 Hz), 7.09 (d, 1H, J= 8.1 Hz), 2.07 - 2.00 (m, 2H), 1.86 - 1.79 (m, 2H) and 0.37 (t, 6H, J= 7.3 Hz): MS ((-)-APCI) mlz 314/316 [M-H]-.
Examine 39 S 5-f4-Fluoro-3-(trifluoromethyl?phenyl)spirofcYClohexane-1,3- [3Hlindoll 2(1H) thione 5-[4-Fluoro-3-(trifluoromethyl)phenyl]spiro[cyclohexane-1,3- [3H]indol]-2(1H)-one was prepared from (2'-oxo-2,3-dihydrospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)boronic acid (2.5 g, 10 mmol) and 5-bromo-2-fluoro-trifluoromethylbenzene (2 g, 8 mmol) as described for Example 5, to afford the title compound (0.87 g, 30%) as a solid: mp. 222 °C; 'H NMR (DMSO-db) 8 1.5 - 1.8 (m, 8 H), 1.8 - 2.0 (m, 2 H), 6.92 (d, 1 H, J = 8.13 Hz), 7.51 (dd, 1 H, J = 8.13, 1.76 Hz), 7.55 (dd, 1 H, J =
10.54, 9.01 Hz) 7.72 (d, 1 H, J = 1.76 Hz), 7.90 (dd, 1 H, J = 7.03, 2.20 Hz), 7.98 (m, 1 H) and 10.39 (s, 1 H); MS (EI) m/z 363 (M+) The title compound was prepared from 5-[4-Fluoro-3-(trifluoromethyl)phenyl]
spiro[cyclohexane-1,3- [3H]indol]-2(1H)-one (90 mg) and Lawesson's reagent (90 mg) in toluene (10 ml) at reflux, according to General Procedure A, to afford the product (0.016 g) as a yellow solid: 'H NMR (DMSO-db) 8 12.75 (br s, 1H), 8.06 -8.00 (m, 1H), 7.96 - 7.92 (m, 2H), 7.66 - 7.56 (m, 2H), 7.16 (d, 1H, J= 8.1 Hz), 1.99 - 1.83 (m, 7H) and 1.41 - 1.38 (m, 3H): MS ((-)-APCI) m/z 378 [M-H]-.
Example 40 4-(1,2-Dihydro-2-thioxospiro f cyclohexane-1,3-l3Hl indoll-5-y1L
lluorobenzonitrile The title compound was prepared from 4-(1,2-dihydro-2-oxospiro[cyclohexane-1,3-[3H]indol]-S-yl)-2-fluorobenzonitrile (90 mg) and Lawesson's reagent (90 mg) in toluene ( 10 ml) at reflux, according to General Procedure A, to afford the title compound (0.050 g) as an orange solid: 'H NMR
(DMSO-db) 8 12.80 (br s, 1H), 8.04 (d, 1H, J= 1.3 Hz), 7.98 (t, 1H, J= 7.5 Hz), 7.92 (dd, 1 H, J = 1 I .3 and 1.3 Hz), 7.76 (d, 2H, J = 8.0 Hz), 7.18 (d, I H, J =
8.2 Hz), 1.99 - I .82 (m, 7H) and 1.40 - 1.38 (m, 3H); MS ((-)-APCI) m/z 335 [M-H]-.
Example 41 5-( 1,2-Dihydro-2-thioxospiro(cyclohexane-1,3-[3Hl indolj-5-yl) 4-n-but thiophenecarbonitrile The title compound was prepared in a manner similar to Example 5 from 5-bromo-4-n-butyl thiophenecarbonitrile (1.24 g, 5.1 mmol), (1,2-dihydro -2-oxospiro[cyclohexane-1,3-[3H] indol)-5-boronic acid (1.24 g, 5.05 mmol), tetrakis(triphenylphosphine) palladium (0.25 g), potassium carbonate (2.75 g, mmol), water ( 10 mL),and dimethoxyethane (50 mL) heated at reflux for 5 hours to afford 5-( 1,2-dihydro-2-oxospiro[cyclohexane-1,3-[3H] indol]-5-yl) 4-n-butyl-thiophenecarbonitrile (1 g, 54%), m.p.130-132° C. 'H NMR ( DMSO-db ) 8 10.56 (s, IH), 7.92 (s, 1H) , 7.52-7.51 (d, 1H, J= 1.2 Hz ), 7.32-7.29 (dd, 1H, J= 1.5 Hz), 6.98 - 6.96 (d, IH, J= 8.0 Hz), 2.64 - 2.59 (t, 2H), 1.99 - 1.86 (m, 2H), 1.70 -1.50 (m, 11 H), 1.32 - 1.22 (m, 2H) , 0.86 - 0.82 (t, 3H ); MS (APCI (+)) m/z 365 [M+H]+;
IR
(KBr) 1620,1700;2200 cm'; Anal. Cz2Hz4NzOS~1/4 H20. calc. C, 71.61; H, 6.69; N
7.59. observed C, 71.13; H, 6.61; N, 6.91.
The title compound was prepared from S-( 1,2-dihydro-2-oxospiro[cyclohexane-1,3-[3H] indol]-5-yl) 4-n-butyl-2-thiophenecarbonitrile (90 mg) and Lawesson's reagent (90 mg) in toluene (10 ml) at reflux, according to General Procedure A, to afford the product (0.050 g) as an orange solid: 'H
NMR
(DMSO-db) 8 12.83 (br s, 1 H), 7.95 (s, 1 H), 7.77 (s, I H), 7.44 (d, 1 H, J =
8.1 Hz), 7.18 (d, 1 H, J = 8. I Hz), 2.63 (t, 1 H, J .79= 8.0 Hz), 1.99 - 1.77 (m, 7H), I .60 - 1.50 (m, 2H), 1.39 - 1.35 (m, 3 H), 1.29 - 1.22 (m, 2H) and 0.81 (t, 3H, 7.3 Hz):
MS ((-)-APCI) m/z 379 [M-H]-.
Example 42 5-(3-Fluoro-5-methoxyphen~)spirolcyclohexane-1,3-f3Hlindolel-2(1H)-thione The title compound was prepared from 5-(3-Fluoro-5-methoxyphenyl)spiro [cyclohexane-1,3-[3H]indole]-2(1H)-one (90 mg) and Lawesson's reagent (90 mg) in toluene ( 10 ml) at reflux, according to General Procedure A, to afford the product (0.043 g) as an off white solid: 'H NMR (DMSO-d6) 8 12.74 (br s, 1H), 7.90 (s, 1H), 7.63 (dd, 1 H, J = 8.1 and 1.2 Hz), 7.13 (d, 1 H, J = 8.1 Hz), 7.08 (d, 1 H, J
= 10 Hz), S 7.01 (s, 1H), 6.83 (dt, 1H, J= 11 and 2.0 Hz), 1.99 - 1.83 (m, 7H) and 1.40 -1.37 (m, 3H): MS ((-)-APCI) m/z 340 [M-H]~.
Example 43 5-(3-Chlorophenyl)-N-hydroxyspiro(cyclohexane-1,3'-(3Hlindoll-2-amine To a solution of 5'-(3-Chlorophenyl)spiro[cyclohexane-1,3'-[3H]indole]-2'(1'H)-thione (0.74 g, 2.25 mmol) in dry THF (15 ml) was added sodium hydride (60% in oil, 0.1 g, 2.5 mmol) at room temperature. After 15 min., methyl iodide (0.18 ml, 2.88 mmol) was added. After lh, the reaction mixture was partitioned between water and EtOAc, the organic layer was washed with brine, dried (MgS04) and evaporated to give 5-(3-chlorophenyl)-2-(methylthio)spiro[cyclohexane-1,3' [3H]indole] (0.80 g, 100%) which was used without further purification:
To a solution of the last cited compound (1.96 g, 5.73 mmol) in DMSO (20 ml) was added hydroxylamine (60% in water, 5 ml) and the mixture was heated to 120 oC. After lh., the reaction was cooled, partitioned between diethyl ether and saturated aqueous ammonium chloride solution. The organic layer was washed with water and brine and then dried (MgS04) and evaporated. The crude product was then crystallized from MeOH to afford the title compound ( 1.67 g, 5.08 mmol, 89%) as a white solid: 'H NMR (CDCl3) 8 7.52 (t, 1H, J= 1.7 Hz), 7.43 - 7.28 (m, 7H), 6.83 (d, 1H, J= 8 Hz) and 1.98 - 1.51 (m, lOH); MS (ESI (+)) mlz 327/329 [M+H]+.
Example 44 N-(Acetyloxy)-5'-(3-chlorophenvl)spiro(cyclohexane-1,3'-(3Hlindoll-2"amine To a solution of 5-(3-Chlorophenyl)-N-hydroxyspiro[cyclohexane-1,3' [3H]indol]-2-amine (0.23 g, 0.71 mmol) in methylene chloride-methanol (9:1, 10 ml) was added acetic anhydride (0.08 ml, 0.8 mmol) and 4-dimethylaminopyridine (catalytic amount) under a nitrogen atmosphere. After 20 min., the reaction was evaporated and the product purified by column chromatography (Si02, methanol:
methylene chloride 5:95). The product was then triturated with di-iso-propylether to afford the title compound (0.12 g, 0.32 mmol, 45%): 'H NMR (CDC13) 8 7.52 -7.51 (m, 2H), 7.43 - 7.27 (m, SH), 6.88 (d, 1H, J = 8 Hz), 2.27 (s, 3H), 2.04 -1.92 (m, 4H), 1.84 - 1.74 (m, 4H) and 1.72 - 1.57 (m, 2H); MS (ESI (+)) m/z 369/371 [M+H]+; C21 H21 C1N2O2. 0.5 H20 requires C 66.98: H 5.64: N 7.34. Found C
66.74:
H 5.86: N 7.41.
Example 45 5'-(3-Fluorophenyl)spirofcyclohexane-1,3'-f3Hlindol-2'(1'H)-one oxime Prepared according to the method for Example 43 from 5'-(3-fluorophenyl) spiro[cyclohexane-1,3'-[3H]indole]-2'(1'H)-thione (0.59 g, 1.90 mmol) to afford the title compound (0.053 g, 0.17 mmol, 10%): 'H NMR (DMSO-d6) 8 9.59 (s, 1H), 9.40 (s, 1H), 7.57 (d, 1H, J = 1.5 Hz), 7.46 - 7.39 (m, 4H), 7.11 - 7.05 (m, 1H), 6.80 (d, 1H, J = 8.1 Hz), 2.04 -1.97 (m, 2H), 1.82 - 1.74 (m, 2H) and 1.66 - 1.42 (m, 6H):
MS (ESI (-)) m/z 309 [M-H]', C19H19FN20 requires C: 73.53, H: 6.17, N: 9.03.
Found C: 73.33, H: 6.07, N: 8.83.
Exam Ip a 46 5'-(2-Fluorophenyl)spiro[cyclohexane-1,3'-f3H]iindol-2'(1'H)-one oxime 5'-bromospiro{cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O- benzyloxime).
5'-Bromo-2'-(methylthio)spiro[cyclohexane-1,3'-[3H]indole] (9.0 g, 28.98 mmol) and O-benzylhydroxylamine hydrochloride (13.8 g, 86.9 mmol) were combined in methanol ( 150 mL) and heated to 45°C for 6 hours. Methanol was evaporated in vacuo. Ethyl acetate was added to the residue and this mixture was washed with ammonium chloride solution. Ethyl acetate was dried over magnesium sulfate, ethyl acetate collected evaporated in vacuo and the residue was flash chromatographed on alumina 90 (9:1 Hexane/EtOAc) to the desired product (6.5 g, 60%).
1H NMR (DMSO-db, 300 MHz) b 1.38-1.70 (m, 8H), 1.92-2.06 (m, 2H), 5.06 (s, 2H), 6.71 (d, 1 H, J = 8.26 Hz), 7.22-7.43 (m, 7H), 9.62 (s, 1 H).
Procedure A
5'-(2-Fluorophenyl)-spiro[cyclohexane-1,3'-[3H]indol}-2'(1H)-one 2(O-benzyloxime). 5'-Bromospiro{cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O-benzyloxime) (1.0 g, 2.6 mmol), and tetrakistriphenyl phosphine Pd (0) (0.14 g, 0.12 mmol) were stirred under an atmosphere of nitrogen in ethylene glycol dimethyl ether (23 mL). After 15 minutes, 2-flurophenyl boronic acid (0.72 mg, 5.2 mmol) was added, followed by sodium carbonate ( 1.6 g, 15.6 mmol) in water (6.0 mL). The reaction was heated to reflux overnight, cooled to room temperature and filtered through a Celite plug. Saturated ammonium chloride was added. The water layer was extracted with ethyl acetate (3 X 100 mL). The combined organic layers were dried (MgS04), filtered, and the solvent removed in vacuo. The product was purified by flash silica gel chromatography; (eluant: 10:0.5 hexane: ethyl acetate) to give the desired target compound (0.75 g, 1.8 mmol, 72%) as a viscous oil. 'H NMR (500 MHz, DMSO-db) 8 1.44 - 1.73 (8H, m) 1.93 - 2.06 ( 2H, q) 5.00 (2H, s) 6.88 (1H, d, J-- 8.1 Hz) 7.24 - 7.38 (6H, m) 7.44 - 7.56 (5H, m) 9.64 (1H, s); MS (ESI(+
ve)) mlz 399 (M-H)'.
Procedure B
A solution of 5'-(2-Fluorophenyl)-spiro[cyclohexane-1,3'-[3H]indol}-2'(1H)-one 2(O-benzyloxime) (0.55 g, 1.37 mmol) in ethanol(15 mL) was added to Palladium on carbon ( 10%, 0.11 g) in ethanol ( 10 mL). The mixture was stirred under an atmosphere of hydrogen (balloon) for 24 h at room temperature. The reaction mixture was filtered through a Celite plug and the filtrate was concentrated in vacuo.
The product was purified by flash silica gel chromatography (hexane: ethyl acetate, gradient elutions) to give the title compound (0.45 g, 1.12 mmol, 82%), mp.
203 °C; 'H NMR (500 MHz, DMSO-db) 8 1.45 - 1.73 (8H, m) 1.96 - 2.00 (2H, q) 6.83 (1H, d, J-- 7.9) 7.23 - 7.50 (6H, m) 9.42 (1H, s) 9.58 (1H, s); MS (ESI(+ ve)) m/z 311 (M+H)+.
Example 47 5'-(4-Fluorophenyl)spirofcyclohexane-1,3' [3H~'indol 2' 1'H) one oxime 5'-(4-Fluorophenyl)-spiro[cyclohexane-1,3'-[3H)indol}-2' (1'H)-one 2'(O-benzyloxime). Prepared from 5'-bromospiro{cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O- benzyloxime) ( 1.0 g, 2.6 mmol), and 4-fluorophenyl boronic acid (0.72 g, 5.2 mmol) according to Example 46 procedure A. The product was purified by flash silica gel chromatography; (eluant: 10:0.5 hexane: ethyl acetate) to give the desired product (0.70 g, 1.7 mmol, 67 %) as a viscous oil. 'H NMR (500 MHz, DMSO-db) 8 1.42 - 1.77 (8H, m) 1.95 - 1.99 (2H, q) 5.00 (2H, s) 6.84 (1H, d, J-- 8.1 Hz) 7.21 -7.63 (1H, m) 9.58 (1H, s); MS (ESI(- ve)) m/z 399 (M-H)-.
The product was synthesized using 5'-(4-Fluorophenyl)-spiro[cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O-benzyloxime) (0.70 g, 1.74 mmol), according to Example 45 procedure B. The product was purified by flash silica gel chromatography; (hexane: ethyl acetate, gradient elution) to give the title compound (0.44 g, 1.4 mmol, 81 %), Mp. 205 - 208°C; 'H NMR (500 MHz, DMSO-db) 8 1.43 -1.77 (8H, m) 2.00 - 2.05 (2H, q) 6.80 (1H, d, J-- 8.2 Hz) 7.21 - 7.24 (2H, m) 7.33 -7.35 (1H, dd, J-- 1.9 Hz) 7.49 (1H, s) 7.60 - 7.63 (2H, m) 9.35 (1H, s) 9.56 (1H, s);
MS (ESI(+ ve)) m/z 311 (M+H)+.
Example 48 5'-(3 4-difluorophenyl)spiro[cyclohexane-1,3' [3Hlindol 2'(1'H) one oxime 5'-(3,4-Difluorophenyl)-spiro[cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O-benzyloxime). Prepared from 5'-bromospiro{cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O- benzyloxime) ( 1.0 g, 2.6 mmol) and 3,4 -diflurophenyl boronic acid ( 1.6 g, 5.2 mmol of a 50 % solution of acid in THF/water) according to Example 46 procedure A. The product was purified by flash silica gel chromatography (eluant: 10:
0.5 hexane: ethyl acetate) to give the desired product (0.75 g, 1.7 mmol, 69 %) as a viscous oil. 'H NMR (500 MHz, DMSO-db) 8 1.41 - 1.78 (8H, m) 1.95 - 1.99 (2H, q) 5.00 (2H, s) 6.82 ( 1 H, d) 7.28 - 7.46 (8H, m) 7.58 ( 1 H, q) 7.67 - 7.71 ( 1 H, m) 9.61 (1H, s); MS (ESI(- ve)) m/z 417 (M-H)-.
Reaction of the last cited compound (0.70 g, 1.6 mmol) according to Example 45 procedure B, afforded the title compound (0.44 g, 1.3 mmol, 80 % ), 'H NMR
(500 MHz, DMSO-db) 8 1.42 - 1.79 (8H, m) 2.01 - 2.05 (2H, q) 6.78 - 6.80 (1H, d) 7.39 - 7.46 (3H, m) 7.55 (1H, s) 7.70 (1H, m) 9.10 (1H, s) 9.59 (1H, s); MS
(ESI(+
ve)) m/z 329 (M+H)+.
Exam In a 49 5'-(3-methoxyphenYlLpirolcyclohexane-1,3'-f3Hlindol-2'(1'H)-one oxime 5'-(3-Methoxyphenyl)-spiro[cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O-benzyloxime). Prepared from 5'-bromospiro{cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O- benzyloxime) ( 1.0 g, 2.6 mmol) and 3-methoxyphenyl boronic acid (0.79 g, 5.2 mmol) according to Example 46 procedure A. The product was purified by flash silica gel chromatography; (eluant: 10:0.5 hexane: ethyl acetate) to give the desired product (0.80 g, 1.9 mmol, 75 %) as a viscous oil. 'H NMR (500 MHz, DMSO-db) 8 1.43 - 1.78 (8H, m) 1.95 - 2.00 (2H, q) 3.80 (3H, s) 5.00 (2H, s) 6.82 - 6.86 (2H, m) 7.10 - 7.16 (2H, m) 7.28 - 7.53 (IOH, m) 9.57 (1H, s); MS (ESI(- ve)) m/z 411 (M-H)-Reaction of the last cited compound (0.80 g, 1.9 mmol) according to Example 46 procedure B, afforded the title compound (0.48 g, 1.4 mmol, 77 %), as a white solid. Mp. 101 - 104°C; 'H NMR (500 MHz, DMSO-db) 8 1.44 - 1.78 (8H, m) 1.99 -2.03 (2H, q) 3.81 (3H, s) 6.78 (1H, d) 6.85 (1H, d) 7.10 - 7.16 (2H, m) 7.30 -7.38 (2H, m) 7.50 (1H, d) 9.35 (1H, s) 9.56 (1H, s); MS (ESI(+ ve)) m/z 323 (M+H)+.
Example 50 5'-(3-nitrophenyl)spirofcyclohexane-1,3'-l3Hlindol-2'(1'H)-one oxime 5'-(3-Nitrophenyl)-spiro[cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O-benzyloxime). Prepared from 5'-bromospiro{cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O- benzyloxime) ( 1.0 g, 2.6 mmol) and 3-Nitrophenyl boronic acid (0.86 g, 5.2 mmol) according to Example 46 procedure A. Purification by flash silica gel chromatography (eluant : 10:0.5 hexane: ethyl acetate) afforded the desired compound (0.60 g, 1.4 mmol, 55 %) as a viscous oil. 'H NMR (500 MHz, DMSO-db) 8 1.42 - 1.82 (8H, m) 2.02 - 2.04 (2H, q) 5.01 (2H, s) 6.88 (1H, d) 7.28-7.71 (8H, m) 8.08 - 8.13 (2H, m ) 8.38 (1H, d) 9.69 (1H, s); MS (ESI(- ve)) m/z 426 (M-H) -.
Procedure C
The last cited compound (0.54 g, 1.26 mmol) was dissolved in dry methylene chloride (25 mL) and cooled to -78 °C under nitrogen. Boron tribromide (3.8 mL, 3.8 mmol, 1.0 M in methylene chloride) was added drop-wise over 5 minutes. After minutes the reaction was quenched with saturated sodium bicarbonate (5 mL).
The reaction mixture was allowed to warm to room temperature, the layers were separated and the aqueous layer was extracted with methylene chloride. The combined organic layers were dried (NazS04), filtered, and the solvent removed in vacuo. The product was purified by flash silica gel chromatography (eluant: 8:1 hexane: ethyl acetate) to give afford the title compound (0.33 g, 0.9 mmol, 78 %). Mp. 221 - 224 °C; 'H
NMR (500 MHz, DMSO-db) 8 1.42 - 1.83 (8H, m) 1.99 - 2.07 (2H, q) 6.84 - 6.85 (1H, dd) 7.50 - 7.52 (1H, m) 7.67 - 7.71 (2H, m) 8.08 - 8.12 (2H, m) 8.37 -8.38 (1H, d) 9.48 (1H, s) 9.64 (1H, s); MS (ESI(+ ve)) m/z 338 (M+H)+.
Example 51 5'-( 3-c,~phen~l?spiro[cyclohexane-1,3'-[3Hlindol-2'(1'H)-one oxime 3-Lpiro Lcyclohexane-1 3'-f 3H]indol]-( 1'H)-one-2'-(O-benzyloxime)lbenzonitrile f3H]indol]-5-yllbenzonitrile. Prepared from 5'-bromospiro{cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O- benzyloxime) (1.0 g, 2.6 mmol) and 3-cyanophenyl boronic acid (0.76 g, 5.2 mmol) according to Example procedure A. The product was purified by flash silica gel chromatography (eluant: 10:
0.5 hexane: ethyl acetate) to give the desired product (0.75 g, 1.8 mmol, 71 %) as a viscous oil.'H NMR (500 MHz, DMSO-db) 8 1.41 - 1.81 (8H, m) 1.96 - 2.03 (2H, q) 5.01 (2H,s)6.86(lH,d)7.28-7.33(9H,m)7.95-7.97(lH,d)8.12(lH,s)9.65 (1H, s); MS (ESI(- ve)) mlz 406 (M-H)-.
Reaction of the last cited compound (0.17 g, 0.43 mmol) and boron tribromide (1.2 mL, 1.2 mmol) according to Example SO procedure C afforded the title compound (0.06 g, 0.2 mmol, 47 %) as a white solid, Mp. 198 - 200°C; 'H
NMR
(500 MHz, DMSO-db) 8 1.41 - 1.80 (8H, m) 1.97 - 2.04 (2H, q) 6.80 (1H, q) 7.45 -7.69 (4H, m) 7.93 - 7.95 ( 1 H, dd) 8.10 ( 1 H, s) 9.42 ( 1 H, s) 9.59 ( 1 H, s); (ESI(+ ve)) mlz 318 (M+H)+.
Example 52 3-11',2'-Dihydro-2'-(hydrox 'mino)spiro[cyclohexane-1,3'-f3H]indoll-5'x11-5-fluorobenzonitrile To a solution of 3-fluoro-5-cyano-bromobenzene (0.4 g, 2.0 mmol) in dry DMF ( 10 ml) was added diboron pinacolate ester (0.63 g, 2.5 mmol), potassium acetate (0.65 g, 6.7 mmol) and PdClz (dppf) (0.2. g) and the reaction was heated to 80 °C under a nitrogen atmosphere. After 8 h. from 5'-bromospiro{cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O- benzyloxime) (0.2 g, 0.5 mmol), PdCl2 (dppf) (0.05 g) and sodium carbonate (1.30 g, 12.5 mmol) were added and heating at 80 °C was continued. After 8h. the reaction was cooled and partitioned between water and ethyl acetate, the organic layer was washed with brine, dried (MgS04) and evaporated. The residue was purified by column chromatography (Si02, EtOAc:hexane 1:20) to give the desired product (0.14 g, 0.33 mmol, 66%).
Reaction of the last cited compound (0.14 g, 0.33 mmol) and boron tribromide ( 1.0 ml, 1.0 mmol) according to Example 50 procedure C afforded the title compound (0.019 g, 0.05 mmol, 17%): 'H NMR (300 MHz, DMSO-db) 8 9.65 (s, 1H), 9.49 (s, 1 H), 8.04 (m, 1 H), 7.89 (dt, 1 H, J = 10.5 and 2 Hz), 7.72 - 7.68 (m, 2H), 7.54 (d, 1 H, J= 8.1 Hz), 6.80 (d, 1H, J= 8.1 Hz), 2.05 - 1.99 (m, 2H), 1.84 - 1.76 (m, 2H) and 1.65 - 1.44 (m, 6H): MS (ESI(+ ve)) m/z 336 (M+H)+.
Examine 53 5-(Spiro f cyclohexane-1,3'-(3Hl indoll-2'-(hvdroxvimino)-5'-yl)-4-methyl-2 thiophenecarbonitrile 4-Methyl-5-trimethylstannanyl-thiophene-2-carbonitrile Prepared from 5-bromo-4-methyl-thiophene-2-carbonitrile (3.08 g, 15.2 mmol), tetrakistriphenyl phosphine Pd (0) (0.82 g, 0.71 mmol), hexamethylditin (5.0 g, 15.2 mmol) and ethylene glycol dimethyl ether (20 mL) under nitrogen. The mixture was heated to reflux for 14 hours. The reaction mixture was concentrated in vacuo and purified using flash silica gel chromatography (eluant: 2% MeOH: methylene chloride) to recover the desired roduct (2.8 g, 0.01 mmol, 67 %) as a runny oil. 1H NMR
(300 MHz, DMSO-db) 8 0.41 (9H, s), 2.28 (3H, s), 7.83 (1H, s).
The last cited compound (0.20 g, 0.50 mmol), dichlorobis (triphenylphosphine) palladium(II) (0.02 g, 0.03 mmol) and triphenylarsine (0.03 g, 0.13 mmol) in DME (8.0 mL) were stirred under nitrogen for 20 minutes. 5'-Bromospiro{cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O- benzyloxime) (0.18 g, 0.64 mmol) was added in a solution of DME (2.0 mL). The solution was heated to reflux overnight. The reaction solution was concentrated in vacuo and purified by flash silica gel chromatography (eluant 12:1 hexane : ethyl acetate) to give the crude product(0.10 g, 0.25 mmol, 50%) which was used without further purification Boron tribromide (2.6 mL, 2.6 mmol of a 1.0 M solution in methylene chloride) was added to a solution of the last product (0.37 g, 0.86 mmol) in dry methylene chloride ( 1.7 mL) at -78°C. The solution was stirred for 30 minutes and quenched with saturated sodium bicarbonate (10 mL). The mixture was allowed to warm to room temperature and the layers were separated. The organic layer was dried (NazS04), filtered and concentrated in vacuo to give crude product which was purified by flash silica gel chromatography (eluant: 6:1 hexane: ethyl acetate) to give the title compound (0.02 g, 24 %): Mp. 173-176 °C; 'H NMR (500 MHz, DMSO-db) 8 1.44 -1.73 (8H, m), 1.96 - 2.00 (2H, m), 2.28 (3H, s), 6.82 - 6.84 (1H, m), 7.24 -7.26 (1H, dd, J-- 1.7 Hz), 7.3 8 ( 1 H, m) 7.82 ( 1 H, m) 9.51 ( 1 H, m) 9.66 ( 1 H, m);
MS (ESI(+ ve)) m/z 338 (M+H)+.
Example 54 5-(Spiro[cyclohexane-1,3'-f3Hlindole]-2'(hydroxyimino)-5'-yl)-2-thiophenecarbonitrile To a solution of 2-cyanothiophene ( 1.0 g, 9.16 mmol) and tri-iso-propylborate (2.3 ml, 10 mmol) in dry THF (30 ml) under nitrogen at -78 °C was added, dropwise, lithium hexamethyldisilazide (1M in THF, 10 ml, 10 mmol). After 30 min., the reaction was quenched with 1N HCI, then extracted with ethyl acetate, the organic layer was washed with water, dried (Na2S04) and evaporated to the product (1.25g, 8.17 mmol, 89%) which was used without further purification: 'H NMR (500 MHz, DMSO-db) 8 8.75 (br s, 2H), 7.97 (d, 1H, J= 8 Hz) and 7.73 (d, 1H, J= 8 Hz):
MS
(ESI(- ve)) m/z 152 (M-H)-.
Prepared from the last cited product (0.91 g, 5.95 mmol) and 5'-bromospiro{cyclohexane-1,3'-[3H)indol}-2' (1'H)-one 2'(O- benzyloxime) (1.53 g, 3.97 mmol) according to Example 46 procedure A. Purification by flash silica gel chromatography (eluant: 5: 1 hexane: THF) gave the desired product (0.66 g, 1.59 mmol) which was used without further purification: MS (ESI(- ve)) m/z 412 (M-H)-.
Reaction of the last cited compound (0.60 g, 1.45 mmol) and boron tribromide (1M in dichloromethane, S mL, 5 mmol) according to Example 50 procedure C afforded the title compound (0.036 g, 0.11 mmol, 8 %): 'H NMR (300 MHz, DMSO-db) 8 9.71 (s, 1H), 9.62 (s, 1H), 7.92 (d, 1H, J= 3.9 Hz), 7.63 (d, 1H, J
= 1.5 Hz), 7.54 (d, 1H, J = 3.9 Hz), 7.47 (dd, 1H, J= 8.1 and 1.6 Hz), 6.78 (d, 1H, J
= 8.1 Hz), 2.13 - 1.90 (m, 2H) and 1.78 - 1.60 (m, 6H): MS (ESI(+ ve)) m/z 324 (M+H)+.
Example 55 4-(Spiro(cyclohexane-1,3'-l3Hlindole)-2'(h~yimino~l-5'-y1L
thiophenecarbonitrile 4-(Trimethylstann~)-2-thiophenecarbonitrile A solution of 3-bromo-2-thiophenecarbonitrile (0.8 g, 4.3 mmol), tetrakis(triphenylphosphine)palladium(0) (0.25 g, 0.2 mmol) and hexamethylditin (1.4 g, 4.3 mmol) in dimethoxyethane (5 cm3) was heated under reflux for 14 h then cooled to RT. The reaction mixture was absorbed onto florisil and purified by column chromatography (Si02, methylene chloride: hexane 1:9) to afford the subtitled compound ( 1.04 g, 3.8 mmol, 90%) as a clear viscous oil: 1H NMR (CDC13) 8 0.35 (s, 9H), 7.56 (d, J= 0.9 Hz, 1H), 7.66 (d, J
= 0.9 Hz, 1 H).
To a solution of 5'-bromospiro{cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O- benzyloxime) (1.65 g, 4.28 mmol), 4-(trimethylstannyl)-2-thiophenecarbonitrile (1.48 g, 5.44 mmol), triphenylarsine (330 mg) in dry dimethoxy ethane (20 ml), under 1 S a nitrogen atmosphere was added bis(triphenylphosphine)palladium (II) chloride, and the mixture was heated under reflux for 16 h. After cooling to room temperature the mixture was evaporated, and the residue purified by column chromatography (Si02, EtOAc:hexane, gradient elution) to afford the desired product (0.61 g, 1.47 mmol, 56%).
Reaction of the last cited compound (0.61 g, 1.47 mmol) and boron tribromide (1M in dichloromethane, 4.5 mL, 4.5 mmol) according to Example 50 procedure C afforded the title compound (0.084 g, 0.26 mmol, 18 %): 'H NMR
(300 MHz, DMSO-db) 8 9.61 (s, 1H), 9.42 (s, 1H), 8.41 (s, 1H), 8.18 (s, 1H), 7.65 (s, 1H), 7.48 (dd, 1 H, J = 8.1 and 0.9 Hz), 6.76 (d, 1 H, J = 8.1 Hz), 2.03 - 1.96 (m, 2H) and 1.78 - 1.42 (m, 6H): MS (ESI(+ ve)) m/z 324 (M+H)+.
Example 56 5-(Spirolcyclohexane-1,3'-l3Hlindolel-2'(h~yimino)-5'-yl)- 1H-pyrrole-1-methyl-2-carbonitrile 2- {S'[spiro[cyclohexane-1,3'-[3H]indol]-( 1'H)-one-2'(O-benzyloxime)] } -1 H-pyrrole-1-carboxylic acid, tert-butyl ester. A solution of S'-bromospiro{cyclohexane-1,3'-[3H]indol}-2' (1'H)-one 2'(O- benzyloxime) (7.4 g, 19.17 mmol) and tetrakis (triphenylphosphine)palladium (0) (2.5 g, 2.00 mmol) in DME ( 100 ml) was stirred under nitrogen for 15 minutes. To the solution was added 1-tert-butoxycarbonylpyrrole boronic acid (5.5 g, 26 mmol) and 1M sodium carbonate (50 ml). The mixture was heated to 80° C for 6 hours and allowed to cool.
The reaction mixture was poured into water and extracted with ethyl acetate (3 x 100 ml).
The organic layers were combined and dried over magnesium sulfate. The solution was filtered, concentrated in vacuo, and the residue was purified by flash chromatography on silica gel (4.5:1 Hexane/ ethylacetate) to give the product (7.7 g, 88 %) as a white solid. 'H NMR (DMSO-d6, 300 MHz) 8 1.28 (s, 9H), 1.55 - 1.66 (m, 8H), 1.83 - 1.98 (m, 2H), 4.99 (s, 2H), 6.12 - 6.14 (m, 1H), 6.22 (t, 1H, J= 3.26 Hz), 6.76 (d, 1H, J= 7.9 Hz), 7.02 (dd, 1H, J= 7.98, 1.4 Hz), 7.19 (s, 1H) 7.27 -7.31 (m, 2H) , 7.35 (t, 1H, J-- 6.8 Hz), 7.43 (d, 1H, J= 8 Hz ), 9.55 (s, 1H).
5'-( 1-tert-Butoxycarbonyl-1 H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-(1'H)one-2'-(O-benzyloxime)-1'-carboxylic acid, tert-butyl ester. To a solution of 2- {5'[spiro[cyclohexane-1,3'-[3H]indol]-( 1'H)-one-2'(O-benzyloxime)] } -1 H-pyrrole-1-carboxylic acid, tert-butyl ester (7.7 g, 16.38 mmol) in THF (anhydrous, 100 mL) was added sodium hydride (0.665 g, 17 mmol) after hydrogen evolution ceased di-tert-butyldicarbonate (10.9 g, 50 mmol) and DMAP( 0.20 g) was added and the reaction stirred at 65 °C for 18 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layers were combined, and dried over magnesium sulfate. The solution was filtered , concentrated in vacuo, to give the product ( 9.0 g, 15.76 mmol) which was taken directly to the next step.
To a solution of 5'-(1-tert-Butoxycarbonyl-1H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-(1'H)one-2'-(O-benzyloxime)-1'-carboxylic acid, tert-butyl ester (9.0 g, 15.76 mmol) in THF (anhydrous, 75 mL) at -78° C was added chlorosulfonyl isocyanate (l.SSmL, 17.54 mmol). After 90 minutes, DMF (21 mL, 275 mmol) was added and the reaction was allowed to warm to room temperature. The reaction was poured into water (200 mL) and extracted with ethyl acetate (2 X 100 mL). The organic layers combined and dried over magnesium sulfate, filtered and concentrated in vacuo. Purification by flash column chromatography on silica gel (10% ethyl acetate/ Hexane) gave 5'-(5-cyano-1-tert-butoxycarbonyl-1H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'( 1'H)one-2'(O-benzyloxime)-1'-carboxylic acid, tert-butyl ester (7.6 g, 82%) as a white powder. 'H NMR (DMSO-dy, 300MHz) 8 1.30 (s, 9H), 1.38 (s, 9H), 1.58-1.83 (m, 8H), 1.72-1.73 (m, 2H), 5.0 (s, 2H), 6.44-6.45 (d, 1H, J= 3.76), 7.25-1.46 (m, lOH).
5'-(5-Cyano-1 H-pyrrol-2-yl)spiro[cylohexane-1,3'-[3H]indol]-2'( 1'H)one-2'-(O-benzyloxime)-1'-carboxylic acid, tert-butyl ester. To a solution of 5'-(5-cyano-1-tert-butoxycarbonyl-1 H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'( 1'H)one-2'(O-benzyloxime)-1'-carboxylic acid, tent-butyl ester (7.6 g, 3.25 g, 48 mmol) in THF (anhydrous, 30 mL) was added a solution of sodium ethoxide in ethanol (120 mL). The reaction mixture was heated to 80° C and stirred overnight.
The mixture was cooled to room temperature and concentrated in vacuo. The residue was dissolved in ethyl acetate and washed with water, brine, and dried over magnesium sulfate. The solvent was evaporated in vacuo to afford the product (6.1 g, 95%). 'H
NMR (DMSO, 500 MHz ) 8 1.38 (s, 9H), 1.63-1.74 (m, 8H), 1.88-1.97 (m, 2H), 5.08 (s, 2H) 6.69-6.7 (d, 1H, J= .BHz), 6.98-6.99 (d, 1H, J= .7 Hz), 7.29-7.37 (m, 1H), 7.35 (m, 2H), 7.42 (m, 3H), 7.63 (dd, 1H, J= 1.8, .3 Hz), 7.76 (d, 1H, J= .4 Hz).
5'-(5-Cyano-1-methyl-1 H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-(O-benzyloxime)-1'-carboxylic acid, tent-butyl ester. To 5'-(5-cyano-1H-pyrrol-yl)spiro[cylohexane-1,3'-[3H]indol]-2'( 1'H)one-2'-(O-benzyloxime)-1'-carboxylic acid, tert-butyl ester (6.1 g, 12.29 mmol) in DMF (75 mL) was added potassium carbonate (6.5 g, 47 mmol) and MeI ( 1 mL, 15.4 mmol) and the reaction mixture was stirred at room temperature for 2.5 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with brine and the solvent was concentrated in vacuo. To give the desired product (6.1 g, 12.29 mmol) which was carried on to the next step without further purification. 'H
NMR
DMSO, 300 MHz) 8 1.38 (s, 9H), 1.62-1.98 (m,IOH), 3.71 (s, 3H), 5.08 (s, 2H), 6.34 (d, 1 H, J = 4.1 ), 7.03 (d, 1 H, J = 3.99), 7.30-7.53 (m, 8H).
5-{5'-Spiro[cyclohexane-1,3'-[3H]indol]-(1'H)-one-2'-(O-benzyloxime)]}-1H-pyrrole-1-methyl-2-carbonitrile. 5'-(5-Cyano-1-methyl-1 H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-(O-benzyloxime)-1'-carboxylic acid, tert-butyl ester (6.1 g,12.29 mmol) was dissolved in dioxane (5 mL) and 4 M HCl in dioxane ( 10 mL) was added and the reaction heated to 45 °C for 3.5 hours. The mixture was carefully neutralized with sodium bicarbonate (sat.). The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with brine and dried over magnesium sulfate. The solvent was evaporated in vacuo. Purification by column chromatography on silica gel (5%
ethyl acetate/hexane) gave the product (4.36 g, 94%). 'H NMR (DMSO-d6, 300MHz) 8 1.57-1.7 (m, 8H), 1.9-2.05 (m, 2H), 3.68 (s, 3H), 5.00 (s, 2H), 6.25 (d, 1H, J= 3.92), 6.85 (d,lH, J= 8.03), 7.00 (d, 1H, J= 4.08), 7.2-7.44 (m, 7H), 9.7 (s, 1H) To 5-{5'-spiro[cyclohexane-1,3'-[3H]indol]-(1'H)-one-2'-(O-benzyloxime)]}-1H-pyrrole-1-methyl-2-carbonitrile (4.36g, 10.6 mmol) in methylene chloride (50 mL) was added 1M boron tribromide (35 mL, in methylene chloride) at -78° C. The reaction mixture was allowed to warm to room temperature. After 4 hours, the reaction mixture was quenched with saturated sodium bicarbonate ( 100 mL). The organic layer was collected and the aqueous layer was extracted with ethyl acetate (2X 100 mL), organic layers combined, washed with brine, dried over magnesium sulfate, and the solvent evaporated in vacuo. The residue was purified by flashed chromatography on silica gel (7:3 hexane/ethylacetate) to give the title compound (1.35g, 40%) as a white solid. 'H NMR (DMSO-d6, 300 MHz) 8 1.58 - 1.71 (m, 8H), 1.99 - 2.00 (m, 2H), 3.69 (s, 3H) 6.24 (d, 1H, J= 4.07 Hz), 6.8 (d, 1H, J=
8.05 Hz), 6.99 (d, 1H, J= 4.01 Hz), 7.20 (dd, 1H, J= 8.04, 1.57 Hz), 7.36 (d, 1H, J=
1.12 Hz), 9.48 (s, 1H), 9.62 (s, 1H).
Example 57 ~spiro f cyclohexane-1,3'-[3H] indoll-2'-(hvdroxyimino)-5'-yl)-1H-pyrrole-2 carbonitrile 5-(spiro[cyclohexane-1,3'-[3]indole]-2' ( 1 H)-(O-benyloxime))-1 H-pyrrole-2-carbonitrile. Prepared from 5'-(5-Cyano-1H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'(1'H)one-2'-(O-benzyloxime)-1'-carboxylic acid, tert-butyl ester (0.395 g, 0.796 mmol) dissolved in 2mL of THF and 4M HCl Dioxane/water (10 mL) following the procedure used to prepare 5-{5'-spiro[cyclohexane-1,3'-[3H]indol]-(1'H)-one-2'-(O-benzyloxime)]}-1H-pyrrole-1-methyl-2-carbonitrile the desired product was obtained (0.220 g, 0.745 mmol, 95%). ' H NMR (DMSO-d6, 500 MHz) 8 1.44 - 1.50 (m, 1H), 1.61 - 1.70 (m, 7H), 1.94 - 1.99 (m, 2H), S.0 (s, 2H), 6.55 (d, 1 H, J = 4 Hz), 6.79 (d, 1 H, J = 8.0 Hz), 6.95 (d, 1 H, J = 4 Hz), 7.27 -7.31 (m, 1 H), 7.34 - 7.37 (m, 2H), 7.42 - 7.43 (m, 2H), 7.47 (dd, 1H, J = 8.0 , 1.4 Hz), 7.65 (d, 1H, J = 1.5 Hz), 9.65 (s, 1 H), 12.4 (s, 1 H).
The title compound was prepared from 5-(spiro[cyclohexane-1,3'-[3]indole]-2'(IH)-(O-benyloxime))-1H-pyrrole-2-carbonitrile (0.325 g, 0.82mmol) and 1M
Boron tribromide (6mL in methylene chloride), following the procedure for 5-(spiro[cyclohexane-1,3'-[3H]indole]-2'-(hydroxyimino)-5'-yl)- IH-pyrrole-1-methyl-2-carbonitrile, to obtain the product as an off white solid (0.110 g, 0.326 mmol, 44%).
' H NMR (DMSO-d6, 500 MHz) 8 1.46 - I.5 (m, 1H), 1.62 - 1.71 (m, 7H), 1.95 -2.05 (m, 2H), 6.55 (d, 1 H, J = 4.0 Hz), 6.75 (d, 1 H, J = 8.0 Hz), 6.94 (d, l H, J
= 3.47 Hz), 7.45 (dd, 1H, J= 8.1, 1.73 Hz), 7.63 (d, 1H, J= 1.73), 9.42 (s, 1H), 9.59 (s, IH), 12.39 (s, 1H).
Examele 58 4-(Spiro(cYclohexane-1,3'-(3Hlindolel-2'(acetoxyimino)-5'-Xl)-2-thiophenecarbonitrile S
To a solution of 4-(Spiro[cyclohexane-1,3'-[3H]indole]-2'(hydroxyimino)-5'-yl)-2-thiophenecarbonitrile (2.21 g, 6.83 mmol) and acetic anhydride ( 1 ml) in dichloromethane-pyridine (30 ml, 9:1 ) was added 4-dimethylaminopyridine (250 mg) at room temperature. After 3h., the mixture was diluted with dichloromethane, washed with water, dil. Hydrochloric acid, water, dried (MgS04), and evaporated.
The residue was purified by column chromatography (EtOAc: hexane, gradient elution) to afford the title compound (0.84 g, 2.29 mmol, 33%) as a white solid: MS
(ESI (+ ve)) m/z 366 [M+H]+.
Example 59 3-Fluoro-N'-hydroxy-5-(2'-(hydrox a~)spiro(cyclohexane-1,3'-(3Hlindoll-5'-benzenecarboximidamide 5'-(3-Cyano-5-fluorophenyl)-2-(methylthio)spiro[cyclohexane-1,3'-[3H]indole]. Prepared from 3-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-5-fluorobenzonitrile (0.451 g, 1.34 mmol) according to the procedure described in Example 43 to afford the desired product (0.316 g, 0.90 mmol, 67%): 'H NMR (DMSO, 300 MHz) 8 7.74 (d, 1H, J= 1.7 Hz), 7.68 (t, 1H, J= 1.4 Hz), 7.5 8 (d, 1 H, J = 8.0 Hz), 7.54 (t, 1 H, J = 2.3 Hz), 7.50 (dd, 1 H, J =
8.0 and 1.9 Hz), 7.33 - 7.29 (m, 1H), 2.67 (s, 3H), 2.04 - 1.78 (m, 7H) and 1.58 - 1.50 (m, 3H);
MS (ESI(+ ve)) m/z 351 (M+H)+.
To a solution of the last cited product (0.30 g, 0.88 mmol) in DMSO ( 10 ml) was added hydroxylamine (SO% aqueous solution, 1 ml), and the reaction was heated to 120 °C. After lh., the mixture was cooled, partitioned between saturated aqueous ammonium chloride and ethylacetate. The organic layer was washed with water, brine, dried (MgS04) and evaporated. The residue was purified by column chromatography (Si02, 5% MeOH in dichloromethane) to afford the title compound (0.079 g, 0.23 mmol, 26%) as a white foam: 'H NMR (DMSO, 300 MHz) 8 9.79 (s, 1H), 9.61 (s, 1H), 9.42 (s, 1H), 7.73 (s, 1H), 7.61 (d, 1H, J= 1.3 Hz), 7.46 (dd, 1H, J
= 8.3 and 1.5 Hz), 7.34 (d, 1H, J= 10 Hz), 6.81 (d, 1H, J= 8.0 Hz), 6.01 (s, 2H), 2.11 - 2.02 (m, 2H) and 1.81 - 1.56 (m, 8H): MS (ESI(+ ve)) m/z 369 (M+H)+.
Example 60 N'-Hydroxy-5-(suiro(cyclohexane-1,3'-(3Hlindolel-2'(hydroxyimino)-5'- lyl)-4-methyl-2-thiophenecarboximidamide 4-Methyl-5-(spiro[cyclohexane-1,3'[3H]indol] 2'-(methylthio)-5'-yl]-2-thiophenecarbonitrile. To potassium tert-butoxide (0.32g, 2.6 mmol) in THF was added 5-(1',2'-Dihydro-2'-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-4-methyl-2-thiophenecarbonitrile (0.84 g, 2.5 mmol). After 15 minutes, methyl iodide (0.50 g, 3.48 mmol) was added. After 3 hours, reaction was poured into ammonium chloride (sat.) and extracted with ethylacetate. The organic layers were combined and dried over magnesium sulfate. The solution was filtered, concentrated in vacuo, and the residue was purified by flash chromatography on silica gel (4:1 Hexane/ethyl acetate) to give the desired product (0.530 g, 85%). (DMSO, 300 MHz) 8 1.48 (m, 3H), 1.70 (m, 2H), 1.81 (m, 5H), 2.32 (s, 3H), 2.62 (s, 3H), 7.48 (dd, 1H, J= 7.87 Hz, 1.46 Hz), 7.5 (d, 1H, J= 8.05 Hz), 7.77 (d, 1H, J= 1.46 Hz), 7.88 (s, 1H).
To 4-methyl-5-(spiro[cyclohexane-1,3'[3H] indol]2'-(methylthio)-5'-yl]-2-thiophenecarbonitrile (.450 g, 1.3 mmol) in DMSO (1 mL) was added hydroxylamine hydrochloride (2 mL, 50% sol. in water) and heated to 100° C for 2.5 hours. Water added until solution became slightly turbid, allowed the mixture to cool to room temperature. The white solid was filtered, collected and dissolved in ethyl acetate and dried over magnesium sulfate. The solution was filtered, concentrated in vacuo, giving (0.320 g, 69%). (DMSO-d6, 500 MHz) 8 1.4-1.74 (m, 8H), 1.94-2.4 9m, 2H), 2.54 (s, 3H), 5.8 (s, 1H), 6.79 (d, 1H, J = 8.0), 7.16 (dd, 1H, J= 8.12, 1.83), 7.39 (m, 2H), 9.42 (s, 1H), 9.56 (s, 1H), 9.58 (s, 1H).
Example 61 N'-Hydroxy-4-(spiro[~cyclohexane-1,3'-f3Hlindole]-2' 9hydroxyimino)-5'-yl-2-thiophenecarboximidamide 4-(Spiro[cyclohexane-1,3'-[3H]indol]-2'-(methylthio)-5'-yl]-2-thiophenecarbonitrile (0.077 g, .237 mmol) was reacted with 50% solution of hydroxylamine ( 1 mL) following the procedure for Example 60 to afford the title compound (0.016g, 0.044 mmol, 20 %). MS (ESI, (+VE)) m/z 357 [M+H]+.
Example 62 N'-Hey-~spirolcyclohexane-1,3'-(3Hjindoll-2'-(hydrox~mino)-5'-ylj-2-thiophenecarboxidamide The title compound was prepared from 5-(spiro[cyclohexane-1,3'-[3H]indol]2'-(methylthio)-5'-yl]-2-thiophenecarbonitrile (0.500 g, 1.5 mmol) and a 50% solution of hydroxylamine (2 mL, excess) following the procedure for Example 60, to afford the product (0.200 g, 0.56 mmol, 56%). 'H NMR (DMSO-d6, S00 MHz) 8 1.45-1.75 (m, 8H), 1.97-2.06 (m, 2H), 5.89 (s,lH), 6.74 (d, 1H, J = 8 Hz), 7.3 (d, 1H, J= 3.9 Hz), 7.34 (dd, 1H, J= 8.06, 1.46 Hz), 7.4 (d, 1H, J= 8.0 Hz), 7.5 (d, 1 H, 1.95 Hz), 9.44 (s, l H), 9.58 (s, 1 H), 9.6 (s, 1 H).
Example 63 5'-(3-Chlorophen~piro f cyclohexane-1,3'-(3Hl indoll-2'-cyanamide 5'-(3-Chlorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'-amine. To a turbid solution of S'-(3-Chlorophenyl)-N-hydroxyspiro[cyclohexane-1,3-[3H]indol]-2-amine ( 0.500 g; 1.53 mmol) in 25 mL of ethanol was added hydrazine hydrate (0.600 mL; 12.24 mmol). The solution was warmed to 55° C, where Raney-nickel (50% in water) was added to the reaction to keep a constant evolution of gas. After 45 minutes, the hot reaction mixture was filtered through a Celite plug and rinsed with a copious amount of hot methanol. The filtrate was concentrated in vacuo to give 0.890 g of an opaque solid. The product was purified by flash silica gel chromatography;
(eluant, 2% to 8 % methanol-methylene chloride with 0.1 % ammonium hydroxide) to afford 0.310 g (65%) of the desired product as a white solid. Mp. 118-120° C. 'H
NMR 8 (300 MHz, DMSO-db) 1.31-1.46 (m, 2H), 1.70-1.93 (m, 8H), 7.0 (d, 1H), 7.1 (br, 2H, 2NH), 7.31-7.34 (dt, 1H, J= 8 Hz), 7.41-7.46 (t, 2H), 7.55-7.58 (d, 1H), 7.62 (s, 1H), 7.72 (s, 1H); MS (ECI(+ve)) m/z 311 (M+H)+.
1-tert-butoxycarbonyl-5'-(3-chlorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'-amine. To a solution of 5'-(3-chlorophenyl)spiro[cyclohexane-1,3-[3H]indol]-2'-amine (0.310 g; 0.96 mmol) in dry methylene chloride at 0° C was added Di-tert-butyl dicarbonate (0.252 g; 1.15 mmol) and 4-dimethylaminopyridine (0.117 g; 0.96 mmol). The solution was allowed to warm to room temperature and stir 24 h. The reaction solution was diluted with water(SO mL) and the layers were separated.
The organic layer was dried over Na2S04 , filtered and concentrated in vacuo to give 0.355 g of a yellow oil. The product was purified by flash silica gel chromatography;
(eluant, 1 %to 3 % methanol- methylene chloride) to afford the desired product (0.081 g, 20%) as a white solid. 'H NMR 8 (300 MHz, DMSO-db) 1.58 (m, 2H), 1.63 (s, 9H, Boc), 1.77-1.79 (m, 8H), 7.42-7.48 (m, 2H), 7.64-7.68 (m, 3H), 7.70-7.80(m, 2H), 9.72 (s, 1H, NH). MS (ECI(+ve)) m/z 411 (M+H)+.
1'-tent-Butoxycarbonyl-5'-(3-chlorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'-amine (0.120 g; 0.29 mmol) in 2.0 mL of dry DMF was added to a solution of 4- dimethylaminopyridine (0.089 g; 0.73 mmol) and cyanogen bromide (0.077 g; 0.73 mmol) in 4.0 mL of dry DMF at 0° C. The yellow solution was heated to 40° C for 16 h. Work-up included pouring the reaction solution into 0.1 N NaHC03 (50 mL) and extracting with ethyl acetate (3 x 50 mL). The combined organic layers were dried over anhydrous NaZS04, filtered and concentrated in vacuo to give 0.091 g of a yellow residue. The product was purified by flash silica gel chromatography;
(stepwise gradient of 5:1 to 3:1 hexane : ethyl acetate) to afford 0.031 g (32%) of the product as a bright yellow solid. Mp. 225°C (dec.). 'H NMR 8 (500 MHz, DMSO-db) 1.46-1.73 (m, 8H), 1.89-1.90 (m, 2H), 7.13-7.16 (d, 1H), 7.38-7.41 (dt, 1H, J=
8Hz), 7.45-7.50 (m, 1H), 7.60-7.63 (dd, 2H, J= 6.4 Hz), 7.71 (s, 1H), 7.85 (s, 1H), 12.1 (s, 1H, NH); MS (ECI(-ve)) m/z 336 (M-H)-.
Other desirable compounds, which can be made according to the methods described herein, include 5'-(3-Cyano-5-fluorophenyl)spiro[cyclohexane-1,3'-[3H]indol]-2'-cyanamide, S'-(5-Cyano-1H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2-cyanamide, 5'-(5-Cyano-1-methyl-1H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-cyanamide cyanamide, 5'-(S-Cyano-thiophen-2-yl) spiro[cyclohexane-1,3'-[3H]indol]-2'-cyanamide, 5'-(5-Cyano-3-methyl-thiophen-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-cyanamide, 5'-(5-Cyano-thiophen-3-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-cyanamide, 3-(2'-Cyanomethylene-spiro[cyclohexane-1,3'-[3H]indol-5'-yl])-5-fluoro-benzonitrile, 5-(2'-Cyanomethylene-spiro[cyclohexane-1,3'-[3H]indol-5'-yl])-1H-pyrrole-2-carbonitrile, 5-(2'-Cyanomethylene-spiro[cyclohexane-1,3'-[3H]indol-5'-yl])-1-methyl-1 H-pyrrole-2-carbonitrile, 5-(2'-Cyanomethylene-spiro[cyclohexane-1,3'-[3H]indol-5'-yl])-thiophene-2-carbonitrile, 5-(2'-Cyanomethylene-spiro[cyclohexane-1,3'-[3H]indol-5'-yl])-4-methyl-thiophene-2-carbonitrile, 4-(2'-Cyanomethylene-spiro[cyclohexane-1,3'-[3H]indol-5'-yl])-thiophene-2-carbonitrile.
All publications cited in this specification are incorporated herein by reference herein. While the invention has been described with reference to a particularly preferred embodiment, it will be appreciated that modifications can be made without departing from the spirit of the invention. Such modifications are intended to fall within the scope of the appended claims.
Claims (32)
- What is Claimed:
A compound of the formula: 1 or 2:
wherein:
R1 and R2 are chosen independently from the group of H, alkyl, substituted alkyl; OH; O(alkyl); O(substituted alkyl); OAc; aryl; optionally substituted aryl;
heteroaryl; optionally substituted heteroaryl; alkylaryl; alkylheteroaryl; 1-propynyl;
or 3-propynyl:
or R1 and R2 are joined to form a ring comprising one of the following:
-CH2(CH2)n CH2-; -CH2CH2CMe2CH2CH2-; -O(CH2)m CH2-; O(CH2)p O-;
-CH2CH2OCH2CH2-; or -CH2CH2N(H or alkyl)CH2CH2-;
m is an integer from 1 to 4;
n is an integer from 1 to 5;
p is an integer from 1 to 4;
or R1 and R2 together comprise a double bond to one of the following:
CMe2; C(cycloalkyl), O, C(cyloether).
R3 is selected from H, OH, NH2, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C6 alkenyl, alkynyl or substituted alkynyl, or COR A;
R A is selected from H, C1 to C3 alkyl, substituted C1 to C3 alkyl, C1 to C3 alkoxy, substituted C1 to C3 alkoxy, C1 to C3 aminoalkyl, or substituted C1 to aminoalkyl;
R4 is selected from H, halogen, CN, NH2, C1 to C6 alkyl, substituted C1 to C6 alkyl, C1 to C6 alkoxy, substituted C1 to C6 alkoxy, C1 to C6 aminoalkyl, or substituted C1 to C6 aminoalkyl;
R5 is selected from the groups a), b) or c):
a) R5 is a trisubstituted benzene ring containing the substituents X, Y
and Z as shown below:
X is selected from halogen, OH, CN, C1 to C3 alkyl, substituted C1 to C3 alkyl, C1 to C3 alkoxy, substituted C1 to C3 alkoxy, C1 to C3 thioalkyl, substituted C1 to C3 thioalkyl, S(O)alkyl, S(O)2alkyl, C1 to C3 aminoalkyl, substituted C1 to C3 aminoalkyl, NO2, C1 to C3 perfluoroalkyl, 5 or 6 membered heterocyclic ring containing 1 to 3 heteroatoms, CONH2, CSNH2, CONHalkyl, CSNHalkyl, CON(alkyl)2, CSN(alkyl)2, COR B, OCOR B, NR C COR B;
R B is selected from H, C1 to C3 alkyl, substituted C1 to C3 alkyl, aryl, substituted aryl, C1 to C3 alkoxy, substituted C1 to C3 alkoxy, C1 to C3 aminoalkyl, or substituted C1 to C3 aminoalkyl;
R C is H, C1 to C3 alkyl, or substituted C1 to C3 alkyl;
Y and Z are independently selected from H, halogen, CN, NO2, C1 to C3 alkoxy, C1 to C3 alkyl, or C1 to C3 thioalkyl;
or b) R5 is a five or six membered heterocyclic ring with 1, 2, or 3 heteroatoms selected from O, S, SO, SO2 or NR6 and containing one or two independent substituents from the group of H, halogen, CN, NO2 and C1 to C3 alkyl, C1 to C3 alkoxy, C1 to C3 aminoalkyl, COR D, or NR E COR D;
R D is H, C1 to C3 alkyl, substituted C1 to C3 alkyl, aryl, substituted aryl, C1 to C3 alkoxy, substituted C1 to C3 alkoxy, C1 to C3 aminoalkyl, or substituted C1 to C3 aminoalkyl;
R E is H, C1 to C3 alkyl, or substituted C1 to C3 alkyl;
R6 is H, or C1 to C3 alkyl; or c) R5 is an indol-4-yl, indol-7-yl or benzo-2-thiophene moiety, the moiety being optionally substituted by from 1 to 3 substituents selected from halogen, lower alkyl, CN, NO2, lower alkoxy, or CF3;
Q1 is S, NR7 CR8R9;
R7 is selected from the group including CN, C1 to C6 alkyl, substituted C1 to alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, acyl, substituted acyl, aroyl, substituted aroyl, SO2CF3, OR11 or NR11R12;
R8 and R9 are independent substituents selected from the group of H, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO2, CN, or CO2R10, R10 is C1 to C3 alkyl; or CR8R9 comprises a six membered ring as shown by the structure below Q2 is selected from the moieties:
R11, R12 and R13 are independently selected from H, C1 to C6 alkyl, substituted C1 to C6 alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyl, substituted acyl, aroyl or substituted aroyl or sulfonyl;
or a pharmaceutically acceptable salt thereof. - 2. A compound of Claim 1 having the formula:
wherein R5 is a disubstituted benzene ring of the formula:
- X is selected from halogen, CN, CONH2, CSNH2, CONHalkyl, CSNHalkyl,
- CONalkyl2, CSNalkyl2, C1 to C3 alkoxy, C1 to C3 alkyl, NO2, C1 to C3 perfluoroalkyl,
- 5 membered heterocyclic ring containing 1 to 3 heteroatoms, or C1 to C3 thioalkoxy;
and Y is a substituent on the 4' or 5'position from the group including H, halogen, CN, NO2, C1 to C3 alkoxy, C1 to C4 alkyl, or C1 to C3 thioalkyl; and Q1 is S, NR7, CR8R9;
or a pharmaceutically acceptable salt thereof.
3. A compound of Claim 1 having the formula:
wherein R5 is a five membered ring with the structure shown below wherein:
U is O, S, or NR6;
R6 is H, or C1 to C3 alkyl, or C1 to C4 CO2alkyl;
X' is selected from halogen, CN, NO2, CONH2, CSNH2, CONHalkyl, CSNHalkyl, CONalkyl2, CSNalkyl2, C1 to C3 alkyl, or C1 to C3 alkoxy;
Y' is from the group of H, F or C1 to C4 alkyl; and Q1 is S, NR7, CR8R9;
or a pharmaceutically acceptable salt thereof.
4. A compound of Claim 1 having the formula:
wherein R5 is a six membered ring with the structure shown wherein X1 is N or CX2, X2 is halogen, CN, CONH2, CSNH2, CONHalkyl, CSNHalkyl, CONalkyl2, CSNalkyl2 or NO2;
Q1 is S, NR7, CR8R9;
R7 is from the group including CN, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or SO2CF3;
R8 and R9 are independent substituents from the group including H, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO2, CN
CO2R10, R10 is C1 to C3 alkyl;
CR8R9 are within a six membered ring as shown by the structure below or pharmaceutically acceptable salt thereof - 6. A compound of Claim 1 which is 5'-(3-Chlorophenyl)spiro [cyclohexane-1,3'-[3H]indole]-2'(1'H)-thione or a pharmaceutically acceptable salt thereof.
- 7. A compound of Claim 1 which is 3-(1',2'-Dihydro-2'-thioxospiro[cyclohexane-1,3'-[3H]indol-5'-yl) benzonitrile or a pharmaceutically acceptable salt thereof.
- 8. A compound of Claim 1 which is 4-(1',2'-Dihydro-2' thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-2-thiophenecarbonitrile or a pharmaceutically acceptable salt thereof.
- 9. A compound of Claim 1 which is 3-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-5- fluorobenzonitrile or a pharmaceutically acceptable salt thereof.
- 10. A compound of Claim 1 which is 4-Methyl-5-(1,2-dihydro-2-thioxospiro[cyclohexane-1,3-[3H]-indol]-5-yl)-2-thiophene thioamide or a pharmaceutically acceptable salt thereof.
- 11. A compound of the formula:
each wherein R5 is a disubstituted benzene ring containing the substituents X
and Y:
X is selected from halogen, CN, CONH2, CSNH2, CONHalkyl, CSNHalkyl, CONalkyl2, CSNalkyl2. C1 to C3 alkoxy, C1 to C3 alkyl, NO2, C1 to C3 perfluoroalkyl, 5 membered heterocyclic ring containing 1 to 3 heteroatoms, or C1 to C3 thioalkoxy;
Y is a substituent on the 4' or 5'position from the group including H, halogen, CN, NO2, C1 to C3 alkoxy, C1 to C4 alkyl, or C1 to C3 thioalkyl;
or a pharmaceutically acceptable salt thereof. - 12. A compound according to claim 11, having the formulae:
are those wherein R5 is a six membered ring with the structure:
wherein X1 is N or CX2, X2 is halogen, CN, CONH2, CSNH2, CONHalkyl, CSNHalkyl, CONalkyl2, CSNalkyl2 or NO2;
Q2 is selected from the moieties:
R7 is from the group including CN, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or SO2CF3;
R8 and R9 are independent substituents from the group including H, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO2, CN
CO2R10, R10 is C1 to C3 alkyl;
CR8R9 are within a six membered ring as shown by the structure below or pharmaceutically acceptable salt thereof. - 13. A compound of the formula:
wherein R14 is chosen from the group H, acyl, substituted acyl, aroyl, substituted aroyl, sulfonyl, substituted sulfonyl.
wherein R5 is a disubstituted benzene ring containing the substituents X and Y
as shown below X is selected from halogen, CN, CONH2, CSNH2, CONHalkyl, CSNHalkyl, CON(alkyl)2, CSN(alkyl)2, CNHNHOH, CNH2NOH, C1 to C3 alkoxy, C1 to C3 alkyl, NO2, C1 to C3 perfluoroalkyl, 5 membered heterocyclic ring containing 1 to 3 heteroatoms, or C1 to C3 thioalkoxy;
Y is a substituent on the 4' or 5'position from the group including H, halogen, CN, NO2, C1 to C3 alkoxy, C1 to C4 alkyl, or C1 to C3 thioalkyl;
or a pharmaceutically acceptable salt thereof. - 14. A compound according to claim 13, wherein R5 is a five membered ring with the structure shown below wherein:
U is O, S, or NR6;
R6 is H, or C1 to C3 alkyl, or C1 to C4 CO2alkyl;
X' is selected from halogen, CN, NO2, CONH2, CNHNHOH, CNH2NOH, CSNH2, CONHalkyl, CSNHalkyl, CONalkyl2, CSNalkyl2, C1 to C3 alkyl, or C1 to C3 alkoxy;
Y' is from the group of H, F or C1 to C4 alkyl;
or a pharmaceutically acceptable salt thereof. - 15. The compound according to claim 13, wherein R5 is a thiophene or furan ring substituted by X' and Y'.
- 16. The compound according to claim 13, wherein R5 is a six membered ring with the structure:
wherein X1 is N or CX2, X2 is halogen, CN, CONH2, CSNH2, CONHalkyl, CSNHalkyl, CONalkyl2, CSNalkyl2 or NO2;
R7 is from the group including CN, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or SO2CF3;
R8 and R9 are independent substituents from the group including H, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO2, CN
CO2R10, R10 is C1 to C3 alkyl;
or pharmaceutically acceptable salt thereof. - 17. A compound of the formula:
wherein R5 is a disubstituted benzene ring containing the substituents X and Y
as shown below X is selected from halogen, CN, CONH2, CSNH2, CONHalkyl, CSNHalkyl, CONalkyl2, CSNalkyl2, CNHNOH, C1 to C3 alkoxy, C1 to C3 alkyl, NO2, C1 to C, perfluoroalkyl, 5 membered heterocyclic ring containing 1 to 3 heteroatoms, or C1 to C3 thioalkoxy;
Y is a substituent on the 4' or 5'position from the group including H, halogen, CN, NO2, C1 to C3 alkoxy, C1 to C4 alkyl, or C1 to C3 thioalkyl;
or a pharmaceutically acceptable salt thereof. - 18. The compound according to claim 17, wherein R5 is a five membered ring with the structure shown below wherein:
U is O, S, or NR6;
R6 is H, or C1 to C3 alkyl, or C1 to C4 CO2alkyl;
X' is selected from halogen, CN, NO2, CONH2, CSNH2, CONHalkyl, CSNHalkyl, CONalkyl2, CSNalkyl2, C1 to C3 alkyl, or C1 to C3 alkoxy;
Y' is from the group of H, F or C1 to C4 alkyl;
or a pharmaceutically acceptable salt thereof. - 19. The compound according to claim 17, wherein R5 is a thiophene or furan ring substituted by X' and Y', as described above.
- 20. The compound according to claim 17, wherein R5 is a six membered ring with the structure:
wherein X1 is N or CX2, X2 is halogen, CN, CONH2, CSNH2, CONHalkyl, CSNHalkyl, CONalkyl2, CSNalkyl2 or NO2;
R7 is from the group including CN, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or SO2CF3;
R8 and R9 are independent substituents from the group including H, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO2, CN
CO2R10, R10 is C1 to C3 alkyl;
or pharmaceutically acceptable salt thereof. - 21. A compound of the formula:
wherein R15 is selected from the group H, Me, CO2R, acyl, substituted acyl, aroyl, substituted aroyl, alkyl, substituted alkyl, CN;
wherein R5 is a disubstituted benzene ring containing the substituents X and Y
as shown below X is selected from halogen, CN, CONH2, CSNH2, CONHalkyl, CSNHalkyl, CONalkyl2, CSNalkyl2, CNHNOH, C1 to C3 alkoxy, C1 to C3 alkyl, NO2, C1 to C3 perfluoroalkyl, 5 membered heterocyclic ring containing 1 to 3 heteroatoms, or C1 to C3 thioalkoxy;
Y is a substituent on the 4' or 5'position from the group including H, halogen, CN, NO2, C1 to C3 alkoxy, C1 to C4 alkyl, or C1 to C3 thioalkyl;
or a pharmaceutically acceptable salt thereof. - 22. The compound according to claim 21, R5 is a five membered ring with the structure shown below wherein:
U is O, S, or NR6;
R6 is H, or C1 to C3 alkyl, or C1 to C4 CO2alkyl;
X' is selected from halogen, CN, NO2, CONH2, CSNH2, CONHalkyl, CSNHalkyl, CONalkyl2, CSNalkyl2, C1 to C3 alkyl, or C1 to C3 alkoxy;
Y' is from the group of H, F or C1 to C4 alkyl;
or a pharmaceutically acceptable salt thereof. - 23. The compound according to claim 21, wherein R5 is a thiophene or furan ring substituted by X' and Y'..
- 24. The compound according to claim 21, wherein R5 is a six membered ring with the structure:
wherein X1 is N or CX2, X2 is halogen, CN, CONH2, CSNH2, CONHalkyl, CSNHalkyl, CONalkyl2, CSNalkyl2 or NO2;
R7 is from the group including CN, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or SO2CF3;
R8 and R9 are independent substituents from the group including H, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO2, CN
CO2R10, R10 is C1 to C3 alkyl;
or pharmaceutically acceptable salt thereof. - 25. A compound of the formula:
wherein R5 is a disubstituted benzene ring containing the substituents X and Y
as shown below X is selected from halogen, CN, CONH2, CSNH2, CONHalkyl, CSNHalkyl, CONalkyl2, CSNalkyl2, CNHNOH, C1 to C3 alkoxy, C1 to C3 alkyl, NO2, C1 to C3 perfluoroalkyl, 5 membered heterocyclic ring containing 1 to 3 heteroatoms, or C1 to C3 thioalkoxy;
Y is a substituent on the 4' or 5'position from the group including H, halogen, CN, NO2, C1 to C3 alkoxy, C1 to C4 alkyl, or C1 to C3 thioalkyl;
or a pharmaceutically acceptable salt thereof. - 26. The compound according to claim 25, wherein R5 is a five membered ring with the structure shown below wherein:
U is O, S, or NR6;
R6 is H, or C1 to C3 alkyl, or C1 to C4 CO2alkyl;
X' is selected from halogen, CN, NO2, CONH2, CSNH2, CONHalkyl, CSNHalkyl, CONalkyl2, CSNalkyl2, C1 to C3 alkyl, or C1 to C3 alkoxy;
Y' is from the group of H, F or C1 to C4 alkyl;
or a pharmaceutically acceptable salt thereof. - 27. The compound according to claim 26, wherein R5 is a thiophene or furan ring substituted by X' and Y'.
- 28. The compound according to claim 26, wherein R5 is a six membered ring with the structure:
wherein X' is N or CX2, X2 is halogen, CN, CONH2, CSNH2, CONHalkyl, CSNHalkyl, CONalkyl2, CSNalkyl2 or NO2;
R7 is from the group including CN, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, or SO2CF3;
R8 and R9 are independent substituents from the group including H, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, NO2, CN
CO2R10, R10 is C1 to C3 alkyl;
or pharmaceutically acceptable salt thereof. - 29. A pharmaceutical composition comprising a compound according to any of claims 1 to 28, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
- 30. A method of inducing contraception in a mammal, the method comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of any of claims 1 to 28, or a pharmaceutically acceptable salt thereof.
- 31. A method of treatment of dysfunctional bleeding in a mammal, the method comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of any of claims 1 to 28, or a pharmaceutically acceptable salt thereof.
- 32. A method of treatment of carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, or prostate in a mammal, the method comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of any of claim 1 to 28, or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17225999P | 1999-05-04 | 1999-05-04 | |
US60/172,259 | 1999-05-04 | ||
US09/552,033 | 2000-04-19 | ||
US09/552,033 US6355648B1 (en) | 1999-05-04 | 2000-04-19 | Thio-oxindole derivatives |
PCT/US2000/011630 WO2000066555A1 (en) | 1999-05-04 | 2000-05-01 | Thio-oxindole derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2371633A1 true CA2371633A1 (en) | 2000-11-09 |
Family
ID=26867898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002371633A Abandoned CA2371633A1 (en) | 1999-05-04 | 2000-05-01 | Thio-oxindole derivatives |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1181275A1 (en) |
JP (1) | JP2002543182A (en) |
KR (1) | KR20020000636A (en) |
CN (1) | CN1143847C (en) |
AU (1) | AU767762B2 (en) |
BG (1) | BG106078A (en) |
BR (1) | BR0010216A (en) |
CA (1) | CA2371633A1 (en) |
CZ (1) | CZ20013950A3 (en) |
EA (1) | EA005034B1 (en) |
GE (1) | GEP20043266B (en) |
HU (1) | HUP0200993A3 (en) |
MX (1) | MXPA01011285A (en) |
NO (1) | NO320912B1 (en) |
NZ (1) | NZ515351A (en) |
PL (1) | PL351407A1 (en) |
SK (1) | SK15902001A3 (en) |
TR (1) | TR200103288T2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602005010065D1 (en) * | 2004-04-08 | 2008-11-13 | Wyeth Corp | METHOD FOR MINIMIZING THIOAMID POLLUTION |
CN100522960C (en) * | 2004-04-08 | 2009-08-05 | 惠氏公司 | Thioamide derivatives as progesterone receptor modulators |
GB201113538D0 (en) * | 2011-08-04 | 2011-09-21 | Karobio Ab | Novel estrogen receptor ligands |
CN104995194B (en) * | 2012-10-12 | 2017-08-29 | 学校法人冲绳科学技术大学院大学学园 | Spiro indole derivative and preparation method thereof |
WO2016057931A1 (en) | 2014-10-10 | 2016-04-14 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
EP3519393B1 (en) * | 2016-09-30 | 2022-05-18 | Epizyme Inc | Substituted fused bi- or tri- heterocyclic compounds as ehmt2 inhibitors |
-
2000
- 2000-05-01 EP EP00928603A patent/EP1181275A1/en not_active Withdrawn
- 2000-05-01 BR BR0010216-4A patent/BR0010216A/en not_active IP Right Cessation
- 2000-05-01 TR TR2001/03288T patent/TR200103288T2/en unknown
- 2000-05-01 PL PL00351407A patent/PL351407A1/en not_active Application Discontinuation
- 2000-05-01 EA EA200101180A patent/EA005034B1/en not_active IP Right Cessation
- 2000-05-01 CZ CZ20013950A patent/CZ20013950A3/en unknown
- 2000-05-01 CA CA002371633A patent/CA2371633A1/en not_active Abandoned
- 2000-05-01 HU HU0200993A patent/HUP0200993A3/en unknown
- 2000-05-01 SK SK1590-2001A patent/SK15902001A3/en unknown
- 2000-05-01 MX MXPA01011285A patent/MXPA01011285A/en unknown
- 2000-05-01 NZ NZ515351A patent/NZ515351A/en unknown
- 2000-05-01 AU AU46814/00A patent/AU767762B2/en not_active Ceased
- 2000-05-01 JP JP2000615386A patent/JP2002543182A/en active Pending
- 2000-05-01 CN CNB008071330A patent/CN1143847C/en not_active Expired - Fee Related
- 2000-05-01 KR KR1020017014076A patent/KR20020000636A/en not_active Application Discontinuation
- 2000-05-01 GE GEAP20006121A patent/GEP20043266B/en unknown
-
2001
- 2001-11-02 NO NO20015380A patent/NO320912B1/en not_active Application Discontinuation
- 2001-11-02 BG BG106078A patent/BG106078A/en unknown
Also Published As
Publication number | Publication date |
---|---|
NO20015380D0 (en) | 2001-11-02 |
BG106078A (en) | 2002-05-31 |
NO320912B1 (en) | 2006-02-13 |
JP2002543182A (en) | 2002-12-17 |
KR20020000636A (en) | 2002-01-05 |
NZ515351A (en) | 2004-01-30 |
EA200101180A1 (en) | 2002-04-25 |
MXPA01011285A (en) | 2003-09-04 |
HUP0200993A2 (en) | 2002-07-29 |
CN1349499A (en) | 2002-05-15 |
PL351407A1 (en) | 2003-04-22 |
EA005034B1 (en) | 2004-10-28 |
CN1143847C (en) | 2004-03-31 |
AU767762B2 (en) | 2003-11-20 |
EP1181275A1 (en) | 2002-02-27 |
GEP20043266B (en) | 2004-06-25 |
SK15902001A3 (en) | 2002-11-06 |
CZ20013950A3 (en) | 2002-06-12 |
AU4681400A (en) | 2000-11-17 |
TR200103288T2 (en) | 2002-04-22 |
NO20015380L (en) | 2002-01-03 |
HUP0200993A3 (en) | 2003-05-28 |
BR0010216A (en) | 2002-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6521657B2 (en) | Thio-oxindole derivatives | |
EP1175398B1 (en) | Indoline derivatives as progesterone antagonists | |
US6544970B2 (en) | Cyclic regimens utilizing indoline derivatives | |
CA2371633A1 (en) | Thio-oxindole derivatives | |
CA2372595A1 (en) | Contraceptive compositions containing indoline derivatives and progestational agents | |
TWI235150B (en) | Thio-oxindole derivates | |
UA73499C2 (en) | Thioxyndol derivatives, pharmaceutical composition containing said derivatives and active ingredients of medicaments for the stimulation of contraception and treatment of disfunctional bleeding with carcin and adenocarcin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |